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Abstract 
 
Head and neck cancer patients face considerable challenges as a result of their 
diagnosis and therapy. Psychosocial aspects are accepted as critically important 
in their care. Our hypothesis was that ‘carefully designed and structured 
questionnaires can be used to improve the quality of life of head and neck 
cancer patients’. This thesis reports the development of and findings from a 
series of studies considering the opinions and preferences of patients and 
clinicians about questionnaires and the process of care, supported by interviews 
and analysis of taped consultations. This work provided a detailed insight into 
aspects of head and neck cancer care from all perspectives.    
In summary, my main conclusions were: 
• The current practice of relying on consultations alone to manage the care 
of cancer patients does not ensure that all concerns are identified. This is 
particularly true for emotional and psychosocial issues. 
• There are substantial differences in patient characteristics, therapeutic 
burden and status between thyroid patients and other H&N cancer 
patients. A specific QoL module should be developed to meet the needs 
of thyroid patients. 
• Patients were not able to choose a questionnaire with any consistency. 
• Patients and clinicians had clear and cogent views about the process of 
care, consultations and questionnaires which provided invaluable insight 
into the needs of this patient population. 
• No current questionnaire is ideal for individual assessment but, from this 
study a combination of the EORTC QLQ C30 and H&N modules and 
HADS is recommended. 
• The main area of omission from current assessments is ‘fear of 
recurrence’. This is common and needs to be addressed in care for H&N 
and also Thyroid cancer patients. 
The results have provided an evidence base for future work in this field building 
towards a model of care which encompasses all aspects of patient needs.  
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Preface 
This study developed through my practice as a NHS Maxillofacial Surgeon. My 
main areas of clinical care, during higher training in the 1980s and Consultant 
practice in the 1990s, have been oncology, trauma and reconstructive surgery 
with an emphasis on free-tissue transfer. These areas bring doctors into close 
contact with patients who have suffered severe and sometimes devastating 
disturbance of key functions and who have to come to terms with a much altered 
life, in terms of personal goals, family life and life in a wider social context. Many 
studies report the impact of facial disfigurement and this continues to have 
negative effects on social interactions and work, people with such problems 
being consistently reported as less employable and less socially acceptable than 
the general population. 
During my NHS years the way that patients and their families adjusted or failed to 
adjust to their new life after surgery or other cancer treatment became an 
increasing interest. This period coincided with the early permeation of health 
related quality of life (QoL) assessment into clinical practice, very much at that 
time as a measurement tool for clinical trials. Some patients would adapt well and 
remain cheerful and composed despite radical and disabling treatment; others 
would withdraw from family and friends despite relatively minor physical 
impairments. Some relationships became stronger, with family engagement with 
the patient and their condition both in and beyond the clinical environment, others 
lost their family support with new partners emerging and coming with them to 
clinic sometimes years after therapy. One patient committed suicide shortly after 
he had learned that his disease was not fully controlled and his family felt that, for 
him, this was the only way out of an intolerable situation with which he could not 
come to terms. 
I had always wished to undertake clinical research into the area of patient 
experience, quality of life and ways to evaluate these aspects of experience in a 
way which meets their needs, given the key place of these factors in the 
management of and support for our patients, their carers and their families. The 
first study in which I played an active role was undertaken in Liverpool during my 
training years in the early 1990s and looked at the support patients needed and 
where they perceived it was offered. The result showed a high dependence on 
the hospital team. Support and where it is best based remains a core theme, 
highlighted again in the Cancer Reform Strategy, published in 2007. 
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At that time publications on QoL were appearing in the literature and Chapter 1 
brings the patient narrative into the philosophy which has underpinned the 
development and progress of this thesis. It then focuses on the strategies 
underpinning provision of cancer care in the National Health Service and the 
theory and development of generic and site specific questionnaires for use in 
clinical trials. 
The study has evolved through a changing environment of care, with increasing 
centralisation of care. Chapter 2 provides an overview of specific items relating to 
H&N and thyroid cancers and of QoL measurement in this patient population. It 
was the change in practice and centralisation of clinics, together with the 
introduction to multi-disciplinary assessment prior to therapy which led to the pilot 
study. We had become accustomed to all team members, including the Clinical 
Nurse Specialist (CNS) and Allied Health Professionals (AHPs) being present at 
the consultation. Although this arrangement was sometimes described as 
intimidating it did have good points in that all present heard the same information 
and acted appropriately to provide information and support. Bringing a larger 
team of oncologists and surgeons together made this impossible and there was a 
fear that issues may not be communicated fully between team members.The pilot 
work looked to determine whether use of a questionnaire might be an acceptable 
way of assisting communication between patients and their doctors and other 
health professionals. The pilot study is reported in chapter 3. 
This pilot study indicated that patients found questionnaire assessments helpful 
but doctors gave a much lower level of support. The area appeared to be worthy 
of further exploration as a potential clinical tool and we commenced our planning 
for the main study with the hypothesis that: ‘carefully designed and structured 
questionnaires can be used to improve the quality of life of head and neck 
cancer patients’.  
The design of this study required a careful review of recent work towards 
introduction of QoL measures into routine clinical practice, with an emphasis on 
questionnaire choice and technology for assessment. Consideration of the 
special site specific requirements of head and neck patients was integral to that 
process. This preparatory phase is covered in Chapter 4. 
This work led to consideration as to which measure patients would find best 
reflected their status and what should form part of a consultation. As the 
consultation lies at the heart of communication I needed a measure which would 
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allow assessment of what patients would wish to see in a consultation and 
whether what they considered was actually included. To achieve this I adapted a 
questionnaire from that of Detmar et al (2000). For QoL questionnaire 
assessment although there were numerous well validated measures, at that time 
no-one had undertaken a study of patient preference as to which to use in a 
routine clinical setting. This became a core goal of the study. Discussions centred 
on what a question consisted of with awareness from the pilot study that an item 
could be well phrased but fail to address a core concern or alternatively address 
a core concern but be written badly and thus be difficult for the patient to interpret 
and score. These issues are considered and the study design is presented in 
Chapter 5. For a measure to be effective, I needed to understand the views of my 
colleagues and a group from all MDT disciplines completed the same QoL 
measure as the patients and also gave detailed interviews, which were formally 
transcribed, about their thoughts on the way we might use questionnaires in 
clinical care and how that care might be guided by the results.  
Chapter 6 describes the study on views and preferences for the content of 
consultations, analysis of the content of recorded consultations, the results and 
specific discussion on this aspect of the work. Chapter 7 considers patient 
aspects of the questionnaire choice study, again with discussion specific to this 
aspect of the thesis. 
As indicated above, taking the patient opinions and preferences into account is 
only half of the work required to bring a questionnaire towards acceptability in the 
clinical setting. The less positive response of the doctors during the pilot study 
has already been reported so a parallel study was undertaken, firstly to gain MDT 
members’ views on questionnaire assessments and secondly to determine which 
team member might best act on a response. The methodology and design of the 
clinician study is presented in Chapter 8 with results and specific discussion. 
Chapter 9 brings the findings together looking at similarities and differences in 
the views of the patients and health professionals. It aims to gain a consensus as 
to whether our hypothesis has or might be achieved. Chapter 10 provides a 
critique of the study and the way in which the work might progress in the context 
of QoL measurements and the evolution towards more sophisticated methods 
and tools for data collection and the modern focus on Patient Related Outcomes 
(PROs). It places the study in context in relation to the current standard of care 
for Head and Neck (H&N) cancer patients and the way in which the questionnaire 
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assessment may contribute to care. A critique of the study in the overall context 
of QoL and clinical care is presented which informs the need for future work in 
this field. 
In Chapter 11 we look to the future, placing this work in context with other current 
and developing work both by the research team and in the field of H&N QoL 
research. The Cancer Reform Strategy has brought ‘survivorship’, patient 
experience and support into the forefront of discussion. As more patients live with 
their cancer as a ‘chronic disease’ the care they need and the service delivery 
and organisational issues which support that care are a matter of priority. How 
we might further develop the work presented to meet those needs is discussed. 
I close with supplementary material outlining my training and personal 
development and also outputs to date from the study. 
In summary this thesis presents a journey for me from NHS practice to clinical 
research and, in a wider sense, the study has evolved alongside developments in 
all aspects of the work; assessment of QoL, the environment of clinical care, 
technology for data collection and a commitment by healthcare professionals to a 
more ‘holistic’ model of patient management and support.      
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Glossary and Abbreviations 
 
AHP Allied Health Professional 
Ca Carcinoma 
CNS Clinical Nurse Specialist 
DH Department of Health 
EL Early Larynx – study sub-group  
ENT Ear, Nose and Throat – study sub-group 
EO Early Oral – study sub-group 
EORTC European Organisation for Research and Treatment of Cancer 
FACT Functional Adaptation to Cancer Therapy 
HADS Hospital Anxiety and Depression Scale 
HRQoL Health Related Quality of Life (abbreviated to QoL in this thesis) 
LL Late Larynx - study sub-group 
LO Late Oral – study sub-group 
MDT Multidisciplinary Team 
MHI-5 Mental Health Inventory 5 
POG Psychosocial Oncology and Clinical Practice Research Group  
PPM Patient Pathway Manager (electronic patient record) 
QoL Quality of Life (abbreviated from HRQoL in this thesis) 
RA Research Assistant 
SALT Speech and Language Therapist 
SCCa Squamous Cell Carcinoma 
SF-36 Short Form 36 
Thy Thyroid – study sub-group 
TNM Tumour, Nodes, Metastasis, the basis of cancer staging 
UWQoL University of Washington Quality of Life Questionnaire 
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Chapter 1 - Introduction 
 
1.1 Overview and Patient Narratives 
This chapter introduces the concepts which underpin this thesis and which are 
subsequently explored in later chapters. The first of these is the study of health 
related quality of life (QoL) and the second is the way in which cancer care is 
provided. The focus throughout is on the opinions of patients about how they talk 
to their doctors and other health professionals and published narratives will be 
considered in this opening section as the views expressed lie at the core of the 
research.. 
QoL is a multidimensional concept which looks at the way which patients feel 
about themselves in the context of a medical condition. Aspects such as physical 
status, emotional status, social factors and the way that patients consider that 
they are able to function in all aspects of their lives outside medical care are 
usually assessed. Methods of assessment include questionnaires; which may be 
validated or non-validated, interviews which may be structured, semi-structured 
and open interviews and case series or case studies. The measures which can 
be used are considered in outline in this chapter and the choices for this research 
are covered in more detail in Chapter 5. This study uses questionnaires and 
interviews as core methodology and tracks the content through to consultation 
and subsequent annotation.  
For patients with head and neck (H&N) cancer, where key functions are affected 
by both the disease and its therapy, the potential for an adverse effect on QoL is 
arguably greater than that for other cancers. It is this impact of the condition on 
the patient’s status which has led to a considerable body of research in this area. 
The challenge has been to bring the findings from QoL assessments into the 
routine clinic in a way that can have a practical impact on their care. At the core 
of this is reliable measurement of status and communication between health 
professionals and the patient and their family.   
Patients have written comprehensively and movingly about their cancer and their 
relationship with health professionals. These narratives allow some important 
themes to be established which are considered in the experimental work that 
forms the core of this thesis, especially in Chapters 6, 7 and 9 where key 
elements of the patients’ experience and wishes are considered. Patient 
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narratives provide an ideal background to illustrate why I chose to undertake a 
study which links patient wishes, doctor/patient communication and QoL tools in 
the setting of everyday practice. 
Mitzi Blennerhassett’s book (Blennerhassett 2008), eloquently describes the 
experience of being a cancer patient, the indignity of multiple intimate 
examinations and disturbance of basic bodily functions whilst attempting to 
continue to support her children at a time when her marriage was deteriorating 
through the pressures of her illness and her husband’s redundancy. Even more 
worrying than facing those aspects of the disease and its treatment which could 
not be avoided, the problems with communication are apparent throughout. In 
her book she deals with this by the use of pictures and poetry and each chapter 
ends with a commentary on how care might be better. The poem at the start of 
Chapter 6 sums up her feelings on communication and the experience of moving 
from one health care professional to another; professionals who do not say the 
same thing, undermining her confidence, and who often seem unwilling to answer 
her questions: 
‘Smiles are not enough 
And now I’m passed from one to another 
And find there is even more to discover 
You don’t seem to value the thing I most need 
But without it, I bleed 
I so much want to believe in your smile 
But it’s clicked on and off (to cover the guile?) 
Why can’t you see that, by shutting me out 
You leave me in doubt.’ 
As this chapter unfolds, Mitzi describes the time when her treatment was 
discussed. ‘There are two options for treatment, ‘removing the lump is not 
possible since it has invaded the muscle’’. This is not what Mitzi has previously 
been led to believe as she had been told that there was a third option, simple 
removal of her lump. In the conversation it becomes apparent that her status had 
not changed but the information she was being given had changed substantially. 
Her anger shines through: ‘the first doctor has known this all along and had lied, 
this was like a sledge hammer; bad news combined with deceit as shocking as 
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my reduced options and as devastating as the diagnosis itself.’ Those of us who 
are health professionals know we face consultations where additional evidence 
has come to light but hearing the impact of this for an individual is chastening. 
Throughout the book the issues of honesty, clear communication between health 
professionals and each other as well as with the patient so that all know what has 
been said, are core to the narrative. Whilst it can be argued that Mitzi’s first 
cancer was treated some years ago and she has since had a more positive 
experience, one wonders how, without a core document to inform the whole 
team, clarity and consistency in communication can be achieved. 
The H&N cancer journey can be particularly harrowing and individual experience 
relates to what is important in everyday life. The broadcaster John Diamond 
depended on his voice and his ability to communicate well and describes the loss 
of specific functions in his narrative. He substituted a column in ‘The Times’ for 
his radio programme, writing an impressive diary about his experience after 
diagnosis of a cancer of the base of the tongue. These columns were later 
expanded into a book about his cancer, his experience and, ultimately 
acceptance that he could not be cured (Diamond, 1999). He describes the effects 
of the cancer undermining his whole personality, having founded his career on a 
witty, satirical and highly articulate form of verbal communication. Losing this left 
him ‘moping ….. and behaving like a crotchety invalid’. In terms of meeting 
friends in a highly social life-style he describes retching, feeling that the tongue is 
a lump of unresponsive tissue, sitting at the dinner table with friends unable to 
articulate words or to share their social meal. This personal account combines his 
experience with thoughts on the impact on his family, his wife and their young 
children, and seeking a way forwards. After one time of bad news the family 
carefully chooses a puppy ‘because a dog is about hope and the future’. 
My final patient narrative, to which interest is further added by the contribution 
from his wife and primary carer, is taken from ‘Our story’; published by the Speak 
Easy Club for Layngectomees, based in Cornwall (Salter, 2008). This book brings 
together a number of peoples’ experience of living after laryngectomy. That of 
Alan and Rosemary Cummins is particularly frank and makes the point that 
patients and their carers face an unending adaptation and an enduring loss: 
‘There’s the loss of my job. I was a business advisor working with an enterprise 
team and spent my days chatting……. It was a huge blow to me when I was 
dropped by my work without any offer of support’. Rosemary adds ‘That hit Alan 
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very hard. His self-esteem plummeted. His personality was taken away. He 
became very depressed which was so unlike him. Even your friends don’t 
understand the problems of being a neck breather. You can’t unless you live with 
it on a daily basis.’ 
They talk through the loss of their future plans for retirement and then move onto 
an area missing from other narratives: 
‘There is the loss of intimacy between us as partners. I no longer feel attractive. I 
don’t like me. ……..Even speaking is very tricky when you’re lying on a bed’, 
Rosemary says ‘I think we have become more detached from each other post 
operation. ……. We expressed our love spontaneously and enjoyed it. We 
walked a lot and talked a lot, sharing almost everything. Now I feel I am walking 
on eggshells. ’Dare I say this?’ Should I do that? ‘Will this help or make matters 
worse?’ I have spent many a night crying alone down here on the sofa. I find it is 
a lonely place to be, living alongside a laryngectomee’ 
Even 5 years down the line from surgery, the hospital remained a place of 
support: ‘There was even the loss of the cancer checks after five years of 
attending regular clinics. At the last one I was told I was alright and there would 
be no need for further attendance, Rose and I were shocked. ………I am very 
pleased and thankful to be told I am free from cancer - but I am not alright! It is 
the other secondary issues, losses, that both of us have difficulty coming to 
accept. ‘Alright’ for me now is a very different state to how I was before March 
2001.’ 
They continue with a narrative on some specific problems; breathlessness, 
fatigue, coughing at the slightest stimulus, running nose, lack of concentration, 
many of the things raised in a QoL assessment. Their final comment is: 
Rosemary: ‘I don’t think life as a laryngectomee or with a laryngectomee gets 
easier as time passes by.’ Alan agrees ‘I have lost everything and gained 
nothing. I am thankful I am alive but perhaps someone needs to come up with a 
definition of what a ‘full recovery’ is. It should not stop people from having a life 
saving operation but perhaps a clear explanation of the bad side (we were really 
told more about the good) would prepare people better.’ 
This narrative brings into the open the cost of ‘survivorship’ and the ongoing 
struggle to regain QoL in its wider dimensions. The limitations affect every area of 
life, physical, emotional, family life, social, financial. Alan and Rosemary were 
grateful to the staff but felt there was a lack of understanding of what they faced. 
Whether the complexity of their experience and needs can be captured through a 
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questionnaire is uncertain but perhaps a suitably worded measure could act as a 
prompt. 
The impact of cancer on families is something which makes this disease such a 
dreaded burden. Carer narratives are less frequent but Ted Walker described his 
perspective of his wife’s cancer journey after her diagnosis of cancer of the 
maxillary antrum (upper jaw and related air sinus), to her death and how he 
coped afterwards (Walker, 1992). Her therapy involved radical combined therapy 
(surgery and radiotherapy) and the fitting of an obturator, a specially constructed 
prosthesis to fill the defect in her upper jaw and allow speech and eating. Ted 
found his wife, Lorna’s, journey distressing throughout and it seemed that she 
was the one who could cope. One wonders, looking at his experience 
retrospectively, what her needs might have been and how much of her courage 
was innate and how much an attempt to protect him, He is open about his deep 
shame because he felt disgust at what she had to go through and what she 
became after her mutilating surgery and finally, what she faced when her disease 
recurred. 
These accounts place a very personal perspective on cancer care. There is much 
that we, as health professionals, can only achieve through support. We cannot 
take away the burden of therapy nor can we always predict what the future or, 
indeed the functional consequences of therapy, might be. We can look to place 
the patient and his/her family at the core of a holistic cancer service and it is to 
that aspiration that I look in this thesis. It is my hypothesis that a measure, in this 
case a carefully designed questionnaire which can identify need, can act as 
a focus for communication and facilitate patient centred care, thus leading 
to improved QoL. 
These narratives provide a unique insight into the impact of cancer in general and 
H&N cancer specifically and the need for the best possible communication, the 
meeting of specific information needs and for appropriate support from the 
member of the multidisciplinary team (MDT) best placed to provide it. It is 
essential that any new initiative has the support and is of value to health 
professionals as well as patients and so, in this thesis, a detailed series of 
interviews are presented with a sample of health professionals from different 
disciplines who work in our MDT. The play ‘Cancer Tales’ (Dunn, 2007) focuses 
on the experience of five women, of life and death, of withdrawing care and 
survivorship. In its final chapter it suddenly changes emphasis to looking at the 
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role of health professionals carrying the burden of coping with patients who can 
often be demanding, are seriously ill and who may be dying. The surgeon, who is 
seen earlier as assured and confident, admits to the stresses of a life where 
‘you’re battling with death and often not winning’. Blennerhasset (2008) and 
Diamond (1999) also acknowledge the skill and care of doctors and cancer 
nurses and particularly value information given simply. In ‘Cancer Tales’, 
likewise, the ‘patients’ praise doctors and nurses who give clear advice with 
compassion, even when this is bad news such as consideration of cessation of 
active therapy. Our health-care system has focussed on improving care for the 
patients; yet ever more aspirational targets can place significant pressures on 
staff and on infrastructure and resources. For this reason, the professional 
narratives in this thesis complement those of the patients. Should a person gifted 
with exceptional technical skills be required to become an advanced 
communicator? Might being faced with the emotional consequences of the 
attempt to cure the patient be one burden too many? How can teams support 
each other as well as those for whom they care? Who should do what? These 
questions lie at the core of providing a first-class but sustainable service for our 
cancer patients. The personalities and the insight of the health professionals but 
also the areas of uncertainty, come across strongly in Chapter 8.       
To set the patient, family and health professional experience in context, it is 
important to understand the way in which cancer care is provided in the UK. The 
principles which underpinned the development of our cancer care are considered 
below. This process continues to be developed and refined and the study is set 
within an evolving clinical service, the pilot work having been done soon after the 
first major changes to team structure and the later and main study being set in a 
MDT which had developed to the point where discussions and treatment planning 
were well established and working relationships had matured. The specific 
environment of care in which this study is set and a synopsis of H&N cancer 
research related to QoL and function is described in Chapter 2. Subsequent 
chapters cover the exploration of questionnaire use in routine clinical practice 
through the pilot study (Chapter 3), the design of the definitive study (4), detailed 
methodology (5), and findings, discussion and critique in subsequent chapters. 
These offer a narrative of the progress of the work from concept to conclusion 
and the thesis ends with a consideration of future work. 
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1.2  Cancer care in the National Health Service 
1.2.1 Cancer Strategy and Development of Specialist Care 
 
The past twenty.years have seen profound changes in the way that cancer care 
is offered. In the past it was common to have individual teams, led by a single 
consultant surgeon or oncologist, working in small centres offering cancer 
surgery and/or radiotherapy with little support from allied health professionals and 
little co-location of surgical and radiotherapy clinics. For oral cancer the need for 
an integrated approach to diagnosis and therapy was raised as early as 1980 
(Rapidis et al). They suggested an approach whereby two teams cared for 
patients, the curative team and the supportive team, who would help with the 
issues we might now term survivorship. They took a very forward looking 
approach and the main criticism looking back at their work is that they consider 
the medical (curative) team as the major team and the allied health professional 
team (supportive) as the minor team. Similar concerns were raised in numerous 
fora and at some cancer sites (H&N being one of these) it was suggested that 
treatment options were too often reliant on which discipline first assessed the 
patient. Concern was heightened by the EUROCARE study (EUROCARE 2, 
1999) which attempted to compare outcomes using registry based ‘like for like’ 
data. The 30 registries held details on 800,000 patients diagnosed with cancer in 
the period 1978-1985. The survival of patients in the UK was lower than that in 
most European countries and it was considered that access to and quality of 
clinical care might be one of the factors. In parallel, initiatives to include patient 
views in influencing the way care was provided were gaining momentum. The 
Patients’ Charter (Department of Health,1991) and the setting up of hospital 
league tables increased consumerism as part of an attempt to develop a market 
system with the aim of improving choice and thereby services. However, in 
practice, choice remains limited by geography, service availability and the 
knowledge of the consumer. As the cost of providing cancer services and unease 
about variations in practice continued the Expert Advisory Group on Cancer 
(1995) recommended a substantial change to cancer services in England and 
Wales. Core principles included: 
• care should be patient centred. 
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• the impact and psychosocial aspects of cancer on patients, families and 
carers should be recognised. 
• information should be clear and accessible. 
• good communication should occur between sectors. 
• patient, family and carer and professional views should be taken into 
account in  the development of services. 
It is interesting to note how closely these recommendations reflect the wishes of 
the patients whose narratives were described in the earlier part of this chapter. 
The model of care produced from this report focussed on primary care with 
specialist care for common cancers being provided at District General Hospital 
(DGH) level and for rarer cancers at Cancer Centre level, with an expectation that 
the number of professionals offering treatment for this group would reduce and 
cancer therapy become the core of their workload. The care would be provided 
by integrated multidisciplinary cancer teams (MDTs) rather than by specialists 
working alone. H&N cancer falls into the ‘less common cancers’ group and was 
one of the sites for which care would be provided by Cancer Centres. However, 
there remained many issues, especially the support needs of patients after 
completion of radical therapy with curative intent. Selby et al (1996) reviewed the 
benefits from specialised cancer care, considering the evidence which 
underpinned the report. Registry data and hospital statistics showed large 
variations in the way that individual treatments were used and in the caseload for 
particular cancers amongst doctors offering therapies. Evidence was strongest 
for breast cancer that higher caseloads and experience conferred benefit. The 
risk ratio of death was 0.85 (95% CI 0.79 - 0.94) for patients managed by 
surgeons who had an annual caseload of more than 30 patients per year, 
compared to those treating less than 30 patients per year. For haematological 
cancer, where care was delivered to an agreed protocol, outcomes were the 
same across hospitals and similar results were seen in colorectal cancer. 
However, in both these instances, the number of patients treated was sufficient to 
maintain training and expertise. When rarer cancers were considered, good 
evidence was available for testicular cancer, with improved survival linked to high 
caseload and adherence to protocol driven management and for sarcoma where 
patients in Sweden treated outside specialist centres had twice as many 
recurrences. Although no evidence was available for some cancers (including 
H&N) the authors considered that significant survival benefits could be attained 
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and that all patients must have access to equally high standards of specialised 
care. A key recommendation was for continued assessment of results and 
attention to development of cancer care in the face of technical and demographic 
challenges. 
This work led to the NHS Cancer Plan (2000) which set out the first 
comprehensive national cancer programme for England, having four main aims: 
• to save more lives 
• to ensure people with cancer get the right professional support and care as 
well as the best treatments. 
• to tackle the inequalities in health that mean unskilled workers are twice as 
likely to die from cancer as professionals. 
• to build for the future through investment in the cancer workforce, through 
strong research and through preparation for the genetics revolution, so that 
the NHS never falls behind in cancer care again. 
These aims are very pertinent to H&N in that, as a less common cancer, services 
tended to be fragmented and delivered at local level with limited co-ordination 
between specialists and, even more critically, with the Allied Health Professionals 
(AHPs) who can make such an impact on recovery and help patients return to as 
near as possible a normal life. The population traditionally affected by this cancer 
is a deprived one, contributing to poor outcomes. The plan aimed to bring 
together prevention, diagnosis, treatment and care for cancer together with the 
investment needed to deliver the services required to meet its aims. Key 
commitments included preventive measures such as reducing smoking, goals 
and targets for referrals and treatment times and investment in palliative care.         
The National Institute for Health and Clinical Excellence (NICE) was 
commissioned to produce recommendations on improving outcomes at site 
specific level and I was a member of the H&N group which brought  together 
recommendations for improving outcomes (Improving Outcomes Guidance, IOG, 
2004) which, in turn, informed the process for peer review of services. Key 
recommendations were that services should be commissioned at Cancer 
Network level and be delivered by MDTs managing at least 100 new cases of 
upper aerodigestive tract cancers per annum. Specialist teams would deal with 
thyroid cancers and rarer H&N cancers such as salivary and base of skull 
cancers.  These teams would have all necessary support services; Clinical Nurse 
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Specialists (CNS), Speech & Language Therapists (SALTs), dietitians and 
dentists. Co-ordinated local teams would be configured to provide long term 
support. At site specific level, I will look further at the service which the patients in 
this study experienced in Chapter 2. 
The next and most recent consideration of cancer services was the Cancer 
Reform Strategy (Department of Health, 2007). Again I was a member of the 
H&N group and our recommendations were published as an annex to the main 
report (Department of Health, 2007, Annex F) In the main report there was an 
emphasis on rehabilitation and support and provision in the best locality for 
patient need. In the H&N appendix we acknowedged the increasing incidence of 
cancer at this site and the need to continue to work to the aspirations of the IOG 
so that care is provided in the best centres but also that supportive care including 
living with the impact of this cancer, is provided locally.  
Although the cancer service now relies on MDTs, it is only very recently that a 
formal report was published, considering health professionals’ views on their 
structure, functions and effectiveness. Taylor and Ramirez (2009), on behalf of 
the National Cancer Action Team, carried out a major survey, with responses 
from 2054 MDT members, of whom 53% were doctors, 26% were nurses and 
15% MDT co-ordinators. The review covered domains considered important for 
effective MDT functioning. These were structure, clinical decision making which 
included a section on patient-centred care/co-ordination of service, team 
governance and professional development and education of team members. 
Most tumour sites were represented, H&N being the fifth most frequent site with 
109 responders (8%). In terms of overall response, at least 90% of MDT 
members agreed that effective MDT working results in: 
• improved clinical decision making 
• more co-ordinated patient care 
• improvement to overall quality of care 
• evidence based treatment decisions 
• improved treatment. 
These findings suggest that, in the opinion of those currently providing the 
service, MDTs have been and are effective in meeting the aspirations of the 
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Expert Advisory Group and the Department of Health Cancer Strategy. In terms 
of patient centred care at least 90% of respondents agreed that: 
• patients should be made aware that an MDT will be advising on their 
treatment/ care. 
• patient demography and co-morbidities should always be considered. 
• patient psychosocial, supportive and palliative care issues should always be 
considered. 
• patient's views should always inform the decision-making process. 
• patient views/preferences should be presented to the MDT meeting by 
someone who has met the patient. 
Aspects of the interaction with the patient were explored by cancer site. On 
identification of a keyworker to provide support, 82% of respondents overall, i.e. 
including responses from all MDTs, agreed, compared to 92% of H&N MDT 
members who felt this action was addressed. The highly positive responses of 
H&N team members continued.with 82% supporting the principle that a patient’s 
care should only be discussed when someone is present who has been involved 
in assessing that individual (compared to 63% overall) and 28% endorsing the 
principle that patients should have the opportunity to attend the MDT discussion 
of their case (compared to 14% overall). 
This survey did not ask for reasons for the responses given. In the context of this 
thesis I believe that these results confirm the complexity and multidimensionality 
of the management of physical, emotional, psychosocial, co-morbidity and other 
aspects of H&N cancer and that those who choose to specialise in this field are 
aware that they must communicate effectively with each other and with their 
patients if effective care is to be provided. 
This section has provided a summary of the evolution and current status of UK 
cancer care. The specifics of H&N cancer and the practice in the centre in which 
my studies have been based will be considered further in Chapter 2. 
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1.3  Health Related Quality of Life in Cancer 
1.3.1 Principles and Theory of Health Related Quality of Life 
Assessment 
QoL is not a new concept having originally been described by Aristotle (BC 384-
322) who understood that ‘being well’ and ‘being happy’ may not be the same 
thing as what constitutes happiness is a matter of dispute. It resumed its place in 
medical and social circles comparatively recently. Shaw (1990), as a celebrated 
writer, indicated that ‘happiness is not the object of life,…..courage consists in the 
readiness to sacrifice happiness for an intense quality of life’. 
In terms of moving this concept towards scientific and hypothesis driven 
evaluation, the World Health Organisation (1948) defined health as ‘a state of 
complete physical, mental and social well-being and not merely the absence of 
disease.’ This definition picks up the additional dimension which constitutes well-
being and, presumably, a state of excellent QoL. These main areas continue to 
form the basis of the key elements of QoL measurements.    
Numerous theories have been proposed but one which has gained acceptance in 
clinical practice as a practical definition is that of Calman (1984), often referred to 
as the ‘gap’ theory of QoL. Exploring the difference between aspiration and 
perception of current status, this theory allows assessment of QoL at individual 
level in a way that can be easily interpreted in clinical practice. 
 
1.3.2  Tools for Health Related Quality of Life Assessment: principles 
underpinning the use of questionnaires 
To allow comparison between populations, largely in relation to clinical trial 
research, a number of measures have been developed. These vary from 
questionnaires designed to consider general health across the population, 
irrespective of the presence or absence of a specific disease state, such as the 
Short Form-36, (SF-36) to those designed to explore specific issues in 
considerable detail according to patient prioritisation. An example of this latter 
approach is the Schedule for the Evaluation of Individual Quality of Life (SEIQOL) 
which is intended for the assessment of individuals (Wettergren, 2009). 
Questionnaires which have been developed for general assessment can be used 
in the cancer setting but through the late 1980s and early 1990s a series of 
generic cancer questionnaires were developed and validated. In Europe much of 
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this work was led by the European Organisation for Research and Treatment of 
Cancer (EORTC) and in the USA by the Functional Assessment of Cancer 
Therapy (FACIT) research teams.  
Further developmental work led to modules being added to the generic 
questionnaires and also to the development of stand-alone measures. The main 
research groups have subjected their measures to carefully designed 
international psychometric validation studies; however some measures in clinical 
practice have been accepted by clinicians and by speciality organisations despite 
much lower levels of formal validation. In H&N, a good example of this approach 
is the University of Washington Quality of Life questionnaire (UWQoLv4). In 
developing the methodology which underpins this research consideration was 
given to the quality of psychometric validation, the ‘track record’ of the 
questionnaires as assessed through a review of the literature, the current place of 
measures within the clinical setting and the views of the multidisciplinary cancer 
team (MDT). This process is considered further in Chapter 4, together with a 
description of questionnaire based research and the reasons for the choices of 
instruments made in my study.  
In addition to the generic and site specific assessments of cancer patients, it is 
acknowledged that mood plays an important part in patient assessment and 
measures have been developed to assess this aspect of QoL as a specific item. 
Measures in widespread use include the Hospital Anxiety and Depression Scale 
(HADS) and the Mental Health Inventory (MHI-5). 
Finally, social status is an integral part of assessment. For H&N cancer it is 
accepted that the patient profile reflects a higher level of deprivation than that at 
many other sites (National Cancer Intelligence Network, 2008a).  Measures 
which consider this as a stand-alone item have been developed more recently, 
an example being the Social Difficulties Inventory (SDI) (Wright et al, 2005). 
Publications on this aspect of QoL have appeared after we developed the 
methodology for this study and so are not included. 
To set the scene for the thesis it is important to understand the tension between 
the use of a measure for population assessment and for individual assessment. 
The scientific processes for validation set clear parameters for the inclusion and 
exclusion of questionnaire items. Thus, a question which is critically important for 
a subset of patients may be removed. This process improves validity at 
population level yet inevitably blunts the sensitivity to individual needs. There is 
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evidence for the use of validated questionnaires to assist in doctor/patient 
communication, particularly the randomised controlled trial (RCT) reported by 
Velikova et al (2004). The choice for investigators working in this field lies 
between accepting the limitations of a validated measure or developing an 
individualised measure and undertaking the substantial task of validating an ever 
changing and evolving reflection of patient needs.  
Undertaking research in this area is complicated by the number and different 
focus of the measures in clinical research. One aspect of choice must be the 
patients’ own views as to whether any measure chosen truly allows them to 
communicate their status to the clinical team. It is this aspect of questionnaire 
choice which is examined in this thesis.  
 
1.3.3 Technology in QoL Research 
Questionnaires are delivered either in paper form, which was the main method 
until recent years, or data is collected by electronic means, including desk-top or 
laptop computers and portable digital handsets. In the first years of this century 
the provision of touch-screen computers has developed and is in active use in 
many centres, Touch-screen technology offers the ability to analyse the data in 
‘real time’ and to feed results back to both patients and clinicians. It therefore 
adds a key element to using QoL questionnaire data in the routine clinic 
environment (Velikova et al, 1999a).  
In this study we were looking to capture a substantial amount of data from a 
planned sample of 150 H&N cancer patients, using multiple questionnaires. The 
availability of a system capable of facilitating this endeavour was critically 
important. Touch-screens were, therefore, the method of capturing questionnaire 
scores in the main study, although paper based clinical report forms were used 
for convenience in the initial pilot study.   
An additional feature of touch-screen technology is that it can capture change in 
status, a theme which has emerged as highly important for the routine use of QoL 
data in the study of clinician opinions and preferences (Chapter 8). This provision 
of patient focused data to clinicians for use in consultations can be powerful in 
driving the general acceptance of day to day use of QoL measurement in 
oncology clinics. As I am describing a simple single intervention cross sectional 
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study in this thesis, the longitudinal element of QoL assessment is not captured 
here. 
1.4  Summary 
This chapter has introduced the main general concepts which underpin the study 
and which will be further developed in subsequent chapters. The specific setting 
of H&N cancer will now be considered in terms of care for patients and QoL 
assessment.
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CHAPTER 2 - Head and Neck and Thyroid Cancers, 
Clinical Overview, Environment of Care and Quality 
of Life Assessment 
 
2.1  Introduction 
 
In this thesis the patient groups studied are those with oral, laryngeal and thyroid 
cancer. This choice was made on the grounds of achieving sufficent coherence 
within participant groups to allow comparison; with subdivisions of ‘early’ and 
‘late’ on therapeutic grounds to represent the treatment burden and very different 
long term outcomes in terms of physical function and side effects related to 
disease.  H&N has much heterogeneity so, to allow comparisons, in the main part 
of this study I have looked at the experiences and opinions of patients with 
oral/oropharyngeal and laryngeal cancers, which constitute the most common 
cancers at this cancer site. 
Thyroid cancer is frequently managed in the same clinical service yet has 
received little attention in the QoL literature. The population and disease profiles 
are different to those for H&N and it was felt important to include this group of 
patients, to give an understanding of their concerns and to ensure their inclusion 
in further work arising from the studies reported in this thesis. 
This chapter will give a summary of the epidemiological and clinical factors which 
underpin the research, considering H&N and Thyroid cancer in turn and consider 
the way in which QoL has been approached in contributing to the management of 
these patients.  
 
2.2  Head and Neck (H&N) Cancer 
2.2.1 Normal Anatomy and Descriptive Terms 
The term head and neck (H&N) cancer describes those cancers arising from the 
mucosal lining of the upper aerodigestive tract and major specific structures 
within this anatomical area, especially the four major salivary glands and the 
thyroid gland. The area covered by this descriptive term is shown in Figure 1.  
There are over 30 specific sites  indicated in the International Classification of 
Disease v 10 (ICD 10) codes and, even at site level, the descriptors are complex. 
The oral cavity sites described include lips, buccal mucosa, alveolus and gingivae 
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(the tooth bearing segment of bone and the mucosa immediately surrounding the 
teeth), the tongue, hard and soft palate and floor of mouth. The anatomy of the 
larynx is similarly complex but is generally separated into 3 key areas; 
supraglottis, above the vocal cords; glottis, at the level of the vocal cords; and 
subglottic below the level of the vocal cords. The pharynx is divided into the 
nasopharynx, the oropharynx and the hypopharynx. In addition, the air sinuses, 
frontal, maxillary, ethmoid and sphenoid are considered as part of H&N as are 
the thyroid, parathyroid and salivary glands. 
Figure 2 1.  Anatomy of the upper areodigestive tract 
Modified from illustration designed by Sanofi-Aventis (with permission) 
It is important for this complexity to be recognised in this thesis as the population 
varies by site, for example, nasopharyngeal cancer tends to be diagnosed in a 
younger population than other H&N sites. This disparity is reflected in therapy 
and, in terms of this study, provides challenges in terms of achieving a 
representative sample of patients from whom to draw conclusions, hence the 
decision to include oral/oropharyngeal, laryngeal and thyroid cancers rather than 
a sample addressing all sites in this thesis.   
 
 
oral  
tongue 
mandible 
submandibular 
salivary gland 
base of tongue 
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2.2.2 Major Aspects of H&NCancer 
The main cancer to be considered in terms of therapeutic impact and experience 
from the point of view of the patients is termed squamous cell carcinoma (SCCa). 
Carcinoma describes a malignant tumour which arises from epithelial elements. 
Over 90% of head and neck cancers are SCCa. Other specialist tissues, such as 
the thyroid and salivary glands have specific cancers. These behave differently 
and, as thyroid patients have been included in this study, a description of this 
group of cancers is provided below.  
The main documented risk factors for head and neck SCCa are smoking and 
heavy alcohol consumption which have an independent but also a synergistic 
effect. Substantial evidence indicates that these habits can cause important 
differences in both the population of patients affected by the disease and its 
biology. Much interest currently focuses on the place of human papillovirus (HPV) 
in the development of oropharyngeal cancers in the young and this is likely to 
have an impact on future therapy for this group (Hennessey PT et al, 2009). This 
will not be considered in more detail as this work gained momentum after 
completion of recruitment to this study and the </=40 years of age H&N cancer 
group is not represented in our study.  
 
2.2.3 Epidemiology 
Head and neck cancer is a global disease. Oral cancer alone accounts for nearly 
220,000 cases in males and 90,000 cases in females each year, constituting 5% 
and 2% respectively of new cancer diagnoses globally (Ferlay et al, 2004). It is 
particularly prevalent in the developing economies, especially India and South-
East Asia but subject to considerable regional variation. For example, in India the 
incidence ranges from 7.2/100,000 population in Bhopal to 2.4/100,000 in Barshi 
(Roden and Wu, 2006). In the USA, in 2008, 47,500 new cases of H&N cancer 
were diagnosed and 11,260 died from their disease (Jemal, 2008). In the UK, 
7.948 new cases were registered in 2000, 5504 males and 2444 females, making 
it the 8th most common cancer (3% of total cancer diagnoses) (Bosch et al, 
2002). This level of variation shows the importance of racial origin, risk factors, 
environment, and also the need to understand underlying genetic susceptibilities. 
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In terms of sex distribution, more males than females are affected and it is 
generally believed that this relates to habits, particularly smoking and alcohol 
consumption. In recent years, reports are emerging of increased incidence in 
younger patients, considered to be related to human papillomavirus. 
UK figures and service detail are captured in the National Head and Neck Cancer 
Audit (DAHNO, 2008). DAHNO data is derived from direct submissions by NHS 
Trusts in England and Wales according to a standard data submission format. It 
attempts to capture incidence, stage, site, waiting times, therapy and outcome 
data. Figures need to be interpreted with some caution as there are limitations in 
data entry, however, it remains the only attempt to capture national data. During 
the period of the current audit, figures were collected for oral and laryngeal 
cancers alone, relating directly to the groups described in this study and the two 
most common sites for H&N cancer. 
A  total number of 2,130 cases were submitted, 1049 larynx and 986 oral. Basic 
demographics indicate that, in the index period, defined as the opening of the 
audit in January 2004 to the census date of October 2007, 82% of laryngeal  
cancer patients were male compared to 58% of oral cancer patients. For both 
cancers the peak incidence lay in the seventh decade, with a median age of 67 
for males and 64 for females with laryngeal cancer and 62 for males and 68 for 
females with oral cancer. 
Young patients were unusual, only 17 laryngeal cancer patients and 41 oral 
cancer patients presenting at less than 40 years of age. In contrast 135 laryngeal 
cancer patients were aged 80 or above, with  331 of oral cancer patients falling 
into this age range. For H&N cancer, a significant concern is the development of 
second primary cancers; either synchronous or metachronous. Eckardt et al 
(1993), in a retrospective study found that 20 (5.2%) of patients from a population 
sample of 379 developed a second upper aerodigestive tract primary malignant 
tumour, the average delay between primary therapy and diagnosis of the second 
cancer being 49.2 months. Crosher and McIlory (1998) considered this risk using 
the resources of the Scottish Cancer Registry to study 1891 patients. Of these 
228 (12%) developed a second primary cancer at a mean follow up time of 38 
months. Fourteen patients had three cancers and two patients had four separate 
malignancies. The overall risk of a second cancer was 2.03 (95% CI 1.77-2.39) 
greater than expected in the general population; the relative risk for male patients 
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was 1.95 (95% CI 1.65 – 2.24) and for females 2.29 (95% CI 1.7-2.9). Reasons 
for this have been postulated as mucosal initiation and promotion by exogenous 
factors, with an emphasis on smoking and alcohol over the years but very 
recently increasing interest in human papilloma virus (HPV), or field cancerisation 
(Batsakis 1984, Slaughter 1953). The practical impact of these findings are 
continued surveillance and a shift with time in surveillance priorities from 
checking the site of the index cancer to diagnosis of new primary cancers. 
There is a need to ensure that symptoms which might ‘flag’ a new cancer, such 
as pain, hoarseness of change in swallow are included in any future QoL 
questionnaire. 
Characteristics of the cancer population can also be considered in socio-
demographic context and this would be expected to have an impact on the 
results of my study, It is acknowledged that H&N patients represent a deprived 
group  Woolley et al (2006) considered a group of 278 consecutive oral and 
oropharyngeal cancer patients, linking social deprivation to QoL, as measured by 
the UWQoLv4. She concluded that patients with the worst QoL outcome were 
single, under 65 years of age and were those who smoked and consumed 
alcohol heavily. There was a trend for these factors and low QoL to be linked to 
indices of deprivation at follow up but not at presentation. The most recent figures 
(NCIN, 2008b) indicate that H&N cancers, defined as ICD C00-C14 & C30-C32 
(lip, oral cavity, pharynx and larynx) and measured by the Income Domain of 
Multiple Deprivation (IMD) (2007) show a particularly strong level of social 
deprivation. For H&N the most deprived quintile had a ratio of 2.1 to 1 comparing 
the incidence rates in the most deprived with the most affluent. This supports the 
aims of the EAGR in ensuring that all patients have access to the best of 
services, confirming the sociodemographic based inequalities in cancer 
experience. In terms of this study, it may well indicate a greater need for 
assistance in communication and needs for support. 
 
2.2.4  Management of H&N Cancer 
To set the experiences of patients enrolled in this study in context, the consensus 
cancer and therapeutic pathways for  H&N patients are outlined below according 
to disease site. Treatment choices depend on the cancer stage. Staging depends 
on three major factors; the size of the primary tumour (T-stage), the involvement 
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of the lymph nodes in region of the cancer (N-stage) and the presence or 
absence of metastatic disease (M-stage). There are two main systems in 
standard clinical and clinical research practice, the TNM system of the Union 
International Contre le Cancer (Sobin and Wittekind, 2002) and the Stage I-IV 
system favoured by the AJCC (American Joint Committee on Cancer, 2002).  
 
Table 2.1 UICC Staging for H&N Cancer 
TNM 
T Status 
Descriptor 
T0 
Definition 
Primary tumour cannot be detected 
 
Tis Cancer ‘in situ’, the histological appearance is that of a 
tumour but invasion cannot be detected 
 
T1 Tumour less than 2cm in its greatest measurable dimension 
 
T2 Tumour between 2 and 4 cm in its greatest measurable 
dimension 
 
T3 Tumour more than 4 cm in its greatest measurable 
dimension 
 
T4 Tumour invades adjacent structures: e.g. cortical bone, 
extrinsic muscles of tongue, external skin 
 
TX Primary tumour cannot be assessed 
N Status N0 No evidence of regional lymph node metastasis 
 
N1 Metastasis in a single ipsilateral lymph node, 3cm or less in 
greatest dimension 
 
N2a Metastasis in a single ipsilateral lymph node, more than 
3cm but less than 6cm in greatest dimension 
 N2b Metastasis in a multiple ipsilateral lymph nodes, none more 
than 6cm in greatest dimension 
 N2c Metastasis in bilateral or contralateral lymph nodes, none 
more than 6cm in greatest dimension  
 N3 Metastasis in a lymph node more than 6cm in greatest 
dimension 
M Status M0 No evidence of distant metastasis 
 M1 Distant metastasis 
 MX Distant metastasis cannot be assessed 
 
T= the primary tumour, N = the lymph nodes of the neck, M = the presence of distant 
metastasis. For any these, the suffix ‘x’ means that aspect of staging cannot be 
accurately assessed.  
 
Both of these staging systems describe cancers according to a numerical system 
where high numbers indicate more advanced disease and are described below.  
Staging using these systems does correlate with outcome in terms of overall 
survival and they represent a common language for researchers. 
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Table 2.2 AJCC Staging of H&N Cancer 
 Stage 
TNM 
items 
  Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T1, T2 N1 M0 
T3 N0, N1 M0 
Stage IV 
T1, T2, 
T3 N2 M0 
T4 Any N M0 
Any T Any N M1 
This correlation allows the TNM staging to be reported as a single figure, bringing 
groups of patients with a similar outcome into a single category. 
Reporting through the AJCC system is clearly simple although some sensitivity in 
terms of understanding the specific characteristics of primary and nodal status is 
lost. In the study I have chosen to use a measure of therapeutic burden to assess 
patient views, however to show the results in comparison with a validated staging 
system, an analysis using the AJCC stage will be presented in chapters 6 and 7. 
It is customary, both in the literature and day to day clinical practice to use the 
staging systems as a guide to therapy. A T1 or T2 cancer without evidence of 
nodal involvement will often be amenable to single modality therapy, whereas a 
larger cancer or one with nodal involvement will need a more complex multimodal 
approach if a radical curative option is to be attempted.  
Modalities of therapy available to the cancer team include surgery, with or without 
reconstruction; radiotherapy, external beam or brachytherapy and systemic 
therapy by means of chemotherapeutic agents. Surgery aims to remove bulk 
disease at the primary cancer site with a margin of non-cancer tissue to achieve 
clearance of the invasive tumour cells. For early disease, surgery or radiotherapy 
may be used alone. By clinical consensus small primary cancers of the oral cavity 
are treated by surgery and occasionally brachytherapy (very localised high dose 
radiotherapy delivered using hollow needles loaded with iridium and left in place 
for 6 days). These techniques spare the jaws and teeth from radiation related 
damage. For larynx the approach has traditionally been to offer external beam 
radiotherapy, although endoscopic surgery is effective for T1 and T2A cancers. 
Where the primary cancer is larger, where the proximity to important anatomical 
structures may limit the margin and where the volume of primary cancer is large  
QoL in Individual Patients
 
or the margins are close or involved ; external beam radiotherapy is advised.
accepted that the outc
margins is less good than for those with clear margins (Sutton et al, 2003). 
Where a large volume of tissue is removed, careful consideration must be given 
to the way the defect is reconstructed; local 
another), pedicled flaps (tissue moved together with its blood supply) and, most 
ambitiously and routinely in modern surgical practice, free flaps (where a piece of 
tissue is harvested from a distant site, detached from
revascularised using microvascular techniques to an artery or a vein situated in 
the neck).  By these means even large and complex defects can be 
reconstructed, although at a lower level of function than the native tissue. Figure 
2.3 shows a soft tissue and a bony reconstruction.
patients, morbidity at the donor site is an important issue, as illustrated in 2.3.c, 
yet this is not addressed in current QoL questionnaires.
Figure 2.3: Methods of advanced surgical r
 
2.3.a. A microvascular anastamosis    2.3.b. Tongue reconstruction using a 
radial forearm free flap 
 
2.3.c Harvesting a fibular flap    2
 
  
23 
ome for patients who have  close or involved surgical 
flaps (tissue moved from one site to 
 its blood supply and 
  For surgically treated 
 
econstruction. 
                                     forearm free flap.
 .3.d: Flap in situ   2.3.e: Radiological view.
Chapter 2 
 It is 
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Oral cavity cancer has consistently failed to respond to radiotherapy or, more 
recently, chemoradiotherapy in the way that other H&N sites have done. The 
reason for this site specific difference is, as yet, not understood.  
The approach to advanced laryngeal cancer is rather different in that, unless 
bone and cartilage has been invaded by the cancer, every attempt is made to 
conserve the larynx, offering chemoradiotherapy wherever possible and radical 
external beam radiotherapy to those unfit for chemotherapy and its systemic 
effects. If non-surgical therapy fails, laryngectomy becomes the only option, 
accepting the functional and social consequences. Voice rehabilitation can be 
attempted using valves, oesophageal voice or electronic external larynx devices 
but is always inferior to the natural voice in strength and quality. 
Consideration of the best therapy includes assessing the neck, as the site of the 
regional lymphatics; the structures which, in health drain tissue fluid and, in 
cancer, act as the first defence against systemic dissemination. As indicated 
above, the neck may be electively accessed for microvascular anastomosis in 
which case the nodes are cleared as a matter of convenience. The lymphatic 
drainage of the neck is shown in Figure 2.4. 
 
Figure 2.4. Lymphatic Drainage of the Neck  
(from Gray’s Anatomy) 
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If there is evidence of lymphatic involvement and surgery is planned for the 
primary disease, then an operation known as ‘neck dissection’ is carried out. The 
most significant predictors are depth of invasion and tumour thickness (Spiro RH 
et al, 1986, Woolgar, 1999) and nodal metastases are most often seen in tongue 
and floor of mouth primary cancers. For other sites, the likelihood of regional 
metastasis increases with the size of the primary cancer (Byers et al, 1988). The 
lowest incidence of neck metastasis is seen in lower alveolar ridge cancers 
(Byers et al, 1981). Treatment planning in the MDT has to take account of these 
factors. 
The aim of a ND is to clear any cancerous lymph nodes. The operation causes 
specific morbidity by dissecting close to the accessory nerve, the nerve which 
plays a major role in shoulder function. It also results in stiffness and scarring of 
the neck and can impact on the lower branches of the facial nerve, resulting in a 
asymmetrical smile. Its place in H&N surgical therapy is well established and well 
supported by evidence from many prospective studies (Ferlito et al, 2009). 
Where the regional lymphatics contain cancer external beam therapy is used as a 
adjunct to surgery. From this discussion it can be seen that external beam 
radiotherapy can be given to the primary cancer site and/or the neck, usually 
commencing about six weeks after surgery. This is known as ‘adjuvant’ therapy. 
It is delivered in treatment ‘fractions’, i.e. a small dose daily, destroying the 
cancer by incremental damage, the principle being that normal tissue has more 
capacity to resist and recover from radiotherapy induced damage.  
The two principal modalities of therapy carry a very different side effect profile 
from the patient and carer perspective. Surgery leads to the worst functional 
status over the immediate post-operative period, followed by rapid progress over 
a few days/weeks and then a comparatively steady state. Radiotherapy continues 
to have therapeutic efficacy after the final fraction. It is usually administered as a 
28 day course with a small dose given each day, producing a cumulative effect. 
Normal tissues which have a high cellular turnover suffer the greatest side 
effects; hence the oral mucosa, mucosa of the gastrointestinal tract and the 
haematopoietic tissues are at risk. It is usual to suffer mucositis (inflammation of 
the oral mucosa), gastro-intestinal symptoms and fatigue. These peak at around 
two or three weeks after therapy, with gradual recovery. Because of the 
anatomical site and the need to protect key structures such as the brain, eyes 
and spinal cord  from  too high  a dose of  radiotherapy, it is usually  impossible to 
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spare the salivary glands from a dose of radiotherapy higher than their tolerance. 
As a result dry mouth and altered saliva are very frequently seen after therapy for 
H&N cancer. 
Treatment has been stable for many years, the most recent therapeutic revolution 
being the addition of free flaps to the surgical reconstruction repertoire in the late 
1980s and early 1990s.  The major change affecting all patients has been the 
increase in chemo-therapy in recent years after a major meta-analysis reported 
an 8% gain in overall survival (Pignon et al, 2000) and this has gained further 
momentum with a further confirmatory update analysis (Bourhis et al, 2004) and 
the advent of targeted therapies. For some sites, especially in the context of this 
study for oro-pharyngeal and laryngeal cancers, chemo-radiotherapy is often the 
first treatment, reserving surgery for treatment failures. In common with most 
cancer sites, the genomic revolution is beginning to provide therapies which are 
having an impact on clinical practice. The most advanced of these is cetuximab, 
a monoclonal antibody. binding to the Epidermal Growth Factor Receptor (EGFR) 
sites. EGF is over-expressed in up to 90% of SCCas and the seminal paper by 
Bonner (2006) showed improved survival in a late stage (Stage III-IV) cohort of 
patients. Treatment for patients in this study was completed before Cetuximab 
became available, however, awareness of these new agents and their mode of 
action and different toxicity profiles is an area which must be taken into account 
in considering tools to facilitate communication, 
This shift in therapies can be expected to continue as advances in molecular 
techniques identify ever more specific targets, allowing effective agents, 
potentially with lower morbidity to be introduced into clinical practice, adding to an 
ever changing and evolving experience of the patients and their carers who face 
this diagnosis. 
 
2.2.5 The Environment of Care and Clinical Pathway 
The clinical setting is the H&N multidisciplinary cancer network, based in the St. 
James’s Institute of Oncology on the St. James’s University Hospital site of the 
Leeds Teaching Hospitals NHS Trust. It brings together patients and clinicians 
from the Leeds Hospitals and also from the Mid-Yorkshire MHS Trust, delivering 
a service to a population base of over 1 million people in compliance with IOG. 
The MDT is one of the largest in the UK, in terms of both its size and complexity 
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and in terms of the number of patients managed through the service, seeing and 
assessing approximately 250 new patients per year, with a network of follow up 
clinics to which patients are returned once their acute care and early follow up is 
complete, separated both by speciality and geographical base. H&N represents 
one of the most complex clinical models as care is given by a number of 
specialities: clinical and medical oncology, maxillofacial, ENT and plastic 
surgeons and requires close integration with specialist pathology and radiology 
services.  
The core MDT is shown in Table 2.3. Out-patients in Leeds and Mid Yorkshire 
are currently managed in six clinics for H&N and two clinics for thyroid cancer, 
situated at six separate hospital sites. This arrangement complies with the 
guidance (DH, 2000) that major surgery and chemoradiotherapy should be 
delivered in Cancer Centres but follow up and support provided locally. Each 
clinician who delivers a local service attends and brings all of his/her patients to 
the weekly MDT meeting and clinic. Out-patient follow up is provided at the 
Institute of Oncology during the acute non-surgical therapy phase. Major in-
patient surgery is currently performed at the two main hospital sites in Leeds and 
diagnosis and surgery which does not require free tissue transfer is carried out at 
the Mid Yorkshire NHS Trust. Longer term follow up and support is provided in 
clinics at LTHT (Leeds General Infirmary and Leeds Dental Institute) and the Mid-
Yorkshire Trust (Wakefield, Dewsbury and Pontefract). Paper records are kept 
separately at each site. An electronic single record for every patient would have 
significant advantages. Such a system, Patient Pathway Manager (PPM), is in 
the process of being rolled out to all sites, allowing integration of records and 
access by all teams members, doctors, nurses and AHPs. The extended MDT, 
involving specialist nurses, speech and language therapists, dieticians and 
occupational therapists is particularly important at this site as treatment routinely 
impacts on key functions such as eating, speech and swallowing as well as 
having an aesthetic impact. These areas of care also very much rely on their 
own, paper based, record. H&N is accepted as being the most demanding site in 
terms of the impact of the disease on patients and the need for integrated care 
pathways is well understood. 
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Table 2.3 The structure of the H&N MDT 
HEAD AND NECK MEETING-ATTENDANCE FORM 
NAME TITLE SIGNATURE 
  
 
CONSULTANTS   
 CONS-RADIOLOGY  
 CONS-DENTAL RADIOLOGY  
 CONS MED ONCOLOGY  
 CONS ENT PINDERFIELDS  
 CONS-ONCOLOGY  
 CONS MAX FACIAL LGI  
 CONS PLASTIC SURG SJUH  
 CONS ENT LGI  
 CONS MAXILLO FACIAL  
 CONS MAX FACIAL PINDERS  
 CONS RESTORATIVE DENTIST  
 CONS MAX FACIAL LDI/LGI  
 CONS-ONCOLOGY  
 CONS RADIOLOGY-PINDERS  
 CONS ENT LGI  
PATHOLOGY   
 PATHOLOGY  
 PATHOLOGY  
 SPR PATHOLOGY  
REGISTRARS   
 SPR ENT  
 SPR MAX FACIAL  
 SPR PLASTIC SURGERY  
 SPR ONCOLOGY  
 SPR MAX FACIAL  
 SPR ENT  
  
 
 SPEECH & LANGUAGE THERAPIST  
 DIETITIAN  
 CNS PINDERFIELDS  
 CNS  
 H & N CO-ORDINATOR  
 CNS LEEDS  
 SENIOR RESEARCH NURSE  
 RESEARCH NURSE  
 SPEECH & LANGUAGE THERAPIST  
 DIETITIAN  
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2.2.5.1 The Patient Pathway 
Patients are referred to the H&N team via their General Medical Practitioners 
(GPs) or General Dental Practitioners (GDPs). Most GDP referrals are for oral 
lesions, of which approximately 50% are referred by doctors and 50% by dentists. 
Referral guidelines have been issued by the DH to assist the referral pathway, 
indicating areas of concern which should prompt a ‘fast-track’ referral. This 
system allows completion of a standard fax which, on receipt prompts an urgent 
appointment to be generated within the DH target time of 14 days. At each Trust, 
patients are seen by the appropriate specialist, an ENT or a Maxillofacial 
surgeon. The full patient pathway is shown in Appendix 2.1. 
At this visit, in addition to a full medical history, a detailed H&N assessment is 
carried out including examination of the neck for lymphadenopathy (enlargement 
of the lymph nodes) and careful inspection of the oral cavity, oropharynx and 
larynx. For the areas which are not immediately visible a flexible fine fibre optic 
tube (nasendoscope) is introduced through the nose and allows inspection of, 
although not biopsy of, the larynx. This also allows assessment of vocal cord 
mobility, an important feature in determining the extent of a laryngeal cancer. 
Careful palpation of all accessible areas is performed as some cancers, 
especially in the base of tongue, manifest only by subtle tissue thickening and 
firmness, rather than by visible features   
At this stage, some suspicious areas are amenable to biopsy (sampling of a small 
piece of tissue to reach a diagnosis through examination of a stained section by a 
Histopathologist) in the clinic under local anaesthesia. More posterior areas, such 
as oropharynx, base of tongue, larynx and pharynx will require examination and 
biopsy under general anaesthesia. 
Once the biopsy has been examined and a report issued by the Pathologist, the 
patient and his/her carer or family return to clinic. The diagnosis is given and the 
main therapeutic options are briefly outlined. All patients are advised that their 
care will be discussed and recommendations will be made by a MDT, in line with 
the core recommendations of the Cancer Plan, to enable a decision regarding 
therapy and whether or not treatment with curative intent is possible Figure 2.5 
shows the steps, from clinical inspection, through scanning to histopathological 
report. 
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Figure 2.5. A: Clinical presentation of Cancer  
 . 
 
 
 
 
 
a) Ulcerated SCCa                       b) SCCa arising in an area of premalignancy 
                                                           indicated by arrows. 
 
B. Magnetic Resonance (MRI scan)        C. Histopathology section 
 
 
 
 
 
 
 
The white area is the cancer                     The arrows show the cancer 
 
At the MDT the patient is presented by a member of the team who has been 
actively involved in the diagnostic pathway. An initial recommendation is made 
and key members of the MDT, usually a surgeon and an oncologist, together with 
AHPs, are identified who will meet and discuss options with the patient. 
Comorbidity and psychosocial issues are covered and, in an observational 
informal audit of 50 decisions which I carried out during the time I was recruiting 
patients to this study, 30 recommendations were influenced by these factors. The 
extent of the cancer as indicated by clinical examination and imaging (as in 
Figure 2.5.B) and the pathological characteristics (Figure 2.5.C) all have a core 
place in reaching a recommendation. 
At consultation a full discussion is held with the patient and carers and the 
options for therapy outlined as already described in section 2.2.4. A frequent 
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complicating factor at this stage is the need for dental treatment to remove teeth 
which lie in potential radiotherapy fields and which place the patient at risk of 
osteoradionecrosis, an highly unpleasant condition where the jaw bone becomes 
necrotic, non-healing and which is difficult to treat. A further consideration is 
management of nutrition and either nasogastric or PEG/RIG (percutaneous 
endoscopic gastrostomy / radiologically inserted gastrostomy) tube feeding has to 
be arranged and completed prior to definitive therapy. All of these interventions 
are known to be effective but they add to the patient burden at a time when they 
are coming to terms with the cancer diagnosis and its implications. Cancer 
targets require that the first definitive treatment is commenced within 30 days of 
definitive diagnosis, hence, for the patient this ‘waiting time’ can be a period of 
intense activity, dominated by hastily arranged hospital visits. 
Definitive treatment may be surgery or (chemo) radiotherapy alone in early 
disease as outlined above. Late stage presentation requires multimodality 
therapy. The therapeutic pathway for multimodality therapy may be as long as 12 
weeks, giving a significant physical, emotional and financial burden to both 
patient and families. 
At conclusion of the acute phase of management the patient enters an intense 
period of monitoring, to assist the management of specific side-effects, to be 
supported in coming to terms with life after cancer and to have surveillance for 
recurrent disease or the development of new H&N primary cancers. It was people 
in this surveillance phase who were invited to enter our study. 
 
2.3  Thyroid Cancer 
2.3.1 Epidemiology 
There are four main types of thyroid cancer: papillary, follicular, medullary and 
anaplastic. Of these, the most common type, accounting for around 60% of 
diagnoses, is papillary cancer which is more common in women and in younger 
people. It is usually slow growing and presents as a lump in the neck. Follicular 
cancer, about 15% of cases, affects young or middle aged people and is more 
likely than papillary to undergo metastatic spread, usually to the lung or bones, 
Medullary  cancer  is  quite rare  (5-10% of thyroid cancers)  and  about  25%  of  
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such cancers have a genetic basis as part of the MEN (Multiple Endocrine 
Neoplasia) syndromes. The remainder, about 15%, are anaplastic, meaning they 
no longer carry the  morphology of thyroid tissue These cancers arise in older 
people (75% over 60 years of age) and carry a poorer prognosis (Cancer 
Research UK, 2009).  
 
2.3.2 Management of Thyroid Cancer 
The pathway is broadly similar to H&N cancers however the key difference is that 
lumps in the thyroid gland are common and often the diagnosis of cancer is made 
after the surgical removal of part of the thyroid gland (lobectomy). Depending on 
the characteristics of the cancer, further treatment can include removal of the 
residual thyroid gland, the giving of radio-iodine (the gland takes up iodine so 
delivering targeted radiotherapy in this way is highly effective) and/or external 
beam radiotherapy.  
The anatomy of the thyroid gland and related structures is shown in Figure 2. The 
gland lies anteriorly in the neck, close to the great vessels. The vagus nerve, 
which has a branch passing immediately behind and to the side of the gland is 
responsible for moving the vocal cords and thus allowing the airway to function. 
The parathyroid glands lie immediately behind the thyroid gland and are 
responsible for calcium homeostasis. Lymphatic drainage is to the neck as for 
head and neck but to the lower levels of nodes. 
 
Figure 2.6. Anatomy of the Thyroid Gland  (from Gray’s Anatomy) 
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The parathyroid glands which control calcium metabolism are situated just behind 
the thyroid gland and often buried in its substance so removal of one or more 
parathyroids is a risk in extensive surgery. The recurrent laryngeal branch of the 
vagus nerve (noted above) is also in close proximity For these reasons 
thyroidectomy is usually done at subtotal level. 
Papillary and follicular cancers retain the ability of the parent thyroid tissue to 
take up iodine. This is used as the basis for radio-iodine therapy, often after 
thyroidectomy, to ablate any residual cancer. Medullary and anaplastic cancers 
do not respond to radio-iodine and external beam radiotherapy is given for 
extensive or recurrent disease. The result is that the morbidity for the most 
common cancers relates to the removal of the functioning thyroid gland and, 
potentially, parathyroid tissue with symptoms of fatigue, lethargy, weight gain, 
constipation and dry skin consistent with a state of hypothyroidism. For this 
reason, thyroxine replacement is a core part of management, monitoring thyroid 
hormonal and calcium status and correcting accordingly to maintain good status 
and, hence, QoL.  
 
2.3.3 The Clinical Pathway 
Core strategy documents for thyroid cancer are the same as for H&N as 
management is often undertaken by the same MDT. This is not the case in Leeds 
/Mid-Yorkshire although some members of the H&N MDT are also members of 
the thyroid MDT. The thyroid MDT meets fortnightly and differs from the H&N 
team in that it manages patients from the whole of Yorkshire. The main clinical 
input is from Clinical Oncologists who manage radio-iodine ablation and external 
beam radiotherapy and from specialist surgeons who carry out cancer thyroid 
surgery. As for H&N, centralisation of services is being driven by the 
recommendations of the IOG, with a smaller number of clinicians managing more 
patients. 
The follow-up pathway is less intense than that for H&N reflecting the nature of 
the cancer. Care is often shared with the GP in terms of assessing thyroxine and 
calcium levels and managing prescribing. 
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In summary, the outcomes, especially for papillary and follicular cancers, tend to 
be good with most patients entering long term remission. The population tends to 
be a younger one than seen for H&N cancer and one would predict that the QoL 
outcomes are likely to be different. 
 
2.4  Health Related Quality of Life in Cancer and in Head and Neck 
and Thyroid Cancer. 
Health related quality of life [QoL] in cancer is an expanding field of interest. Over 
the past twenty years the clinical care of H&N cancer patients has developed 
significantly. The pace of change in medical technology is such that new 
interventional procedures and treatments will continually require evaluation. 
These developments give impetus to initiatives to understand the patient’s 
experience and the impact of the disease and its therapy on the patient and 
his/her family. Decisions involve not only the greatest probability of cure but also 
judgements about the morbidity associated with treatment options. To ensure that 
treatments are used in the best way there is a need to focus not only on local 
disease control and survival but on the experience for the patient in terms of the 
effects both of the treatment and potential longer term morbidity. QoL studies aim 
to evaluate this aspect of patient care. In H&N cancer, patients and their 
clinicians face considerable variation both in the disease and in the therapy 
given. To facilitate best care, any investigation of QoL should reflect the 
experience of the patient group as a whole but also be sensitive to the needs of 
individuals. Although there is a substantial literature of H&N cancer, thyroid 
cancer is a disease which has seldom been addressed. In this section I will 
consider H&N cancer and then thyroid cancer with an emphasis on evidence 
which relates to the impact of the conditions and how this changes with time from 
diagnosis. The sources of information used in this section are: 
• personal library derived from a long term interest in this area. 
• conference abstracts and communications. 
• literature searches carried out at intervals during this study, using Medline     
         and search terms: ‘quality of life;, ‘head and neck cancer’, ‘oral cancer’,    
         ‘larynx   cancer’. These yielded a large number of studies, often of small  
         numbers and often a mix of clinical factors and QoL.  
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The search strategy is shown in Table 2.5. 
I have, therefore, been selective in the papers quoted here, limiting inclusion to 
those which I considered were related to the aims of my study, after manually 
reviewing those papers identified by the search 
 
Table 2.5 Search Strategy for Literature Review, QoL H&N and Thyroid 
Cancers 
Searches Results 
1 Quality of Life.mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier] 117908 
2 Quality of Life.mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier] 117908 
3 limit 2 to (english language and humans)   97824 
4 (Head and Neck Cancer).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier]    9459 
5 4 and 3      694 
6 Laryngeal Cancer.mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier]    3375 
7 limit 6 to (english language and humans)    1788 
8 3 and 7      104 
9 oral cancer.mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier]    4713 
10 limit 9 to (english language and humans)    3839 
11 3 and 10       99 
12 Thyroid Cancer.mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier]    8293 
13 limit 12 to (english language and humans)    6399 
14 3 and 13       98 
15 from 8 keep 2, 8-9, 18, 22, 25-27, 32-33...       33 
16 from 14 keep 1, 6, 8, 11, 21, 30...       11 
17 from 11 keep 19, 23, 39-40, 42-43, 66, 68...       14 
18 from 17 keep 1-10       10 
 
I will commence this section with an appraisal of the one comprehensive study 
which looks at the views of patients and health professionals in detail, that of 
Edwards (1997). 
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2.4.1 QoL and Patient and Health Professional Opinions, the 
Edwards’ study 
The most detailed consideration of patients’ views in the field of H&N cancer care 
remains that of Edwards (1997). As this study is unique in its exploration of the 
views of patients, their carers and of health professionals I will cover its findings 
in some detail  The author considered a number of issues which were part of my 
study and prioritised some common issues, some which fall outside the remit of 
my work, emphasising the importance of a continuing dialogue with patients and 
their carers. 
The main findings were summarised as: 
• inpatient accommodation was often inappropriate. The main need was to 
be on a ward with privacy and where others faced the same treatments and 
nurses experienced in their care. 
• internal communication and co-ordination of care. 
• information on what to expect and on the side-effects. People wanted to be 
involved in treatment options. Choice was a contentious issue. 
• a need for someone to listen and advise. Psychosocial needs to be 
acknowledged and support made available and accessible to patients, 
relatives and professionals. 
• teamwork was valued. 
• the proposed changes to cancer care (Expert Advisory Group Report 
[EAGR]) were welcomed. 
This report matches the narratives of the patients in terms of the need for good 
internal communication and for information on what to expect. It adds weight to 
the EAGR emphasis on the importance of psychosocial issues and on teamwork 
and appropriate facilities with care by staff experienced in meeting their needs. 
Considering the aims of Edwards’ seminal study, these were: 
•  to document patient experiences of UAT (Upper Aerodigestive Tract) 
cancer and cancer care. 
•  to explore patient and carer views of UAT cancer services. 
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•  to explore professional views of UAT cancer services. 
•  to suggest ways in which these services could be made more patient 
focussed. 
The study used focus groups with patients and carers and separately, with 
professionals. There are similarities with my study here but I allowed, for 
convenience, carers to be present at interviews and to contribute to the opinions 
expressed and undertook in depth interviews with individual professionals. 
In the narrative of patient experience it is noted that most people were given their 
diagnosis in the presence and with the support of a family member. This is in 
accord with the practice of our MDT members. This approach had the support of 
participants in Edwards’s study as did the breaking of bad news ‘honestly, openly 
and sensitively’. The treatment itself was the least controversial and some who 
had surgery were surprised at how little the scars showed. The areas of concern 
were about insufficient information or choice about treatment and side effects or 
the giving of conflicting information. Again, here, the concerns raised in the 
patient narratives from Chapter 1 are echoed.  
The next area of concern was unexpected adverse effects or complications of 
treatment. These were often blamed on the condition rather than the clinician. 
However, several people had post-operative complications which were not 
detected early enough. The worst of these was that one woman lost her leg. 
Considering the tension between questionnaires designed for population use and 
individual experience, this episode emphasises the difficulties. In a 
psychometrically valid instrument, it is unlikely that donor site morbidity would be 
included. This has certainly not been the case to date. 
Patients judged success of treatment not only on whether their cancer was gone 
but how they could live and their quality of life. One woman had a first 
reconstruction which would have resulted in little morbidity but the graft did not 
take. The second operation allowed healing but left her unable to eat and 
disfigured, again an experience difficult to capture and including donor and 
recipient site morbidity. These facets of individual experience, specifically surgical 
matters, need to be considered in recording QoL at individual level. 
The period around discharge was felt by patients to be challenging as the routine 
and support of the ward or radiotherapy team was put behind them. After 
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discharge the frequency of review was initially welcomed as a chance to keep in 
touch with hospital based support but later as a burden with participants reporting 
that they spent almost all their lives at the hospital. The consideration is whether 
new technologies, if they allow communication, could ease this burden. 
From the professionals’ viewpoint, team working was felt to be important and 
communication and organisation of services. Challenges to this were the urgency 
of treatment and managerial separation of services which needed to work 
together. They welcomed the EAGR proposal of services in a setting with 
specialist expertise. However there remained a tension between centralisation 
and accessibility, a tension which persists today. 
They considered that the principles of ‘gold standard’ therapy were: 
• to treat the person with cancer as an individual respecting their needs and 
wishes. 
• give the best possible clinical care. 
• involve patients in their care. 
• have an open and caring attitude. 
• work as a team. 
• have good communication skills. 
• provide information on what to expect and on the side effects of treatment. 
Again familiar themes are emerging and these were taken into account in 
designing the questionnaire relating to the wishes for and perceived content of 
consultations which are the main part of Chapter 6. 
The main physical impacts were pain, in the acute phase, often associated with 
radiotherapy rather than surgery, eating, often related to dry mouth and the pain 
associated with mucositis and weight loss. Other physical problems reported 
were fatigue, difficulty in speaking, hearing and tinnitus. In this study people were 
open about the everyday things they could not do including licking their lips for 
lubrication or licking stamps, kissing, opening their mouths, moving limbs from 
which flaps had been harvested and, in the one case already mentioned, losing a 
limb. In terms of the emotional journey embarrassment, shock, anxiety and 
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depression and the social impact were all reported as major aspects of life with 
and after H&N cancer.  
This study gives a unique insight into H&N cancer from the point of view of both 
patients and carers and health professionals, a plan for research which I have 
attempted to emulate in my work.    
2.4.2  Health Related Quality of Life Studies in Head and Neck Cancer 
In this section I have considered the literature in the context of what we learn 
about the QoL of patients with head and neck cancer throughout their cancer 
journey. In the context of the study I was interested in use of the established 
questionnaires, identification of common or specific problems and the pattern of 
QoL findings with progression from the acute into the follow up phase. 
As my study has concentrated on two H&N sites, oral/oropharyngeal (Oral) and 
laryngeal (Larynx) I searched for papers which also related to these specific H&N 
sites as well as more general papers, with an emphasis on determining the QoL 
measures used in the literature and also the longer term concerns of patients. 
Hammerlid, Bjordal et al undertook a series of prospective studies which followed 
the self-reported QoL status of a cohort of H&N from diagnosis to 5 years post 
therapy using the European Organisation for Research and Treatment in Cancer 
core (EORTC QLQ C30) and H&N modules, QoL was assessed at 1,2,3,6 and 12 
months after therapy. In the first report (Hammerlid et al, 2001a) findings from 
357 patients (mean age 63, 72% males) were presented and site specific 
differences at diagnosis related to communication for laryngeal patients and pain 
for oral cancer patients. Those presenting with late stage disease reported 
significantly worse QoL over a range of domains. At 12 months (Bjordal et al, 
2001), 68% of the surviving patients (218/280) completed questionnaires. QoL 
deteriorated significantly during treatment, followed by a slow recovery up to 12 
months, except for senses, dry mouth and sexuality. Stage remained an 
important factor. Hammerlid et al (2001b) reported outcomes at 3 years, adding 
HADS to the EORTC measures. By this time QoL scores had returned to pre-
treatment levels, with few exceptions. The greatest improvements were for 
mental health but significant deteriorations were recorded for dry mouth, senses, 
teeth and mouth opening. The difference between early and late stage responses 
gradually increased over time with stage remaining the most significant predictor 
of longer term QoL. Age and gender had little effect. Findings remained similar at 
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the end of five years (Abendstein et al, 2005). The cancer patients were 
compared with a general population, using SF-36 (Hammerlid et al, 2001c) and 
scores did not differ much from age/sex matched controls. Fang et al (2004) also 
compared SF-36 scores for oral cancer patients with population norms (Taiwan) 
but found that scores for the cancer patients remained lower, especially for older 
patients, those with lower incomes, the unemployed and, again, those presenting 
at a later stage. Rogers et al (1998a and b) used SF-36 and the University of 
Washington QoL questionnaire (UWQoLv4) and found, in a group of 50 
consecutive patients who had had primary surgery for oral cancer, that status as 
reported by almost all domains fell by three months post-therapy but improved up 
to one year. This combination of SF-36 as a general measure with UWQoLv4 
was considered suitable for comparative studies. They also looked at site specifc 
differences using the same questionnaires plus the EORTC QLQC30 in a 
consecutive population of 130 patients, finding that there were site specific 
differences in QoL (Rogers et al, 2000).  
For oral cavity cancers there has been an emphasis on outcomes after radical 
surgery, given the major role of such surgery in management and also on 
shoulder function as these patients have a neck dissection as part of their 
operation. There has been interest in the use of QoL measures to predict 
outcome  We looked at a series of oral cancer patients treated by primary surgery 
(Rogers, Fisher et al, 2002) finding that the main predictor of QoL was the size of 
the resection, which correlates to stage. Markkanen et al (2006) reported similar 
findings. Rogers et al (1999) considered the UWQoL as a predictor of outcome 
and again related poor scores to stage and also to poor outcome, which also 
correlates to stage. Wilgen et al (2004) and Rogers et al (2004) reported that 
shoulder and neck morbidity are important determinants of QoL for patients who 
have had neck dissection. Long term survival remains linked to reduction in QoL 
domains assessed by EORTC, Functional Adaptation to Cancer Therapy General 
and H&N measures (FACT-G and H&N) and UWQoLv4 questionnares, especially 
for dry mouth, mouth opening, shoulder function, chewing, speech and teeth. The 
results at one year predicted the long-term areas which would continue to score 
poorly (Nordgren et al, 2003, Rogers et al, 1999c, Smith et al, 2005). 
For laryngeal cancer there is an emphasis on voice preservation strategies 
versus laryngectomy. Trivedi et al (2008) used FACT-G and FACT-H&N in a 
group of 40 patients and found comparable scores in both groups, although ‘dry 
mouth’ was slightly worse in the non-surgical group and ‘ability to communicate 
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with others’ was worse for the laryngectomy group. Boscola-Rizzo et al (2008) 
used the EORTC questionnaires for long term QoL evaluation and found 
significant results in favour of non-surgical therapy for physical function, role 
function and global QoL. Surgical patients reported problems with senses, social 
contact and speech whereas the chemoradiotherapy group reported greater 
problems with dry mouth and saliva. Singer et al (2009), in a larger study (323 
patients) to validate the EORTC QLQ C30 and H&N modules for post-surgical 
laryngeal cancer patients found that the questionnaire was able to differentiate 
groups. 
Psychological issues are acknowledged to be important for this patient group 
because of the impact of the cancer on social function and integration as well as 
the challenges common to all cancer patients and their carers. We found that the 
adjustment begins at the beginning of the cancer journey (Shepherd and Fisher, 
2004) with realisation of the impact but also concern about longer term survival 
and return of the cancer. Hodges and Humphris (2008) recently reported 
concerns about fear of recurrence (FoR) in H&N patients and their carers with 
carers reporting higher levels than patients. The literature on this aspect of 
cancer management has gained prominence in recent years and I will return to 
this in more detail in later chapters when considering the patient priorities which 
have emerged from the interviews (Chapter 7). In this section I am considering 
the use of questionnaires to measure distress and Rose and Yates (2002),  
Jenewein et al (2008), Llewellyn et al (2008) and Singer et al (2009) used the 
HADS questionnaire amongst other measures. Rose and Yates reported levels of 
‘caseness’ for depression of 41.3% by the final week of non-surgical treatment, 
reducing to 29.9% by three months after therapy. Jenewein et al (2008)found 
better scores and less distress in patients who were in strong marital 
relationships. Llewellyn et al (2008), comparing oral (n=115) and throat cancer 
(n=47) patients and a group with benign H&N pathology (N=33) against an age 
matched normative sample did not find any effect on cognitive or emotional 
adaptation. Singer et al (2009), however, placed the relative frequency of mental 
disorders at 19.8%. The HADS gave the best sensitivity and specificity for the 
measures compared in their study. Aarstad et al (2005) looked in detail at mood, 
anxiety and sense of humour comparing their cancer population (n=78) with 
patients suffering benign H&N disease (n=61). They found more anxiety and 
depression in patients with more advanced disease and scores at diagnosis 
predicted outcome. 
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From these papers, Hodges & Humphris (2008) and Singer (2009) have 
emphasised the need for screening for mental disorder and managing this early 
in the cancer journey. Humphris (2008) has brought the evidence together to 
make a case for inclusion of a psychologist in the H&N MDT.  
 
2.4.3  Health Related Quality of Life Studies in Thyroid Cancer 
In this section I have considered the literature in the context of what we learn 
about the QoL of patients with thyroid cancer, throughout their cancer journey. 
Although the number of studies was limited, precedents were found for my 
intended use of questionnaires to explore the QoL status at this cancer site. Tan 
et al (2007) used the SF-36 to compare thyroid cancer patients (n=152) with a 
non-cancer population finding a reduction in physical functioning in patients aged 
over 50 and that being employed had a positive influence on role physical and 
role emotional scores. They recommend active recommendation of return to 
work. Almeida et al (2009) used the UWQoLv4 to assess a population of 154 
patients. Patients who had had neck dissection reported worse chewing and 
shoulder scores and those who had more than 150mCi of radiotherapy reported 
significantly worse pain, swallowing, chewing, speech, taste, anxiety and 
composite scores. 
Other papers looked at the effects of therapy. Dagan et al (2004) also used the 
UWQoL with similar findings to those above but also related the results to thyroid 
status and found that distress increased significantly during periods of hormone 
withdrawal during periodical imaging, which could have a physiological basis but 
could also be related to concern about the need for and possible result of the 
scan. Global low (good) scores were found in those patients who were in work 
and for those on effective  thyroxine replacement therapy. Tagay et al (2006) also 
related short term hypothyroidism to poor Qol scores using the SF-36 and Taieb 
et al (2009) reported similar results using the FACT-G modules and FACIT-F, 
which measures fatigue. Schultz et al (2003) related QoL responses to somatic 
symptoms reporting musculoskeletal and psychological problems as the most 
prevalent and troubling. On psychological impact, Larisch et al (2004) related 
hormonal imbalance to critical mood deterioraton. 
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2.4.4  Summary of QoL Literature 
For the H&N groups there was a consensus that H&N patients report a decrease 
in QoL as measured by validated questionnaires from therapy to three months 
with a return towards pre treatment levels by one year, although some deficits 
remain and patients presenting at a late stage report worse status and continue 
to do so. Despite increasing use of non-surgical treatments, the evidence 
suggests long term reduction in QoL due to specific side effects of therapy for all 
patients. The psychological impact of H&N cancer is important. 
For thyroid patients the establishment of a euthyroid state has been shown to be 
important for both physical and psychological well being. 
Both cancer sites showed diminished QoL scores in some aspect of assessment 
over a range of measures. I did not find any study which included thyroid patients 
as part of the broader category of H&N.  
In designing my definitive study, I took note of these findings and of the measures 
used in the studies reported and will develop this aspect of the study further in 
Chapter 4. 
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CHAPTER 3 - The Pilot Study 
3.1 Aims and Objectives  
The aim of the pilot study was to determine whether use of a H&N QoL 
questionnaire might assist in the care of patients in a H&N clinic. Objectives 
included an exploration as to whether and, if so how, the questionnaire had an 
effect on consultation, whether it was used by doctors and whether they found it 
helpful and whether issues raised were or were not already addressed in the 
standard consultation.  
 
3.2 The Clinical Setting  
The MDT, at the time of the pilot study, was based in the H&N Oncology Out-
Patient Department of Cookridge Hospital, a specialist Cancer Hospital situated 
in the outskirts of Leeds. The patient population and team structure was as 
already described in Chapter 2. This study took place at a time of transition. 
Historically the team had been divided into an oral cancer team with maxillofacial 
surgeons and a specific oncologist and a laryngeal service with ENT surgeons 
and a specific oncologist and each consultation was attended by all AHPs who 
might have a place in treatment or patient support.  With increasing centralisation 
of care, the MDT had increased in both size and complexity. In a satisfaction 
survey, led by our CNS, patients reported that they found the presence of an ever 
growing team of health professionals at their consultation intimidating and that 
they preferred to be seen by a limited number of people whose expertise was 
core to their immediate management. After this change some members of the 
team felt referrals for specialist help and support may not be directed efficiently 
and consistently. If they were excluded from consultations, they worried that they 
may miss some patients who might benefit from their expertise. 
One possible answer appeared to be the use of a questionnaire to provide an 
assessment of patients’ needs and a simple study was designed to explore the 
place and acceptability of such an approach. 
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3.3  Method 
A number of prospective questionnaires were identified through a review of QoL 
instruments for use in oral cancer (Rogers, Fisher & Woolgar, 1999) In this 
review a Medline search identified 21 studies of QoL in H&N cancer and 9 in oral 
cancer. These could be grouped into four main groups: global and broader 
dimensions, general cancer, H&N cancer specific and H&N performance (specific 
physical functions). Candidate questionnaires identified by this classification 
were: 
• Global measures: General Health Questionnaire (GHQ), Global 
Assessment of Recent Stress, Health Index, Hospital Anxiety & Depression 
Scale (HAD), Karnofsky Performance Index, Life Satisfaction (LS), Medical 
Outcomes Study Short-Form 36 Item Health Survey (SF-36), Memorial 
Symptom Assessment Score, Sickness Impact Profile (SIP), Spitzer Quality 
of Life Index (QL-Index). 
• General cancer measures: EORTC Quality of Life Questionnaire (EORTC 
QLQ C30), Functional Assessment of Cancer Therapy Scale (FACT-G), 
Functional Living Index (FLIC), Rotterdam Symptom Checklist (RSCL), 
Quality of Life Index. 
• H&N specific: EORTC Quality of Life H&N module (H&N 35), Functional 
Assessment of Cancer Therapy- H&N subscale (FACT-H&N), Functional 
Status in H&N Cancer (FSH&N-SR), H&N Specific Quality of Life 
(H&NCSQL), H&N Survey (H&NS), McMaster University Head & Neck 
Radiotherapy Questionnaire, Quality of Life Questionnaire, University of 
Washington Quality of Life Scale (UWQoL). 
• Performance measures: Functional Intra-roal Glasgow Scale, Obturator 
Function Scale.  
A further literature search did not identify further available instruments in common 
use in H&N practice. To decide a short-list we, as a MDT development group, 
decided that the global measures were too general and that the performance 
measures were too specific. The remaining measures were photocopied and 
distributed to MDT members and comments requested. A pilot group of 20 
patients with H&N cancer were approached by the CNS as part of a separate 
qualitative research study and asked for their opinions on important issues to 
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address in clinic. Following completion of these preparatory tasks a MDT meeting 
was held to which all members were invited and at which all specialist groups 
were represented. 
The group was asked to comment on available questionnaires and following 
discussion selected, by a well supported consensus, the University of 
Washington v4 (UWQoLv4) as the preferred questionnaire, considering that this 
instrument covered the issues most commonly raised by patients, was simple in 
both structure and wording and capable of completion without assistance. This 
questionnaire combines a series of questions relating to common problems for 
H&N patients, followed by a choice of concerns from which patients are asked to 
select the three most relevant to their experience. The questionnaire closes with 
a self-assessment of current and past QoL. 
However, certain important issues were noted to be absent or included with 
insufficient clarity. For example, the questionnaire contains a question about 
eating whereas patients might be tube fed, use a mixture of tube and oral feeding 
or oral feeding alone and it was considered that this question was confusing. A 
decision was taken to add a box to indicate whether or not tube feeding was 
employed. Other issues patients had stated were important included social 
eating, sticky saliva, lymphoedema and nausea. Questions related to these areas 
were phrased in the style of the questionnaire and added. The questionnaire in 
its adapted form is appended [Appendix 3.1]. 
We wished to explore at what level of response we should pursue individual 
concerns with patients. At the time of this study there was no literature on the use 
of ‘cut-off’ scores. We used the MDT members as an expert group and reached 
an ‘a priori’ consensus on ‘cut-off’ scores. Scores at a level which were agreed to 
indicate concern are shown in red in Appendix 3.1.  
Approval for the study as described below was granted by the Chairman of the 
Leeds West Research Ethics Committee (Leeds Research Committee ref 
074aw/jl),   
A cross sectional study was undertaken over a 12 week period in early 2002, 
inviting patients attending the MDT clinic to complete a single questionnaire 
assessment. We aimed to obtain a sample of convenience on which a definitive 
study could be based. On arrival, all follow up patients were handed a letter of 
information and a paper version of the questionnaire to complete prior to their 
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medical consultation. No assistance was offered in completing the questionnaire, 
to test its suitability for use in a routine setting. 
Patients gave the clinician their completed questionnaire at consultation. 
Afterwards, patients and clinicians were asked to complete a simple form rating 
its usefulness and acceptability [Appendix 3.2] 
I collected, collated and scored all questionnaires. Patients with low overall 
scores, with a low score in a specific domain or who asked for help in a specific 
area were contacted by the CNS, who reported back on the outcome of the 
intervention. 
Data was analysed using SPSS v11; using descriptive methods to determine the 
main issues in the patient population and the frequency with which responses fell 
below the ‘a priori’ cut off level. Items of missing data were corrected to the group 
mean. 
The CNS reported the concerns raised by the subset of patients who had 
specifically requested contact. 
 
3.4  Results 
3.4.1 UoWQoLv4 Questionnaire 
171 eligible patients were identified from clinic lists. 152 agreed to enter the 
study; reasons for refusals were not formally documented. After exclusions for 
errors in completion, 146 questionnaires were suitable for full analysis, giving an 
81% response rate.  
The demographic data [Figure 1] indicated that this population was comparable 
with other similar studies.  
Site was recorded in all cases. These were classified as oral [58], ENT [61], 
salivary gland [12], thyroid [8] and other [7]. Within these groups the two most 
common sites were tongue [23 cases], and larynx [43 cases]. ‘Other’ describes 
patients presenting with a neck lump; in whom, despite examination under 
anaesthesia, surveillance biopsies and full scanning, a primary tumour was never 
found. 
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Therapy was most commonly combined; i.e. surgery followed by radiotherapy [66 
cases], radiotherapy alone in 48 cases, surgery alone in 21, brachytherapy in 8, 
followed by surgery in 1 case; 2 patients did not have details of their therapy 
recorded. Time from completion of treatment varied from 1 to 144 months, with a 
median of 7 months. 
Figure 3.1 Patient Demographics 
   
The scoring was interesting in that there was considerable variation amongst 
categories. Patients would often score highly in some, then dip below the 
‘problem’ line in others or in a single domain.  The relationship between scores 
and the ‘cut off’ values is shown in Figure 3.2. 
117 patients [80%] fell below the previously agreed cut off point in at least one 
area. 29 patients [20%] scored above the cut off in all areas. Patients were most 
likely to state activity and recreation [44 patients] as problem areas, followed by 
social eating, taste, quality of saliva and pain. Later in the questionnaire they 
could indicate which areas were most important for them. 97 patients 
commented; identifying taste [32], social eating [32], sticky mucus/secretions [29], 
swallowing [26] and speech [23]. Two of these, social eating and sticky mucus 
had been added by members of the MDT during the development phase. 
Anxiety was reported by 29% and depression by 35%. The final part of the 
questionnaire asked patients to rate their overall QoL. This was rated as good by 
49% and fair to poor by 41%. 
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Figure 3.2. Issues from scoring 
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40 patients were identified by direct request for help, for contact by the CNS. 
Figure 3.3 shows the areas reported as being of concern to those patients. 
As in other studies in this area, the most common problem was psychological 
distress. However, in contrast to those studies, in this one we are looking at 
unmet rather than population need. The CNS reviewed the records and 
contacted the patients identified as requiring help in the same way as she would 
have done had the issue been identified during the consultation.  
10 patients, including the 8 citing sexuality/body image as areas of concern, were 
already having the issues identified addressed. For the remaining 30, 
interventions as a result of the study were new; these included referral to GPs, 
benefits agencies, charitable funds, physiotherapy and follow up by the CNS.   
Figure 3.3. CNS Feedback on Patient Interventions 
CNS Intervention required
anxiety +/or 
depression
44%
smoking 
cessation
24%
trismus
8%
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8%
social
8%
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40 patients
 
QoL in Individual Patients  Chapter 3 
53 
 
 
3.4.2 Patient and Clinician Feedback 
147 full responses were received from patients. Feedback was positive. 57% 
considered the questionnaire helped them talk to their doctor whereas only 7% 
felt it hindered the consultation. 70% wished us to continue using the 
questionnaire and the 6% who gave a negative response had all reported 
depression. Informal feedback indicated that patients felt that a more individual 
view was being taken of their status and that the questionnaire reminded them of 
issues that they may otherwise not have raised.  
 
Figure 3.4. Patient Feedback on Questionnaire Use 
Results
NO
7%
NO ANSWER
36%
YES
57%
Helped talk to the doctors?
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NO
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NO ANSWER
24%
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70%
Continued use?
147 responses
Patient feedback
 
Feedback from clinicians was disappointing, with returns relating to only 39 
consultations being received. Returns varied between members of the team. All 
returned at least one feedback form and returns were evenly divided between 
specialist areas, except for Plastic Surgery which had the lowest return (1), 
however this did result in a new intervention, the only one recorded by a clinician. 
Of these returns, in 18 consultations use of the questionnaire was rated as 
‘helpful’ or ‘very helpful’, in 8 it had interfered with priorities and the one noted 
above recorded an additional intervention (referral of one of the patients who had 
responded negatively to use of the questionnaire and indicated depression for 
psychiatric assessment). Informal feedback, from all clinicians, was that the 
process of using the questionnaire was too time consuming and that, for most 
patients, there was no effect on management.   
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3.5  Discussion 
This study showed: 
• The majority of patients scored below our ‘a-priori’ cut off level in at least 
one area.  
• Despite a coherent MDT, patient needs were not always met, 30 out of 146 
patients [21%] gaining an additional intervention as a result of the use of 
the questionnaire. 
• Patients often had isolated areas of concern and need. At individual level it 
is important to look at each question and domain rather than the total score. 
Resource implications limited CNS contact to those who scored below our 
predetermined cut off level in more than one area or who had a baseline 
[lowest possible] score in a specific question and confirmed a wish for 
further contact..   
• Patients welcome a questionnaire assessment. 
• Clinicians did not integrate the questionnaire into their patient assessment 
at a useful level for analysis. 
Our choice of questionnaire was pragmatic, by team (investigator) preference. 
Whilst this is in accord with many recommendations we did not follow the 
established practice of combining a general cancer measure with a H&N specific 
measure and we may have failed to identify a number of concerns as a result. 
However, given the number of previously unidentified problems found in this 
study, this limitation did not influence the conclusion that the questionnaire might 
assist in helping patients identify their needs. 
Because of the cross-sectional nature, it was not possible to assess whether 
some issues considered important by patients remained constant or were 
transient. There was a clustering towards the early period after therapy as the 
MDT policy is to return patients to their local clinic as soon as their condition is 
stable. This would have the effect of bias towards the most dependent population 
and it is accepted that patients’ QoL scores are lowest at 6 months, returning 
towards pre-treatment levels by 1 year (de Graeff et al, 2000, Rogers et al, 2002). 
Despite this bias, the level of problems reported was much higher than that 
anticipated in the team discussions during the preparation phase. We were 
limited by resource in the level to which we could explore those concerns but had 
anticipated that the questionnaire findings would reinforce our information on 
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those patients we knew to be struggling. The emergence of new, unmet need 
was a matter of concern. Although new initiatives were undertaken by the CNS 
according to her normal practice, i.e. taking the action she would have done had 
the issue been reported through a consultation rather than identified via the 
questionnaire, it is not possible to determine how effective the interventions were 
in meeting the patients’ needs, however we would expect the areas addressed 
would form part of normal patient care. 
Clinician returns were disappointing, especially in an environment in which 
support for the research and for QoL assessment was considerable. At the time 
of the study, there were vacancies in key posts and staff members were hard 
pressed. They reported insufficient time and that the questionnaire was unlikely 
to directly affect medical decisions. This mirrors the findings of Mehanna and 
Morton (2004) who reported that only 34% of H&N cancer clinicians had ever 
used a QoL measure, because use was too time consuming and there was no 
proven benefit for patient care. Our limited return from clinicians indicates the 
need for MDT members to perceive gains from the provision of information 
provided by the questionnaire. Mehanna and Morton reported that 88% of their 
clinical colleagues would favour the use of a ‘core’ questionnaire, with a clear 
structure and a limited number of questions.   
Despite these shortcomings, the study indicated that the use of a carefully 
designed QoL questionnaire has potential to improve the care of patients 
attending a H&N clinic.  
As a result of these findings, a definitive study was planned in an attempt to 
identify the best questionnaire; from the patients’ and clinicians’ point of view.  
The principles underpinning the design of this study are considered in Chapter 4 
and the detailed methodology and conduct of the study in Chapter 5. 
  
QoL in Individual Patients  Chapter 3 
56 
 
 
Appendix 3.1 
 
 
University of Washington Quality of Life 
Questionnaire (UW-QOL v4) (modified for pilot study) 
 
Cut-off values: red= a problem, below cut-off score, green= above cut-off score. 
 
This questionnaire asks about your health and quality of life over the past seven days.  
Please answer all of the questions by ticking one box for each question. 
 
1. Pain.  (Tick one box:  ) 
 
   I have no pain. 
   There is mild pain not needing medication. 
   I have moderate pain - requires regular medication (e.g.       
paracetamol). 
   I have severe pain controlled only by prescription medicine (e.g. 
morphine). 
   I have severe pain, not controlled by medication. 
 
2. Appearance.  (Tick one box:  ) 
 
   There is no change in my appearance. 
   The change in my appearance is minor. 
   My appearance bothers me but I remain active. 
   I feel significantly disfigured and limit my activities due to my 
appearance. 
   I cannot be with people due to my appearance. 
 
3. Activity.  (Tick one box:  ) 
 
   I am as active as I have ever been. 
   There are times when I can't keep up my old pace, but not often. 
   I am often tired and have slowed down my activities although I still 
get out. 
   I don't go out because I don't have the strength. 
   I am usually in bed or chair and don't leave home. 
 
4. Recreation.  (Tick one box:  ) 
 
   There are no limitations to recreation at home or away from home. 
   There are a few things I can't do but I still get out and enjoy life. 
   There are many times when I wish I could get out more, but I'm not 
up to it. 
   There are severe limitations to what I can do, mostly I stay at home 
and watch TV. 
   I can't do anything enjoyable. 
Name _____________________ 
Date ______________________ 
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5. Swallowing.  (Tick one box:  ) Are you receiving feed via a feeding 
tube, if so, please tick □ 
 
   I can swallow as well as ever. 
   I cannot swallow certain solid foods. 
   I can only swallow liquid food. 
   I cannot swallow because it "goes down the wrong way" and 
chokes me. 
 
6. Chewing.  (Tick one box:  ) 
 
   I can chew as well as ever. 
   I can eat soft solids but cannot chew some foods. 
   I cannot even chew soft solids. 
 
7.  Eating (Tick one box: )                          Additional Question for Pilot Study. 
 
 I enjoy eating out and have no problems 
 I eat out whenever possible, but order foods that are not messy to eat 
 I eat only with certain persons at selected places 
 I eat at home and only with certain people 
 I always prefer to eat alone. 
 
 
8.  Speech.  (Tick one box:  ) 
 
   My speech is the same as always. 
   I have difficulty saying some words but I can be understood over 
the phone. 
   Only my family and friends can understand me. 
   I cannot be understood. 
 
9. Shoulder.  (Tick one box:  ) 
 
   I have no problem with my shoulder. 
   My shoulder is stiff but it has not affected my activity or strength. 
   Pain or weakness in my shoulder has caused me to change my 
work / hobbies. 
   I cannot work or do my hobbies due to problems with my shoulder. 
 
10. Taste.  (Tick one box:  )  
 
   I can taste food normally. 
   I can taste most foods normally. 
   I can taste some foods. 
   I cannot taste any foods. 
 
11. Saliva.  (Tick one box:  ) 
 
   My saliva is of normal consistency. 
   I have less saliva than normal, but it is enough.   
   I have too little saliva.   
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   I have no saliva. 
 
12. Sticky secretions (Tick one box:  )          Additional Question for Pilot Study 
 I do not have any problems with sticky mucus/secretions 
 I have some sticky mucus/secretions, but it isn’t too bad 
 I am bothered by sticky mucus/secretions in my mouth/throat which are difficult to 
clear 
 I have trouble eating and breathing due to awful sticky mucus/secretions in my 
mouth/throat 
 
 13.  Nausea    (Tick one box:  )                              Additional Question for Pilot Study 
  
 I do not have any nausea 
 I experience nausea once or twice a week 
 I have nausea every day and need to take anti-nausea medication 
 I have awful nausea and medication does not help 
 
 15. Lymphoedema (swelling) (Tick one box: )    Additional Question for Pilot Study 
 I do not have any swelling at all 
 I have some swelling under my chin and jaw, but not in my face 
 I have swelling under my chin and jaw, and also a small amount in my face 
 There is a lot of swelling in my face as well as under my chin and jaw 
 
 
11. Mood.  (Tick one box:  ) 
 
   My mood is excellent and unaffected by my cancer. 
   My mood is generally good and only occasionally affected by my 
cancer. 
   I am neither in a good mood nor depressed about my cancer. 
   I am somewhat depressed about my cancer. 
   I am extremely depressed about my cancer. 
 
12. Anxiety.  (Tick one box:  ) 
 
   I am not anxious about my cancer. 
   I am a little anxious about my cancer. 
   I am anxious about my cancer. 
   I am very anxious about my cancer. 
 
Which issues have been the most important to you during the past  7         
days?   
Tick  up to 3 boxes. 
    Pain   Swallowing   Taste 
    Appearance   Chewing   Saliva 
    Activity   Speech   Mood 
    Recreation   Shoulder   Anxiety 
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Appendix 3.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quality of Life Questionnaire 
Multidisciplinary Head & Neck Clinic 
Leeds Teaching Hospitals. 
 
Patient Feedback Sheet 
 
Please give this sheet to the doctor who sees you in clinic. 
Today’s date: 
About you:  Your name:                     Your date of birth: 
                     (or please ask the Receptionist to put one of your sticky  
                     labels from your notes here) 
 
Where is/was your cancer?:  mouth / throat / voicebox / other 
(please ring the correct answer) 
How long ago did you finish your treatment?: 
Did you choose to use the questionnaire:                              yes / no 
If yes, did you find that it: 
Helped you talk to the doctors about what concerns you:   yes /no 
Made it more difficult to talk in clinic:                                           yes / no 
Helped you to find help or advice from new members of the 
Team?                                                                                         yes /no 
Should we continue to use it?                                                  yes /no 
Please add any extra comments over the page. 
 
Thank you very much for your help. 
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Quality of Life Questionnaire 
 
Multidisciplinary Head & Neck Clinic 
Leeds Teaching Hospitals 
 
Clinician Feedback Sheet 
 
Today’s date:    
Clinician(s) seeing patient……………….. 
 
Patients details:         (affix sticker from notes) 
 
Site of primary:    
 
Did you use the questionnaire?   yes          no 
 
If yes, did you find that it useful in your consultation? 
Please score from 1 to 5 by circling the appropriate number, 
1= unhelpful / no, 5 = very helpful / yes 
 
Helped you talk to the patient about what concerns them 
 
1 2 3 4 5 
Interfered with your priorities for the consultation 
 
1 2 3 4 5 
Altered your perception of the patient’s problems 
 
1 2 3 4 5 
Rating of the availability of the questionnaire to you in 
assisting with your care of this patient 
 
1 2 3 4 5 
Did the questionnaire prompt you to seek advice from additional team members?  
   yes       no 
 
If so, whom?…………………………………………………………… 
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CHAPTER 4 - Designing the Questionnaire 
Assessment Study 
 
4.1 Aims and Objectives 
The main outcomes from the pilot study were: 
• Patients supported use of a questionnaire in clinic. 
• They considered it helped them to raise issues of concern with their doctors. 
However doctors were much less supportive of the initiative. 
The pilot study allowed the generation of a hypothesis for exploration in a 
definitive piece of work. Our working hypothesis was ‘that the use of a carefully 
designed QoL questionnaire has potential to improve the care of patients 
attending a H&N clinic.’  
The aim was to prove or disprove this hypothesis by means of a definitive study 
of patients’ and clinicians’ opinions and to formulate a strategy for continuing to 
develop this area of study in the future with the ultimate aim of introducing a 
suitable measure to use in routine clinical practice. 
Key objectives of the study were: 
• To gain patients’ opinions on preference and content of a questionnaire for 
individual assessment. 
• To ascertain whether the issues patients wished to raise could be 
effectively communicated by the use of an existing validated questionnaire. 
• To determine which issues were considered important in a medical 
consultation.  
• To ascertain if the questionnaire offered ‘added value’ or simply identified 
matters already addressed in the current MDT model of care. 
• To determine the views of clinicians of all disciplines practising in the MDT  
about questionnaire assessment in general and choice of questionnaire as 
a specific item. 
The structure of the study is shown in Figure 4.1 
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Figure 4.1 Overview of design 
 
 
  
 Part 1: Planning the study 
             : review of questionnaires 
              : consideration of information to be gathered  
              : consideration of technology 
              : definitive project plan 
              : external peer review 
             ETHICS and R&D APPROVAL 
             FUNDING 
             NCRI and NIHR CRN adoption 
Part 2: Carrying out the study 
                : completion of questionnaires and interviews 
                  : data validation and analysis 
                  : generation of results 
                 : critique 
Part 3: Clinician study 
                  : questionnaire and interviews 
                  : data validation and results 
                  : critique 
Part 4: Bringing the findings together 
                  : consideration of consensus or divisions between  
                    patients and clinicians  
                  : conclusions                          
                  : defining the next stage 
               : further work 
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4.2 Overview of Methodology 
To come to a decision as to whether to accept or reject our hypothesis it was 
essential to determine a way to allow the patients to state their opinion on 
questions and on questionnaires. We also wished to gain insight into their views 
beyond simply capturing questionnaire data. For consistency and comparison 
with other population groups the preferred method is to use a well developed and 
robustly psychometrically validated questionnaire. However, to gain the best 
assessment of an individual in routine clinical practice there is a need for an 
approach which allows them to prioritise issues of importance for discussion but 
which avoids ‘questionnaire fatigue’ by offering items which are related to their 
needs and care. This is particularly true for the specific items in H&N cancer 
questionnaires, where an item may relate to some patients’ experience but not 
that of others. 
Core items in design included how to rate questions and questionnaires, the 
choice of candidate questionnaires, the choice of study population, how to 
capture the experience and views of patients more fully and management of data 
burden.  
Once the basic elements of design had been decided, the next phase involved 
the practical aspects of running the study and how to incorporate this into the 
clinic without either disrupting the way that the clinic functioned and also without 
causing inconvenience to participants. Finally we needed to bring the various 
strands together to reach a cogent conclusion.  
 
4.3 Factors to Consider in Questionnaire Choice 
In considering potential measures there were simple requirements to be met. If 
the questionnaire is to come into routine use throughout the cancer journey it 
must be short enough for completion not to be a burden and suitable for self-
completion, yet responsive enough to allow needs to be communicated to 
members of the MDT. 
A further issue was that any chosen questionnaire must be acceptable to the 
clinicians; easy to use and offering information of relevance. For this reason we 
considered it important to include a parallel study which gained knowledge of 
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clinician opinion and also explored how the MDT might manage information 
generated by questionnaires and who might take responsibility for specific areas 
of patient concern. 
We determined that our preferred option would be to use a validated 
questionnaire as the basis for a future assessment, given the number of 
questionnaires already in the literature, providing patients and clinicians 
endorsed one of the measures to be tested. The next decision was the choice of 
questionnaire. 
In general, the choice of measures depends on the target population and the 
areas which are to be studied. H&N cancer holds issues in terms of the patients’ 
general health and also site specific and treatment specific issues. The cancer 
questionnaires in extensive use have often been developed as core (i.e. general) 
and site specific modules, designed to be used together. In deciding the 
suitability of  a questionnaire, Fayers and Machin (2007) provide a simple and 
effective checklist for researchers, which I have summarised below: 
Documentation: 
• Is there formal written documentation about the instrument? 
• Are there peer-reviewed publications which support the claims of the 
developers? 
• Is there a user manual? 
Development: 
•    Are the aims and intended usage clearly defined? 
•    Is there a clear conceptual basis for the dimensions assessed? 
•    Was the instrument developed using rigorous procedures, supported by 
published peer-reviewed evidence? 
Validation: 
•   Comprehensiveness and sample sizes for validation studies. 
•   Correspondence of validated dimensions to the study proposed. 
•   Reliability and reproducibility of results. 
•   Sensitivity and responsiveness. 
Target population: 
• Previous use in intended population 
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• If the population differs, is it reasonable to expect the instrument to be 
applicable? 
Feasibility: 
• Is the method of administration feasible? 
• How long does it take to complete (patient burden) 
• Is help necessary? 
• Are there difficult or potentially embarrassing items? 
• Is processing easy or is coding required? 
• Are they compatible? In which order should they be delivered? 
Scoring: 
• Is the scoring procedure defined? 
• Are there global questions about QoL? 
Interpretation: 
• Are there guidelines for interpreting the scale scores? 
All instruments have common properties in terms of performance. The level to 
which they meet these is variable and all the factors indicated in this section must 
be considered in choosing a measure for a study. 
Validity is the process of deciding whether an instrument measures what it is 
intended to measure and is based on content or face validity (the extent to which 
items are sensible and reflect the intended domain of interest) and criterion 
validity (whether the scale has empirical association with external criteria, such 
as other established instruments). All instruments considered for this study carry 
support from the literature, although the strength of the validation studies varies 
as indicated in the section for each chosen measure. Reliability addresses the 
random variability associated with measurements. If patients’ QoL status has not 
changed, then their responses should remain similar. My main study is cross-
sectional in nature but this aspect is addressed by an attempt to achieve 
test/retest reproducibility. Sensitivity is the ability to detect differences. A main 
part of my study is to determine whether there are differences between sub-
groups and, if so, whether specific measures or questions allow these to be 
identified. 
All instruments considered have peer-reviewed validity studies in the H&N cancer 
population. They have not been validated for the thyroid population, however, 
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well validated thyroid measures are not available and, in respect of this cancer 
group, the use of the questionnaires used in this study must be considered 
exploratory.  
 
4.3.1 Choice of Questionnaire 
A review of QoL questionnaires in H&N cancer did not support claims of 
superiority for any of the current commonly used instruments and concluded that 
the choice depended primarily on the research question (Rogers, Fisher & 
Woolgar 1999a, Ringash & Bezjak 2001). A search of appropriate databases and 
a detailed group discussion at the 6th International Workshop on H&N Cancer, 
held under the auspices of the Sixth Workshop on the Biology, Prevention and 
Treatment of H&N Cancer in July 2002 identified a small number of 
questionnaires which have gained acceptance in H&N oncology. The general 
questionnaires are the European Organisation for Research and Treatment in 
Cancer Core Questionnaire [EORTC QLQ C-30], the Functional Analysis of 
Cancer Therapy General questionnaire [FACT G] and the Short Form 36 [SF-36]. 
H&N specific questionnaires include the EORTC H&N, FACT H&N and University 
of Washington Quality of Life Questionnaire [UWQoLv4]. The latter has been 
adopted by the British Association of Oral and Maxillofacial Surgeons [BAOMS] 
and the British Association of Head and Neck Oncologists [BAHNO] for the 
monitoring of patients. On these grounds I decided that three general 
questionnaires: SF-36, EORTC QLQC30 and FACT-G and three head and neck 
specific questionnaires: EORTC H&N module, FACT H&N and the UWQoLv4 
had enough support both in the literature and in UK clinical practice to justify their 
inclusion in the study.  
Scoring of psychological status is important in this group of patients and the 
Hospital Anxiety and Depression [HAD] scale has been most extensively used in 
H&N studies with the Mental Health Inventory [MHI 5 UK] scale also having 
support as a short and useful measure for assessing psychological status. 
Evidence suggests that a combination of the MHI 5 UK with the HAD provides the 
most sensitive and specific short way of detecting anxiety and depression in the 
assessment of cancer patients (Cull et al, 2001); and although not yet applied to 
H&N cancer, this combination was used in our study. 
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Examples of the questionnaires are appended (Appendix 4.1-4.8) to this chapter 
to allow comparison of their content and the number of items included in each 
measure. The general and H&N questionnaires show variation in questions 
asked, i.e. variation in face validity, variations in method of scoring and 
interpretation. The language has a format to suit the structure of the 
questionnaire and the practices of the organisation responsible for development, 
for example, the EORTC phrases questions in the third person whereas the 
FACT questionnaires are phrased in the first person. I accepted that a direct 
comparison of questionnaire scores would not be possible but interpretation of 
scores, especially at domain level may yield evidence about interpretation of that 
instrument. I will explore this further in chapter 6, where we look at the areas 
most likely to be raised in consultations and chapter 7, where I explore the 
findings from patient assessment of the selected questionnaires. The 
characteristics of each of the selected QoL measures are described below: 
 
4.3.2 The Short Form-36 in Healthcare Research (SF-36v2) 
The SF-36 is a well established questionnaire for use in the evaluation of patient 
groups and has the advantage that it can be used to compare study groups with 
normalised data (Rogers et al, 1998). It was first developed and reported by 
Ware (Ware & Sherbourne, 1992, Ware et al 1993). It has been extensively 
validated and is one of the most common tools in use for patient self-reporting in 
QoL research and is now available in more than 120 languages. It is a general 
measure designed to capture the QoL rating of patients across a range of 
medical areas unlike the other measures considered for the study which are 
cancer specific. In terms of the desired qualities of a questionnaire above, its 
validation is extensive, it has been reported in thousands of peer-reviewed 
papers, is simple to complete, contains an overall rating of QoL and covers the 
domains important for patient reported outcomes. Its only weakness from the 
point of view of this study is that, unlike the other measures selected, it was not 
designed to be specific for cancer but rather to allow comparison between 
disease states.  Scoring options are the simple score model which was used in 
the early developmental phases giving an overall rating out of 100 across the 
domains, In later versions norm based scores for each domain: Physical 
functioning (PF), Role functioning (RF), Bodily pain (BP), General health (GH), 
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Vitality (V), Social functioning (SF), Role emotional (RF) and Mental health (MH) 
(Quality metric 2009) have been developed allowing comparison between 
populations. For simplicity and because we are not attempting comparisons, in 
this study I shall report the simple scoring model, relying on the face validity of 
individual and groups of questions to explore similar phrasing and reporting 
across the general measures. In terms of simple description the 36 questions are 
as follows: 
• 2 general questions on self-perception of health now and compared to 
one year ago. 
• 4 on limitations on work and everyday living as a result of physical health 
• 3 on limitation on work or daily activities as a result of emotional health. 
• 10 which constitute a de-escalating scale of physical status, 
commencing with vigorous activities and ending with bathing and 
dressing. 
• 1 question on interference with social activities. 
• 1 question on bodily pain. 
• 1 question on limitation of everyday activities due to pain. 
• 9 on various aspects of feeling of energy and vigour and mood. 
• 1 general enquiry about impact of physical or emotional problems on 
social activities. 
• 4 true or false statements about self-perception of health. 
From this list it can be seen that the questionnaire offers a multidimensional 
assessment of health. Its complexity lies in the use of single questions to explore 
more than a single item. 
   
4.3.3 The European Organisation for Research and Treatment of 
Cancer: General and Head and Neck Specific Measures (EORTC 
QLQ-C30 and H&N module) 
 
The EORTC has developed an integrated system for assessing the QoL of 
cancer patients participating in clinical trials. It was founded in 1962 as an 
international not for profit organisation. In 1980 the QoL study group was founded 
which in 1986 initiated a programme to develop a modular integrated approach 
for evaluating QoL in patients participating in clinical trials (Fayers et al, 1997). 
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The core questionnaire was first developed on 1987 and subsequently refined.  
Its aims were to be: 
• cancer specific. 
• multidimensional in structure 
• appropriate for self-administration 
• applicable across a range of cultural settings. 
The first report of international field testing was that of Aaronson et al (1991), the 
QLQ C30, the current format, was reported in 1993 (Aaronson et al 1993).The 
current core questionnaire (EORTC QLQ C30 v3) incorporates nine multi-item 
scales: five functional scales (physical, role, cognitive, emotional and social), 
three symptom scales (fatigue, pain and nausea and vomiting) and a global 
health and quality of life scale. It ends with a number of single-item symptom 
measures. To return to the suggested list of attributes above: this questionnaire is 
cancer specific and thus designed for the study group I am exploring, it has been 
subject to rigorous validation and translated into many languages, it is suitable for 
self-reporting, and widely used and accepted in the field of cancer research.   
It is designed to be used as a combination of core and H&N modules and this 
combination represents the most commonly used instruments in H&N cancer 
QoL research in Europe and has been well validated (Bjordal and Kaasa, 1992; 
Aaronson et al, 1993; Aaronson et al, 1996; Bjordal et al, 1999).This is 
complemented by a H&N module which is designed to capture items which relate 
specifically to the experience of patients with head and neck cancer. Each site 
specific module is developed according to a well defined methodology from 
exploration of items with professionals and patients, through to item selection and 
wording and rigorous field testing as reported in the studies noted above. The 
EORTC H&N module has 35 questions assessing symptoms and side-effects of 
treatment, social function and body image/sexuality. When a combination of the 
QLQ C30 and H&N module is used the total QoL assessment contains sixty five 
questions. 
Scoring is as described in the manual (Fayers et al 1995, revised 1997). All of the 
scales and single item measures range in score from 0-100. A high scale score 
represents a higher response level, hence whether a high score represents good 
function or not depends on the wording of that domain. Thus a high score for a 
functional scale represents a high/healthy level of functioning, a high score for 
global health status/ QoL represents a high QoL, however a high score for the 
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symptom scales/items represent a high level of problems. The scores need to be 
considered as to whether they represent positive (function/QoL) or negative 
(symptom) items. The scoring system in the manual takes account of these items 
and is used in the scoring in this study.       
 
4.3.4 The Functional Assessment of Cancer Therapy General and 
Head and Neck Specific Measures (FACT-G and H&N) 
 
The FACIT Measurement System is a collection of QoL questionnaires targeted 
to the management of chronic illness which began with the development of the 
FACT-G in 1987. The FACT-G has been gradually refined through field testing 
and reports and, in version 4, the current version, consists of 27 items made up 
of general questions divided into four primary QoL domains. (Cella, 1987). These 
are: 
• physical well-being (7 items) 
• social/family well being (7 items) 
• emotional well being (6 items) 
• functional well-being.(7 items) 
The model for development has been reported as being broadly similar to that 
already reported for the EORTC measures; the generation of items using an 
expert group of professionals and patients and subsequent sequential field 
testing (Webster et al, 2003). FACT G and H&N questionnaires have been 
validated and are more extensively used in the USA than in Europe (Cella et al, 
1993; List et al, 1996). The design was formulated specifically for ease of 
administration and the FACT-G is reported to take 5 -10 minutes to complete, 
and the FACT-H&N, which consists of a series of 12 supplementary items is 
reported to take 2-3 minutes to complete. The FACT-H&N represents a list of 
common experiences for H&N patients which are described as ‘additional 
concerns’. The scales are designed to be used together. Both scales hold 
positive statements; e.g. ‘I am able to eat the foods that I like’ and negative 
statements, e.g. ‘I am unhappy with how my face and neck look’. Scoring is on a 
Likert scale of 0-4 to be scored positively in the case of a question where a high 
score represents good function and negatively where a high score equates to a 
poor status/symptom. As a rating on the lowest point scores 0, the highest 
possible score for the FACT-G is, therefore 108 and for the H&N module 40 (10 
QoL in Individual Patients  Chapter 4 
71 
 
items are scored and two are simply noted). In this study, scoring was done 
according to the Users’ Manual (Cella, 1987). 
This measure is cancer specific, supported by the literature and easy to 
complete. The literature supporting its use in cancer research made it a suitable 
measure to include in the study as a potential measure to explore QoL at 
individual level. 
 
4.3.5 The University of Washington Quality of Life version 4 
Questionnaire (UWQoLv4) 
 
The UWQoL questionnaire was first described by Hassan and Weymuller (1993) 
The advantages claimed for the instrument were: 
• it is brief and self-administered. 
• it is multifactorial, allowing sufficient detail to identify subtle change. 
• it provides questions specific to H&N cancer. 
The first version contained 9 domains: pain, appearance, activity, recreation, 
swallowing, chewing, speech, shoulder, and employment. It was compared to two 
standard instruments, the Karnofsky scale and Sickness Impact Profile (SIP). 
Using the SIP as a gold standard the UWQoL demonstrated an average criterion 
validity of 0.849 and a slightly lower level (0.826) for the Karnofsky scale. The 
UWQoL questionnaire scored >0.90 on reliability coefficients versus 0.80 for the 
Karnofsky and 0.87 for the SIP scale. Over subsequent years a body of literature 
has been published supporting the use of the UWQoL, however it has to be 
accepted that, as it was designed as a stand-alone instrument (Weymuller et al, 
2000) for use at a less common cancer site, its psychometric validation has 
inevitably been less robust than that of the other main tools  and, for this  reason, 
I have reported the development of this questionnaire in some detail. It has 
gained considerable popularity amongst investigators working in H&N surgery, 
particularly in oral cancer (Rogers, 1999b).  A study indicated that 65% of 
maxillofacial surgeons in the UK who assess QoL use this tool (Kanatas and 
Rogers, 2004). 
The content has gradually evolved. In version 2 each of the 9 domains was 
followed by an importance rating scale and three new single item QoL questions 
were added (Deleyiannis et al, 1997). Version 3 added two new domains (taste, 
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saliva) and removed employment (Weymuller et al, 2000). The main change was 
to replace the ranking of importance for each domain, patients were asked to 
choose the three most important. The current version (v4) added a simple 
emotional assessment, adding anxiety and mood. Version 4 was first published in 
2001 (Weymuller et al, 2001, Rogers et al, 2002).  
Scoring is on a scale from 0-100, the scores for intermediate answers between 
the highest and lowest possible answers depending on the number of options. 
So, a question with 5 options has scores of 100, 75, 50, 25 and 0; those with 4 
options can score 100, 70, 30 or 0 and the one question with three options 
(chewing) has scores of 100, 50 and 0. In each case a high score reflects better 
quality of life. A similar scheme is applied to the QoL questions.   
 
4.3.6 The Hospital Anxiety and Depression Scale (HADS) 
The HAD scale (Zigmond and Snaith, 1983) was developed as a result of the 
need to assess the contribution of mood disorder, especially anxiety and 
depression, to understand the contribution of these factors to suffering in the 
setting of medical practice. It is a general, not a cancer specific, measure. It has 
been extensively used in health science research to screen anxiety and 
depression across a wide range of conditions. The interaction between physical 
and mental disorders has been explored. Pain which was previously tolerable 
may become intolerable if a depressive state supervenes (Bradley, 1963). Of 
specific interest to my study, in maxillofacial cancer patients who had undergone 
therapy with curative intent it was found that one in three had significant anxiety 
and somatic symptoms which were reduced by discussing the nature of anxiety 
and its ability to manifest as somatic distress (Telfer & Shepherd 1993).  
The measure was developed as a response to recognition of need and the fact 
that previous questionnaires were lengthy and represented a significant burden 
to patients who may already be distressed. During development much thought 
was given to the term ‘depression’. Its use varies from major states considered by 
specialist psychiatric practice, to matters of general states of distress including: 
demoralisation from prolonged suffering, reaction to loss (grief), tendency to 
undervalue self (loss of self-esteem) and pessimistic outlook on life. In 
developing the HADS it was decided to concentrate on the loss of pleasure 
response (anhedonia) as the best guide of to the type of disorder which might be 
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amenable to therapy (Snaith, 2003).  It can be used either with predetermined 
‘cut off’ scores for ‘probable’ and ‘cases’ of anxiety and depression or as a 
continuous scale. Controversy has been reported about using the ‘cut offs’ 
derived from studies of psychological distress in cancer patients. Studies in 
breast cancer (Hall et al, 1999) and lymphoma (Razavi et al, 1992) reported 
equivocal results. Ibbotson (1994) recommended different ‘cut off’ scores for 
patients with cancer. However the H&N studies reviewed in Chapter 2, section 
2.4, used the standard ‘cut-off’ so this approach has been adopted for this study.  
 
4.3.7 Mental Health Inventory 5 (MHI-5) 
The MHI-5 is derived from the SF-36 and is well validated within the parent 
measure and accepted in clinical practice. One disadvantage is that, unlike the 
HADS, the MHI-5 does not have accepted cut-off scores (Kelly et al, 2008). It 
consists of five questions, with rating scales which increase or decrease 
depending on the wording of the question. In this study scores will simply be 
summed to allow comparisons between groups and sub-groups.   
 
4.3.8 Summary 
In this section we have looked at the measures to be used and justified their 
selection on the basis of merit in terms of psychometric validation or of use in the 
scientific and clinical setting in which my study is based. I have focussed on 
including a general measure, a site specific measure and an assessment of 
anxiety and depression in any future recommendations,     
A challenge for questionnaire assessment in H&N cancer is the variation in the 
disease at different sites, its treatment and the impact of therapy. QoL varies not 
only because of basic personality factors which link to patients’ perception of their 
QoL (Calman, 1984) but also aspects of family and social support and the 
morbidity resulting from treatment. The challenges of attempting to derive an 
instrument that allows patients to record their status and concerns and presents 
them in a useful way to clinicians are considerable. The instruments accepted for 
current use provide the most robust baseline from which to work towards 
acceptance of an already existing measure into clinical practice or to develop any 
future assessment tool. Other authors, for example Ringash and Bejak (2001), 
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emphasise the challenge and extensive validation requirement for new measures 
and advise that research should focus on learning as much as we can about the 
questionnaires already available to us. I have adopted that philosophy in my 
study, looking to use, or perhaps adapt our current measures to best reflect the 
issues patients wish to communicate to MDTs rather than to look or develop a 
new questionnaire. 
 
4.4  Studies Comparing the Chosen Measures 
Interpreting the meaning of scores can be difficult at individual level. Work in this 
area directly considering the needs of H&N cancer patients is limited. A study 
comparing the EORTC QLQ C30 and the FACT-G indicated that scores achieved 
in each area by the same patient may differ considerably (Kemmler et al, 1999). 
Comparison of the three general QoL indicators has been attempted in oral 
cancer reporting some correlations (Rogers et al, 1998), but the numbers of 
patients recruited was very small. Comparison studies have not been carried out 
in the wider context of H&N cancer or with consideration of patient preference. 
Despite the burden of data collection, usable responses were achieved in these 
studies. Comparison of the available and accepted tools is required before a 
single measure can be proposed and these studies would indicate that 
participants would be capable of completing a complex dataset to allow this 
comparison.   
The key features of a proposed questionnaire are that it must be acceptable to 
and easily interpreted by patients, both in terms of the content and the wording of 
questions. In determining a design, the patients’ views are imperative. Clinicians 
and MDT members must have a clear understanding of the relevance of the data 
supplied and the action required to meet the patient’s need. Other important 
factors are the inclusion of issues which arise as part of consultations or which 
may indicate a change in disease status.  
 
4.5 Quality of Life Assessment: technology for data 
collection 
 
The utility of QoL assessments using standard questionnaires in the oncology 
clinic has gained support (Velikova et al, 1999a). Information technology allows 
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data to be collected rapidly and scored automatically (Velikova et al, 1999b) 
allowing the doctor information about present and cumulative QoL. In H&N 
cancer, using the UoWQoLv4 questionnaire, the acceptability of touch screen 
technology in a group of patients with oral cancer, including those who had never 
previously used a computer, has been confirmed (Millsopp, 2004). Detmar et al 
(2002) and Velikova et al (2004) reported randomised controlled trials showing 
the benefits of making available a QoL record at consultation in a routine clinic 
setting in terms of identification of issues and patient satisfaction. The potential 
benefit of quality of life data in individual patients to help prioritise problems, 
identify preferences and monitor changes was highlighted by Higginson (2001). 
 
4.5.1 Technology for Data Capture 
The Cancer Research UK Centre in Leeds has undertaken substantial research 
into the use of touch-screen computers in health related quality of life (HRQoL) 
research, successfully capturing data from patients in an acceptable and reliable 
way (Velikova et al, 1999b). The use of touch-screen technology has proved very 
successful in previous studies investigating HRQoL in patient populations. The 
ability to rapidly collect and automatically score data allows the doctor easy 
access to information about present and cumulative HRQoL (Detmar et al, 2002).  
This intervention resulted in an increase in the number of issues discussed at 
consultation and patients considered questionnaires a useful tool to inform their 
doctors about their problems. The benefit of making QoL scores readily available 
at clinic through availability of touch-screen data, in terms of identification of 
issues and patient satisfaction, has been demonstrated by randomised control 
trials (Velikova et al,  2002, Velikova et al, 2004). This work opened the path to 
the development of an integrated clinical/ research electronic database 
combining, the clinical pathway, clinical trials management and direct entry of 
patient generated data.  
 
4.5.2 The Technology System Used in this Study 
 
I was fortunate as the work led in terms of the electronic patient record, Patient 
Pathway Manager (PPM) by Mr Colin Johnston and Drs Geoff Hall and Michael 
Leahy, and in terms of the clinical trials database, led by Mr Alexander Newsham 
and Dr Adam Smith had reached the stage where the integrated system was 
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ready for use at the time I was finalising development of this study. My study was 
the first to use this technology which I have described briefly below. 
The basis of the integrated system is the ability to use new generation on-line 
touchscreens to identify eligible patients and ‘flag’ them so that their research 
record, should they choose to join the study, can be linked to their clinical status. 
Should they choose not to participate, the system ensures that they are not 
approached twice. Data entered onto the touch-screen is automatically uploaded 
into the Trust’s secure server, meeting the best possible standards for data 
security. If the system is used ‘off-line’; as was the case for our clinics which, at 
the time the study was conducted, had not yet linked to PPM, synchronisation of 
the data took place as soon as the clinic had finished and the RA had returned to 
the Cancer Centre. 
PPM is an integrated oncology information and data management system, built 
around a Microsoft SQL Server 2000 database and can be viewed and 
administered via a user interface application developed using Visual Basic 6. The 
system employs both remote desktop technology and thin client applications to 
deliver the application to a variety of user desktops, using a combination of MS 
Windows and SQL Server security technologies to manage user authentication 
on a secure NHS Trust network of servers. PPM integrates all the information 
relating to the care, treatment and management of oncology patients seen within 
the Trust and the user interface presents this information through a series of 
browsers, including a patient pathway browser, a search browser, a trial browser, 
clinics browser, MDT meeting browser, the combination of which allows a variety 
of activities to be managed and integrated through PPM. The information is 
presented as a ‘pathway’ of patient specific events which appears in a ‘patient 
folder’; as shown in Figure 4.2. 
 
Figure 4.2 PPM Pathway of Patient Events 
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Through this interface, files can be opened to view and manage consultation 
records, MDT decisions, therapy given, and current status. One option relates to 
entry into clinical trials and this links through to a trial specific database, using 
unique identifiers to protect anonymity so that the study related data can be 
exported to the University server and managed as a ‘stand alone’ Access 
database. 
 
4.5.3 Capturing Patient Opinion on the Content of Questionnaires 
The traditional way of using QoL measures has involved completion and scoring 
of a questionnaire, with a comparison to status represented by demographic 
factors such as age, sex or disease factors such as stage at diagnosis and 
therapy. 
In this study we wished to gain opinions on the questionnaires. At the time the 
study was devised no published work was available to aid design. Scientific 
literature on asking questions suggests that questions should be direct and 
should not be biased towards a positive or a negative response. 
Questions include two main dimensions, the first being that they may ask about 
something which has had an impact on the patient and thus is an important issue. 
The second relates to the way the question is written and whether the language 
clearly expresses the subject area and can easily be understood and answered. 
After discussion within our research and clinical teams, my decision was to 
explore these two areas individually to gain an insight into these aspects of 
questionnaire choice. 
As already noted, we had three general, three H&N and two psychological 
measures in the study. A strategy needed to be considered to engage 
participants to answer the questions and give opinions but to maintain the data 
burden at an acceptable level. For the general questionnaires, it was decided to 
ask patients to complete the whole measure and then to grade the entire 
questionnaire with regard to ‘importance’ and ‘well written’. A rating scale ranging 
from 1= ‘not at all’ to 4= ‘very’ was used throughout the study whenever an 
opinion was sought. A second question was designed to allow them to express a 
clear preference between the three measures. 
My wish was to focus on the specific domains and questions which are core to 
the experience of patients treated for H&N cancer and these are contained in the 
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H&N modules. Despite the data burden I felt that it was important to record a 
rating of ‘importance’ and ‘well written’ for each question. 
The psychological measures were included in ac
this allowed the best assessment of an important dimension of patient welfare 
(Cull, et al, 2001). I did not include a formal rating but patients had the chance to 
comment as outlined in section 4.4.2.
This simple arrangement
the questionnaire ratings was as shown in Figure 4.
touch-screen in Figure 4.4.
 
Figure 4.3  Rating a question in the H&N modules 
                                                                                                       
                                                                                                           
26.  Has your physical condition or medical treatment
        interfered with your family life?                                    
                                     
                                                                                                          
                                                                                                             
                                                                                            
26 (1) How  important do you think this question is?               
 
                                                                               
                                                                                                         
 
26 (2) How well written is this question?                                    
 
Figure 4.4 Rating a question on the touch
For the study involving clinicians
collection was performed.
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cord with data suggesting that 
 
 was incorporated into the touch-screen. The format of 
3. and as presented on the 
  
 
Not at            A           Quite      Very                                                                                                                         
all             little         a bit      much 
 
             1                 2                3             4 
Not at          A           Quite       Very                
all            little         a lot        
                                                   
        1                2               3              4 
                           Very         Poorly      Well      Very 
poorly                                      well 
        1                2               3              4 
-screen 
 (reported in Chapter 8), an identical data 
 
Chapter 4 
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4.5.4.Interviews 
Whilst direct data capture using questionnaires and the touch-screen would 
produce quantitative data, the core of this work lies in attempting to understand 
patients’ and clinicians’ opinions about data collection and its relevance in the 
clinical setting. Building on informal comments from patients and carers in the 
pilot study, a proforma to guide a semi-structured interview was devised 
(Appendix 4.9). This was designed to be administered on a one to one basis by a 
trained Research Assistant (RA). As I was a clinician working within the H&N 
MDT in Leeds, it was important that data be gathered by someone who would not 
be seen as directly involved in patient care and independent of the clinical team. 
For interviews with clinicians, I felt that the day to day working relationship would 
ease, rather than confound, the interaction so I personally performed all 
interviews with clinicians.    
 
4.5.5 Capturing the Environment of Care 
 
Recommendations to include QoL assessment as part of routine care can only be 
justified if there is gain for the patient, and ideally also the health professionals, 
as a result of the data made available. Consultation is the standard method of 
doctor/patient communication and depends on a historical model of enquiry which 
has evolved over the years. UK practice relies on an open dialogue model with 
the items raised depending on the interaction between the participants  
I wished to explore both patients’ and clinicians’ views on the ideal and actual 
content of consultations. To do this, I used the questionnaire reported by Detmar 
et al (Detmar et al 2000) but adapted this to include issues which, from the 
literature, have been reported as important for H&N patients (such as 
‘appearance’) The first set of questions covered what patients would wish to see 
included in consultations, recorded on a scale of 0= ‘not discuss’, 1= ‘would 
discuss if the doctor raises this’ and 2= ‘I would wish to discuss this item’. The 
second set related to perceptions as to what was discussed in consultations on a 
Likert rating from 0= ‘never’ to 4= ‘almost always’. The full list of questions and 
scoring scheme is given in Appendix 4.10.  
To gain an understanding of the patient/doctor interaction, each consultation was 
tape recorded, with permission, and analysed thematically according to a simple 
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scheme (rating frequency and importance of items raised). This could then be 
compared with the data from questionnaires and interviews to determine how 
fully the issues of importance were being covered in the discussion. The interview 
included comments about the system of care and inevitably communication 
between health professionals  allowing consideration as to whether more issues 
might have been addressed to the benefit of patients had the questionnaire data 
been available at consultation.  
 
4.6  Recruitment and Patient Population 
The consensus view from the literature is that, irrespective of measure used, QoL 
in H&N patients decreases from baseline to reach its lowest level at 3-6 months 
after completion of radical curative therapy and then improves back to baseline 
levels at about 1 year. It is reasonable to assume that the periods of greatest 
need and, thus the most useful time to employ a QoL assessment would be at 
the critical periods in the cancer journey, the acute phase (usually defined as the 
first 100 days), the time of relapse and the time of end of life care. We have 
studied the first of these in detail (Shepherd, 2002, Shepherd and Fisher, 2004) 
confirming the needs of patients in the acute phase. The pilot study, as a cross-
sectional study, recruited patients mainly from the period shortly after treatment, 
with a median of 7 months, simply because it is in this period that patients have 
frequent appointments. However, for this definitive study, we were asking 
patients to complete a much more demanding and intense data collection. 
Discussion with the MDT and research group confirmed my belief that this level 
of data collection represented an inappropriate burden to a patient group 
recovering from therapy. A compromise was necessary in either the data-set or 
the patient population. I considered that the primary question was to determine 
whether patients endorsed a specific measure and that their experience would be 
sufficient to allow them to record their views and choices even if the demanding 
part of the cancer journey was behind them. I therefore set entry criteria of ‘at 
least one year after completion of primary therapy and currently disease free’.  
The next patient related question was management of sub-sites, the profile of 
treatment related morbidity and side effects varying according to site and therapy. 
To attempt to obtain consensus views on the important issues, I decided to limit 
the study to the two most common sites ‘oral and oropharyngeal’ and ‘laryngeal’ 
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cancer. In addition I wished to explore the opinions and preferences of patients 
with thyroid cancer. 
In terms of stratification for presentation of results it is usual to present patient 
groups by disease stage; the higher the stage, the more advanced the disease at 
presentation. I wished to capture experience and particularly the impact of 
therapy. The staging system may not reflect therapeutic burden. The concept of 
therapeutic burden as a category for outcome analysis is new and differs from the 
classical analysis by stage because stage does not necessarily represent the 
complexity of therapy required for the cancer. A number of early stage patients 
fail to respond to single modality therapy and undergo the therapeutic burden of 
someone presenting at a later stage and others are deemed either unfit or refuse 
to accept multimodality management yet, despite limitation in therapy achieve a 
complete response. To capture this aspect of their status, I divided the population 
into ‘early’ and ‘late’ cancer, the decision being made on treatment modality(ies) 
as shown in Figure 4.5. 
Figure 4.5  Defining the Study Population 
 
 Early (single modality) Late (Multimodality) 
Oral EO LO 
Larynx EL LL 
Thyroid 
                       Thy 
 
The result of this reasoning was that we had five study sub-groups: ‘early oral’ 
(EO), ‘late oral’ (LO), ‘early larynx’ (EL), ‘late larynx’ (LL) and thyroid. To 
determine sample size we made a number of assumptions, using the experience 
of previous work in this field by the research group. 
Measurement of preference as a primary end-point is a new field. The most 
pertinent work to consider in devising a statistical method is that of Velikova et al 
(1999b) who compared preferences with regard to paper or touch screen 
completion of questionnaires. They used ‘a priori’ agreed criteria for acceptable 
levels of acceptance and preference. In this study we have chosen a method 
using a four point Likert scale in order to be able to assess the preference scale 
as ordinal data, in the same way as the QoL scores. 
To assess choice of questionnaire, we planned to consider the stated preference 
for a given questionnaire over the others using a confidence level analysis. It was 
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considered that a questionnaire would be defined as the preferred one if it had 
been given the highest score by 40% of patients who expressed a preference. 
Given, this ‘a priori’ level we could determine a sample size for the total group. To 
detect a proportion of at least 61% with a 95% confidence interval [CI] of 10%, a 
sample size of 100 patients would be required. If such a response was not 
achieved, it was decided that a decision of ‘no preference’ would be taken. To 
assess the clinicians’ ratings frequency analysis of results was planned, 
accepting a majority opinion but taking account of all areas identified as important 
in the whole group (core response) and for sub-groups (site specific response).      
If we consider the comparison of scores to calculate sample size, then an 
accepted level of difference between the group scores gives us the basis for the 
calculation. Each questionnaire was scored by the standard method and by 
rating, giving us sets of ordinal data for comparison at whole group and subgroup 
level. As the primary endpoint is the patient preference and rating of importance, 
assuming a difference of between two groups, such as ‘early’ and ‘late’ of 0.5 
points on the rating of a questions within a questionnaire or domain (such as the 
EORTC-QLQ C30) and that the standard deviation of the means is 
(approximately) 20. Then the standardised difference (d) between the means of 
the two groups is 0.75 (mean1- mean2/ st. dev. 15/20). 
Sample size can be calculated from this equation: 
delta = d * sqrt(N/2) 
In order to achieve a power of .80 and an alpha of 0.05, we need a delta of 2.7 
(Howell, 1999).  
Rearranging the equation, we can derive N (Sample size for each group) i.e. 
N = 2 * (delta/d)squared, which in this case gives us around 26 for each 
group. To allow for incomplete completion we decided to attempt to recruit 30 
patients to each subgroup.  
We planned to assess patients’ and clinicians’ preferences by calculating the 
proportion stating a preference for a single instrument in each category, core, 
H&N and psychological and the proportion in each of the preference categories, 
as well as those stating no preference. Comparison to determine whether 
particular questionnaires were preferred by a definable subgroup of patients, 
used a one way analysis of variance ANOVA for analysis of multiple factors (sub-
groups) and the independent t-test, with equal variances not assumed, for 
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comparisons between two groups using categoric variables (H&N vThy, Early v 
Late, Oral v Larynx, Stage I&II v III&IV, Gender) (Bland, 1986). 
Patients’ ratings were assessed using the scales indicated, treating them as 
ordinal data, in the same way as the QoL scores. At individual question level, the 
‘a priori’ setting was the inclusion of any question rated as ‘very important’ by at 
least 5% of patients or ‘quite important’ by 30%. The phrasing was considered 
secondarily, the preferred style being used in the wording of the question for any 
proposed tool. All questions rated as ‘very’ or ‘quite’ important by clinicians would 
be analysed to determine whether they form part of a ‘core’ assessment across 
H&N cancer sites or whether they relate to assessment of a subgroup of patients. 
Their place in any candidate measure was to be decided by consensus clinical 
opinion. 
Agreement between ratings at test and retest can be determined by determining 
the proportions of exact and global agreement and weighted kappa coefficients. 
Exact agreement refers to the number of patients giving the same response, 
considered in terms of each option; status, importance and phrasing. Global 
agreement is defined as one category either side of the original choice. The 
percentage agreement depends on the number of response categories. Although 
for ‘importance’ and ‘phrasing’, this number is consistent, for questionnaire 
scores it is not. Kappa is a coefficient of agreement that is corrected for chance 
agreement (Fleiss,1986; Armitage and Berry, 1995). For ordinal data, 
questionnaire and ‘importance’ and ‘phrasing’ scores, weighted kappa is 
calculated by giving different weights to disagreements according to the 
discrepancy. Values of kappa range from 0-1, with 0 indicating an agreement 
consistent with chance alone and 1 indicating perfect agreement. Interpretation of 
variables between 0 and 1, will follow the guidelines set out by Landis and Koch 
(1977): ≤0.2, poor agreement; 0.21 to 0.40, fair agreement; 0.41 to 0.60 
moderate agreement and 0.81 to 1.00 very good agreement. The kappa 
coefficient was calculated for the QoL scores, the ‘importance’ scores and the 
‘phrasing’ scores. 
To ensure test/retest reproducibility, we aimed to gain two responses from a 
sample of 10% of the participant population. 
Given the exploratory nature of this study and the complexity of the data-set, I 
accepted that we may well achieve ‘soft’ rather than ‘hard’ and statistically proven 
results and that we may well not reach the levels of difference in patient or 
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clinician opinions to justify the level of analysis described. Should this prove to be 
the case, simple measures such as frequency analysis, were considered to be 
valid in gaining understanding of patient and clinician opinions in a new field of 
scientific exploration. 
 
4.7  Data Handling and Verification 
From the design above, I designed a series of clinical report forms to gain 
information on the demographics of potential and actual participants (Appendix 
4.11). The questionnaires were offered using the touch-screen, beginning with 
the modified consultation questionnaires, leading on to the three general 
questionnaires which were delivered in random order, then the three head and 
neck specific questionnaires and finally the psychological measures. Each 
question was manually typed onto the system together with the relevant scores.  
The electronic system automatically uploaded responses to a central server. This 
included the allocation of a unique identifier to allow us to link the clinical trials 
database to the clinical records. As a member of the clinical team, I was able to 
confirm the details through PPM so that we could link technical data, such as 
staging, to the responses, maintaining the study base as a ‘stand alone’, 
anonymised dataset. 
To attempt to gain an understanding of the reproducibility of responses, we 
attempted to link test/retest data on the subset of patients who underwent two 
interventions.       
 
4.8  Data Analysis 
Data analysis was planned to answer the primary questions and to allow 
understanding of the study population. depending on the level of differences seen 
in the responses and whether we met our ‘a priori’ requirements. 
 
4.8.1 Demographic Analysis  
This included the gender, age, site and stage of disease, therapy given and time 
from completion of therapy. The aim was to allow reporting by sub-group; i.e. 
QoL in Individual Patients  Chapter 4 
85 
 
therapeutic burden but to also allow other potentially significant areas to be 
explored. The demographics of the sample are reported in Chapter 5. 
 
4.8.2 Preferences and Perception of Consultation Content 
This was analysed according to the scoring scheme as below and is reported in 
Chapter 6. Comparisons were made between groups and sub-groups as to what 
patients would wish to have covered in a consultation and what they felt was less 
important. A second set of questions explored what they considered actually took 
place in a consultation..  
To set the findings in context, a simple analysis of the consultations was done, 
considering the number of issues raised and, across the groups, the frequency 
with which each was raised and how problematic that area seemed to be  We 
also recorded the consultation, allowing direct comparison between interview 
data and the content of the consultation, to determine whether patient priorities 
were identified and addressed and where there might be omissions which the use 
of a standardised questionnaire might help address. To determine the 
characteristics of the doctor/patient interaction, a note was made of who 
introduced that item for discussion. 
To determine severity, we rated responses on a simple scheme:  
1 = mentioned  
2 = mentioned as a problem 
3 = mentioned as a priority requiring advice or action. 
 
4.8.3 Questionnaire Analysis  
Questionnaire analysis included the quality of life scores and preference rating for 
each questionnaire. Although direct comparisons across questionnaires is not 
possible, comparison between patient groups could be performed, looking at the 
areas highlighted for each sub-group in each questionnaire. Scoring for the 
questionnaires was done in accordance with User manuals. as described in 
section 4.3.1. Scoring for ‘importance’ and ‘well written’ was common to each 
questionnaire and so allowed comparisons both within study sub-groups and 
between measures. For this to take place a mean score was derived for each 
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general questionnaire and for each individual item in the H&N measures. These 
were compared by total study group and sub-groups. 
This was supplemented by analysis of the semi-structured interview by the 
number of items raised and the priority which each item was accorded on a 
simple scale following the method used for the analysis of content of 
consultations. Patients were invited to comment on questionnaires, individual 
questions which were considered particularly good or poor and on issues which 
were particularly important to them :These results are reported in Chapter 6. 
I analysed the recording of each interview and consultation. To check inter-rater 
reliability a subset (10% of the sample) was analysed by two researchers, myself 
and one of the research assistants (RAs) who administered the questionnaires 
and the results were compared. To check test/retest reliability, I re-analysed and 
re-scored the same subset of interviews, leaving a minimum period of 1 month 
between assessments. 
A similar approach was taken to the clinician responses, however, this was 
extended to allow a more detailed analysis and all interviews were transcribed. 
These interviews were analysed by myself, again considering items and their 
importance, extending the scheme above. 
 
4.9 Governance and Peer-Review 
 
The study design was discussed within the research team and the multi-
disciplinary cancer team. All suggestions were considered and the design refined 
to that presented above. All clinicians agreed that they were happy for their 
patients to participate. 
For external peer review, the study was submitted to the National Cancer 
Research Institute Local Studies Group and was approved for entry into the 
national portfolio in the Head & Neck Cancer site section, in August 2005. 
Ethics approval was granted by the Leeds West Research Ethics Committee on 
29th April 2005 (Ref: Leeds West REC 05/1205/26). 
Funding was required to provide salaries for Research Assistants (RAs). This 
was initially funded by the Head and Neck Oncology Research Fund of the Leeds 
Teaching Hospitals NHS Trust. Funding to cover purchase of touch-screen 
computers and digital recorders was granted by the British Association of Oral & 
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Maxillofacial Surgeons. Completion of recruitment was made possible by two 
successful peer-reviewed applications for research support; the first to the 
Charitable Trustees of the Leeds Teaching Hospitals NHS Trust and the second 
to the British Association of  Oral & Maxillofacial Surgeons. 
Once the first funding had been confirmed, arrangements to conduct the study 
within the multi-disciplinary and specialist clinics based in the Leeds Teaching 
Hospital NHS Trust could be made. Practical aspects of conducting the study and 
the basic demographics which underpin the descriptions of the individual studies 
will be reported in the next chapter.  
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Appendices: Questionnaires 
4.1: SF-36 v2 
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4.2: EORTC QLQ C30 
Please go on to the next page
EORTC QLQ-C30 (version 3)
We are interested in some things about you and your health. Please answer all of the questions
yourself by circling the number that best applies to you. There are no "right" or "wrong"
answers. The information that you provide will remain strictly confidential.
Please fill in your initials:
Your birthdate (Day, Month, Year):
Today's date (Day, Month, Year):
Not at A Quite Very
all little a bit much
1. Do you have any trouble doing strenuous activities,
like carrying a heavy shopping bag or a suitcase? 1 2 3 4
2. Do you have any trouble taking a long walk? 1 2 3 4
3. Do you have any trouble taking a short walk outside
of the house? 1 2 3 4
4. Do you need to stay in bed or a chair during the day? 1 2 3 4
5. Do you need help with eating, dressing,washing
yourself or using the toilet? 1 2 3 4
During the past week: Not at A Quite Very
All little a bit much
6. Were you limited in doing either your work or other
daily activities? 1 2 3 4
7. Were you limited in pursuing your hobbies or other
leisure time activities? 1 2 3 4
8. Were you short of breath? 1 2 3 4
9. Have you had pain? 1 2 3 4
10. Did you need to rest? 1 2 3 4
11. Have you had trouble sleeping? 1 2 3 4
12. Have you felt weak? 1 2 3 4
13. Have you lacked appetite? 1 2 3 4
14. Have you felt nauseated? 1 2 3 4
15. Have you vomited? 1 2 3 4
16. Have you been constipated? 1 2 3 4
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© Copyright 1995 EORTC Quality of Life Study Group.  All rights reserved.  Version 3.0 
During the past 
week:
Not at A Quite Very 
all little a bit much 
17.  Have you had diarrhea? 1 2 3 4 
18.  Were you tired? 1 2 3 4 
19.  Did pain interfere with your daily activities? 1 2 3 4 
20.  Have you had difficulty in concentrating on 
things, like reading a newspaper or watching 
television? 
1 2 3 4 
21.  Did you feel tense? 1 2 3 4 
22.  Did you worry? 1 2 3 4 
23.  Did you feel irritable? 1 2 3 4 
24.  Did you feel depressed? 1 2 3 4 
25.  Have you had difficulty remembering 
things?
1 2 3 4 
26.  Has your physical condition or medical 
treatment interfered with your  family life? 1 2 3 4 
27.  Has your physical condition or medical 
treatment interfered with your  social activities? 1 2 3 4 
28.  Has your physical condition or medical 
treatment caused you financial difficulties? 1 2 3 4 
For the following questions please circle the number between 1 and 7 
thatbest applies to 
you
29. How would you rate your overall  health  during the past 
week? 
1 2 3 4 5 6 7 
 Very poor          Excellent 
30. How would you rate your overall  quality of life  during the past 
week? 
1 2 3 4 5 6 7 
 Very poor          Excellent 
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4.3 FACT-G 
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Please go on to the next page
EORTC QLQ-H&N35
Patients sometimes report that they have the following symptoms or problems.  Please indicate
the extent to which you have experienced these symptoms or problems during the past week.
Please answer by circling the number that best applies to you.
Not at A Quite Very
During the past week: all little a bit much
1.
 
Have you had pain in your mouth? 1 2 3 4
2.
 
Have you had pain in your jaw? 1 2 3 4
3.
 
Have you had soreness in your mouth? 1 2 3 4
4.
 
Have you had a painful throat? 1 2 3 4
5.
 
Have you had problems swallowing liquids? 1 2 3 4
6.
 
Have you had problems swallowing pureed food? 1 2 3 4
7.
 
Have you had problems swallowing solid food? 1 2 3 4
8.
 
Have you choked when swallowing? 1 2 3 4
9.
 
Have you had problems with your teeth? 1 2 3 4
10.
 
Have you had problems opening your mouth wide? 1 2 3 4
11.
 
Have you had a dry mouth? 1 2 3 4
12.
 
Have you had sticky saliva? 1 2 3 4
13.
 
Have you had problems with your sense of smell? 1 2 3 4
14.
 
Have you had problems with your sense of taste? 1 2 3 4
15.
 
Have you coughed? 1 2 3 4
16.
 
Have you been hoarse? 1 2 3 4
17.
 
Have you felt ill? 1 2 3 4
18.
 
Has your appearance bothered you? 1 2 3 4
 
4.4: EORTC H&N 35 
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© Copyright 1994 EORTC Quality of Life Study Group.  Version 1.0.  All rights reserved.
Not at A Quite Very
During the past week: all little a bit much
19.
 
Have you had trouble eating? 1 2 3 4
20.
 
Have you had trouble eating in front of your family? 1 2 3 4
21.
 
Have you had trouble eating in front of other people? 1 2 3 4
22.
 
Have you had trouble enjoying your meals? 1 2 3 4
23.
 
Have you had trouble talking to other people? 1 2 3 4
24.
 
Have you had trouble talking on the telephone? 1 2 3 4
25.
 
Have you had trouble having social contact with your family?1 2 3 4
26.
 
Have you had trouble having social contact with friends? 1 2 3 4
27.
 
Have you had trouble going out in public? 1 2 3 4
28.
 
Have you had trouble having physical contact
 with family or friends? 1 2 3 4
29.
 
Have you felt less interest in sex? 1 2 3 4
30.
 
Have you felt less sexual enjoyment? 1 2 3 4
During the past week:
No Yes
31.
 
Have you used pain-killers? 1 2
32.
 
Have you taken any nutritional supplements (excluding vitamins)? 1 2
33.
 
Have you used a feeding tube? 1 2
34.
 
Have you lost weight? 1 2
35.
 
Have you gained weight? 1 2
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4.5: FACT H&N 
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4.6: UWQoLv4 
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4.7: HADS                                   HAD Scale 
Name:    
Doctors are aware that emotions play an important part in most illnesses. If your doctor knows 
about these feelings he will be able to help you more. 
This questionnaire is designed to help your doctor to know how you feel. Read each item and 
place a firm tick in the box opposite the reply which comes closest to how you have been feeling 
in the past week. 
Don’t take too long over your replies: your immediate reaction to each item will probably be more 
accurate than a long thought-out response. 
 
Tick only one box in each section 
I feel tense or ‘wound up’:             I feel as if I am slowed down: 
 
            
Most of the time……………………    Nearly all the time……………………   
A lot of the time……………………    Very often……………………………   
Time to time, Occasionally…………    Sometimes……………………………   
Not at all…………………………..    Not at all…………………………….   
I still enjoy the things I used to enjoy:    I get a sort of frightened feeling like  
‘butterflies’ in the stomach: 
  
Definitely as much…………………    Not at all…………………………….   
Not quite so much………………….    Occasionally…………………………   
Only a little…………………………    Quite often…………………………..   
Hardly at all…………………………    Very often……………………………   
I get a sort of frightened feeling as if  
Something awful is about to happen: 
   I have lost interest in my appearance:    
Very definitely and quite badly…….    Definitely……………………………   
Yes, but not too badly………………    I don’t take as much care as I should.   
A little, but it doesn’t worry me……    I may not take quite as much care…..   
Not at all……………………………    I take just as much care as ever……..   
I can laugh and see the funny side of 
things: 
   I feel restless as if I have to be on the 
move: 
  
 As much as I always could…………    Very much indeed…………………..   
 Not quite so much now……………    Quite a lot……………………………   
 Definitely not so much now……….    Not very much………………………   
 Not at all…………………………     Hardly at all…………………………   
Worrying thought go through my mind:    I look forward with enjoyment to things:   
A great deal of the time…………….    As much as I ever did……………….   
A lot of the time……………………    Rather less than I used to……………   
From time to time but not too often..    Definitely less than I used to………..   
Only occasionally…………………..    Hardly at all…………………………   
I feel cheerful:    I get sudden feelings of panic:   
Not at all……………………………    Very often indeed……………………   
Not often……………………………    Quite often…………………………..   
Not often……………………………    Not very often………………………   
Most of the time……………………    Not at all…………………………..   
I can sit and feel relaxed:    I can enjoy a good book or radio or TV 
programme: 
  
Definitely……………………………    Often………………………………   
Usually……………………………..    Sometimes…………………………   
Not often……………………………    Not often…………………………….   
Not at all………………    Very seldom………………………..   
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4.8: MHI 5 
MHI-5 UK Version 
These questions are about how you feel and how things have been with 
you during the past 4 weeks.  For each question, please give one answer 
that comes closest to the way you have been feeling.  
How much of the time during the past 4 weeks: 
 
All of 
the 
time 
Most 
of the 
time 
A good 
bit of 
the 
time 
Some 
of the 
time 
A 
little 
of the 
time 
None 
of the 
time 
Have you been a 
very nervous 
person? 
1 2 3 4 5 6 
Have you felt so 
down in the dumps 
that nothing could 
cheer you up? 
1 2 3 4 5 6 
Have you felt calm 
and peaceful? 
1 2 3 4 5 6 
Have you felt 
downhearted and 
low? 
1 2 3 4 5 6 
Have you been a 
happy person? 
1 2 3 4 5 6 
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4.9 Interview Schedule 
Recruitment structured interview 
 
Note identification details on tape, then proceed through items as 
listed: 
 
General Questionnaires: EORTC QLQ 30, FACT-G, SF36 
1. Did you have a clear preference for one or particular questionnaires?             
                                             Yes/No 
If yes: explore reasons: the way the questions were phrased, the holistic 
approach to the patients’ experience of cancer, the way a particular question 
related to their current state, (go to 2) other. 
 
2. Where there any particular questions you felt were particularly important for 
you?                                              Yes/No 
 
If yes, explore and note which ones and why. 
 
Head & Neck Questionnaires: EORTC H&N, FACT-H&N, UWQoL 
1. Did you have a clear preference for one or particular questionnaires?  Yes/No 
If yes: explore reasons: the way the questions were phrased, the holistic 
approach to the patients’ experience of cancer, the way a particular question 
related to their current state, (go to 2) other. 
 
2. Where there any particular questions you felt were particularly important for 
you?                                              Yes/No 
If yes, explore and note which ones and why. 
 
Psychological Questionnaires: HAD, MHI 5 
 
Did you consider that these questions helped you indicate how you are feeling?                                   
                                                       Yes/No. 
If yes, did you prefer one questionnaire?   HADS/ MHI 5 / no preference 
 
General points: 
 
Is there anything which was not covered by the questionnaire that you think we 
should know to help the doctors/other team members to help you? : 
 
Note any issues raised: 
  
Are there any comments you would like to make about this study? 
 
 
Date of appointment for follow up questionnaire:    
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Follow up structured interview 
Before questionnaire: 
Has anything changed since your last questionnaire in terms of problems related 
to your cancer, or your life in general?                                                              
Yes/No 
If yes, note change and willingness to continue, if no, check willingness to 
continue. 
After completion: 
1. Did you have a clear preference for one or particular questionnaires?          
Yes/No 
 
If yes: explore reasons: the way the questions were phrased, the holistic 
approach to the patients’ experience of cancer, the way a particular question 
related to their current state (go to 2), other. 
2. Where there any particular questions you felt were particularly important for 
you?    Yes/No 
If yes, explore and note which ones and why and note. 
 
Recheck answers at first interview and note and explore any changes in 
preference. 
Is there anything which was not covered by the questionnaire that you think we 
should know to help the doctors/other team members to help you? 
Note any issues raised: 
 
Are there any comments you would like to make about this study?             
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Appendix 4.10 
Quality of Life Assessment in Individual Head 
& Neck Patients 
Baseline patients’ preferences for communication and attitude 
to QOL issues 
 
Doctor-patient communication is at the centre of good clinical practice and is receiving 
increasing attention in clinical training. We are interested in which topics you feel you 
should discuss with your patient during outpatient appointments.  
 
Please tick the appropriate box below. 
 
Would you discuss with your doctor during the clinic appointments: 
 
Rather not Yes, provided 
the doctor 
mentions it first 
Yes, I would 
like to discuss 
this topic 
Physical symptoms of illness or side effects of  
treatment (e.g. pain, sickness, cough, tiredness)? 
 
Limitations in  physical activities (walking,  
climbing stairs, general fitness) 
 
Limitations in  physical activities specific to   
their disease (eating, speech, swallow, shoulder 
function) 
 
How they feel emotionally (nervous, anxious,  
depressed) as a consequence of their illness 
 or treatment 
  
The impact of illness or treatment on their work,  
housework, leisure activities? 
 
The impact on their social activities (visiting friends,  
neighbours, clubs)? 
 
The impact of illness and treatment on  
relationships with their partner or family? 
 
The impact of illness or treatment on  
their appearance? 
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Generally, how often do you discuss these issues with your doctor 
during clinic consultations? 
 
Never Rarely Sometimes Often Almost always 
 
Overall health 
 
Symptoms of disease 
or side effects of treatment 
 
Limitations in physical  
activities as a results  
of disease / treatment 
(walking, climbing stairs) 
 
Limitations in  physical             
 activities specific to                  
their disease (eating, 
speech, swallow, shoulder 
function) 
 
Limitation in doing  
work / housework or  
leisure activities 
 
Emotional distress 
 
Impact of disease on  
relationships with  
family/partner 
 
Impact of disease on  
social activities (visiting 
friends, neighbours) 
 
The impact of disease on  
appearance? 
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Appendix 4.11 
Recruitment to Study 
 
Clinic:                                                                               Date: 
 
Hospital number (or identifier):  
 
 
 
 
 
Sex:                                                          Date of Birth: 
 
Consultant(s):                                         Speciality(ies): 
 
Ethnic Origin: British (white)/ British (other)/ European / Asian (Indian)/  
                         Asian (Chinese)/ Afrocaribbean/ Other.   
 
Marital status: married; living with partner/ other close family / living alone 
 
Occupation: employed: yes / no. If yes: manual / non-manual. 
                      change since diagnosis: yes /no. 
  
Study group for which eligible:   
                             early larynx  /  late larynx  /  early oral  /  late oral /  thyroid 
 
TNM: clinical:..………./ na.   pathological:…………./ na. (na=not applicable) 
 
Treatment:         surgery / radiotherapy / combined [surgery + RT] /        
                           chemotherapy / brachytherapy (note all that apply) 
Date treatment completed: 
 
Agreed to take part:                            yes   / no 
 
If no, please note reason given 
 
 
If yes:  all questionnaires completed           yes/no 
             
            interview completed                         yes/no 
  
            consultation taped                            yes/no 
 
            annotation requested                       yes/no 
     
            copy of letter requested                   yes/no 
 
 
Date of second study (if possible note contact details in case date changes) 
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CHAPTER 5 - Practical Aspects of Study 
Management and Recruitment 
 
5.1  Managing the Study 
5.1.1  Appointment, Training and Governance of Staff 
The need for the patient interviews to be performed by someone independent of 
the clinical team required appointment of suitably trained research assistants. I 
prepared a job description which was duly approved by Human Resources, the 
key elements being: 
• Experience of working with patients, ideally with vulnerable patients. 
• Experience of data collection and management. 
• Experience of working with Microsoft Office and basic IT skills. 
During the study, we had the services of two Research Assistants (RAs); the first 
held a Master’s Degree in Psychology and she supported the study for the first 
period of recruitment (November 2005 – November 2006). The second had 
experience in clinical Oral & Maxillofacial Surgery and some research 
experience. He was Asian by ethnicity. One of our aims was to try to include 
ethnic minorities, an aim we hoped he might facilitate. In fact, the pattern of 
recruitment and characteristics of participants who entered remained constant 
between the two periods. 
On appointment, given the direct contact with patients, a full CRB check had to 
be completed and, as well as a contract with the University, evidence supplied to 
support the granting of a Hon Contract as a Clinical Research Assistant by the 
Trust.  Training was given to the staff according to the Standard Operating 
Procedures of the Cancer Research UK Psychosocial Oncology and Clinical 
Practice Research Group (POGCPRG), based at the University of Leeds. I 
undertook Induction to the study, data collection and entry together with practice 
in ‘dummy’ study entries to ensure compliance with the Clinical Report Forms and 
consistency in data collection. Practical experience in recruiting patients to 
studies was kindly provided by members of the POGCPRG, by allowing the RAs 
to observe their studies. During the second period of recruitment, the Good 
Clinical Practice guidelines (GCP) had been introduced. Both I and the second 
RA completed GCP training. 
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5.1.2 The Clinical Environment: 
The study was based in the Head and Neck (H&N) Oncology team. This allowed 
recruitment through a number of clinics: the multidisciplinary head and neck clinic 
(MDC), based initially at the Cookridge Hospital and latterly at the Institute of 
Oncology, St James’s University Hospital, the Maxillofacial Out-Patient Clinics 
based at the Leeds Dental Institute, the Ear, Nose and Throat (ENT) Clinics, 
based at the Leeds General Infirmary and the Thyroid Clinic which had some 
presence in the ENT clinic and also a medical oncology clinic based initially at the 
Cookridge Hospital and latterly at the Institute of Oncology. Recruitment 
opportunities were available for much of the working week. 
 
Figure 5.1: Clinics from which participants could be recruited. 
Day/Time Monday Tuesday Wednesday Thursday Friday 
Morning MDC 
St. 
James’s 
 Max-fac 
LDI 
ENT 
‘valve’ 
clinic 
Max-fac 
LDI 
Afternoon Thyroid 
St. 
James’s 
ENT 
LGI 
 Max-fac 
LDI 
 
Key to recruitment by study group:  
MDC: All H&N groups (EO, LO, EL & LL),Thyroid: Thyroid patients 
only.ENT: EL & LL and occasional thyroid. Max-fac: EO & LO  
Note: Access to the ‘valve’ clinic was only possible in the second study period. 
 
5.1.3 The Process of Recruitment 
Information sheets (Appendix 5.1) were placed in all clinics and renewed as 
necessary. Clinic staff from all disciplines were briefed about the study. 
On a weekly basis I opened and searched the clinical database to pre-screen for 
potentially eligible participants by disease site and stage. PPM allows a ‘watch’ 
system which can flag individuals and generate a trial episode.. For patients 
attending clinics where the records were still paper based we created a small 
number of ‘slots’ which allowed details to be entered manually and later 
synchronised with the main server. In practice this worked well for most cases, 
although the system was not able to be activated for 7 potential entrants (from 
159). Ours was the first study to use the PPM clinical trials system and these 
failures occurred in the early period, each problem being rectified as the system 
was refined. 
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In clinic, the RA sought an introduction and provided the participant with an 
information sheet. Basic details (Appendix 5.2) were collected from those who 
agreed and further discussion or study entry arranged according to the wishes 
and convenience of the participant. In practice, people were keen to enter the 
study. In accord with our ethics approval, we were not allowed to formally record 
reasons for refusal to enter or withdrawal but the main reasons offered informally 
were lack of time and use of hospital transport requiring a return to the central 
waiting area. 
Once a patient had agreed to enter, the consent form (Appendix 5.3) was 
completed and arrangements made for the interview and questionnaire 
completion. Much discussion had been held on whether the intervention should 
take place before or after the consultation. In practice, we needed to 
accommodate the participants, most of whom were keen to use the ‘waiting time; 
for the study. The clinics were relatively flexible in timing and usually running late, 
so participants simply completed the study and then had their consultation. When 
more practical, the consultation took place before the intervention. 
The interview was conducted in a quiet room to provide privacy and a lack of 
distractions. Data was entered directly into the touch-screen computer. 
Figure 5.2: Collection of data in the ‘quiet room’  
 
Participants could break off the intervention at any stage. In practice, this was 
very unusual and of 144 datasets, 138 held a complete set of General and H&N 
questionnaire responses (reduced to 135 when psychological questionnaires 
were also considered, however these were not formally analysed in terms of 
opinion and preferences). The usual reason for interruption was the arrival of 
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hospital transport, although in one case, a  participant’s young child became 
restless so the intervention was terminated. 
The touch-screen was configured to guide the participant through the intervention 
offering the questionnaires in random order automatically as shown in the 
following figures. 
 
Figure 5.3 Using the Touch-screen: the  welcome screen  
 
 
 
Figure 5.4 Using the Touch-screen: answering a question 
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Figure 5.5 Using the Touch-screen: completion of intervention 
 
 
At the conclusion of the interview data could either be saved to the touch-screen 
computer or, if a link to the Trust server was available, immediately uploaded into 
the central server. This approach was used whenever possible and was carried 
out for all participants who held a PPM clinical record and hence an electronic 
‘identity’; the only exceptions being the ‘new’ patients whose study identity had 
been created manually and offline. For these, synchronisation with the server 
was undertaken as quickly as was practically possible, The advantage of this 
approach was that sensitive data was not held on the laptop computer. 
 
5.1.4 Day to Day Governance 
 
Recruitment was monitored by means of an ‘Excel’ spreadsheet which linked to a 
graph showing target and actual figures. In the early stages, recruitment was 
rapid in line with target. After around six months, the number began to reduce. 
The reasons for this were explored. The usual follow up pattern for H&N cancer is 
of frequent appointments in the first three years after definitive therapy and less 
frequent ones thereafter. The ratio of eligible to already recruited patients was 
gradually decreasing, and we had increasingly to ensure that we identified 
patients returning for a longer term review and those reaching their first 
anniversary of their therapy and becoming eligible to join the study.  
Recruitment was also monitored against sub-group and we perceived that two 
groups, early larynx (EL) and late larynx (LL) were progressing very slowly. I 
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explored the reasons for this with clinical colleagues. One problem was that in the 
ENT clinics there was a concentration of oncology surgical review patients on the 
third Tuesday of each month. Given the time required for the study intervention, 
recruitment of two patients per clinic was the maximum likely to be achieved. This 
was in contrast to the Maxillofacial clinics where oncology reviews were held in 
every clinic and the available population was therefore much greater. Although 
there was only one thyroid clinic per week, patients appeared very keen to join 
the study and this group achieved the highest recruitment figures but also had 
the highest refusal rate, usually due to time constraints.. 
We attempted to address the imbalance by preferentially approaching ENT 
patients at the MDC. During the second period of recruitment a new ‘valve’ clinic 
opened on Thursday mornings and arrangements were made to attend this clinic. 
Despite these measures, recruitment of ENT patients remained a challenge 
throughout the study 
 
5.1.5 Test/Retest 
 
The plan was to achieve this in 10% of the population. Practical limitations 
included the frequency of follow up appointments. H&N patients had frequent 
appointments but thyroid patients often attended only once per year and 
arranging two interventions proved extremely difficult in this group. 
 
5.1.6 Closure of Intervention 
 
Participants were thanked at the end of their intervention and permission sought 
to approach them again. In practice this was done opportunistically, when new 
patients (especially ENT patients), were not available for approach. 
 
5.2  Recruitment 
 
Recruitment took place over two periods, November 2005 – November 2006 and 
December 2007 – September 2008. The reason for the gap was the need firstly, 
to obtain external funding for a Research Assistant to conduct the interviews and 
secondly the period required to gain the necessary contracts (academic and 
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honorary), permissions (CRB check) and to ensure that the Research Assistant 
had been given full training to undertake the task.   
Over the period of recruitment, 243 patient records were entered into the clinical 
trials management system (PPM Clinical Trials Database). Of these, 220 were 
approached at their clinic appointment and considered study entry. At completion 
of the study all hard copy consent and demographic forms were checked to 
ensure reconciliation with the questionnaire data. 152 patients consented to 
undertake the intervention and ‘hard copy’ clinical report forms, were completed. 
This represents a lower level of recruitment than is usually achieved in interview 
studies and I believe this was due to fully informing all eligible people about the 
length of the intervention. The high level of completion once entry had been 
agreed would support that view. Full ‘hard copy’ and electronic study records 
were retrieved for 144 patients. For 8 participants questionnaire data was not 
available via the server although hard copy records indicated that it had been 
collected (2 LO, 2 EL and 4 Thy).  
We planned follow up interventions on 10% of the total sample and these were 
carried out for 22 participants. 10 full electronic records for test/retest could be 
retrieved automatically from the database but all patients were identified by 
manual checking. PPM had assigned new entry ‘slots’ to the remainder, although 
the unique identifiers were repeated and allowed manual linking of the 
anonymised records.  
Data handling was made manageable through the ability to export study data 
directly as an ‘Access’ database to a University desk top computer and 
eliminating any need for manual data entry. PPM had applied its automatically 
generated identifiers using a binary numerical system so, to analyse by group 
and sub-groups, I simply needed to add our own study identifiers which were by 
study group and sequential entry study numbers. I exported the data into an 
‘Excel’ spreadsheet and added a column to allow analysis according to study 
group, using our own identifiers by sub-group. Data was sorted by study group, 
basic demographics by questionnaire and by intervention. Once data had been 
fully verified it was entered into a SPSS v15 database for analysis. 
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28 12.7 12.7
25 11.4 24.1
40 18.2 42.3
47 21.4 63.6
80 36.4 100.0
220 100.0
EL
LL
EO
LO
Thyroid
Total
Frequency Valid Percent
Cumulative
Percent
EL
LL
EO
LO
Thyroid
Total
Group
Frequency
Statistics
0.0
50.0
100.0
150.0
200.0
Va
lu
es
5.2.1 Demographics of Study Population: 
5.2.1.1 Comparison of Participants v Non-Participants: 
The entry status is as shown in Tables 5.1-5.3. Slightly more males were 
approached than females (52.9% compared to 46.6%). 
 
Table 5.1 Entry to study by number and percentage (all groups) 
  
Table 5.2 Entry to study by gender (all groups) 
 
 
In terms of eligible subjects per group, the highest availability was for oral cancer 
representing 39.3% of the study population and divided into late oral (21.3%) and 
early oral (18.1%). Thyroid patients represented 36.2% of the population 
approached. It proved more difficult to approach laryngeal patients who 
represented 24% of the population approached, divided into early (12.7%) and 
late (11.3%) subgroups. 
 
Table 5.3 Entry to study by Sub-Group 
 
 
 
 
Translating those who were approached and who spoke to the RAs about the 
study to actual entrants the figures are 144 from 220 (65.5%) for the whole study 
61 27.7 27.7
159 72.3 100.0
220 100.0
Refused
Entered
Total
Frequency Valid Percent
Cumulative
Percent
117 53.2 53.2
103 46.8 100.0
220 100.0
Males
Females
Total
Frequency Valid Percent
Cumulative
Percent
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group and 101 out of 140 (72.1%) for the H&N sites. Figures for each sub-group 
were EL 17 out of 28 (60.7%), LL 15 out of 25 (60.0%), EO 33 out of 40 (82.5%), 
LO 36 out of 47 (76.6%) and Thy (53.8%). 
 
Table 5.4 Entry to study by sub-group, age and gender 
 
 
Comparisons between those who chose to enter and those who did not were 
similar for gender, age and stage of disease by total group and by sub-groups. 
Considering the eligible study population by age, this was as expected for the 
H&N population with values lying mainly in the 6th and 7th decade. Age is shown 
in Figure 5.4, by mean, standard deviation and range, for the whole group and 
also by gender. It is worthy of note that the youngest H&N patients to be 
considered for entry to the study were 40 years of age and the oldest 96 years of 
age, compared to 20 and 79 for thyroid. Considering the data in terms of the 
population over 80 entered into the DAHNO database (Chapter 2) representation 
of older patients was welcome, as this group is often excluded from studies. Data 
was further explored using an ANOVA, showing that thyroid patients were 
significantly younger than the H&N groups. This difference is apparent for all 
H&N groups and Table 5.5 also confirms that there were no significant 
differences between the different H&N subgroups with respect to age. 
Age
67.00 21 10.488 50 89
58.43 7 11.872 34 69
64.86 28 11.273 34 89
66.67 18 8.616 49 79
65.86 7 9.599 54 76
66.44 25 8.704 49 79
67.09 23 13.853 42 96
66.53 17 13.766 40 85
66.85 40 13.641 40 96
57.50 36 9.776 40 81
73.91 11 7.803 62 86
61.34 47 11.631 40 86
58.11 19 13.068 28 73
47.67 61 14.348 20 79
50.15 80 14.670 20 79
62.60 117 11.959 28 96
55.55 103 16.490 20 86
59.30 220 14.657 20 96
Gender
Males
Females
Total
Males
Females
Total
Males
Females
Total
Males
Females
Total
Males
Females
Total
Males
Females
Total
Group
EL
LL
EO
LO
Thy
Total
Mean Age N Std. Deviation Minimum Maximum
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Table 5.5 Comparison of thyroid v H&N subgroups by age. 
 
 
My final exploration of data in relation to entry relates to my use of ‘early’ and 
‘late’ based on therapeutic burden rather than the conventional comparator of 
stage. Stage at presentation is shown in 5.6a, numerically and in 5.6b, 
graphically, confirming that the highest frequency was presentation with Stage IV 
disease (47.9%) a figure which corresponds to the literature for this cancer, 
where the frequency of late presentation is well recognised.  
 
 
  
Dependent Variable: Age
Bonferroni
-1.58 3.370 1.000 -11.14 7.98
-1.99 3.018 1.000 -10.55 6.57
3.52 2.924 1.000 -4.78 11.81
14.71* 2.689 <0.0001 7.08 22.34
1.58 3.370 1.000 -7.98 11.14
-.41 3.122 1.000 -9.27 8.45
5.10 3.031 .940 -3.50 13.70
16.29* 2.806 <0.0001 8.33 24.25
1.99 3.018 1.000 -6.57 10.55
.41 3.122 1.000 -8.45 9.27
5.51 2.634 .377 -1.96 12.98
16.70* 2.371 <0.0001 9.97 23.43
-3.52 2.924 1.000 -11.81 4.78
-5.10 3.031 .940 -13.70 3.50
-5.51 2.634 .377 -12.98 1.96
11.19* 2.251 <0.0001 4.81 17.58
-14.71* 2.689 <0.0001 -22.34 -7.08
-16.29* 2.806 <0.0001 -24.25 -8.33
-16.70* 2.371 <0.0001 -23.43 -9.97
-11.19* 2.251 <0.0001 -17.58 -4.81
(J) Group
LL
EO
LO
Thy
EL
EO
LO
Thy
EL
LL
LO
Thy
EL
LL
EO
Thy
EL
LL
EO
LO
(I) Group
EL
LL
EO
LO
Thy
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
Based on observed means.
The mean difference is significant at the .05 level.*. 
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Stage I
Stage II
Stage III
Stage IV
Total
Stage
Frequency
Statistics
25.00
50.00
75.00
100.00
125.00
Va
lu
e
s
Table 5.6.a. Numerical table of entry by Stage  
 
 
 
Table 5.6.b. Stage by recruitment presented graphically. 
 
 
 
 
 
 
 
 
 
 
The key question was whether I was looking at the same population using the 
‘early’ ‘late’ burden of therapy rating as would have been the case had I used 
stage. To explore this we compared the two groups by category. Figures 5.7a 
and 5.7b show the comparisons for the whole H&N study population and by sub-
group. To aid the comparison, we grouped Stages I and II as early, and Stages III 
and IV as late. This approach is commonly used in the H&N cancer literature. 
 
Table 5.7 Comparing ‘early’/’late’ by therapeutic burden to stage I/II 
and III/IV. 
 
5.7 a  All H&N Patients. 
 
 
‘Early’ ‘Late’ Total 
  Stage I/II 37 4 41 
  
      Stage III/IV 13 47 60 
  
      Total 50 51 101 
  
30 13.6 21.4 21.4
25 11.4 17.9 39.3
18 8.2 12.9 52.1
67 30.5 47.9 100.0
140 63.6 100.0
Stage I
Stage II
Stage III
Stage IV
Total
Frequency Percent Valid Percent
Cumulative
Percent
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5.7b Sub-group comparison. 
 
 
Stage 
I/II 
Stage 
III/IV 
EL 14  3 
LL  2 13 
EO 23 10 
LO  2 34 
 
It has to be accepted that the concept of therapeutic burden is new and in 
practice represents a continuum  ranging from narrow field radiotherapy to the 
larynx, through radical radiotherapy to larynx and neck to addition of 
chemotherapy. As the ‘cut off’ for ‘late’ in the larynx group was laryngectomy it 
must be accepted that there is heterogeneity in the ‘early’ group. Nevertheless, 
given the number of patients who were assigned to different categories using 
‘therapeutic burden’ rather than stage, it was considered appropriate to continue 
to explore therapeutic burden for comparison to the more traditional analysis by 
stage. The use of this parameter is supported by the fact that the largest number 
of transitions from ‘early’ to ‘late’ occurred in the oral group where, because the 
radiotherapy fields are much more standardised and chemotherapy is less often 
used, the ‘cut offs’ between the ’early’ and ‘late’ categories are more clearly 
defined.       
In the analysis of the definitive study the therapeutic burden was represented by 
‘early’ v ‘late’ and stage by comparing Stage I&II with Stage III&IV. 
 
5.2.1.2 Lifestyle and Return to Work in Head and Neck Cancer 
Patients 
To gain an understanding of the impact of cancer on participants’ lives and to 
give some background and context to later comments on issues and concerns, 
we asked for basic information on work (Appendix 5.2). Interest in this area is 
growing as more people survive cancer therapy and the financial challenge of 
both therapy and life beyond a cancer diagnosis becomes clear (Macmillan 
Cancer Support 2007). Peteet (2000) describes return to work as an important 
transition in the pathway from patient to survivor at individual level and at 
population level Cancer Research UK (CRUK, 2007) figures predict an increase 
in the prevalence of cancer amongst the working population. Although these 
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studies do not relate to H&N or thyroid cancer as distinct entities, it can be 
expected that the advances in therapy which have had an impact on other sites 
will become effective at this cancer site in coming years.  
Data collected included whether the patient had been in work at the time of 
diagnosis, whether they were still in work and whether their working status had 
changed as a result of their cancer. Given the age profile of this population, it is 
not surprising that the majority of entrants (79 from a total of 140 H&N records)  
described themselves as beyond working age 
61 patients were working at diagnosis and 43 remained in work at the time of the 
study, however 18 had or had chosen to change employment. A summary of 
working status for the H&N cancer patients is provided in Table 5.8 and the 
experience of return to work by subgroup, which proved to be very varied 
depending on whether the patient had ‘early’ or ‘late’ status and is therefore 
described in detail below. 
 
Table 5.8 Return to work by subgroup, H&N cancer patients  
Total group=61 responses 
Group  Gender  Employment Status 
Diagnosis Working Same Changed  
EL Male 9 4 3 1 
Female 1 0 0 0 
LL Male 8 5 1 4 
Female 3 0 0 0 
EO Male 11 10 7 3 
Female 5 4 4 0 
LO Male 23 19 10 9 
Female 1 1 0 1 
Total   61 43 25 18 
Key: EL= ‘early’ larynx, LL= ‘late’ larynx, EO= ‘early’ oral, LO= ‘late’ oral 
 
Early larynx (EL): 10 patients (9 males, 1 female)   
Of the 9 males, 4 were in paid work at diagnosis. A HGV driver, builder and 
salesman reported no change in occupation, however a car restorer did report a 
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change in occupation but did not indicate whether this was related to his cancer. 
Of those who had been in work, 1 patient was unemployed (unchanged) and 2 on 
incapacity benefits (unchanged), for the 2 remaining patients, no occupation had 
been entered. For the one female, no occupation was noted. 
Late larynx (LL): 11 patients (8 males, 3 females). 
Of the 8 males, 5 were in paid work at diagnosis. Only one, a successful local 
politician, is known to have remained in his previous employment. One patient 
reported the change to highways inspector was due to his previous business 
entering receivership, an event he did not associate with his cancer. A bakery 
worker took early retirement as he could not cope with the dust and the current 
working status of a courier driver is uncertain. The final patient in this group 
reported a positive outcome from his cancer. He has come out of retirement in his 
70s to teach skills in communication with cancer patients to medical students and 
Allied Health Professionals (AHPs). I patient was unemployed (status 
unchanged). For 2 male patients no details were entered; however, one of these 
had had multiple primary cancers and the other reported with a second primary 
cancer shortly after completing the study and died a few months later. It would 
seem unlikely that either of these patients were able to undertake work.  
None of the 3 females were in paid employment at diagnosis. One was and 
remained a housewife, the other two were and remained unemployed. One noted 
that she felt very discriminated against when she applied for work and that her 
laryngectomy prevented her applying for posts which met her previous skills in 
telemarketing. 
Early oral (EO): 16 patients (11 males, 5 females) 
Of the 11 males: 10 were in paid employment at the time of diagnosis, and of 
these 7 reported continued employment in the same job. Work ranged from self-
employed businessmen (2), civil service, TV presenter and broadcaster to 
haulier, engineering fitter and warehouseman. The remaining three whose 
current status is uncertain included a printer, warehouseman and a washing 
machine repairer. Only in one instance is a cancer related loss of job with 
subsequent continued unemployment noted. 
Of the 5 females: 4 were in paid employment, as a manager (2 patients), a 
property developer and a dental nurse. All continued in their previous work. The 
remaining patient was and remained a housewife. 
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Late oral (LO): 24 patients (23 males, 1 female). 
Of the 23 males: 19 were in paid employment at diagnosis.10 of whom continued 
in their previous employment (an accountant, engineers [4 patients], a manager, 
a postman a lorry driver, a welder and one man who did not state his occupation). 
One patient chose to train as a teacher and, although his previous employment is 
not noted, this may well represent choice; a further patient notes a change to 
agency work but not a reason for this. Outcomes are not noted for 2 patients, a 
gardener and a security officer. Of the remainder a Carer in a Residential Home 
had to cease work because of PEG feeding and continued severe morbidity; a 
medical physics technician struggled to return to work and achieved this 
transiently after prolonged absence but then developed paroxysmal atrial 
fibrillation and had to stop. Three patients reported losing their jobs (one manual 
worker and the other two occupation unknown) specifically as a result of their 
cancer and its treatment. The four who were not in paid employment at diagnosis 
were unemployed (2) or on incapacity benefit (2). 
There was only 1 female who reported work at diagnosis although she did not 
enter its nature. She changed her occupation to carer as a result of her cancer.  
 
5.2.1.3 Lifestyle and Return to Work in Thyroid Patients  
The thyroid patients present a different profile and experience of work. From 80 
participants, only 18 described themselves as retired. In this group, there is a 
higher proportion of females patients to males. Table 5.9 summarises their 
responses. 
Table 5.9 Working status of thyroid cancer patients  
Gender Work Status 
 Diagnosis Working Same Changed Unknown 
Male 12   9   7   1   1 
Female 50 28 17   6   5 
Total 62 37 26   7   6 
Total group=62 responses 
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62 (50 female, 12 male) described themselves as ‘working age’. Of the female 
patients, 28 were working. 17 in their previous employment, 6 had changed roles 
and for 5 the outcome was not noted. 14 patients were housewives, 4 were 
students. 1 was incapacitated, I unemployed and 2 had missing data.  Of the 12 
males, 7 remained in their previous role, 1 had changed jobs and for 1 no 
outcome was noted. 1 was a family carer and 2 unemployed. When their 
experience of living with cancer was explored in a semi-structured interview, the 
value of work was acknowledged and the main limiting factors were reported to 
be fatigue. This was worst after radio-iodine and often delayed return to work. 
5.3  Discussion 
The practical elements of identifying, approaching and recruiting patients, on the 
whole, worked well and the availability of the electronic record was critically 
important in terms of the number of subjects who were approached and the 
number who entered the study. Attempting to complete this task using manual 
records would have proved impossible, emphasising  the value of modern IT for 
comparative studies of patient experience and opinion using multiple measures. 
Inevitably we experienced some problems and in this first part of the discussion I 
will consider the technical aspects of data entry. 
There was a mismatch between the number of hard copy records and the 
electronic records. A number of electronic records were identified by study 
number and anonymised unique PPM number only. I manually cross checked 
against the date of recruitment to the study and was able to reconcile the data in 
all but 8 cases. This study was the first to use the PPM database which evolved 
throughout our period of recruitment. It was designed to work seamlessly with the 
oncology records, however, most patients were accrued through the surgical 
clinics which were not using the electronic database. The most likely explanation 
for the loss of data would appear to be errors during uploading and synchronising 
remotely acquired data with the central server. 
The allocation of a unique automatically generated identifier, rather than one 
generated through the study, meant that study numbers which had meaning in 
terms of group and sub-group analysis had to be manually entered. This feature 
has now been added to PPM. Participant numbers were allocated in binary 
system numbering; i.e. 1, 10, 101, rather than by consecutive numerals and 
again, this required manual cross checking and validation as our numbering was 
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by ordinal progression, included entry number and sub-group and included 
participants only rather than all people approached. As the first patient recorded 
and numbered using PPM declined to enter, this was a considerable task, 
requiring new study related identifiers being manually applied to the whole 
dataset.    
Given the size of the study and the complexity of the database, the PPM clinical 
trials system was critically important to study management. However the need to 
carefully validate, check and cross-check the data rather than relying on PPM 
Access queries alone became apparent as the analysis progressed. This was an 
important learning point as we move towards automated collection and 
presentation of data in clinical practice. Where a patient’s NHS record lies within 
the PPM system on a day to day basis, it is almost certain that the system will 
capture and link a second study entry. We knew from our hard copy, that 22 
participants had completed test /retest, however PPM only identified 10 directly. It 
is likely that the duplicate records arose with uploads from locations remote from 
the PPM system, entered as new patients at the source of data collection and 
subsequently processed as such. Manual cross checking using recruitment date, 
gender and date of birth allowed me to identify the test/retest subjects. 
Although this represented a substantial workload, at completion the data had 
been fully validated and was offered through the ‘Access’ database and the 
‘Excel’ database to which I copied it for ease of editing, in a way which  facilitated 
the analysis of each further episode. 
In terms of the practical conduct of the study, a core requirement for successful 
recruitment was that participation would not cause inconvenience to either the 
participants or the clinical teams. We, therefore, had to take a pragmatic attitude 
to the timing of the interview and consultation. In practice most interviews took 
place prior to consultation, the potential bias associated with this approach being 
that patients may well be prompted to raise items for discussion which might 
otherwise have been omitted. The result of this would be that consultations might 
appear more effective at capturing issues than would otherwise be the case. This 
aspect of the study is addressed in detail in Chapter 6, page 128.    
We had been concerned about the burden of data collection, and indeed this was 
the only substantial issue raised by peer-reviewers and the ethics committee. The 
choice of questionnaires had been carefully addressed and, to ‘anchor’ the study 
to a medical event, the consultation, I considered that a baseline measure of 
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opinion and perceived content of consultations was essential information. The 
added value of the psychological measures has already been discussed. I 
reduced the ‘importance’ and ‘well written’ questions to inclusion only in the H&N 
questionnaires, where specific questions reflected different issues. I also 
compromised on patient status. It would have been most interesting to interview 
those at active stages in their cancer journey but I elected to ask people who had 
reached a stable stage to enter the study as my priority was to achieve as full a 
dataset as possible and to make informed choices about the value of 
questionnaire assessment. To ensure the dataset was acceptable, we carefully 
monitored the first ten and then the next ten subjects for completion and whether 
they considered the intervention unduly burdensome. This aspect continued to be 
monitored monthly as the study progressed and did not prove to be a problem, as 
indicated by the high rate of completion of the full dataset. Factors which 
contributed to this success are most likely to be the availability and support of a 
trained RA throughout the intervention, the use of the touch-screen which was 
simple and quick to complete and the enthusiasm and support of the clinical team 
and the participants themselves. 
The imbalance between the number of entrants to each study group remained a 
challenge throughout the period of the study. ENT patients (EL, LL) proved very 
difficult to accrue. Entry figures (EL 60.7% and LL 60%) are lower than for the 
oral sites (EO 82.5% and LO 76.8%). As we were not able to request reasons for 
non-participation, I can only suggest explanations. The availability of clinics did 
reduce the chances to make contact with this group but sufficient contact was 
achieved to achieve higher figures than those seen. I briefed colleagues from all 
clinics and the ENT Consultants and Nurses did all possible to ensure the study 
was introduced and patients given a chance to enter. This study is not alone in 
facing challenges with this group and likely explanations are problems in 
communication and perhaps low self-esteem and problems in adjustment. This 
would be supported by the results of the return to work data where LL patients 
fared especially badly. A further challenge to recruitment which is also recognised 
more widely in the literature is participation by ethnic minorities. We only 
achieved two entries from this group, one Asian male and one Philippino woman. 
One hope had been that the appointment of an Asian male as a RA might have 
facilitated ethnic inclusiveness but this was not the case. 
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The group achieving the lowest translation through from approach to entry 
(53.8%) was thyroid cancer. Again the data on age and work status may provide 
an explanation as well as the follow up practice for this cancer site. For the H&N 
sites, hospital appointments take place at frequent intervals and, if entry was 
inconvenient at one visit, rescheduling was comparatively easy and, at the next 
visit, participants were prepared for the time required for the study and could plan 
accordingly. Thyroid patients attend at infrequent intervals, often 6 to 12 monthly, 
so recruitment had to more ‘opportunistic’ accepting those patients who were 
willing to spend additional time at the hospital on that day. Consultations in the 
thyroid clinic tended to be briefer and more straightforward and delays were 
unusual. Many potential entrants were accustomed to this and also often had 
work or family duties to return to, making recruitment least successful in 
percentage terms through this group, although a level of entry beyond the target 
was easily achieved. 
The one significant finding in relation to demographics was that thyroid patients 
were significantly younger than each of the other H&N groups. Given this, and 
their different disease experience, I shall consider them separately in each of the 
following sections, although I will relate their scores to those of the H&N groups 
to allow understanding of where their views are similar and where they differ. 
The most controversial area in this section is my use of ‘early’ and ‘late’ based on 
therapeutic burden, not on stage at presentation. I have been sceptical of the use 
of stage at presentation for some time, knowing that some Stage I/II patients 
undergo extensive therapy after relapse whilst others with Stage III/IV disease 
respond unexpectedly well to single modality management. In QoL studies, I 
believe it to be essential to capture therapeutic burden and my study gives the 
chance to explore this concept further. 
My final comments relate to the data on return to work. I wished to gain some 
insight into the status of the participants in terms of their day to day lives. 
Strategies to achieve this have included measurement of educational status, 
postcode and social deprivation and questionnaire assessments. Given the data 
burden of the whole study, I wished to use a measure which could be quickly and 
simply completed for as many potential participants as possible. Return to 
important aspects of ‘normal’ life has been a frequent discussion in my years of 
clinical practice and return to work has been many patient’s measure of their 
success. It has limitations in terms of the age profile of the population and also 
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incomplete data as completion of this item was entirely voluntary, however, it has 
provided a useful insight in an area where there has been no previous published 
work specific to this cancer site. In a more general cancer population Amir et al 
(2008) have examined UK cancer survivors’ views of work three years post 
diagnosis, looking at a sample of 225 patients, resulting in interviews with 41 
participants. The reasons for attrition of the sample were the same as those in my 
small sample, the need to confine the interview to those who were of working 
age, had been working at the time of diagnosis and willing to offer details about 
their employment status. The importance of work was emphasised in the 
interviews and pre-treatment 35 of the 41 participants continued to work until 
treatment commenced and 33 returned to work at varying times after completion 
of therapy. Important aspects were finance and the therapeutic benefit of keeping 
busy, social support from colleagues and resuming their pre-cancer life. The 
attitudes of and relationships with work colleagues and managers were important 
and return was often easier for those who had been in the same employment for 
some years; i.e. return to the same or a similar post. Sadly the study identified a 
lack of information or advice from healthcare professionals on this aspect of 
survivorship, an area which I will consider further as I report the experience of 
patients in consultations in Chapter 6.  
My small study reports very different experiences by stage and site of H&N 
cancer and for those patients with thyroid cancer. For the H&N groups the results 
indicated that patients diagnosed with early stage disease and requiring single 
modality therapy had a good chance of returning to their previous employment, 
this being the case for 3 out of 4 early larynx patients and 11 out of 14 early oral 
patients who were in paid employment at diagnosis. In these groups only one 
patient reported loss of employment which he thought was related to his cancer 
diagnosis. There is a marked contrast between early and late stage disease. The 
work experience of late larynx patients is particularly poor with two notable 
exceptions. Approximately 50% of the late oral patients in this study returned to 
work in their previous post. Although the figures represent a small number of 
patients and therefore limit the conclusions which can be drawn, the difficulties 
faced by ‘late’, i.e. multimodality therapy patients, are striking and indicate that 
exploration of work and finance is an important aspect of any future assessment.  
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5.4 Summary 
In this chapter we have considered the practical conduct of the study and the 
characteristics of the study population has been described. The concept of ‘early’ 
and ‘late’ based on therapeutic burden has been considered. Subsequent 
chapters will consider specific aspects, commencing with a consideration of 
consultations as the core of the interaction between patients and the health 
professionals who provide their cancer care. 
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Appendices: 
5.1: Information Sheet 
Development of a Patient Specific Questionnaire for Use in a Head & 
Neck Clinic 
You are being invited to take part in a research study to help us determine whether or not 
a questionnaire can be developed to help in the care of patients in a head & neck clinic. 
Before you decide it is important for you to understand why the research is being done 
and what it will involve. Ask if you are uncertain about anything or if you feel uncertain. 
There is a leaflet called ‘Medical Research and You’ and we shall be happy to provide a 
copy if you wish to have one. 
The study we are doing follows on from the one we did recently in this clinic. In that first 
study we used a single questionnaire to see if it either helped patients in consultations or 
raised new issues that might be helped by a member of the multi-disciplinary team. In 
that study, 30 out of 147 patients had new issues explored and a considerable majority of 
patients supported the continued use of a questionnaire in the clinic. The problem was 
that the doctors and other clinicians had to look through the full questionnaire and, in a 
busy clinic setting, that is difficult to achieve. We wish to explore whether we can adjust 
the way the questionnaire is completed to see if we can make it specific to the needs of 
individuals. 
Our next stage is to ask people attending the clinic for follow up to help us look at the 
main questionnaires used in the assessment of people attending head & neck clinics and 
to tell us their opinion of them. This involves answering questions on a touch screen and 
having a short interview. The investigation will take about 30 minutes and to check that 
we get similar responses, we need you to repeat the study in 3 to 4 months. We record 
your clinic consultation to see whether the same areas are covered and study a copy of 
the letter the clinic doctor sends to your own doctor for the same reason. 
If you wish to take part, please let either myself or the nurse researcher know. If you 
prefer not to, we understand and your treatment will not be affected in any way. 
This study forms part of a development programme for a patient specific questionnaire 
and results will form part of my doctoral thesis. 
If you have any questions, please do not hesitate to ask us. 
 
Yours faithfully, 
 
 
Sheila E. Fisher, MSc, FDS, FRCS. 
Senior Lecturer in Oral & Maxillofacial Surgery, 
University of Leeds  
 
Aine M. Donnelly MSc, 
Research Assistant, Psychosocial Oncology and Clinical Practice Research Group, 
University of Leeds.  
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Chapter 6 - Preferences and Perceptions of the 
Content of Consultations 
 
The medical consultation lies at the core of the patient / professional interaction 
and, for the purposes of this study, an understanding of how both participants in 
this interaction, patients and clinicians, perceive it provides core material. The 
components of a consultation can be considered according to the WHO definition 
(1948) as physical, mental and social well-being and one could define a ‘gold 
standard’ consultation as one in which each of these is considered.  
The aims of this chapter are to capture the opinions of patients in terms of what 
they would wish to have included in a consultation, to determine what they 
consider is discussed in consultations and to follow this through using a series of 
examples from routine consultations which were taped as part of this study and 
comments made by patients to the RAs about their main areas of concern in 
terms of their current status. 
The literature indicates that physicians tend to focus in discussing medical and 
technical issues and emotional issues were usually raised by patients (Dimoska 
et al, 2008, Fagerlind H et al, 2008). When patients initiated such discussions, 
this was often terminated without further exploration (Pollak et al, 2007). These 
descriptions of modern cancer practice do not accord with the aspirations of the 
Cancer Plan or the more recent Cancer Reform Strategy (Chapter 1, Section 1.2) 
or the needs of the patients as captured in the narratives (Chapter 1, Section 
1.1). There have been no studies of communication in the highly complex H&N 
environment of care and this lack of evidence led to including an analysis of 
consultation as part of this thesis. To consider my primary hypothesis that 
‘carefully designed and structured questionnaires can be used to improve 
the quality of life of H&N cancer patients’ it is essential to first understand 
patients’ aspirations and their perception of reality and to measure the reality of 
H&N medical consultations. 
This chapter reports the views of patients on what they would wish to see as part 
of a medical consultation and what they believe is included in a consultation 
together with comments made during their interviews. These aspects of the study 
are covered in the consultation content analysis derived from Detmar et al (2000) 
(see Chapter 4. Section 4.5.5). We followed the delivery of care through the 
QoL in Individual Patients  Chapter 6 
130 
 
content of consultations by exploring the level of communication through the 
number of items raised, who raised them and how important they appeared to be. 
To gain an understanding of the dynamics of consultation and the place a future 
questionnaire might play, a note was made of whether patients or doctors 
initiated discussion of specific areas. 
 
6.1 The Questionnaire Study: patient responses 
To determine patients’ views on medical consultations a questionnaire was 
adapted from Detmar et al (2000) (Appendix 6.1). The first group of questions 
related to wishes with regard to the content of consultations and the second 
covered a similar range of areas but considered whether patients felt that these 
were included in consultations. The question lists each began with a general 
question then items relating to physical matters both general and disease specific 
and symptoms and side effects arising from therapy. The next area to be 
addressed was emotional impact and emotional distress followed by social 
impacts on relationships and activities which form part of normal life. To this list, I 
added an item on appearance in view of its relevance to H&N cancer. 
For the first set of questions the responses were: 
0 = ‘I would not wish to discuss this item’ 
1= ‘I would like to discuss this item if the doctor raises it’ 
2= ‘I would like to discuss this item’ 
For the second set of questions the patients used a Likert scale to rate how 
frequently they considered the area was discussed in consultations in a range 
from 0= ‘never’ through to 5= ‘almost always’. The questionnaires were presented 
using the touch-screen system which automatically uploaded responses to a 
central server for analysis. This part of the study preceded the standard quality of 
life questionnaires. A parallel initiative, reporting clinicians’ views, was carried out 
and is reported in Chapter 8. 
To ensure that the range of experience and treatment related effects were 
included in the sample, I divided the participants into treatment groups as 
described in Chapter 4, Section 4.6 (Early Larynx [EL], Late Larynx [LL], Early 
Oral [EO], Late Oral [LO] and Thyroid [Thy]. To explore test /retest reliability a 
subgroup of patients completed the intervention twice. 
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6.1.1 Results 
Full records were achieved for 144 participants (33 EO, 36 LO, 17 EL, 15 LL and 
43 Thy). 22 patients achieved 2 interventions (7 EO, 9 LO, 3 EL, 2 LL and 1 Thy). 
The results for the wh
Figure 6.1: Patients’ wishes for consultations
Total group= 144 responses 
Key 0= I would not wish to discuss this item
doctor wishes it: 2 = I would like to discuss this item.
 
In  general,  patients  most  wanted  to  discuss ‘physical  activities  affected  by 
treatment’, a  category  which includes key areas  such  as  speech,  swallowing 
and  eating,  with  their  
side effects of treatment’. 
Figure 6.2: Patients’ perceived content of a medical consultation
Total group= 144 responses
Key 0 = Never; 1 = Seldom; 2 = Sometimes; 3 = Often; 4 = 
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ole group were as presented in Table 6.1. 
                                                   
 
: 1 = I would like to discuss this item if 
 
doctors. This was closely followed by ‘symptoms and 
 
 
Almost always
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These matched the patients’ views on what was perceived most likely to be 
discussed (Table 6.2), although 24% of patients indicated that symptoms and 
side effects were ‘never’ or ‘rarely’ mentioned and 29% considered this was also 
true for physical limitations due to the disease or its treatment. 
Once the questions moved beyond ‘hard’ clinical evaluations, the gap between 
aspiration and reality became more marked. Although 61.8% of patients indicated 
a wish to discuss how they felt emotionally, this was perceived to be addressed 
‘almost always’ or ‘often’ in only 11.2% of consultations. Patients endorsed a wish 
to discuss the impact of their disease on aspects of their daily living at a lower 
level and these aspects of living with a cancer diagnosis were unlikely to be 
raised in the consultation. 
Patients rated a discussion about the impact of their disease on their appearance 
highly with 59.7% wishing to raise it, yet in only 12.6% of consultations was this 
issue ‘almost always’ or ‘often’ addressed.  
Sub-group responses were explored using an ANOVA to analyse the results from 
the five sub-groups. Because the sub-groups represent small populations with 
numbers ranging from 15 to 43, the potential for spurious significant results was 
addressed by using the Bonferroni adjustment, thus setting a more stringent 
alpha level for each comparison. To ensure that the results were robust, the level 
for statistical significance was set at p=0.01, rather than the p=0.05 level usually 
adopted for population studies. To explore the data we looked at aspects of 
patient status which might impact on their experience of cancer and thus, their 
results. The sub-groups represent two aspects of H&N cancer, site and 
therapeutic burden. The latter was defined as the requirement for single modality 
therapy (early) or the requirement for multimodality therapy (late). To avoid 
omitting findings of importance because this classification derives from two 
aspects of disease I explored the data looking specifically at site (oral v larynx) 
and therapeutic burden (early v late) separately. In my study there were sufficient 
such patients to achieve statistical significance between these two groups, 
justifying considering them as separate categories in the analysis (Chapter 5, 
Section 5.2.1).  
To explore the likelihood that thyroid patients would represent a different 
population with different experiences and priorities an analysis was performed of 
Thyroid v H&N cancer patients. Gender is another factor which might be 
expected to influence the outcome. Exploratory analyses indicated a difference in 
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results when all groups were included compared to analysis of H&N cancer 
patients alone. This appeared to be due to the presence of a large enough 
number of thyroid patients of relatively high status in terms of QoL to skew the 
analysis. For this reason, all group gender analysis and H&N patient gender 
analysis was performed. The final category which we felt might impact on the 
results was age. On exploring the data, this did not emerge as a factor and was 
not considered further.  
The descriptive statistics for the whole study group and sub-groups are shown in 
Table 6.3 A and Table 6.3 B. 
 
Table 6.3 A. Preferences for Content of Consultations by Group and 
Sub-group 
 
Study 
Group 
Number 
of 
subjects 
Physical 
Sympt-
oms 
Side 
Effects 
Limitation 
in 
physical 
activity 
Limitation 
in 
physical 
activity 
specific to 
disease 
How 
you 
feel 
emotio-
nally 
Impact 
on work, 
house, 
leisure 
Impact 
on 
family, 
partner 
& social 
Impact  
on 
appear
-ance 
All 
Mean (SD) 
144 1.79  
(0.53) 
1.60  
(0.61) 
1.75  
(0.55) 
1.50  
(0.70) 
1.44 
(0.72) 
1.24 
(0.766) 
1.33 
(0.77) 
EL 
Mean (SD) 
  17 1.47 
(0.62) 
1.47 
(0.80) 
!.71 
(0.69) 
1.47 
(0.80) 
1.29 
(0.85) 
0.94 
(0.90) 
1.24 
(0.83) 
LL 
Mean (SD) 
  15 1.67 
(0.62) 
1.87 
(0.35) 
1.93 
(0.26) 
1.47 
(0.74) 
1.40 
(0.74) 
1.47 
(0.64) 
1.47 
(0.74) 
EO 
Mean (SD) 
  33 1.79 
(0.49) 
1.67 
(0.54) 
1.73 
(0.57) 
1.36 
(0.78) 
1.33 
(0.65) 
1.12 
(0.70) 
1.30 
(0.73) 
LO 
Mean (SD) 
  36 1.69 
(0.53) 
1.58 
(0.55) 
1.72 
(0.57) 
1.58 
(0.65) 
1.47 
(0.77) 
1.36 
(0.76) 
1.28 
(0.82) 
Thyroid 
Mean (SD) 
  43 1.74 
(0.49) 
1.53 
(0.67) 
1.74 
(0.54) 
1.56 
(0.63) 
1.56 
(0.67) 
1.26 
(0.79) 
1.37 
(0.76) 
Key: Mean based on the score 0= would not discuss, 1= discuss if doctor raises 2= would wish to 
discuss. 
 
Sub-group scores (EO, EL, LO, LL and Thy) followed the pattern of the study 
group as a whole across the range of issues addressed in this study in that 
symptoms and side effects of disease scored most highly followed by the other 
physical items with a gradual reduction as the ‘softer’ and social aspects were 
considered. A notable finding was the higher scores, mainly for LL but, to a lesser 
extent, for LO across a range of questions. This would indicate that these 
patients consider that clinicians discuss a wider range of issues. Whether this is 
perception or whether there may be variations in the content of consultation 
depending on status cannot be determined from this table alone but it is a finding 
worth further exploration. 
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Table 6.3 B Perceptions of the Content of Consultations by Group 
and Sub-group  
  
SG NS OH S&SE PG 
 
PS LWH ED ImpFP ImpSoc Imp 
App 
All mean 
(SD) 
144 1.69 
(1.14) 
2.50 
(1.23) 
2.48 
(1.28) 
1.60 
(1.51) 
2.30 
(1.36) 
1.31 
(1.29) 
1.02 
(1.19) 
1.09 
(1.89) 
1.03 
(1.20) 
EL mean 
(SD) 
  17 1.82 
(1.29) 
2.24 
(1.30) 
1.88 
(1.45) 
1.00 
(1.41) 
1.82 
(1.59) 
0.82 
(0.95) 
0.53 
(0.72) 
1.00 
(1.17) 
1.06 
(1.44) 
LL mean 
(SD) 
  15 1.80 
(1.37) 
2.93 
(1.34) 
2.87 
(1.25) 
2.07 
(1.67) 
2.53 
(1.36) 
1.87 
(1.51) 
1.20 
(1.47) 
1.73 
(1.58) 
1.53 
(1.69) 
EO mean 
(SD) 
  33 1.55 
(1.18) 
2.00 
(1.32) 
2.03 
(1.33) 
1.15 
(1.37) 
2.06 
(1.34) 
0.82 
(1.01) 
0.73 
(1.01) 
0.61 
(0.83) 
0.67 
(0.92) 
LO mean 
(SD) 
  36 1.72 
(1.03) 
2.72 
(1.03) 
2.72 
(1.11) 
1.97 
(1.44) 
2.97 
(0.97) 
1.72 
(1.34) 
1.22 
(1.15) 
1.36 
(1.20) 
1.14 
(1.07) 
Thyroid 
mean (SD) 
  43 1.67 
(1.09) 
2.65 
(1.15) 
2.72 
(1.20) 
1.72 
(1.55) 
2.02 
(1.39) 
1.35 
(1.31) 
1.21 
(1.32) 
1.05 
(1.15) 
1.05 
(1.15) 
Key: SG=Study Group, NS=Number of Subjects, OH=Overall Health, S&SE= Symptoms and Side 
Effects of Disease or Therapy, PG=Limitation in Physical Activities, PS=Limitation in Physical 
Activities Specific to Disease or Treatment, LWH=Limitation in Work or Housework, ED=Emotional 
Distress, ImpFP=Impact of Disease on Relationships with Family or Partner, ImpSoc=Impact of 
Disease on Social Activities, ImpApp=Impact on Appearance. Mean score is shown as main result, 
Standard Deviation in brackets.  Score: 0-4 Likert where 0= never to 5=almost always. 
 
The ANOVA exploring the relationship between preferences for the content of a 
consultation and sub-group was remarkable for the similarity between all sub-
groups, with most of the results yielding a significance result of p=1.000 and the 
remainder showing a very minor trend. This indicates a consistency in terms of 
what our patients would wish to see included in a consultation. The results for 
perceived content were rather different, although given the relatively stringent 
definition of a statistically significant difference, this was not achieved. However 
trends were seen in ‘symptoms and side effects of disease or treatment’ between 
EO and LL and LO and similarly for ‘limitations in physical activity’, both general 
and specific to disease, work and housework and social activities. Despite the 
lack of a significant result, these trends are of interest as evidence that the 
content of consultation might, or at least be perceived to be, different depending 
on therapeutic burden has not been considered before. The results of the 
independent t-tests which achieved statistical significance were as shown in 
Table 6.4. 
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Table 6.4 Independent t-test results: Patients’ Perceptions of 
Consultation Content 
 
Parameter Question T df Sig  StdError 95% CI 
      
Lower Upper 
Early v Late S&SE -2.91 96.11 p=0.005 0.24 -1.19 -0.22 
 
PS -3.15 98.58 p=0.002 0.29 -1.47 -0.33 
 LWH -3.41 92.35 p=0.001 0.25 -1.37 -0.36 
 ED -3.97 90.46 p<0.0001 0.24 -1.42 -0.47 
Stage I/II v 
III/IV 
ED -3.78 99.00 p<0.0001 0.23 -1.33 -0.41 
 
ImpFP -3.42 97.44 p=0.001 0.20 -1.08 -0.29 
 
ImpApp -2.89 95.48 p=0.005 0.23 -1.12 -0.21 
Key: S&SE=Symptoms & Side Effects of Disease or Therapy, PS=Limitation in Physical Activities 
Specific to Disease or Treatment, LWH=Limitation in Work or Housework, ED=Emotional Distress, 
ImpFP=Impact of Disease on Relationships with Family or Partner, ImpApp=Impact of Disease on 
Appearance. 
 
 
These results emphasised the difference in patient experienced depending on 
the burden of disease and therapy. For the early v late therapeutic burden based 
parameter the significant differences were seen for ‘symptoms and side effects 
related to the disease and its therapy’ (S&SE) and ‘physical limitations specific to 
the disease and its therapy’ (PS), capturing the difference in therapeutic burden 
and the consequences in terms of long term status. The other significant finding 
was for emotional distress, a finding which was also present when Stage I&II 
disease at presentation was compared with Stage III &IV. For Stage the impact 
on relationships with family or partner (ImpFP) and impact on appearance 
(ImpApp) were also statistically significant. This may reflect the attitudes imparted 
at the beginning of the cancer journey when a more cautious prognosis and also 
likelihood of returning to normal function would be offered to these patients. 
Although no firm conclusions can be drawn from the quantitative data alone, it 
provides a basis for exploration of the consultations. 
 
6.1.2 Test/retest 
22 participants completed the intervention twice (EL3, LL2, EO7, LO9 and Thy1).  
Dr Adam Smith and I explored the data and carried out a weighted kappa 
analysis for measure of agreement as described in the proposed statistical 
method (Chapter 4) (Pallant, 2007) For preferences for communication we used 
the 0, 1, 2 scoring but for ‘perceived’ content we combined the two lower 
responses to give an overall ‘infrequent’ (i.e. negative) rating and the two upper 
responses to give a ‘frequent’  (i.e. positive) rating. The small numbers limited 
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this approach. For the most highly endorsed response in the first section, 
‘limitation in physical activities specific to disease’ the kappa was 0.52, but overall 
it was 0.3, signifying a modest association. 
When we looked at patterns from the results, responses of 1 or 2 were usual in 
the ‘preferences’ section and it was variation between these two responses which 
were being assessed. The availability of 5 responses for the ‘perceptions’ 
category made a statistically valid result very unlikely.  
I, therefore limited further analysis to descriptive considerations of the data. Table 
6.5 a and b compared the means between the first and second interventions for 
‘preferences’ and ‘perceptions’. 
 
Table 6.5 a Comparison of Means, Test/Retest, Preferences 
 
Question Scores Mean (SD) 
 Intervention 1 Intervention 2 
Physical symptoms & 
side effects of treatment 
1.55 (0.67) 1.55 (0.60) 
(Limitations in physical 
activities (general) 
1.64 (0.58) 1.64 (0.66) 
Limitations in physical 
activities (specific) 
1.64 (0.66) 1.77 (0.53) 
Emotional impact 1.41 (0.85) 1.59 (0.67) 
Impact on work, 
housework, leisure 
1.41 (0.73) 1.45 (0.80) 
Impact on social 
activities, family & 
friends,  
1.27 (0.83) 1.32 (0.78) 
Impact on appearance 1.27 (0.83) 1.18 (0.85) 
 
 
I carried out an independent t-test comparing the means for each individual 
question confirming the impression from the tables that there was no statistical 
difference between the mean scores comparing the first and second 
interventions. 
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Table 6.5 b Comparison of Means, Test/Retest, Perceptions 
 
Question Scores Mean (SD) 
 Intervention 1 Intervention 2 
Overall health 1.22 (1.19) 1.31 (0.78) 
Symptoms of disease 
and side effects of 
treatment 
2.59 (1.18) 2.31 (1.36) 
Limitations in physical 
activities (general) 
2.18 (1.22) 2.27 (1.16) 
Limitations in physical 
activities (specific) 
1.64 (1.43) 1.77 (1.27) 
Impact on work, 
housework, leisure 
2.45 (1.22) 2.27 (1.08) 
Emotional impact 1.23 (1.02) 1.45 (1.22) 
Impact on relationships 
with family/partner 
0.95 (1.17) 1.09 (1.15) 
Impact on social 
activities,   
friends/neighbours,  
1.22 (1.02) 1.14 (1.25) 
Impact on appearance 0.95 (1.13) 0.82 (0.91) 
 
 
 6.2 Consultation priorities derived from interview 
 
The interview schedule asked participants to identify areas which were important 
to them, either from those included in the questionnaire or additional items. For 
the purpose of this thesis I reviewed the responses from a subset of patients.  
Twenty interviews were selected from the whole sample, looking to identify at 
least 5 from the longest recorded tapes, 10 from medium length tapes and 5 from 
the shortest tapes. The sub-groups represented in this sample were: EL (n=2), LL 
(n=2), EO (n=5), LO (n=5), Thy (n=6). 
The patients had been asked firstly which were the important issues and 
secondly what they considered was important but not included in questionnaires.   
They could also comment on their interactions with the clinical team and these 
findings were combined with those from the consultation in the next section. 
Material from this part of the study was highly varied and inevitably subjective. To 
allow analysis we devised a scheme whereby the answer was coded into a main  
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areas: physical, emotional, social and/or financial and then by name, e.g. 
physical /:chewing, emotional / family distress. To grade severity a simple 
scheme was applied where: 
1= item mentioned 
2= item mentioned as a problem 
3= item mentioned as a priority. 
A score of 0 indicated that one rater has scored an item but the second had not 
included it. I scored all responses; a subset of 5 was scored together as a 
‘training set’ by myself and one of the RAs who had accrued patients to the study. 
We then independently rated a further subset of interviews to determine inter-
rater reliability and I rescored the same set of interviews at a time at least one 
month apart from the initial score.  
The results of the inter-rater analysis are shown in Table 6.6.  
The categories of response were developed through listening to the tape, making 
a summary of material and then identifying the key words, as one would code a 
medical intervention. There were no predetermined limits to the number of 
categories, in practice they were well defined and relatively easy to fit into the 
coding scheme as shown in Table 6.6.    
From this table it can be seen that patients were much more likely than doctors to 
initiate discussion of significant problems. For H&N Rater 1 scored 42 items as 
initiated by patients compared to 43 for Rater 2. Both identified 18 issues raised 
initially by doctors. The majority were physical for both issues raised by patients 
and issues raised by doctors with both Rater 1 placing 30 (from 42) and Rater 2 
placing 32 (out of 43) responses in this category for patient initiated discussions 
and 15 (from 18) for doctor led items. However a wider range of problems was 
captured, including responses at a level indicating a priority. The most common 
issues raised in consultations were site specific in keeping with the ‘preferences’ 
and ‘perceptions’ ratings already discussed. Eating was most common but, where 
swallowing was raised, it was likely to be scored at the highest level by both 
raters. Considering issues not included in questionnaires, fear of recurrence was 
the most prevalent issue.  
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Table 6.6 Rating Consultations: Results from Inter-rater Analysis 
H&N Patients 
Issue- 
General 
Issue Specific Rater 1 Rater 2 
Patient Doctor Patient Doctor 
Physical Weight 1, 0,1, 1, 1, 1, 
2, 2, 
1, 2, 1, 1, 1, 1, 
2, 3, 
 
     
Physical H&N Mouth Opening 2, 2, 3,  2, 2, 3,  
 Dry Mouth/Saliva 1, 3, 3,  1, 3, 3,  
 Tongue Mobility 1, 2  2, 3  
 Numbness 2, 2,  1, 2,  
 Eating 2, 1, 2, 3, 3, 
2,  
2, 1, 1, 
2, 
2, 2, 2, 3, 3, 
3,  
2, 1, 1, 
3, 
 Teeth/Chewing 0, 3,  2, 3,  
 Swallowing 3, 3, 3, 1, 3, 3, 3, 1, 
 Oral Hygiene 1, 1, 2, 1, 
 Voice/Comm 2, 1, 2, 1,1, 2, 2, 1, 2, 1, 1, 2, 
 Sore Throat 1,  2,  
 Neck Pain/Stiff  1, 2,  2, 3,  
 Appearance 1  1  
 Medication  1,  1, 
Emotional Fear Recurrence 1, 2, 2, 2,  0, 3, 2, 3,  
 Anxiety 2, 3,  3, 0,  
 Bereavement 3,  3,  
Social Eating  3,  3, 
 Family 3,  2,  
 Work 1, 2, 2, 1, 2, 2, 
 Activities 2, 1, 2, 1, 
Other Smoking 1, 2,  3, 3,  
 Sun Protection 1,  0,  
Thyroid Patients 
Issue- 
General 
Issue Specific Rater 1 Rater 2 
Patient Doctor Patient Doctor 
Physical Fatigue 1,   0  
 Weight 1  0  
 Medication 1, 1, 1, 1, 2, 1, 1, 1, 
Physical H&N Mouth Opening 1  0  
 Dry Mouth/Saliva 2, 3  3, 3,  
 Numbness     
 Eating 2  2  
 Sore Throat 2,  3,  
 Swallowing 2,  2,  
 Neck Pain/Stiff 2 1, 3 1, 
 Parotid Swelling 3, 3  3, 3  
 Scar  2,  2, 
Emotional Fear Recurrence 2,  2,  
 Anxiety 2,  2,  
 
Thyroid patients had some common issues with H&N but of note was the 
importance of medication related issues and also that for 2 out of the 6 patients 
an episode of parotid swelling had occurred at a level which caused both raters to 
give a score of 3, representing a significant concern. Rater 1 identified 16 issues 
raised by patients and Rater 2 identified 13. In the thyroid patients selected no 
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social issues were identified. Anxiety, which may relate to thyroid status and fear 
of recurrence were the two emotional factors identified. 
The scoring system showed, on face validity, a good degree of consensus. Rater 
2 tended to score a little higher than Rater 1. On checking the data together, 
discrepancies in scores were explained by difficulties in hearing the tape, where 
one Rater had missed a short comment. Apart from those occasional problems, 
all scores were within one point of each other. The main area for debate was 
whether an issue was mentioned as a problem (score 2) or mentioned as a 
priority (score 3). Within the limits for this type of analysis it was concluded that 
the scheme was acceptable. 
On retesting, my scores were very similar to the first occasion, indicating that 
such differences as were found were due rather to individual variation in scoring 
than subtleties in the language in the consultation which would have led to 
variation during repeated scoring by one person. I also scored ten further records 
but no further issues were identified, indicating that the majority of pertinent 
issues had been identified in the first series of results. 
This indicated that specific problems were the focus of consultations but that fear 
of recurrence was raised in a number of consultations. 
 
6.2.1 The Medical Consultation 
As described in Chapter 5, these were taped with the permission of both patient 
and doctor. All patients were in the follow up stage and were familiar with the 
clinical teams. Although my emphasis was on issues raised, the way in which the 
consultation was conducted was of interest and I observed three styles of 
consultation. The first, which represented the majority of episodes, commenced 
with a broad opening question from which emerging themes were then explored. 
The second, often employed when a new doctor was meeting a patient for the 
first time, commenced with a brief summary of presentation, past therapy and 
current status and a check with the patient that this was accurate, then moving on 
to an open question about current status and problems. The final style, 
encountered least frequently, was at a recall visit for the results of specific tests 
when the immediate focus of the discussion was that element of care and the 
wider aspects of the patient’s status were omitted. Examples of all three styles 
have been reported. 
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We recorded the time of consultation in an attempt to link this to the number of 
issues explored and to who raised them. Considering the results above, I had 
hoped that this information might allow exploration of the length of consultation 
by therapeutic burden. However, for H&N cancer, the process of clinical 
examination is a core part of the consultation and the interaction usually moved 
seamlessly between the two with comments being made by patients and their 
doctors throughout. At the time of clinical examination, comments were made on 
areas checked or matters of advice but sporadically. To determine the actual 
verbal period of interaction with any accuracy proved impossible. 
 
6.2.2 Examples of Consultations and Comments on Consultation 
Content 
 
The effectiveness of a consultation is a consideration in whether the use of a 
questionnaire might add new and useful information or whether it might help in 
priority setting. To set this in context it is important to understand the dynamics of 
the patient/doctor interaction. In this section I have given examples from the 
consultation styles noted above and also two examples of where there were 
problems in communication. 
The first example is an open consultation in which the priority for the patient 
was the impact of his cancer and its treatment on his daughter. He also had 
concerns of his own about specific aspects and also there was a strong sense of 
psychological concerns. 
Doctor (D): Maxillofacial Surgery Registrar (higher surgical trainee).   
Patient (P): LO35, Male, Aged 46. 2 years post surgery and postoperative 
RT. Duration: 12mins 45secs. 
D: ‘How are you doing?’ 
P: ‘Terrible’. 
D: ‘Why?’ 
P: ‘My daughter has been playing up for the last 18 months, going out, staying 
out. Police are involved and she has been taken into care. She’s only 12 and out 
all night, must be about 100 times this year. Playing truant, acting up and I’ve 
been told I mustn’t let her in if she tries to come home but let the Police know, I 
could be in trouble if I do anything.’ 
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D: ‘Is this giving you a hard time?’ 
P:  ‘I’ve got another 4 years’ (note presumably of planned follow-up). If I’ve got 
cancer in my mouth now I won’t have an operation. I don’t care. I’m not having it 
cut out.’. 
D: ‘I hope it will be alright.’ 
P: ‘I don’t care.’ 
D: ‘OK if I take a look?’ 
P: ‘I’ll take teeth out……..daughter…she is well brought up, went to Church, 
seemed to have nice friends…..I’m getting an awful lot of thrush (oral 
candidiasis), phoned doctor, got cream stuff to put on it.’ 
D: ‘It doesn’t look too bad.’ 
P: ‘I can’t touch anything with this side of my tongue. It stings all the time. Feels 
like nerves in it jingling all the time.’ 
D: ‘The nerves do get damaged.’ 
P: ‘My mouth is always dry. I have to carry water all the time. I’ve not had a 
sweet, I mean a desert, for about 2 years.’ 
D: ‘Did you get RT to your mouth?’ (note: the Consultation was held at another 
Trust site, remote from the Cancer Centre, with access to specific records only at 
the time of the study. Now all have access to PPM and the full pathway record).’ 
P: ‘There was a wee lump in my mouth.’ 
D:  Looks good, nice and healthy.’ 
P: ‘I’m still smoking.’ 
D: ’We could talk about risks but you probably have too much going on in your 
life to stop right now.’ 
P:‘I stopped for 6 months. Doctor couldn’t give me more tablets. I take 
paracetamol for my pain. If I take anything stronger I might get addicted. How 
much does that matter?’ 
D: ‘All seems healthy today’ 
P: ‘Has thrush gone?’ 
D: ‘It looks fine but we do need to keep you under review’ 
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P: ‘Social Services are messing things up. Once things are sorted I want to get 
away from here and go back to Pontefract.’ 
D: ‘We need to give you an appointment.’ 
P: ‘I’ll send you my new address.’ 
In this example, the doctor was quick to acknowledge and not to dismiss the 
patient’s concern although there was little, as a health professional, that she 
could do to assist his social problems. She showed empathy then used the 
strategy of asking to check the local disease site to bring the consultation back to 
the cancer and current medical status. At this point, more specific concerns 
begen to emerge. She sounded throughout in control. Considering this interaction 
in the context of whether a questionnaire might have helped, it may have alerted 
her to the likelihood of a difficult and intense conversation about personal 
psychological and family concerns and perhaps a provided a prompt to suggest 
that she might explore psychological support for her patient, an element of this 
interaction which was not addressed, In the end the patient had been reassured 
about his physical status and the broader issues were acknowledged but not 
proactively addressed. 
Psychiatric help had emerged as an issue in the interview where, again, much 
emphasis had been on the family’s problems with the comment that ‘my daughter 
went haywire when my cancer was found, totally off the rails.’ The patient had a 
clear view of the function of the clinic. ‘The clinic is only here to do the physical. It 
does not look at the mental, that is as much a wound. It would be so good to 
have someone care about that part of it…..a Psychiatrist. someone who can help 
with this part’. It is worthy of note that this participant scored at ‘caseness’ level 
using HADS (score of 16 for the Anxiety Scale and 19 for Depression [caseness 
defined as a score of 11 or above]). 
On questionnaires, the patient preferred the EORTC – ‘this is the one which gives 
some insight into how I feel about things’ and also expressed support for the 
inclusion of psychological questionnaires in a patient assessment. 
This information indicates that a chance to offer psychological support which 
could have been identified using a questionnaire assessment and which would 
have been welcome was missed at this consultation and probably on an ongoing 
basis. 
QoL in Individual Patients  Chapter 6 
144 
 
The second type of consultation differed from the first only in the entry and scene 
setting, so I have quoted only the opening statement here: 
Doctor (D): Clinical Oncology Registrar (higher oncology trainee) 
D: ‘Hello, Mr xxxxx. We have not met before so I would like to go through what I 
understand from your notes before we talk about how you are now. I understand 
that you had a cancer of the voice box and this was treated by radiotherapy and 
you finished treatment in April last year. Is that correct?’ 
The patient acknowledged the summary and the consultation then followed the 
pattern of the open model as above, although, in this case, the patient was doing 
well with no significant physical or apparent emotional or social concerns. 
The next example is of a focussed consultation where a patient had been 
referred back to clinic for a common problem, concerns about teeth some years 
after completion of therapy. 
Doctor (D): Maxillofacial Senior House Officer (doctor with basic surgical 
training. This individual had gained her postgraduate diploma and was 
experienced in the care of post-therapy oncology patients).  
Patient (P): Male, LO17, Male, Aged 80. 5 years + after surgery with 
reconstruction and postoperative RT. 
Duration: 14mins 30 secs. 
D: ‘We have a letter from your dentist saying that your teeth are causing you 
trouble and I understand that you have had an operation to remove part of your 
tongue and also radtiotherapy a few years ago.’ 
P: ‘I had come to the clinic for a few years but my Consultant discharged me last 
summer. I had an op on the floor of my mouth. This tooth, its affecting the teeth at 
the back of my mouth – they’ve been trying to save them. Getting quite loose and 
sore, really tender.’ 
D: ‘Did your problems start after your radiotherapy?’ 
P: ‘Only the last 2-3 years. Teeth have got worse. Really tender. Had to have 
false teeth at the top. Keep rubbing against side of mouth and gums, makes my 
mouth very sore. I had my op in the February and waited 11 months for things to 
heal before I got my first false teeth. I did so well for the first three years. My 
speech improved. After that I just haven’t got any better. Worried about teeth, I’ve 
heard of osteoradionecrosis (note: an uncommon but serious condition where the 
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irradiated jaw bone necroses often after dental infection or extractions and which 
is difficult to control and manage). My whole jaw can feel quite tender. 
Sometimes the tooth is almost untouchable. People have told me how wonderful I 
am, doing things again with my arm. I know a lot of people are worse off than 
me.’ 
D: ‘Are your flap and mouth OK?’ 
P: ‘I want treatment here. I am struggling with my denture, have to use fixative, 
teeth can drop out, it gets very embarrassing.’ 
D: ‘Is it affecting your eating?’ 
P: ‘I can’t eat lost of things – meat. I can manage fish. Adjust to that, avoid hard 
food, lots of veg. I make own soup, am sick to death of soup. I wish my mouth 
was just more comfortable, that’s the main thing.’ 
D examines mouth 
D: ‘Would you like to have all these teeth out?’ 
P: ‘I know they are in a terrible state.’ 
D: ‘Your main problem is trying to keep them clean when you have so little saliva. 
It may be that they can be made more comfortable and I suggest we start with 
removing the worst tooth only then see how you go. I’ve checked the area where 
you had radiotherapy and the tooth is not in that area so you are not at risk of 
osteoradionecrosis.’ 
Patient accepts treatment plan and appointments are arranged. 
This consultation was well focussed but illustrated the long term cost of 
successful therapy for oral cancer. It also indicated that patients are happy to 
raise issues providing they are in the presence of an empathetic doctor. 
The examples above were typical of the range of consultations, from simple 
interactions with people who appeared to be coping well to those with profound 
physical, emotional and social concerns. Despite their training, doctors have to 
manage the consultation with no prior knowledge of what may emerge during the 
conversation and there is thus a risk that important prompts may be lost. Detmar 
et al (2000) and more recently Fagerlind et al (2008) reported that oncologists are 
more likely to address physical rather than psychosocial concerns. 
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The risk of undertaking a complex interaction such as a consultation without any 
prior briefing is that immediate responses are required which will occasionally be 
unhelpful, and at worst can lead to problems. This challenge to the core element 
of the way care is delivered takes us back to the patient narratives in Chapter 1 
and the two examples quoted below both relate to communication, one within the 
clinic and the other relating to exchange of information and mutual trust between 
health professionals. 
Doctors: Consultant Clinical Oncologist (D1) and Consultant ENT Surgeon 
(D2). 
Patient: Male, aged 50, approximately 12 months after radical 
chemoradiotherapy.  
Duration: 12 minutes. 
D: ‘it is good to see you gaining weight. You have put on 2 kg since your last 
visit.’ 
P: ‘I am feeling better and have more energy now’. 
D: ‘We should think about removing your PEG’ (feeding tube inserted directly into 
the stomach). 
P: ‘I really wouldn’t want to do that.’ 
D: ‘but your weight is so good, It is time to make progress.’ 
P: ‘I would not want to have the tube out.’ 
This narrative continued for over two minutes without any significant advance. At 
this time a second Consultant intervened 
D2: ‘How much of your daily intake of nutrition do you still use your tube for?’ 
P: ‘Virtually all of it.’ 
From this point the consultation became focussed on nutritional aspects. It is 
difficult to know how the misunderstanding arose. The first doctor was pleased at 
the improvement in an element of the patient’s status which had clearly been 
causing concern but made an assumption about the route for nutrition. This 
distressed the patient who simply repeated a wish to keep the tube. This was the 
one occasion where communication broke down and a second professional had 
to intervene before mutual understanding was re-established. Given the 
pressures on medical staff, it was remarkable that this kind of event happened 
rarely. There would seem to be a role for collecting information via a 
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questionnaire to establish priorities and status so that doctors are as well briefed 
as possible.  
The second example of a problematic consultation came from a patient and 
partner narrative as part of the interview.  
Patient: ‘My main problem is I can’t eat, I just cannot eat at all.’ 
Partner: ‘The one thing I didn’t like – ‘do a swallow test.’ The dietitian had done 
one before and told him he would never swallow again. After Christmas this 
young doctor decided he needed another test. I said ‘don’t get your hopes up.’ 
The dietitian, a smashing young woman, had told us straight. Doctor then got his 
hopes up. He (patient) said ‘what if everybody’s wrong?’ That put him back 
further than anything else because it got his hopes up when he had learned to 
cope. Young doctor (with emphasis in tape on ‘young’) gave false hope. If I could 
have got my hands on him, I would have slapped him. It was so unfair.’ 
It was clear that the consultations did focus on physical issues and a few patients 
commented on what they would expect from the clinical team, reinforcing this 
perception of the way the clinics were structured and the roles of their doctors. 
Although this is anecdotal, the views were consistent and no participant 
mentioned experience of their doctor taking a wider role.  
LO31, male, aged 63 said: ‘We’ve got this wonderful doctor who saved my life. 
He does his job. He is a brilliant surgeon. We need to be able to talk to someone 
else about other things but who and when? The only doctors in the clinic are 
surgeons and at home there is my GP. My surgeon knows about surgery. The 
GP hasn’t a clue about what is going on and there is nobody in the middle.’ His 
partner concurred ‘We need someone with common sense in the middle who 
understands. We get ‘support’, there have been times when we have been 
inundated with highly trained expensive people. The specialist should do his job 
but we do need someone else with a general approach who can give help and 
support with the non-medical bits.’   
 
6.3 Summary 
This chapter has raised a number of important and interesting issues. The 
concept that consultations might be tailored to the perceived needs of the patient 
with a concentration on a wider range of issues for those with more advanced 
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disease has not been raised in the literature but is of interest in a field where the 
literature suggests that stage is the most prominent predictor of QoL. The 
findings confirmed the literature in terms of the emphasis in the physical and 
arguably the ‘medical’ aspects of the cancer journey. The issues identified in the 
analysis of consultations are in accord with the literature, however, the level of 
concern about fear of recurrence is something which lay beyond the remit of 
questionnaire assessments at the time this study was developed.  
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Chapter 7 - Patient Opinions on Health Related 
Quality of Life Questionnaires (QoL) in Head & 
Neck(H&N) Clinical Practice 
 
This chapter reports on the findings from the questionnaire rating study in which 
the series of general and H&N specific questionnaires was presented to patients 
in random order, followed by the psychological questionnaires.  
The aims of this chapter are to explore the opinions and preferences of the study 
population for the questionnaires, to explore their self-reported QoL and to 
determine which items assisted in understanding the needs of the study group 
and sub-groups. To supplement this data and to allow consideration the views on 
questions expressed by individuals and also to determine what was important but 
excluded from the questionnaires, material arising from the interviews is 
discussed in the latter part of the chapter. 
The core part of this work considers patient opinions and preferences and, in 
terms of the primary outcomes from this chapter these are reflected in: 
• self-reported status 
• questionnaire preference 
• ratings for ‘importance’ and ‘well written’. 
• opinions of the content of questionnaires and areas which should be 
incorporated to reflect patient status.  
This was supported by analysis, according to scoring manuals for each 
questionnaire, of the actual scores arising from completion of the questionnaires.  
Differences between participant groups were an important part of this analysis. 
The experience of therapy, demographic profile (Chapter 5.2.1) and the symptom 
profile of the thyroid group was very different to that for the H&N sites (EL, LL, 
EO & LO) (Chapter 5), so the findings are presented by whole group, H&N 
patients compared to thyroid and by each H&N sub-group separately to attain the 
best possible understanding of the way status relates to questionnaires. My 
hypothesis was that significant differences between thyroid and H&N patients 
would emerge from the analysis. Having divided the H&N population into sub-
groups this hypothesis extended to likely differences between sub-groups. Sub-
groups were defined by two factors: therapeutic burden (early or late) and site 
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(larynx v oral) so these were explored independently. To compare the findings 
from this study with the traditional descriptions of early and late presentations by 
stage, the findings from early stage (Stage I&II) and late stage (III&IV). Staging of 
cancer was described in Chapter 2, section 2.2.4.  
In the first section I have considered the way in which the questionnaires were 
scored and the data analysed for each measure, ending with a brief comment 
relating to findings from that analysis alone. In this part of the study three general 
questionnaires: the SF-36, EORTC QLQ C30 and FACT-G were delivered by 
touch-screen computer in random order. Participants were asked to answer each 
question and then, once the questionnaire had been completed, to score the 
whole questionnaire on ‘importance’ and how ‘well written’ the instrument was 
considered to be. The three H&N measures were then delivered, also in random 
order but, on this occasion an ‘importance’ and ‘well written’; rating was attached 
to each individual question, rather than asking for a rating of the whole 
questionnaire. The two psychological questionnaires were simply completed 
without comment or rating, although opinions were requested during the 
interview. This section provided a valuable insight into the way that the 
questionnaires allowed self-reporting of status. Attempting in any way to compare 
the findings from different questionnaires is challenging. Their structures and 
scoring systems are very different, and even though I adapted some methods to 
facilitate understanding relationships between questions direct comparison is not 
possible using statistical methods alone. On analysing the data, there were 
common features, allowing some comparisons at descriptive level and also items 
unique to a single instrument where it is of interest to consider how well these 
were endorsed and by which populations of patients. This section on scoring has 
allowed the ratings of questionnaires and opinions about questionnaires to be 
placed in context. At the end of this section I have brought together comments 
relating to the findings from the whole range of questionnaires. 
The second part of the chapter describes the opinion ratings and preferences in 
regard to questionnaires. For the general measures this was done through a 
single question but for the H&N questionnaires, as each question often 
functioned as a ‘stand-alone’ rating of a matter of specific function or experience, 
an opinion was given for each question individually. The development of the 
scoring system was described in Chapter 4 and considered the views expressed 
on questionnaires, on actual choices for whole measures and why some 
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questions were supported and where concerns were voiced. The final interview 
question was ‘Is there anything which was not included which you would wish to 
see in a future questionnaire?’ The range and frequency of requests were noted 
as this may be important in assembling any future measure or updates of current 
measures from a patient centred point of view.  
 
7.1 H&N Patient responses to questionnaires  
!44 participants entered the study. Although participants almost always 
completed the full set of questions and there was a little attrition as the study 
progressed, with the lowest number of participants (135) completing the 
psychological questionnaires. There were small differences in numbers between 
the measures due to the random allocation of the questionnaires and occasional 
inability to fully complete the intervention. The main reason for interruption of the 
study intervention was the arrival of hospital transport. The maximum number of 
responses possible was 144 (33 EO, 36 LO, 17 EL, 15 LL and 43 Thy). Results 
for each questionnaire indicate the number of responses by total and by each 
sub-group. 
Scoring was done according to manual for each measure and statistical analysis 
performed to compare H&N v Thy, Early v Late, Stage I&II v III&IV. Age was 
explored but did not show significant results and was not considered further.  
 
7.1.1 SF-36 
As data was entered, scores on an ascending scale were recorded as shown in 
the example of the questionnaire (Appendix 4.1). Corrections to the recorded 
scores were required for ‘negative’ items as, on this questionnaire, a high score 
indicates a better status. Once this had been completed a mathematical 
transformation was carried out to express all scores on a scale of 0-100. The 
domains which emerge from grouping individual questions as indicated in the 
scoring manual are physical function (PF), role physical (RP), bodily pain (BP), 
general health (GH), vitality, social function (SF), role function (RF) and mental 
health (MH). The mental health score includes all elements of the MHI-5. The raw 
data scores are shown in Table 7.1.1.1.1 – 7.1.1.1.5. Particularly poorly scoring 
participants’ records are shown in red (most scores <=50 across the range of 
items). 
QoL in Individual Patients  Chapter 7 
152 
 
Table 7.1.1.1 SF-36 Scores by Sub-groups 
 
Table 7.1.1.1.1 Early Larynx (EL): 17 Responses 
Study 
number 
PF RP BP GH Vitality SF RF MH 
EL1 100 100 100 95 88 100 100 95 
EL10 15 50 19 40 31 25 50 30 
EL11 40 31 11 35 31 68 0 55 
EL12 30 25 23 35 56 38 33 40 
EL13 85 88 100 70 69 100 75 65 
EL14 100 93 100 75 75 50 92 70 
EL15 70 50 78 40 75 75 50 65 
EL16 40 50 100 35 38 88 50 45 
EL18 100 88 100 75 100 50 100 95 
EL19 95 81 89 75 56 75 83 75 
EL2 100 100 100 80 88 100 100 80 
EL3 65 31 45 30 25 38 42 30 
EL4 20 38 56 45 56 50 17 55 
EL5 10 25 11 20 31 25 17 50 
EL6 0 0 100 45 69 0 8 40 
EL7 80 50 78 85 69 68 67 50 
EL8 70 93 78 50 63 88 83 45 
EL Average 60 58.41 69.88 54.71 60 61.06 56.88 57.94 
 
 
Table 7.1.1.1.2. Late Larynx (LL): 15 Responses 
Study number PF RP BP GH Vitality SF RF MH 
LL1 100 100 78 90 81 75 92 75 
LL10 40 63 45 65 81 75 75 65 
LL11 95 100 78 75 88 100 100 70 
LL12 70 63 78 50 63 100 83 70 
LL13 80 100 100 60 93 50 100 85 
LL14 90 100 100 70 63 50 92 75 
LL15 20 69 89 70 81 88 58 65 
LL2 40 31 67 90 50 50 50 50 
LL3 85 93 100 55 88 100 92 80 
LL4 100 100 100 95 100 100 100 95 
LL5 85 63 100 90 88 100 92 95 
LL6 40 31 45 60 75 88 33 60 
LL7 70 81 100 60 81 88 92 80 
LL8 100 100 100 85 88 50 100 95 
LL9 80 100 100 50 88 100 100 80 
LL Average 73 79.6 85.33 71 80.53 80.93 83.93 76 
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Table 7.1.1.1.3. Early Oral (EO): 32 Responses 
Study number PF RP BP GH Vitality SF RF MH 
EO1 70 81 100 60 69 100 75 60 
EO10 55 88 67 60 75 100 100 75 
EO11 95 100 89 95 100 100 100 85 
EO12 30 38 45 40 69 88 25 45 
EO13 80 66 100 90 81 100 50 75 
EO14 100 100 100 90 88 100 100 90 
EO15 75 100 100 100 88 50 100 85 
EO16 45 88 89 75 63 38 83 50 
EO17 55 81 100 65 63 88 75 55 
EO18 100 100 78 50 44 38 100 35 
EO19 100 100 78 80 63 100 100 75 
EO2 100 100 100 90 88 100 100 95 
EO20 40 50 45 55 75 75 67 70 
EO21 80 75 67 55 81 100 92 85 
EO22 50 50 78 40 50 50 83 50 
EO23 5 25 45 45 50 38 33 55 
EO24 5 19 89 55 69 88 33 50 
EO25 100 100 100 95 88 100 100 95 
EO26 30 38 100 85 81 100 75 80 
EO27 100 100 100 75 88 100 100 85 
EO28 90 100 89 90 100 100 100 100 
EO29 75 75 56 60 69 100 75 70 
EO3 96 100 100 80 81 100 100 90 
EO30 80 81 100 65 81 100 58 75 
EO32 25 13 78 40 56 68 17 55 
EO33 65 19 100 75 81 100 83 65 
EO34 100 100 89 95 93 100 100 95 
EO4 95 88 78 90 81 100 92 75 
EO5 100 100 89 75 81 100 100 90 
EO6 95 100 100 80 88 100 100 75 
EO7 95 93 100 70 75 100 92 75 
EO9 100 100 89 80 75 100 100 85 
EO Average 72.84 77.13 85.56 71.88 76.06 88.16 81.5 73.28 
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7.1.1.1.4. Late Oral (LO): 35 Responses 
Study number PF RP BP GH Vitality SF RF MH 
LO1 5 100 100 55 81 100 100 90 
LO10 10 0 45 25 0 13 0 0 
LO11 30 44 45 10 31 25 42 40 
LO12 25 25 11 15 13 0 25 10 
LO13 70 63 34 35 56 68 75 65 
LO14 25 25 34 40 38 38 25 30 
LO15 5 0 100 50 56 13 0 35 
LO16 50 25 0 40 69 50 0 40 
LO17 100 100 100 85 93 100 92 100 
LO18 25 25 34 25 38 0 25 45 
LO19 80 25 11 45 25 25 25 25 
LO2 65 44 45 45 38 68 67 30 
LO20 35 93 100 80 81 88 92 70 
LO21 90 75 89 70 56 100 58 60 
LO22 100 100 100 80 93 100 100 90 
LO24 100 100 89 80 88 88 100 75 
LO25 95 75 67 85 81 75 50 70 
LO26 95 88 100 90 93 100 83 90 
LO27 100 100 89 95 100 100 100 90 
LO28 90 100 100 50 88 100 100 85 
LO3 10 6 78 0 31 38 42 30 
LO30 100 100 100 65 100 100 100 95 
LO31 50 50 67 50 75 25 75 50 
LO32 15 0 45 25 44 25 17 35 
LO34 95 56 89 65 56 100 67 35 
LO35 5 25 0 10 0 0 0 0 
LO36 80 69 100 50 69 100 67 60 
LO37 40 63 45 30 50 68 42 55 
LO38 0 50 11 65 88 75 92 70 
LO39 65 56 78 75 88 100 58 65 
LO5 10 100 56 80 75 100 100 55 
LO6 20 31 23 55 81 25 33 65 
LO7 20 13 23 15 50 88 8 25 
LO8 45 50 34 35 56 50 58 50 
LO9 100 93 89 40 88 100 100 85 
LO Average 52.86 56.26 60.89 50.29 61.97 64.14 57.66 54.71 
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7.1.1.1.5. Thyroid (Thy): 43 Responses 
Study number PF RP BP GH Vitality SF RF MH 
Thy1 95 100 100 100 100 100 100 90 
Thy11 55 81 100 60 88 88 50 75 
Thy12 70 81 78 85 63 50 75 55 
Thy13 70 44 78 30 44 68 50 40 
Thy14 100 100 100 75 93 100 100 95 
Thy15 85 100 100 85 88 100 100 80 
Thy16 80 100 100 70 93 100 100 75 
Thy17 75 63 78 75 56 88 67 60 
Thy18 85 100 100 70 88 100 100 95 
Thy2 100 100 67 90 75 100 100 85 
Thy20 100 100 100 70 75 75 100 75 
Thy21 65 100 78 70 88 100 92 80 
Thy22 40 56 56 75 81 25 50 65 
Thy23 100 100 100 60 63 100 100 80 
Thy24 95 93 100 90 75 88 100 50 
Thy25 100 93 100 45 75 100 58 75 
Thy26 95 88 67 75 75 88 83 70 
Thy27 90 100 100 40 63 100 100 55 
Thy29 60 81 78 45 69 75 75 55 
Thy3 95 81 100 90 93 100 100 90 
Thy30 80 56 89 65 75 68 58 40 
Thy31 50 50 34 15 50 13 42 50 
Thy32 65 50 67 20 50 88 75 35 
Thy33 90 93 100 90 81 100 100 75 
Thy34 100 100 100 90 75 100 100 75 
Thy36 55 56 78 40 69 75 50 55 
Thy37 95 100 100 50 81 100 92 80 
Thy38 85 81 78 60 44 88 83 35 
Thy39 100 100 100 50 75 100 100 85 
Thy4 90 100 100 95 63 100 92 95 
Thy40 70 93 100 80 88 100 92 90 
Thy41 100 100 100 80 88 100 100 80 
Thy42 90 56 78 55 31 68 50 30 
Thy43 50 19 0 30 13 0 33 10 
Thy44 100 93 89 80 88 100 92 85 
Thy45 95 100 78 80 93 100 100 95 
Thy46 85 100 100 50 44 100 100 40 
Thy47 90 100 89 80 69 100 100 85 
Thy48 100 100 100 90 81 100 100 95 
Thy5 55 63 67 55 44 88 67 55 
Thy6 100 81 100 85 88 50 100 90 
Thy7 100 100 100 90 81 100 100 85 
Thy9 100 100 100 55 81 100 100 75 
Thyroid 
Average 
83.72 84.93 86.67 67.09 72.02 85.65 84.33 69.42 
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The raw data allowed the range of scores and the variation between individuals 
to be appreciated. This was reflected in the standard deviations in the sub-group 
tables. The sub-group tables allowed a visual comparison of the data and an 
understanding of where the main differences lay. 
The scores for EL appeared low compared to those of the other groups, 
especially in comparison to LL, whereas the scores for EO were consistently 
higher than for LO. This is reflected in the number of participants considered to 
be scoring poorly, defined as scores <=50 across the item range. 6 out of 17 EL 
patients fell into this category, 4 from 15 LL, 4 from 32 EO and 14 from 35 LO. No 
thyroid patient scored at a low enough level to be included in this group.  All sub-
groups, including thyroid entered their lowest score for GH. For EL the next 
lowest ratings were for RF and RP. LL, in contrast scored at a low level on PF, 
with MH also comparatively low. This pattern was mirrored by the EO and LO 
groups. Thyroid patients had the highest scores and thus reported better quality 
of life, although three areas: GH, MH and Vitality were scored at a lower level 
than the other items. Bringing these scores together allowed an easier 
comparison between sub-groups and the aggregated scores were as presented 
in Table 7.1.1.2. 
 
Table 7.1.1.2. Descriptive Statistics for SF-36  
Study 
group 
PF 
Mean 
(SD) 
RP 
Mean 
(SD) 
BP 
Mean 
(SD) 
GH 
Mean 
(SD) 
Vitality 
Mean 
(SD) 
SF 
Mean 
(SD) 
RE 
Mean 
(SD) 
MH 
Mean 
(SD) 
All n=142 
mean (SD) 
69.69 
(31.14) 
72.37 
(30.41) 
77.92 
(30.41 
62.96 
(23.02) 
69.92 
(21.55) 
77.47 
(29.55) 
73.79 
(29.99) 
65.96 
(22.56) 
EL n=17 
mean (SD) 
60.00 
(35.62) 
58.41 
(31.58) 
69.88 
(34.86) 
54.71 
(22.74) 
60.00 
(22.57) 
61.06 
(29.84) 
56.88 
(33.86) 
57.94 
(20.08) 
LL n=15 
mean (SD) 
73.00 
(25.97) 
79.60 
(25.01) 
85.33 
(19.79) 
71.00 
(15.61) 
80.53 
(13.07) 
80.93 
(21.09) 
83.93 
(20.90) 
76.00 
(13.26) 
EO n=32 
mean (SD 
72.84 
(29.97) 
77.12 
(29.09) 
85.56 
(17.77) 
71.88 
(18.08) 
76.06 
(13.90) 
88.16 
(21.34) 
81.50 
(25.05) 
73.28 
(16.93) 
LO=35 
mean (SD) 
52.86 
(36.65) 
56.26 
(34.633) 
60.89 
(34.4.3) 
50.29 
(25.81) 
61.97 
(28.14) 
64.14 
(36.66) 
57.66 
(35.34) 
54.26 
(27.56) 
Thy=4 
mean (SD) 
83.72 
(17.60) 
84.93 
(20.68) 
86.67 
(20.55) 
67.09 
(21.39) 
72.02 
(18.92) 
85.65 
(20.55) 
84.33 
(20.86) 
69.42 
(21.22) 
Key: PF=Physical Function, RP=Role Physical, BP= Bodily Pain, GH= General Health, SF= Social 
Function, RF= Role Function and MH= Mental Health. 
 
 
To allow statistical comparison between sub-groups but also between factors 
which might influence the overall score, the data was entered into SPSS v 15. In 
common with the previous chapter, I applied the Bonferroni adjustment and the 
level for statistical significance was set at p<=0.01. Factors included in the 
analysis included: H&N v Thyroid, Early v Late, Oral v Larynx, and Gender. An 
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ANOVA was used to test significance between sub-groups, an independent T-
test was used for the direct comparisons between two groups. 
 
Table 7.1.1.3 ANOVA SF-36 by Sub-group 
 
Dependent 
Variable 
Study 
Group (I) 
Study 
Group (J) 
Mean 
diff (I-J) 
Std 
Error 
Sig  (2 
tailed) 
 95%  Confidence 
Interval 
 
     Lower 
Bound 
Upper 
Bound 
PF Thy LO 30.86 6.63 p<0.0001 11.94 49.79 
RP Thy LO 28.67 6.44 p<0.0001 10.29 47.05 
BP EO LO 24.67 6.36 p=0.002 6.52 42.84 
 Thy LO 25.79 5.92 p<0.0001 8.89 42.69 
GH EL LO 21.59 5.27 p=0.001 6.54 36.63 
 Thy LO 16,81 4.91 p=0.008 2.80 30.81 
SF EO LO 24.01 6.79 p=0.006 4.64 43.39 
 Thy LO 21.51 6.32 p=0.009 3.47 39.54 
RF EO LO 23.84 6.76 p=0.006 4.56 43.13 
 Thy  EL 27.44 7.92 p=0.007 4.85 50.04 
 Thy  LO 26.67 6.29 p<0.0001 8.72 44.62 
MH EO LO 19.02 5.259 p=0.004 4.04 33.99 
 
The ANOVA indicated significant differences between sub-groups. For PF and 
RF thyroid patients scored significantly higher than LO. For BP thyroid patients 
again scored significantly higher than LO but LO patients also scored at a 
significantly lower than EO, for the first time in this analysis suggesting a 
difference related to therapeutic burden. The trend for LO patients to score at a 
lower level than the other sub-groups continued and for GH they again scored 
significantly lower than thyroid but also than another H&N sub-group, this time 
EL. For SF thyroid and EO patients scored significantly better than LO. RF 
showed similar results, again with thyroid scoring significantly higher than LO and 
EL, and LO, in turn had a significantly lower score than thyroid as noted above 
but also than EO. For the final item, MH, the one result reaching significance 
according to our criteria was for EO patients compared to the LO sub-group. 
This first group analysis brought together some interesting findings. Despite the 
reported problems in returning to normal life after cancer as illustrated by the 
patient and carer narrative in chapter 1 and the figures on return to work (Chapter 
5, section 5.2) LL patients scored consistently higher than not only LO but EL 
although this did not reach significance. Trends emerging from this data were that 
EO patients scored generally well, followed by EL and LL with LO consistently 
entering the lowest scores. Thyroid patients appeared to be scoring significantly 
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higher than the H&N groups, explored using an independent samples t-test, with 
equal variances not assumed, as shown in the table below.  
 
Table 7.1.1.4 H&N v Thyroid, Independent Samples t-test 
 
Item T df Sig Mean diff Std 
error 
95% CI 
Lower Upper 
PF -4.65 135.33 p<0.0001 -20.13 4.32 -28.68 -11.57 
RP -3.98 120.46 p<0.0001 -18.02 4.53 -26.99 -9.05 
BP -2.89 113.56 p=0.005 -12.56 4.34 -21.16 -3.96 
RF -3.3 119.28 p=0.001 -15.11 4.54 -24.1 -6.13 
Equal variances not assumed. df=degrees of freedom, sig=significance (2 tailed), mean diff=mean 
difference, std error= standard error difference, 95%CI= 95%Confidence Interval of the difference. 
 
This indicates a significant difference for BP and RF highly significant differences 
for PF and RP. Vitality and MH showed a trend towards higher scores for thyroid 
patients but this did not reach significance. This would support the hypothesis 
that thyroid patients report QoL in a different way to H&N and that they should be 
considered as a separate entity in QoL studies. 
The relationship between early (i.e. single modality therapy) and late (i.e. 
multimodality therapy) was analysed in the same way, but no significant 
differences were seen, although there was a trend for early patients to report 
better QoL. For oral v larynx no significant differences were seen. Stage I&II 
patients tended to score higher than late Stage III&IV patients and this reached 
significance for BP. (Table 7.1.1.5). 
 
Table 7.1.1.5 Stage I-II v Stage III-IV. Independent Samples t-test 
 
Item T df Sig Mean 
diff 
Std 
error 
95%CI 
Lower Upper 
BP 2.83 92.52 p=0.006 16.11 5.69 4.8 27.41 
 
Gender proved interesting in that the results varied depending on whether the 
whole study group was selected or H&N patients alone. When the whole group 
was selected (81 males and 61 females) the female scores were consistently 
higher, although this only reached significance for GH (t=-2.81, df=138.26, sig [2 
tailed] p=0.006, std error=3.72, 95%CI= -17.84 to -3.117). However, when the 
thyroid patients were removed from the analysis, this tendency to higher scores 
for females was reversed although statistical significance was not reached. 
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7.1.1.1 SF-36 Summary 
The results from the SF-36 indicated that thyroid patients have higher scores 
than the H&N groups and, for a number of items, this was a statistically 
significant difference. The surprising result was the low level of scores recorded 
by the EL sub-group and the relatively high scores recorded by LL. When the 
effect of the thyroid patients was removed, multiple significant differences within 
the H&N sub-groups remained, mainly between LO and EO. Early patients 
tended to score more highly than late and Stage I&II compared to Stage III&IV, 
which would be expected if QoL reflects the impact of diagnosis and therapy. The 
effect of analysing the thyroid patients and H&N separately when gender was 
considered was shown to influence results and this practice was followed when 
considering the remaining questionnaires. 
 
7.1.2 EORTC QLQ C30 and Head & Neck Modules 
7.1.2.1 Scoring 
The QLQ C-30, as already described (Chapter 4, Appendix 4.2), has a score 
derived from the sum of individual items. The way in which these items contribute 
to the overall score is shown in Table 7.1.2.1. 
 
Table 7.1.2.1 Scoring and Scales for EORTCQLQ C30 
 
Item range is the difference between the highest possible and the lowest possible score 
for  an individual question. 
 
The raw score (RS) is the sum of the scores for each domain or item, divided by 
the number of questions answered in that domain. The score for the functional 
 
Abbreviation Number  
of items 
Items (question 
numbers) 
Item 
range 
Functional Scales 
Physical functioning PF 5 1 – 5 3 
Role functioning RF 2 6,7 3 
Emotional functioning EF 4 21 – 24 3 
Cognitive functioning CF 2 20,25 3 
Social functioning SF 2 26,27 3 
Global health status/QoL 
Global health status/QoL QL 2 29,30 6 
Symptom scales/items 
Fatigue FA 3 10,12,18 3 
Nausea & vomiting NV 2 14, 15 3 
Pain PA 2 9, 19 3 
Dyspnoea DY 1 8 3 
Insomnia IN 1 11 3 
Appetite loss AP 1 13 3 
Constipation CO 1 16 3 
Diarrhoea DI 1 17 3 
Financial difficulties FI 1 28 3 
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domains is derived from the raw score using the equation: Score = {1-(RS-
1)/range} x100. 
For the symptom domains the equation is: Score = {(RS-10/range) x100. 
The health and quality of life ratings are combined and scored as for the 
symptom scores. 
The responses from a study group are considered valid if more than 50% of items 
have been scored. The usual convention is that the missing scores are corrected 
to the mean, that the missing scores are corrected to the pattern of inter-relations 
calculated using multivariate analysis or that the scores are corrected to the 
average of items present for that respondent (Ware et al 1993, Morris & Coyle 
1994).  
The final scores range from 1-100. For the functional scales, as a result of the 
linear transformation achieved using the equation above a higher score 
represents a higher level of functioning. For the symptom scores, the linear 
transformation is omitted therefore a higher score represents a higher level of 
symptoms. 
The results are presented by functional domain and by individual symptoms. 
Because this represented a cumbersome method for reporting which differs from 
that used in the other questionnaires, I combined the symptom ratings to form a 
single overall score. The limitations of this approach were recognised, however to 
gain comparability, some manipulation of the data was necessary and I 
considered this method represented a reasonable interpretation for the purposes 
of this study. 
 
7.1.2.2 Results EORTC QLQ C30 
For the QLQ C30, 143 records were available for analysis. All participants 
completed the questionnaire fully so there was no requirement to correct for 
missing values.  The scores were shown in Table 7.1.2.2. For this questionnaire, 
there are two aspects to consider, the functional domains and the symptom 
scores. The following tables present the functional scales and overall symptom 
score by sub-group to allow an overview of the scoring and the level of individual 
variation. As for SF-36, poorly scoring participants’ records were marked in red. 
Again we saw a pattern of marked individual variation between the different sub-
group, both for the functional domains and the overall symptom score.  
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Table 7.1.2.2 EORTC QLQ C30 Scores 
Table 7.1.2.2.1. Early Larynx (EL): 17 responses 
Group PF 
Score 
RF 
Score 
EF 
Score 
CF Score SFScore Symptom 
Score 
EL1 100 100 100 83 100 0 
EL10 54 33 42 33 33 30 
EL11 14 17 8 33 0 48 
EL12 33 17 67 67 67 45 
EL13 93 100 67 100 100 6 
EL14 47 17 50 83 50 37 
EL15 100 83 83 50 83 13 
EL16 54 83 50 50 100 20 
EL18 100 100 100 100 100 0 
EL19 93 100 58 83 83 19 
EL2 100 100 83 100 100 0 
EL3 63 67 8 33 67 38 
EL4 47 50 58 50 67 18 
EL5 20 0 67 100 33 22 
EL6 40 0 92 83 0 11 
EL7 87 100 100 100 100 0 
EL8 87 83 67 67 100 33 
 EL Average 66.58 61.76 64.71 71.47 69.59 20.00 
 
 
Table 7.1.2.2.2  Late Larynx (LL): 15 responses 
 
Group PF Score RF Score EF Score CF Score SFScore Symptom 
Score 
LL1 100 100 67 83 67 12 
LL10 60 100 58 67 50 36 
LL11 100 83 92 83 83 19 
LL12 80 100 83 83 100 5 
LL13 93 100 100 83 67 5 
LL14 100 83 58 100 67 4 
LL15 67 100 67 50 83 51 
LL2 54 33 50 67 50 21 
LL3 87 67 100 67 100 9 
LL4 100 100 100 100 100 0 
LL5 100 83 83 83 83 19 
LL6 60 50 67 100 83 19 
LL7 87 83 75 100 83 14 
LL8 100 100 100 100 100 0 
LL9 87 83 92 100 100 4 
LL Average 85.00 84.33 79.47 84.40 81.07 14.53 
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Table 7.1.2.2.3. Early Oral (EO): 31 responses 
 
Group PF Score RF Score EF Score CF Score SFScore Symptom 
Score 
EO1 100 100 92 100 67 4 
EO10 60 67 92 83 100 12 
EO11 93 100 100 100 100 9 
EO12 54 33 67 67 100 34 
EO13 93 83 83 83 67 2 
EO14 100 100 100 100 100 4 
EO15 67 83 92 100 100 12 
EO16 67 83 67 83 67 16 
EO17 63 83 83 83 100 7 
EO18 100 100 58 50 50 17 
EO19 93 100 67 67 67 11 
EO2 100 100 100 100 100 7 
EO20 80 67 83 83 67 22 
EO21 93 100 75 83 83 6 
EO22 67 50 83 83 100 26 
EO23 27 0 58 33 50 38 
EO24 63 83 83 67 100 10 
EO25 100 67 92 100 100 7 
EO26 60 67 100 83 100 10 
EO27 100 100 100 100 100 0 
EO28 93 100 100 100 100 0 
EO29 87 100 75 100 83 6 
EO3 100 100 100 83 83 12 
EO30 87 100 100 100 100 2 
EO32 67 50 92 100 83 17 
EO34 100 100 100 83 100 0 
EO4 93 83 92 100 100 8 
EO5 100 100 83 100 100 6 
EO6 100 100 100 83 100 2 
EO7 100 100 100 100 83 5 
EO9 80 100 83 83 100 6 
EO Average 83.45 83.84 87.10 86.45 88.71 10.26 
 
 
 
 
 
 
QoL in Individual Patients  Chapter 7 
163 
 
 
 
Table 7.1.2.2.4. Late Oral (LO): 36 responses 
 
Group PF Score RF Score EF Score CF Score SF Score Symptom 
Score 
LO1 54 100 100 100 100 0 
LO10 40 0 0 0 0 44 
LO11 60 33 58 83 33 45 
LO12 47 50 0 0 33 63 
LO13 87 17 67 100 33 27 
LO14 63 50 33 50 33 36 
LO15 14 33 67 100 50 19 
LO16 14 33 100 33 100 22 
LO17 100 100 100 100 100 7 
LO18 27 0 8 17 0 41 
LO19 63 100 33 100 33 38 
LO2 67 83 67 67 67 63 
LO20 60 83 92 83 67 22 
LO21 87 83 58 67 83 23 
LO22 100 100 100 100 100 0 
LO23 93 100 58 100 83 10 
LO24 100 100 92 83 100 4 
LO25 100 67 75 100 100 1 
LO26 100 83 100 83 100 5 
LO27 100 100 92 100 100 4 
LO28 87 100 100 100 100 6 
LO3 33 17 58 67 67 24 
LO30 100 100 100 100 100 0 
LO31 54 67 75 100 33 25 
LO32 40 0 50 50 67 39 
LO34 93 33 67 100 83 7 
LO35 14 0 0 33 0 70 
LO36 80 83 33 83 67 19 
LO37 60 33 58 67 33 43 
LO38 14 33 100 83 67 19 
LO39 87 83 83 83 100 10 
LO5 54 100 100 100 100 9 
LO6 40 33 67 67 67 32 
LO7 33 33 8 67 83 67 
LO8 60 50 83 50 50 37 
LO9 100 100 100 100 100 6 
LO Average 64.58 60.56 66.17 75.44 67.56 24.64 
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7.1.2.2.5. Thyroid (Thy): 43 responses 
 
Group PF Score RF Score EF Score CF Score SF Score SymptomScore 
Thy1 100 100 100 100 100 1 
Thy11 77 83 92 100 100 7 
Thy12 80 100 75 83 67 21 
Thy13 63 67 67 67 50 20 
Thy14 100 100 100 100 100 0 
Thy15 100 100 100 83 100 6 
Thy16 87 100 100 83 100 0 
Thy17 54 100 92 33 100 19 
Thy18 100 100 100 100 100 0 
Thy2 100 100 83 83 100 6 
Thy20 100 100 67 83 100 0 
Thy21 63 100 92 100 83 6 
Thy22 63 100 83 100 100 5 
Thy23 100 100 75 100 100 4 
Thy24 87 67 50 83 83 14 
Thy25 93 83 83 83 100 4 
Thy26 87 67 58 83 67 20 
Thy27 80 100 75 83 100 1 
Thy29 63 67 83 83 67 11 
Thy3 100 100 100 100 100 2 
Thy30 87 100 92 67 100 28 
Thy31 63 17 17 33 0 63 
Thy32 80 67 67 83 100 22 
Thy33 87 100 67 100 100 5 
Thy34 100 100 75 83 100 0 
Thy36 60 67 67 67 83 32 
Thy37 100 100 75 67 100 1 
Thy38 93 100 75 67 83 22 
Thy39 100 100 83 100 67 7 
Thy4 93 100 92 100 100 5 
Thy40 93 100 100 100 83 0 
Thy41 100 100 100 100 67 0 
Thy42 100 100 67 100 100 6 
Thy43 67 67 42 17 33 50 
Thy44 100 100 92 83 100 5 
Thy45 87 100 100 100 100 0 
Thy46 87 100 67 33 83 14 
Thy46 100 100 83 83 100 10 
Thy48 100 100 100 100 100 0 
Thy5 60 67 50 83 50 32 
Thy6 100 100 100 100 100 0 
Thy7 100 100 83 100 100 1 
Thy9 93 100 92 100 100 4 
Thyroid Av 87.14 91.14 80.49 83.63 87.58 10.56 
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The scores had some similarity to SF 36 in that thyroid patients reported the best 
QoL, followed by EO and LL. Again, the high scores entered by LL patients were 
surprising, as were the relatively low scores entered by EL patients. LO patients 
scored at a lower level than the other sub-groups. In terms of poorly scoring 
individual records, less patients were identified using the EORTC QLQ C30 than 
SF36 although 4 from the list of 6 EL patients appeared in both questionnaire 
subsets. One different patient (EL14) was identified as scoring poorly through the 
EORTC QLQ C30 but not through SF-36. Only one LL patient (LL2) appeared in 
both SF-36 and EORTC QLQ C30 subsets and only one (EO23) remained from 
the four EO patients identified from SF-36. EO27 was the one individual who 
scored very differently on the two questionnaires and this must raise a query 
about the accuracy of this participant’s use of the touch-screen system. For LO, a 
smaller number of patients (5) were identified as low scoring using the EORTC 
QLQ C30 and all were also included in the SF-36 list. As with the SF-36, no 
thyroid patient scored at a low enough level to be considered in this category. 
The second part of this questionnaire looked at specific symptoms and the final 
part of the questionnaire asked about health and QoL. These were combined as 
a global HQoL rating as advised in the manual. 
The descriptive tables present the results for all items in the QLQ C30 by all 
participants and by sub-groups. In reading this data it should be remembered that 
in the functional scales a high score represents good status and this is also true 
for HQoL; however, for the symptom scales, a low score represents good status. 
Table 7.1.2.4. EORTC QLQ C30 descriptive statistics: functional 
scales 
 
Study group PF 
Mean 
(SD) 
RF 
Mean 
(SD) 
EF 
Mean 
(SD) 
CF 
Mean 
(SD) 
SF  
Mean 
(SD) 
Symptom 
Score 
Mean (SD) 
All n=142 
mean (SD) 
77.93 
(24.20) 
77.56 
(30.42) 
76.30 
(24.58) 
80.80 
(23.05) 
79.91 
(26.83) 
15.61 
(16.32) 
EL n=17 
mean (SD) 
66.59 
(30.17) 
61.76 
(39.34) 
64.71 
(28.11) 
71.47 
(25.57) 
69.59 
(35.00) 
20.00 
(16.25) 
LL n=15 
mean (SD) 
85.00 
(16.87) 
84.33 
(20.43) 
79.47 
(17.53) 
84.40 
(15.95) 
81.07 
(17.60) 
14.53 
(14.03) 
EO n=31 
mean (SD) 
83.45 
(18.87) 
83.84 
(24.14) 
87.10 
(13.28) 
86.45 
(16.36) 
88.71 
(16.27) 
10.26 
(9.29) 
LO n=36 
mean (SD) 
64.58 
(29.32) 
60.56 
(35.89) 
66.17 
(32.94) 
75.44 
(29.38) 
67.56 
(32.65) 
24.64 
(20.50) 
Thy n=43 
mean (SD) 
87.14 
(14.88) 
91.14 
(17.46) 
80.49 
(18.58) 
83.63 
(21.05) 
87.58 
(21.84) 
10.56 
(13.88) 
Key: PF=Physical Function, RF=Role Function, EF=Emotional Function, CF=Cognitive Function, 
SF=Social Function. 
 
QoL in Individual Patients  Chapter 7 
166 
 
Table 7.1.2.5 EORTC QLQ C30 descriptive statistics: symptom scales  
 
 
 Study Group 
Symptom All 
(n=142) 
EL 
(n=17) 
LL 
(n=15) 
EO 
(n=31) 
LO 
(n=36) 
Thy 
(n=43) 
 
PA 
Mean (SD) 
19.63 
(27.21) 
20.59 
(22.34) 
12.20 
(17.14) 
14.55 
(17.58) 
35.19 
(37.28) 
12.47 
(22.78) 
 
FA 
Mean (SD) 
31.15 
(28.46) 
39.71 
(29.14) 
41.60 
(32.00) 
20.58 
(19.57) 
42.69 
(32.41) 
22.07 
(24.17 
 
IN 
Mean (SD) 
29.56 
(33.77) 
37.24 
(42.33) 
35.53 
(36.73) 
18.23 
(24.12) 
35.19 
(35.67) 
27.88 
(32.54) 
 
AP 
Mean (SD) 
17.82 
(29.64) 
19.53 
(28.99) 
15.53 
(30.53) 
17.19 
(30.91) 
29.61 
(33.67) 
8.51 
(21.94) 
 
NV 
Mean (SD) 
9.58 
(20.81) 
11.71 
(26.15) 
6.60 
(13.66) 
5.35 
(15.13) 
13.81 
(23.00) 
9.28 
(22.21) 
 
DY 
Mean (SD) 
3.27 
(13.34) 
3.88 
(10.96) 
2.20 
(8.52) 
1.06 
(5.93) 
9.25 
(23.40) 
0.00 
(0.00) 
 
CO 
Mean (SD) 
11.23 
(21.69) 
9.76 
(19.58) 
13.33 
(30.37) 
8.55 
(17.09) 
17.53 
(23.22) 
7.72 
(20.34) 
 
DI 
Mean (SD) 
8.42 
(19.60) 
13.71 
(29.02) 
6.67 
(18.73) 
2.13 
(8.24) 
14.75 
(24.46) 
6.16 
(14.95) 
 
FD 
Mean (SD) 
13.68 
(27.51) 
22.88 
(28.29) 
8.87 
(19.80) 
5.00 
(18.97) 
26.83 
(37.25) 
6.95 
(19.98) 
 
Key: PA=Pain, FA=Fatigue, IN=Insomnia, Ap=Appetite, NV=Nausea&Vomiting, DY=Dyspnoea, 
CO=Constipation, DI=Diarrhoea, FD=Financial difficulties. 
 
These tables indicated that functional status scores were lower for EL than the 
other groups, especially PF and RF. The PA and FA symptoms scores appeared 
to be the most problematic for patients and FA scores were particularly high in 
the LL and LO sub-groups. IN was also considered to be an issue across the 
groups and especially for EL, LL and LO patients. Given the return to work profile 
described in chapter 5 and the importance of work in living after cancer, the 
financial difficulties item might be expected to mirror those findings. However, it 
was EL and LO patients who reported difficulties and LL patients appeared not to 
rate this item highly compared to other aspects of their status. No thyroid patient 
reported dyspnoea using this scale, hence the nil return in the table. 
 
Table 7.1.2.5 Significant ANOVA results by sub-groups EORTC QLQ 
C30. 
 
Dependent 
Variable 
Study 
Group (I) 
Study 
Group (J) 
Mean diff 
(I-J) 
Std 
Error 
Significance 
(2 tailed) 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Physical 
Functioning (PF) 
EO LO  18.87 5.48 p=0.008 3.22 34.51 
 Thy LO  22.56 5.06 p<0.0001 8.13 36.98 
Role Functioning 
(RF) 
EO LO  23.28 6.82 p=0.008 3.84 42.73 
 Thy EL 29.38 7.97 p=0.003 6.64 52.11 
 Thy LO  30.58 6.28 p<0.0001 12.66 48.51 
Emotional 
Functioning (EF) 
EO LO  20.93 5.72 p=0.004 4.61 37.25 
Social Functioning 
(SF) 
EO LO  21.15 6.25 p=0.009 3.31 38.99 
 Thy LO  20.03 5.77 p=0.007 3.58 36.47 
Symptom Score E O LO  -14.38 3.76 p=0.002 -25.11 -3.65 
 Thy LO  -14.08 3.47 p=0.001 -23.98 -4.18 
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To explore these findings further the statistical method was followed as described 
above for the SF-36. The results of the ANOVA by sub-group were as shown in 
Table 7.1.2.5. Thyroid patients scored at the highest level for PF; significantly 
above the LO with EO also achieving a significantly higher score than LO.  For 
RF, EO patients again scored significantly higher than LO and Thyroid 
significantly higher than both EL and LO. EF had significantly different scores in, 
again, EO v LO, and this item was unusual in that thyroid patients had a relatively 
high score. There were no significant results for CF. For SF, EO and Thyroid had 
significantly better scores than LO. Finally the same two sub-groups also had 
significantly better scores than LO for the combined symptom score. 
When thyroid patients were compared with the H&N group, using an independent 
samples t-test; highly significant differences were seen for PF (p=<0.0001 95%CI 
-20,109 to -6.312), RF (p=<0.0001, 95%CI -27.884 to -11.082). and Symptom 
Score (p=0.009, 95%CI 1.867 to 12.633), This again confirmed the better status 
of the thyroid patients in terms of the items measured in these questionnaires. 
For early v late, no statistically significant results were found although there was 
a trend towards better scores for the early group for each of the items scored. 
No significant differences were found for oral v larynx with larynx patients scoring 
slightly higher for PF and RF but oral patients scoring slightly higher for EF, CF 
and SF and almost the same score for the combined Symptom Score (mean 
score= 17.44 for larynx and 17.99 for oral). 
Stage I-II v III-IV had significant results for EF and Symptom Score, with the 
Stage I-II patients reporting better scores (Table 7.1.2.6). 
  
Table 7.1.2.6 EORTC QLQ C30 Stage I-II v Stage III-IV 
Dependent Variable Study 
Group 
(I) 
Study 
Group 
(J) 
t df sig (2 
tailed) 
Mean 
diff 
(I-J) 
Std 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Emotional 
Functioning (EF) 
Stage 
I-II 
Stage 
III-IV 
2.90 94.78 p=0.005 14.38 4.96 4.53 24.22 
Symptom Score Stage 
I-II 
Stage 
III-IV 
2.87 95.60 p=0.005 -8.96 3.12 -15.16 -2.767 
 
 
The symptom score explored important facets of patient experience in more 
detail. Analysing this part of the measure using the same statistical method I 
found significant results by sub-group for pain (PA) fatigue (FA), appetite (AP), 
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and financial impact (FI). The statistically significant results were as presented in 
Table 7.1.2.7. 
Again, the main statistical significance was between thyroid and LO and other 
sub-groups, LL and EO also showed significantly better results than LO in some 
domains (PA, FA and FI). 
 
Table 7.1.2.7 ANOVA Results for EORTC Symptom Score by Sub-
Group 
 
Dependent 
Variable 
Study 
Group (I) 
Study 
Group (J) 
Mean diff 
(I-J) 
Std 
Error 
Significance 
(2 tailed) 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Pain (PA) Thy LO -22,73 5.85 p=0.002 -39.41 -6.04 
Fatigue (FA) EO LO -22,11 6.60 p=0.01 -40.96 -3.27 
Financial Impact 
(FI) 
Thy LO -19.88 5.93 p=0.01 -36.80 -2.96 
 
There were no statistically significant differences for Insomnia (IN), nausea and 
vomiting (NV), constipation (CO) and diarrhoea (DI), It should be remembered 
that these were follow up patients and also that they were treated in the time 
before chemotherapy was routinely offered. In this study group, I would not 
expect to see any significant difference or even a trend in these areas and that 
was confirmed by the results where the significance score was commonly 
p=1.000. 
The relationship between the H&N and thyroid scores was significant for PA, FA, 
AP, DY and FI. The scores for the remaining domains (IN, NV, CO and DI) were 
higher for the H&N groups but did not reach statistical significance. The 
significant results were as presented in Table 7.1.2.8. 
 
Table 7.1.2.8 Independent samples t-test for H&N v Thyroid, EORTC 
QLQ C30 Symptom Score 
 
Dependent 
Variable 
T df sig (2 tailed) Mean diff (I-J) Std Error 95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
FA 2.76 96.23 p=0.007 13.02 4.72 3.65 22.40 
AP 2.89 112.84 p=0.005 13.35 4.62 4.20 22.50 
DY 2.96 98.00 p=0.004 4.70 1.59 1.559 7.85 
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For early v late, scores were consistently higher in the late group than the early 
group. This reached significance for FA as shown in Table 7.1.2.9. 
 
Table 7.1.2.9 Independent samples t-test for Early v Late, EORTC 
QLQ C30 Symptom Score 
 
Dependent 
Variable 
T df sig (2 
tailed) 
Mean 
diff (I-J) 
Std 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
FA -2.64 93.09 p=0.01 -15.02 5.69 -23.32 -3.71 
 
For Stage, the scores were again consistently higher for the Stage III&IV patients 
than for the Stage I&II but statistical significance was not reached for any 
individual symptom. 
The final consideration was again for gender, where, although there were 
consistently lower scores for females, no individual item reached statistical 
significance. 
The final element of the EORTC QLQ C30 was the overall rating of health and of 
quality of life. These were scored on a scale of 1-7 and transformed in the same 
way as the symptom scores such that a high score indicated better status. For 
reporting, these two scales were combined to given a single rating of HQoL. 
 
Table 7.1.2.10 Descriptive Statistics for EORTC HQoL 
 
Study Group 
 
All EL LL EO LO  Thy 
HQoL score 
mean (SD) 
72.21 
(23.76) 
70.71 
(21.29) 
76.60 
(18.40) 
80.35 
(16.92) 
59.47 
(29.77) 
76.07 
(21.34) 
 
EO reported the best HQoL, followed by LL and Thy which also had scores 
above the group mean. In line with the findings so far, EL and LO reported HQoL 
below the group mean with LO reporting a much lower mean score than the other 
sub-groups.  
At individual level, two EL patients scored below the mid-point (EL5 [42] &EL14 
[33]) and three thyroid patients (Thy31 [8], Thy32 [33] & Thy 43 [40]). For LO, 
twelve patients scored at this level and two of these entered a score of 0 (LO10 
[17], LO11 [33], LO12 [8], LO14 [33], LO18 [0], LO19 [33], LO2 [33], LO3 [33], 
LO32 {25], LO35 [0], LO37 [33] & LO38 [33]).  
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The consistent finding was that LO patients individually and collectively reported 
poor QoL as defined by the EORTC QLQ C30. The core module is designed to 
be used in conjunction with the EORTC QLQ H&N module to give an 
understanding of status at both general and site specific levels as reported in the 
next section.   
 
7.1.2.3 EORTC QLQ H&N Module 
7.1.2.3.1 Scoring for EORTC QLQ H&N Module 
The H&N 35 is scored in a similar fashion to the QLQC30. Again, it is a symptom 
scale, thus a higher score represents a high level of symptoms. The raw 
scores for the 35 questions are reduced to 13 main items, pain (HNPA), 
swallowing (HNSW), senses (HNSE), social eating (HNSO), social contact 
(HNSC), sexuality (HNSX), teeth (HNTE), opening mouth (HNOM), dry mouth 
(HNDR), sticky saliva (HNSS), coughing (HNCO), and feeling ill (HNFI), plus five 
additional questions on specific aspects of status; use of painkillers (HNPK), 
nutritional status (HNNU), use of feeding tube (HNFE), weight gain (HNWG) and 
weight loss (HNWL).   
 
7.1.2.3.2 Results from EORTC QLQ H&N Module 
The results were analysed using descriptive statistics to illustrate the 
characteristics of participants at study and sub-group level and then explored 
definitively using the method as for the previous questionnaires.  
The items of concern for the entire study group were HNDR, HNCO, HNSS and 
HNSX. For sub-groups the items differed. EL reported HNDR, HNSP, HNCO, 
HNSS and HNSX. LL prioritised HNSE, HNCO, HNSO, HNSS and HNDR above 
HNSP. EO patients scored at a lower level but reported HNDR, HNOM, HNCO 
and HNSX as their main concerns, LO scored at the highest level overall 
reporting HNDR, HNOM, HNSO, HNCO and HNSX. Thyroid patients had much 
lower scores and only HNDR and HNCO had scores of note. 
This scoring pattern emphasises the morbidity due to dry mouth and allowed the 
symptom profile for each sub-group to be compared. It was again remarkable that 
EL patients reported difficulties at a higher level than would be expected 
compared to LL. For the oral sites, the EO sub-group reported a generally higher 
QoL in terms of site specific items than LO.    
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Table 7.1.2.3.1 Descriptive Statistics by Group and Sub-Groups 
  Study Group   
Item All (n=139) EL(n-16) LL(n=15)  EO(n=30) LO(n=15) Thy(n=43) 
HNPA 
mean (SD) 
16.06 
(19.97) 
15.13 
(15.08) 
10.60 
(13.95) 
  16.97 
(17.63) 
27.34 
(25..84) 
8..49 
(15.27) 
HNSW 
mean (SD) 
15.17 
(20.99) 
17.19 
(20.55) 
21.07 
(26.70) 
7.83 
(12.20) 
29.23 
(25.28) 
6.05 
(11.71) 
HNSE 
mean (SD) 
20.15 
(26.93) 
24.00 
(21.90) 
52.20 
(33.24) 
16.63 
(27.29) 
25.29 
(25.28) 
5.81 
(12.50) 
HNSP 
mean (SD) 
18.96 
(22.54) 
38.56 
(25.79) 
25.07 
(29.15) 
7.70 
(11.61) 
27.46 
(23.36) 
10.43 
(15.17) 
HNSO 
mean (SD) 
22.19 
(30.56) 
17.69 
(25.29) 
37.27 
(44.80) 
14.40 
(19.89) 
46.83 
(32.17) 
3.98 
(9.13) 
HNSC 
mean (SD) 
8.54 
(16.54) 
10.00 
(13.89) 
4.73 
(7.74) 
5.27 
(9.51) 
16.86 
(24.84) 
4.84 
(12.74) 
HNSX 
mean (SD) 
26.76 
(34.61) 
33.31 
(38.98) 
21.20 
(31.18) 
27.20 
(39.24) 
37.17 
(36.18) 
17.47 
(27.22) 
HNTE 
mean (SD) 
20.85 
(33.43) 
25.00 
(33.40) 
20.00 
(37.40) 
23.27 
(30.53) 
31.43 
(42.76) 
9.30 
(21.04) 
HNOM 
mean (SD) 
25.15 
(36.23) 
10.38 
(25.40) 
19.93 
(35.16) 
28.87 
(34.78) 
55.23 
(41.23) 
5.40 
(14.38) 
HNDR 
mean (SD) 
43.86 
(35.98) 
52.12 
(38.51) 
35.47 
(34.48) 
42.20 
(31.60) 
62.83 
(37.80) 
29.42 
(30.25) 
HNSS 
mean (SD) 
27.56 
(35.92) 
33.31 
(36.58) 
35.60 
(38.84) 
22.17 
(33.15) 
50.49 
(39.97) 
7.72 
(17.56) 
HNCO 
mean (SD) 
31.84 
(30.07) 
37.50 
(27.04) 
42.20 
(34.53) 
27.70 
(32.87) 
39.94 
(30.15) 
22.42 
(24.95) 
HNFI 
mean (SD) 
13.36 
(21.09) 
10.31 
(15.80) 
6.60 
(13.66) 
8.80 
(14.84) 
19.94 
(24.56) 
14.87 
(24.45) 
Key: HNPA=Pain, HNSW=Swallowing, HNSE=Senses, HNSP=Speech, HNSO=Social Eating, 
HNSC=Social Contact, HNSX=Sexuality, HNTE=Teeth, HNOM=Opening Mouth, HNDR=Dry 
Mouth, HNSS=Sticky Saliva, HNCO=Coughing, HNFI=Feeling Ill. 
 
The findings were explored statistically as described above. The results which 
reached statistical significance were as tabulated below. 
 
Table 7.1.2.3.2. EORTC QLQ H&N ANOVA by Sub-group 
  
Study 
Group (I) 
Study 
Group (J) 
Mean diff 
(I-J) 
Std 
Error 
Significance 
(2 tailed) 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
EO LO 20.88 5.57 p=0.003 5.00 36.77 
 
 
As before, LO was the sub-group to score at the lowest level. 
On direct comparisons using an independent t-test with equal variances not 
assumed no significant differences were found for H&N v Thyroid, Oral v Larynx 
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or Gender although the results for gender changed from a mean of 75.08 for 
females and 70.05 for males with thyroid patients included to 71.55 for females  
and 70.11 for males once thyroid patients were excluded. Significant results were 
as shown below. 
 
Table 7.1.2.3.3 Independent t-test for EORTC HRQoL 
 
Dependent 
Variable 
t df sig (2 
tailed) 
Mean 
diff (I-J) 
Std 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Stage I&II v III&IV 3.16 94.77 p=0.002 14.42 4.56 5.37 23.47 
 
The variables which showed significance were those which relate most strongly 
to the impact of cancer therapy, i.e. EO v LO and Stage. 
In terms of individual impact, I returned to the overall symptom score, presented 
in Tables 7.1.2.2.1-5. Taking a ‘cut off’ of <=50 no EL or EO patients scored at a 
level for concern, LL15 [score 51], LO12 [63], LO35 [70], LO7 [67], Thy31 [63] 
and Thy43 [50] were identified as the most symptomatic patients according to the 
symptom score. Of this group LL15, LO12 and LO35 had scored consistently 
poorly on SF-36, EORTC QLQ C30, EORTC HQoL and the symptom score, 
giving cause for concern about their status. 
 
7.1.3.4. Summary of findings from EORTC QLQ C30 and H&N Modules 
The three parts of the EORTC QLQ measure provided detailed and 
complementary information, allowing an understanding of the QoL status at sub-
group level and statistically significant variation in some parameters which might 
affect status. The factors which most often emerged as significant were EO v LO 
and Stage I&II v III& IV, i.e. those which affected the therapeutic pathway and the 
burden of therapy. In terms of sub-group, thyroid patients might be expected to 
score more highly than the H&N sub-groups, given the fact that much of the H&N 
module addressed symptoms which may lie outside their experience, however, 
aspects of their status which caused them concern were identified. Significant 
differences were found in both the items which at individual level scored most 
highly but also across the measures as a whole with LO patients scoring 
significantly lower than the other groups in a number of analyses. 
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7.1.3 FACT-G and H&N Module 
 
7.1.3.1 FACT-G 
7.1.3.1.1 Scoring of the FACT-G questionnaire 
The FACT-G consists of 27 questions scored on a Likert scale from 0-4. The 
mean scores from individual questions, after correction for negative items, are 
combined into the main domains of Physical (GP), Social (GS), Emotional (GE) 
and Functional (GF). The questionnaire aims to measure wellbeing. For each a 
higher score represents better quality of life. The domains can be added 
together to give a total score, the highest possible score attainable being 108.  
 
7.1.3.1.2 Results from the FACT-G questionnaire 
The results, by study group and sub-groups were as shown in Table 7.1.3.1. 
 
Table 7.1.3.1 FACT-G Descriptive Statistics Study Group & Sub-
groups 
 
Domain Study Group 
All (n-143) EL (n=17) LL (n=15) EO (n=32/31) LO (n=36) Thy (n=43) 
GP  
Mean (SD) 
19.91 
(4.19) 
19.29 
(4.25) 
21.20 
(2.46) 
21.22 
(2.56) 
17.06 
(5.49) 
21.12 
(3.14) 
GS  
Mean (SD) 
21.07 
(5.27) 
17.76 
(5.87) 
22.67 
(5.95) 
21.37 
(5.46) 
19.64 
(5.87) 
22.79 
(2.86) 
GE  
Mean (SD) 
13.20 
(3.90) 
14.18 
(4.48) 
13.20 
(2.43) 
13.58 
(2.13) 
17.11 
(2.18) 
9.28 
(2.20) 
GF  
Mean (SD) 
19.11 
(5.11) 
17.65 
(5.47) 
19.60 
(3.72) 
20.45 
(4.68) 
16.72 
(5.84) 
20.53 
(4.27) 
FACT-G 
Mean (SD) 
73.25 
(11.98) 
68.88 
(15.00) 
76.67 
(11.05) 
76.48 
(9.74) 
70.53 
(15.56) 
73.72 
(7.74) 
 
 
For the whole study group GE gave the lowest score and this was also true at 
individual sub-group level for EL, LL and EO. GF was the lowest scored item for 
LO. GE was scored at a particularly low level for thyroid patients. On simply 
inspecting the data, the means appear to be relatively similar across domains 
and between study sub-groups than was the case with SF-36 or EORTC; the 
exception to this was GE as noted above. This is reflected in the SD which is 
much lower than those for the other questionnaires. 
I reviewed the raw data to check which patients scored most poorly, again 
selecting 50% [score <=54] of the highest possible score as an arbitrary but 
consistent ‘cut off’. Two EL, one EO, one LL and five LO patients fell below a 
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score of 54 (EL11 [37], EL12 [47], EO18 [42], LL12 [40], LO10 [29], LO11 {51], 
LO12 [37], LO18 [51] and LO35 [39]. Of these, four, EL11, LO10, LO18 and 
LO35 fell into the poorly scoring category for all three general QoL 
questionnaires. The number of LO patients scoring poorly were reflected in the 
lower scores for the sub-group as a whole. 
Comparisons between factors were carried out using the same methodology as 
for the previous questionnaires. The statistically significant results were as shown 
in the following tables. 
The ANOVA showed a number of significant findings. For GP LL and EO 
recorded significantly and highly significantly better scores than LO. For GS the 
only result reaching significance was Thy v EL. GE was the domain with most 
significant findings. The LO sub-group, unusually, scored highest with a mean of 
17.11 and Thy unusually low with a mean of 9.28. This led to all other sub-groups 
scoring at a significant level in relation to these with LO scoring significantly 
higher than EL and LL, EO and Thy at a highly significant level. Thy scored lower 
than all the other sub-groups at a highly significant level. For GF the LO sub-
group returned to the lower level of scoring, with significant differences in relation 
to EO and Thy. 
 
Table 7.1.3.2. FACT-G ANOVA Scores by Sub-group 
 
Dependent 
Variable 
Study 
Group (I) 
Study 
Group (J) 
Mean diff 
(I-J) 
Std 
Error 
Sig (2 
tailed) 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
GP LL LO  4.14 1.18 p=0.006 0.77 7.52 
 EO LO  4.16 0.94 p<0.0001 1.49 6.83 
GS Thy EL 5.03 1.45 p=0.007 0.90 9.15 
GE EL Thy  4.90 0.74 p<0.0001 2.79 7.00 
 LL Thy  3.92 0.79 p<0.0001 1.72 6.12 
 EO Thy 4.30 0.61 p<0.0001 2.57 6.03 
 LO EL  2.94 0.76 p=0.002 0.77 5.09 
 LO LL 3.91 0.79 p<0.0001 1.66 6.17 
 LO EO 3.53 0.63 p<0.0001 1.73 5.33 
 LO Thy 7.83 0.58 p<0.0001 6.17 9.49 
GF Thy LO 3.81 1.11 p=0.008 0.65 6.97 
 
 
Factors which might impact on scoring were tested as for the preceding 
questionnaires. 
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Table 7.1.3.3 FACT-G Independent t-test H&N v Thy 
 
Dependent 
Variable 
t Df sig (2 
tailed) 
Mean 
diff (I-J) 
Std 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
GP -2.63 111.36 p=0.01 -1.73 0.66 -3.03 -0.43 
GS -3.16 94.77 p=0.002 -2.46 0.73 -3.91 -1.01 
GE 12.17 112.87 p<0.0001 5.63. 0.46 4.71 6.55 
 
The point of interest from this table was that three of the factors, GP, GS and GF 
showed significant differences with thyroid patients scoring better than H&N. For 
GE the reverse was true and this was such a highly significant result that, when 
the FACT-G total score was analysed, there was no significant difference as GE 
had skewed the entire score. 
For Early v Late GP scores just reached our criteria for significance (p=0.01) with 
better scores for the early patients, however for GE the late patients scored  
higher than the early patients, due mainly to the influence of the LO score for this 
domain, although this result did not reach statistical significance.. 
 
Table 7.1.3.4 FACT-G Independent t-test Early v Late 
 
Dependent 
Variable 
t Df sig (2 
tailed) 
Mean 
diff (I-J) 
Std 
Error 
95% Confidence 
Interval 
      
Lower 
Bound 
Upper 
Bound 
GP 2.64 86.21 p=0.01 2.28 0.86 0.56 3.99 
GE -3.59 94.89 p=0.001 2.17. 0.60 -3.37 -0.97 
 
For Oral v Larynx, no significant differences were found. Stage, reflecting the 
impact of therapy, showed significant results for GP, GE and GF (Table 7.1.3.5). 
  
Table 7.1.3.5 FACT-G Independent t-test Stage I&II v III&IV. 
 
Dependent 
Variable 
t df sig (2 
tailed) 
Mean 
diff (I-J) 
Std 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
GP 3.11 96.99 p=0.002 2.56 0.89 0.80 .4.31 
GE -3.25 68.56 p=0.003 -2.03 0.65 -3.33 -0.73 
GF 2.85 84.18 p=0.005 2.97. 1.04 0.90 5.04 
For gender, significant results again were higher for females for GP and GF but 
lower for GE when thyroid patients’ scores were included, due to the low score 
entered by this group (Table 7.1.3.6). 
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Table 7.1.3.6 FACT-G Independent t-test Gender 
 
Dependent 
Variable 
t df sig (2 
tailed) 
Mean 
diff (I-J) 
Std 
Error 
95% Confidence 
Interval 
      
Lower 
Bound 
Upper 
Bound 
GP 3.11 96.99 p=0.002 2.56 0.89 0.80 .4.31 
GE -3.25 68.56 p=0.003 -2.03 0.65 -3.33 -0.73 
GF 2.85 84.18 p=0.005 2.97. 1.04 0.90 5.04 
 
For H&N patients there were no significant results although there was a trend 
towards higher scores for females for GP, GS, GF and FACT-G total score but 
lower scores for females for GE. 
 
7.1.3.2 Summary of FACT-G findings. 
Results for FACT-G were influenced by the low score for thyroid patients for GE 
and the relatively high score, for LO patients in the same domain. This influence 
carried forward to some of the other groupings. 
Nevertheless the questionnaire allowed findings at significant levels in a number 
of domains, reflecting on the whole, the better status of early stage patients 
compared to those diagnosed at a more advanced stage of disease. 
In common with the other questionnaires, a small group of patients who scored 
particularly poorly could be identified, mainly from the LO sub-group. 
 
7.1.3.3 FACT H&N Module 
7.1.3.3.1 Scoring the FACT H&N Module 
The H&N Module consists of 12 additional items. Two of these relate to risk 
factors, smoking and alcohol consumption, and are not scored. The other 10 
items are scored according to the same scheme as in the FACT-G, reversing the 
scores on the questionnaire for negative items so that a high score represents 
better status. The maximum score attainable is 40. 
 
7.1.3.3.2 Results from the FACT H&N Module 
The method for scoring the module was the same as for previous questionnaires. 
The items have been abbreviated to allow tabulation using the following scheme: 
 
I am able to eat the foods that I like Eat 
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My mouth is dry DryM 
I have trouble breathing Breath 
My voice has its usual quality and strength Voice 
I am able to eat as much food as I want Food 
I am unhappy with the way my face and neck 
look 
App 
I can swallow naturally and easily Swallow 
I am able to communicate with others Comm 
I can eat solid food Solid 
I have pain in my mouth, throat or neck  Pain 
 
The H&N group reported lowest scores for breathing, pain and appearance and 
these items were repeated as the most problematic areas for each sub-group, 
with some variation in order. Speech was not covered as a single item but LL 
patients scored well for both voice and communication, the two questions linked 
to speech. 
 
Table 7.1.3.3.1 FACT H&N Module Descriptive Statistics 
  
 
Question Study Group 
All (n=138) EL (n=16) LL (n=15) EO (n=30) LO (n=35) Thy (n=42) 
Eat 
Mean (SD) 
2.71 
(1.45) 
2.81 
(1.05) 
2.53 
(1.69) 
2.90 
(1.35) 
1.89 
(1.55) 
3.29 
(1.20) 
DryM 
Mean (SD) 
1.69 
(1.49) 
2.00 
(1.55) 
1.47 
(1.51) 
1.53 
(1.33) 
2.51 
(1.48) 
1.07 
(1.28) 
Breath 
Mean (SD) 
0.52 
(0.87) 
1.25 
(1.24) 
0.73 
(1.03) 
0.13 
(0.43) 
0.63 
(1.00) 
0.36 
(0.53) 
Voice 
Mean (SD) 
2.38 
(1.48) 
1.00 
(1.21) 
2.07 
(1.79) 
3.20 
(1.06) 
2.14 
(1.44) 
2.62 
(1.32) 
Food 
Mean (SD) 
2.64 
(1.53) 
2.50 
(1.41) 
2.33 
(1.63) 
3.03 
(1.40) 
1.63 
(1.61) 
3.38 
(1.04) 
App 
Mean (SD) 
0.87 
(1.30) 
0.81 
(1.47) 
0.47 
(0.92) 
0.73 
(1.20) 
1.14 
(1.26) 
0.90 
(1.43) 
Swallow 
Mean (SD) 
2.65 
(1.43) 
2.38 
(1.36) 
2.40 
(1.64) 
2.93 
(1.41) 
1.71 
(1.43) 
3.43 
(0.80) 
Comm 
Mean (SD) 
3.51 
(0.79) 
3.19 
(0.98) 
3.27 
(1.10) 
3.67 
(0.76) 
3.37 
(0.73) 
3.74 
(0.54) 
Solid 
Mean (SD) 
2.88 
91.51) 
3.06 
(1.06) 
2.73 
(1.67) 
3.10 
(1.32) 
1.51 
(1.62) 
3.83 
(0.49) 
Pain 
Mean (SD) 
0.78 
(1.10) 
0.94 
(1.12) 
0.60 
(1.06) 
0.63 
(0.85) 
1.34 
(1.37) 
0.43 
(0.83) 
 
 
At individual level, a ‘cut-off’ at 50% highest possible score (<=20), as applied to 
the other questionnaires, did not discriminate between patients in sub-groups. 
The numbers scoring at <=15, an arbitrary choice to identify the lowest scoring 
patients, were EL=2, LL=4, EO=3, LO=12 and Thyroid=0. At the higher score the 
numbers were EL=6, LL=7, EO=9, LO=27 and Thyroid=7. Taking the lower ‘cut-  
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off’ some patients identified were those who had been noted to score at a low 
level on other questionnaires but most had not previously been identified as 
reporting problems. 
The patients who had previously scored poorly and who fell into that category 
again were EL5, LL6, LO18, LO32, and LO35. 
 
Table 7.1.3.3.2 FACT-H&N ANOVA  
 
Dependent 
Variable 
Study 
Group (I) 
Study 
Group (J) 
Mean diff 
(I-J) 
Std 
Error 
Sig 95% Confidence 
Interval 
      Lower 
Bound 
Upper 
Bound 
Eat Thy LO  1.40 0.31 p<0.0001 0.51 2.29 
DryM LO Thy 1.43 0.32 p<0.0001 0.53 2.36 
Breath EL EO  1.23 0.25 p<0.0001 0.39 1.84 
 EL Thy  0.89 0.24 p=0.003 0.21 1.58 
Voice  EO EL  2.20 0.42 p<0.0001 1.01 3.39 
 Thy EL 1.62 0.40 p=0.001 0.49 2.75 
Food  EO LO 1.41 0.35 p=0.001 0.42 2.39 
 Thy LO 1.75 0.32 p<0.0001 0.85 2.66 
Swallow  EO LO 1.22 0.32 p=0.002 0.31 2.13 
Solid EL LO 1.55 0.38 p=0.001 0.48 2.62 
 EO LO 1.59 0.31 p<0.0001 0.70 2.47 
 Thy LO 2.32 0.28 p<0.0001 1.51 3.13 
Pain  LO Thy 0.91 0.24 p=0.002 0.23 1.60 
 
The statistically significant ANOVA findings for the FACT-H&N were as tabled 
above: For ‘I am able to eat the foods I like’ [Eat] EO scored significantly and 
Thyroid highly significantly better than LO. LO patients, rather oddly given the 
responses to measures reported earlier, on this questionnaire scored highly for 
‘my mouth is dry’ [DryM]. For interpreting the analysis of this question, it is 
important to remember that the scores have been reversed so that a good status 
gives a high score. This response reached significance in comparison to thyroid 
patients who scored at a low level for this item.  
For ‘I have trouble breathing’ [Breath] all sub-groups entered low scores but EL 
had the highest score and this reached significance in comparison with EO and 
Thyroid, For ‘voice quality and strength’ [Voice], most scores were reasonably 
high with EL and LO scoring significantly worse than EO and Thyroid EL also 
significantly higher than EL. 
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LO patients indicated less ‘ability to eat as much food as they desired’ [Food] 
than the other groups, at a  statistically significant level compared to EO and 
Thyroid and this relationship continued with LO scoring significantly lower than 
EO on the ‘swallow easily and naturally’ [Swallow] item and with all other sub-
groups on ‘able to eat solid food’ [Solid]. On this latter question Thyroid also 
scored significantly higher than LL. On the final question, ‘I have pain in my 
mouth, throat and neck’ [Pain] LO patients scored surprisingly high considering 
they had had both surgery and radiotherapy to this area, This score reached 
significance compared to the Thyroid group, who scored particularly poorly on 
this item. 
For the comparison between H&N and Thyroid, statistical significance was 
reached for all questions except ‘trouble breathing; and ‘voice quality and 
strength’. For ‘able to eat as much food as I want’, ‘can swallow naturally and 
easily’ and ‘I can eat solid food’ this difference was highly significant (p<0.0001).  
 
Table 7.1.3.3.3 FACT-H&N Independent t-test Early v Late 
 
Dependent 
Variable 
t df sig (2 
tailed) 
Mean 
diff (I-J) 
Std 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Able to eat food 
wanted 
2.71 91.41 p=0.008 0.79 0.29 0.21 1.37 
Eat as much food 
as want 
3.24 93.67 p=0.002 1.01 0.31 0.39 1.63 
Swallow naturally 2.75 93.99 p=0.007 0.82. 0.30 0.23 1.41 
Eat solid food 4.00 88.86 p<0.0001 1.21 0.30 0.61 1.81 
 
These eating related questions were again significant in the comparison between 
‘early’ and ‘late’ giving the impression that early patients reported significantly 
better QoL. However these responses were clustered around a single physical 
entity (Table 7.1.3.3.3.). 
For Oral v Larynx, statistical significance was reached for ‘trouble breathing’ and 
‘eating solid food’ where the oral sub-groups scored at a low level. This 
relationship was reversed for ‘voice quality and strength’ where the oral sub-
groups scored at a higher level than laryngeal patients (Table 7.1.3.3.4). 
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Table 7.1.3.3.4 FACT H&N Independent t-test Oral v Larynx 
 
Dependent 
Variable 
t df sig (2 
tailed) 
Mean 
diff (I-J) 
Std 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Voice quality & 
strength 
-3.35 52.16 p=0.001 -1.15 0.33 -1.78 -0.45 
 
For Stage, highly significant differences (P<0.0001), with Stage I&II scoring at a 
higher level for all, were found for ‘able to eat the foods I like’, ‘my mouth is dry’, I 
am able to eat as much food as I want’, ‘I can swallow naturally and easily’ and ‘I 
can eat solid food’. Again the emphasis is on oral problems and on eating. The 
only question to reach significance from another aspect of H&N QoL was ‘I have 
pain in my mouth, throat and neck, where again Stage I&II showed better status 
(p=0.008). 
Finally, for gender, significant differences were seen when Thyroid patients were 
included in the analysis but not when H&N patients alone were scored. 
 
Table 7.1.3.3.5 FACT-H&N Independent t-test Gender-All Groups 
 
Dependent 
Variable 
t Df sig (2 
tailed) 
Mean 
diff (I-J) 
Std 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Swallow naturally 
& easily 
-3.36 133.00 p=0.001 -0.78 0.23 -1.24 -0.32 
 
Men scored at a higher level on the ‘my mouth is dry’ question but women higher 
than men on the other questions. It seems most likely that this is a direct result of 
including the thyroid patients, which has skewed the results given that it is 
unlikely that they would have problems with these functions. 
7.1.3.3.4 Summary of Findings from the FACT-H&N Module 
This module forms part of a QoL assessment and yet holds 4 questions about 
eating which are closely related to each other when considered in terms of face 
validity. It was difficult, using this module, to gain a balanced view of the study 
population as the ‘eating’; items dominated the analysis. In terms of 
understanding the needs of this patient population the information derived from 
this questionnaire was limited in comparison to that from the other measures. 
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7.1.4 The University of Washington Quality of Life (UWQoLv4) 
Questionnaire 
 
The UWQoL was designed specifically for use in H&N cancer. It has 12 symptom 
scores, a single question which allows the participant to choose the three most 
important domains, and a global rating of QoL (Chapter 4, Appendix 4.6). 
 
7.1.4.1 Scoring the UWQoL Questionnaire 
There are two methods of scoring the UWQoLv4 questionnaire. The first method 
applies the numerical score, as assigned in the manual, to each of the 12 
symptom scores and presents the data by median and by quartiles for each 
question. This is in contrast to the recommendations for the other measures 
presented in this chapter and, for consistency, I have used the same method for 
the UWQoL as for the other questionnaires as my aim was comparison in terms 
of this study population rather than to reference the data to other studies. I have, 
therefore, presented the data using the mean and SD as for the other measures 
used in the study.  
Using an overall composite score for this questionnaire is not recommended but 
recent work has suggested that groups of questions can be aggregated to form 
two composite scores, one for physical function derived from the simple average 
of chewing, swallowing, speech, taste, saliva and appearance and one for social 
function derived from the average of anxiety, mood, pain, recreation and social 
function (Rogers et al 2008). 
 
7.1.4.2 Results from the UWQoLv4 Questionnaire 
Both methods of scoring were used to explore the way the questionnaire could 
be used to report patient status. Table 7.1.4.2.1.  
For the combined scores, PF and SF were highest for Thyroid and this sub-group 
again returned high scores overall, followed by EO, also with high scores 
throughout. EL scored higher than LL for PF but lower for SF, maintaining the LL 
sub-group’s positive scoring for socially related items across the range of 
questionnaires. LO again had the lowest scores. At individual item level, the 
lowest scores varied by sub-group but saliva was prominent (All, EL, LO and 
second to lowest for EO). LL scored lowest for speech. This is the first time a 
question has achieved a low rating from this group who, by definition, have had a 
laryngectomy. The language of the question (Chapter 4, Appendix 4.6) relates 
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Table 7.1.4.2.1. UWQoLv4 Descriptive Statistics 
 
Domain Study Group 
All (n=138) EL (n=16) LL (n=15) EO (n=30) LO (n=35) Thy (n=42) 
PF 
Mean (SD) 
79.39 
(19.34) 
80.10 
(17.58) 
74.00 
(21.04) 
82.53 
(14.66) 
62.81 
(20.38) 
92.62 
(7.55) 
SF 
Mean (SD) 
79.24 
(17.32) 
75.52 
(18.38) 
80.94 
(14.34) 
83.72 
(12.03) 
67.43 
(22.31) 
86.69 
(9.84) 
Pain 
Mean (SD) 
78.62 
(27.11) 
78.13 
(28.69) 
78.33 
(29.68) 
82.50 
(19.86) 
63.57 
(33.40) 
88.69 
(18.48) 
Appearance 
Mean (SD) 
85.69 
(22.38) 
87.50 
(22.36) 
83.33 
(18.09) 
90.83 
(25.83) 
77.14 
(22.99) 
89.29 
(19.24) 
Activity 
Mean (SD) 
73.55 
(23.74) 
64.06 
(24.10) 
80.00 
(19.37) 
80.83 
(19.35) 
62.86 
(28.03) 
78.57 
(20.34) 
Recreation 
Mean (SD) 
78.26 
(21.95) 
68.75 
(23.27) 
76.67 
(25.82) 
86.67 
(18.26) 
64.29 
(22.01) 
88.10 
(13.79) 
Swallowing 
Mean (SD) 
81.16 
(24.91) 
83.13 
(15.37) 
74.67 
(28.75) 
88.33 
(20.36) 
62.00 
(29.69) 
93.57 
(12.46) 
Chewing 
Mean (SD) 
77.17 
(31.46) 
84.38 
(23.94) 
70.00 
(36.84) 
75.00 
(28.62) 
54.29 
(35.09) 
97.62 
(10.78) 
Speech 
Mean (SD) 
85.07 
(22.64) 
79.38 
(27.68) 
66.67 
((38.48) 
89.00 
(14.70) 
77.14 
(18.24) 
97.62 
(11.65) 
Shoulder 
Mean (SD) 
81.01 
(27.43) 
79.38 
(32.45) 
76.00 
(27.46) 
85.33 
(20.63) 
64.00 
(33.71) 
94.52 
(16.56) 
Taste 
Mean (SD) 
76.09 
(32.18) 
74.38 
(32.30) 
68.67 
(35.43) 
80.00 
(30.51) 
56.86 
(36.76) 
92.62 
(15.47) 
Saliva 
Mean (SD) 
71.88 
(31.52) 
71.88 
(34.30) 
80.67 
(24.92) 
75.33 
(27.64) 
49.43 
(35.72) 
85.00 
(20.87) 
Mood 
Mean (SD) 
81.16 
(24.13) 
76.56 
(28.09) 
86.67 
(12.91) 
83.33 
(23.06) 
72.14 
(29.56) 
86.90 
(19.32) 
Anxiety 
Mean (SD) 
82.83 
(21.61) 
86.25 
(26.55) 
88.00 
(15.21) 
83.67 
(18.10) 
77.71 
(28.19) 
83.33 
(17.20) 
 
mainly to articulation and the level of understanding achieved in different settings 
(over the phone, family and friends) and this practical wording may be a factor in 
this response. EO scored lowest for chewing and then saliva, emphasising the 
local aspects of the disease and therapy. LO returned a score of 49.43 for saliva, 
the only item to fall below 50. The domains returning the highest scores were 
appearance (All, EO and second highest for LO). Anxiety scored at a high level, 
higher than might normally be expected in this cancer population, however, the 
item relates to anxiety about your cancer rather than an overall rating of anxiety. 
Thyroid patients reported a different experience and their lowest score was for 
activity and their highest for chewing/speech. 
Looking at individuals, the arbitrary ‘cut off’ of <=50 in either PF, SF or both was 
applied. This produced 20 records, 2 EL (SF<50), 3LL (PF<50), 1 EO (SF,50) 
and 14 LO (5 PF & SF <=50, 6 PF<50, 3 SF <50). The domains in which low 
scores were recorded varied but chewing, speech, taste and saliva were 
commonly in this category and shoulder for the LO patients, who would be 
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expected to have had a neck dissection. This showed an interesting contrast with 
‘Early’ sub-groups tending to have low SF scores and ‘Late’ sub-groups tending 
to have lower PF scores. In terms of individual participants, a number already 
noted to score at a low level in the SF-36, EORTC and FACT measures were 
identified by the ‘cut-off’, including EL10, EL11, EO23, LL10, LL15, LO10, LO11,  
 
Table 7.1.4.2.2 UWQoLv4 ANOVA by Study Group and Sub-groups 
 
Dependent 
Variable 
Study 
Group (I) 
Study 
Group (J) 
Mean diff 
(I-J) 
Std 
Error 
Sig (2 
tailed) 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Physical 
Function (PF) 
EL LO  17.29 4.79 p=0.004 3.63 30.97 
 EO LO 19.72 3.95 p<0.0001 8.44 30.99 
 Thy LL 18.62 4.78 p=0.002 4.99 32.25 
 Thy LO 29.81 3.63 p<0.0001 19.44 40.18 
Social Function 
(SF) 
EO LO  16.29 3.92 p=0.001 5.10 27.49 
 Thy LO 19.26 3.61 p<0.0001 8.96 29.55 
Pain Thy LO 25.12 5.89 p<0.0001 8.31 41.93 
Recreation EO LO  22.38 4.90 p<0.0001 8.40 36.36 
 Thy LO 23.81 4.51 p<0.0001 10.95 36.67 
Swallowing EO LO 26.33 5.44 p<0.0001 10.82 41.85 
 Thy LO 31.57 5.00 p<0.0001 17.30 45.84 
Chewing EL LO 30.09 8.19 p=0.003 6.71 53.47 
 Thy LL 27.62 8.16 p=0.009 4.32 50.92 
 Thy EO 21.62 6.49 p=0.007 4.10 41.14 
 Thy LO 43.33 6.21 p<0.0001 25.60 61.06 
Speech EO LL 22.33 6.45 p=0.007 3.91 40.75 
 Thy LL 30.95 6.14 p<0.0001 13.43 48.47 
 Thy LO 20.48 4.67 p<0.0001 7.15 33.81 
Shoulder EO LO 21.33 6.26 p=0.009 3.45 39.21 
 Thy LO 30.52 5.76 p<0.0001 14.08 46.97 
Taste Thy LO 35.76 6.76 p<0.0001 16.46 55.07 
 
 
Saliva LL LO 31.24 8.86 p=0.006 5.93 56.54 
 EO LO 25.91 7.15 p=0.004 5.50 46.30 
 Thy LO 35.57 6.57 p<0.0001 16.81 54.34 
 
LO12, LO18, LO35, LO6, LO7 and LO8. Therefore, these 13 patients were 
identified as being consistently low scoring across the range of measures. No 
Thyroid patient scored at a low enough level to be included in this section.  
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The same statistical comparisons were carried out as for the other 
questionnaires. and significant results noted. The results across the domains 
continued to mirror the main findings from the other questionnaires, that EO 
patients consistently reported the best scores from the H&N sub-groups, often 
coming close to the highest level which was consistently achieved by Thyroid 
patients. EL had the next best scores and LL achieved an intermediate status 
with LO patients scoring at the least functional and most symptomatic levels. This 
was highly significant compared to EO in recreation and swallowing and reached 
significance for most domains. 
There were no significant differences for appearance, mood or anxiety. 
For the direct comparisons the results were as tabulated below: 
 
Table 7.1.4.2.3 UWQoLv4 H&N v Thyroid Independent samples t-test 
 
Dependent 
Variable 
t Df sig (2 
tailed) 
Mean 
diff (I-J) 
Std 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Physical Function -8.07 133.89 p<0.0001 -19.02 3.20 -23.68 -14.35 
Social Function -4..37 131.78 P<0.0001 -10.71 2.45 -15.56 -5.86 
Pain -3.51 118.24 p=0.001 -14.47 4.12 -22.63 -6.32 
Recreation -4.41 124.53 p<0.0001 -14.14 3.21 -20.48 -7.97 
Swallowing -5.31 135.58 p<0.0001 -17.84 3.36 -24.49 -11.19 
Chewing -7.76 128.78 p<0.0001 -29.39 3.79 -36.89 -21.90 
Speech -5.92 134.62 p<0.0001 -18.04 3.05 -24.06 -12.01 
Shoulder -4.95 126.95 p<0.0001 -19.42 3.92 -27.18 -11.66 
Taste -5.55 135.95 p<0.0001 -23.77 4.29 -32.24 -15.29 
Saliva -4.00 120.33 p<0.0001 -18.85 4.71 -28.18 -9.53 
 
These findings emphasised the differences between Thyroid and H&N, especially 
in a H&N specific questionnaire. All domains reached a highly significant 
difference except pain and mood for which significance was reached. 
 
Table 7.1.4.2.4 shows that UWQoL was effective at differentiating between early 
and late cases and this was most marked in the physical function and swallowing 
domains, however, early patients had significantly better scores than late in all 
but activity, mood and anxiety. 
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Table 7.1.4.2.4 UWQoLv4 Early v Late Independent samples t-test 
 
Dependent 
Variable 
t Df sig (2 
tailed) 
Mean 
diff (I-J) 
Std 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Physical Function 4.13 90.05 p<0.0001 15.52 3.80 7.97 23.07 
Recreation 2.68 93.18 P=0.009 12.44 4.63 3.24 21-63 
Swallowing 4.12 83.61 p<0.0001 20.72 5.03 10.72 30.72 
Chewing 2.97 90.66 p=0.004 19.26 6.48 6.39 32.13 
Shoulder 2.75 89.06 p=0.007 15.66 5.69 4.35 26.97 
 
For Oral v Larynx there were no significant differences. 
For Stage a number of highly significant differences were apparent (Table 
7.1.4.2.5). 
 
 
Table 7.1.4.2.5 UWQoLv4 Stage I&II v III&IV Independent samples t-
test 
 
 
Dependent 
Variable 
T Df sig (2 
tailed) 
Mean 
diff (I-J) 
Std 
Error 
95% Confidence 
Interval 
      
Lower 
Bound 
Upper 
Bound 
Physical Function 6.09 93.83 p<0.0001 20.53 3.37 13.84 27.23 
Social Function 3.48 93.94 p=0.001 11.95 3.44 5.13 18.78 
Pain 3.88 90.42 p<0.0001 19.81 5.11 9.66 29.95 
Appearance 3.19 70.66 p=0.002 15.40 4.83 5.78 25.03 
Recreation 3.56 89.37 P=0.001 15.89 4.46 7.03 24-73 
Swallowing 5.50 87.91 p<0.0001 24.49 4.45 15.64 33.34 
Chewing 4.01 93.81 p<0.0001 24.27 6.05 12.26 36.29 
Shoulder 3.02 93.91 p=0.003 16.37 5.43 5.59 27.17 
Taste 3.80 92.52 p<0.0001 24.54 6.46 11.73 37.37 
Saliva 4.46 93.67 p<0.0001 26.42 5.93 14.64 38.19 
 
 
UWQoL proved effective at distinguishing between Stage I&II and III&IV disease 
across almost all domains, most of which reached a highly significant statistical 
difference with Stage I&II patients reporting better QoL. The only domains which 
did not reach significance were activity, mood and anxiety giving very similar 
results to the analysis between ‘early’ and ‘late’ cases, a relationship to be 
expected due to the nature of the queries for a questionnaire effective in 
measuring QoL in this patient population. 
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The final comparator in the main part of the questionnaire was gender. When 
thyroid patients were included the pattern seen in other questionnaires was 
repeated with physical function (p=0.007), swallowing (p=0.009) and speech 
(p=0.007) reaching statistical significance. Only for appearance did males score 
more highly than females but the difference was not statistically significant.  
 
7.1.4.3 UWQoLv4: the Importance Question 
 
For this question the participant is presented with the domains above, each 
presented as a single word. They are asked to choose the three which they 
consider to be the most important. 
To allow comparison between the study group and sub-groups, I summed the 
responses thus indicating the frequency with which each domain was selected. 
The data was as shown in tabulated and graphical form below. 
 
Table 7.1.4.3.1 Descriptives (Frequency) UWQoLv4 Important 
Domains Question 
 
Domain Study Group 
All 
(n=137) 
H&N 
(n=95) 
EL 
(n=16) 
LL 
(n=15) 
EO 
(n=29) 
LO 
(n=35) 
Thy 
(n=42) 
Pain 23 19 2 2 5 10 4 
Appearance 33 30 6 6 5 13 3 
Activity 9 8 0 2 4 2 1 
Recreation 16 8 2 1 3 2 8 
Swallowing 16 16 0 1 5 10 0 
Chewing 35 28 4 2 7 15 7 
Speech 18 9 1 2 2 4 9 
Shoulder 20 20 5 5 2 8 0 
Taste 17 12 3 4 1 4 5 
Saliva 17 12 2 5 1 4 5 
Mood 11 10 3 2 1 4 1 
Anxiety 13 10 2 0 3 5 3 
Other 12 4 0 1 3 0 8 
 
This table allowed comparison between site specific priorities. Of all domains, 
chewing had the overall highest score, based mainly on the number of LO 
patients who selected this option. Appearance was next, both of these scoring 
considerably higher than the next two choices, pain and appearance. Pain is 
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acknowledged as important, not only for ensuring therapy but also as a marker of 
recurrent disease or a new primary cancer. 
 
Figure 7.1.4.3.1 UWQoLv4 Graphical representation of domain 
choices 
 
 
The graph emphasises the overall pattern of responses and that the biggest H&N 
group, LO, contributed to the domains prioritised overall as most important, 
whereas responses for the Thyroid patients had a very different profile.  
Conclusions cannot be drawn from the questionnaire data alone but its 
prioritisation by patients may reflect the view that having pain is unacceptable or 
that it remains an unresolved issue for a sub-set of patients. Appearance was 
endorsed across the sub-groups, which is surprising as only a sub-set would be 
directly affected. The relatively high score for shoulder pain, as a consequence 
primarily of surgery, indicates that those who have had a neck dissection were 
likely to rank this as a priority. My hypothesis that thyroid patients represent a 
different population from the remainder of H&N was supported by their ranking of 
speech and recreation, which did not achieve high frequencies for the other sub-
groups as their main priorities, followed by ‘other’. Although the paper version of 
this questionnaire has a free text option, we were not able to explore this further 
in our study, as this was not available on the touch-screen. 
 
7.1.4.4 UWQoLv4 The Global QoL Ratings 
The global QoL rating enquires about HRQoL and general QoL over the  month 
before developing cancer and the past week. Combining these items can be 
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done as they have a high correlation with each other (Rogers et al, 2008). This 
was the approach taken in analysis of my study data. 
The mean scores for each group were as shown in Table 7.1.4.4.1. 
 
Table 7.1.4.4.1 UWQoLv4 descriptive statistics: mean scores by sub-
group  
 
Domain Study Group 
All (n=137) EL (n=16) LL (n=15) EO (n=29) LO (n=35) Thy (n=42) 
QoL 
Mean (SD) 
3.82 
(0.85) 
3.63 
(0.59) 
4.16 
(0.73) 
4.02 
(0.51) 
3.24 
(1.10) 
4.10 
(0.67) 
 
As for the previous measures, the relationships were explored using an ANOVA. 
 
 
Table 7.1.4.4.2 UWQoLv4 ANOVA for comparison of sub-groups (QoL 
scores)  
 
Dependent 
Variable 
Study 
Group (I) 
Study 
Group (J) 
Mean diff 
(I-J) 
Std 
Error 
Sig (2 
tailed) 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
QoL EL LO 0.92 0.24 p=0.002 0.11 1.72 
 EO LO 0.78 0.19 p=0.001 0.13 1.44 
 Thy LO 0.87 0.18 p<0.0001 0.27 1.46 
 
This analysis, in one single question, confirmed the core findings to date, in terms 
of the poor status of LO compared to Thy, EO and EL. The level of significance 
tailed off in accord with the findings so far from analysis of all measures. 
Considering the factors using the same method as for the previous analyses, 
significant differences were found for H&N v Thyroid with thyroid reporting better 
QoL (p=0.003, 95%CI -0.69 to -0.14) and Stage I&II v III&IV (p=0.005, 95%CI 
0.15 to 0.78). 
 
7.1.4.5  UWQoLv4 Summary 
This questionnaire performed well in terms of reflecting QoL in this study 
population, mirroring the findings of more comprehensive measures. The 
limitations are the lack of measures of items which have been prioritised in those 
questionnaires which incorporate general scores and this factor carries the risk 
that important aspects of status may not be identified. Its strength lies in including 
aspects of QoL which appear to be endorsed by H&N patients. This is particularly 
true of shoulder function and this is the only questionnaire which includes this 
important parameter for those treated by surgery. 
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7.1.5 HADS & MHI5 
7.1.5.1 HADS 
 
The HADS incorporates a simple scoring system on a scale from 0-3 for each 
item. 7 questions measure depression and 7 measure anxiety. Scales for each 
question are scored so that a high score represents a high level of anxiety 
and/or depression. giving a maximum score of 21 for each item. There is much 
debate in the literature about the cut off levels which indicate psychological 
morbidity and different scores are suggested for different diseases, however, the  
main body of the very substantial literature about this questionnaire uses this 
scheme: 
Subscale score     Interpretation 
8-11                       Probable borderline anxiety and/or depression 
>11                        Probable clinical case of anxiety and/or depression. 
These scores were used in this evaluation. 
From the descriptive statistics, the population for the whole study group and each 
sub-group could be considered. 
 
Table 7.1.5.1.1 HADS scoring by Study Group and Sub-groups 
 
Domain Study Group 
All (n=135) EL (n=16) LL (n=15) EO (n=27) LO (n=35)  Thy (n=42) 
Anxiety 
Mean (SD) 
4.93 
(4.32) 
5.63 
(4.30) 
3.40 
(2.95) 
2.93 
(3.97) 
6.03 
(4.87) 
5.60 
(4.03) 
Depression 
Mean (SD) 
3.64 
(3.84) 
4.75 
(3.79) 
2.40 
(2.20) 
2.48 
(3.46) 
5.57 
(4.87) 
2.79 
(2.87) 
 
The scores followed the pattern seen so far with EL and LO scoring more highly 
than the other groups for both anxiety and depression however, in this 
questionnaire thyroid patients scored relatively high for anxiety but below the all 
participant mean for depression. 
For this questionnaire, the core findings were gained by looking at the data at 
individual level and Table 7.1.5.1.1 showed the patients with a score above the 
‘cut-off’ level.   
The most likely sub-groups for borderline and probable case lay in the EL and LO 
groups, those who scored poorly in the QoL measures. Of probable cases,  
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Table 7.1.5.1.2  HADS individual scores 
Key: Red numbers represent scores at probable ‘case’ level. Black entries are at borderline level. 
 
Sub-
Group 
Gender Age Stage TNM Time from 
therapy 
Occupation Working Changed Anxiety Depression 
L L10 M 59 4 T4N0 64 Car restorer Yes Yes 8 8 
EL 11 F 58 1 T1 36 Retired No No 16 8 
EL 8 M 50 2 T2N0 44 Sales Man No No 8 8 
EL3  M 54 4 TisN2 51 Sickness 
Benefit 
No Yes 11 12 
EO 16 F 77 4 T4N0 30 Retired No No 9 na 
EO 18 F 57 1 T1N0M0 12 Property 
developer 
Yes No 18 15 
EO23 F 71 3 T3N0 19 Retired No No 8 10 
LL12 M 69 4 T4N2 20 Unemployed No No na 9 
LO 1 M 53 1 T1N0M0 48 Accountant Yes No 18 18 
LO 14  M 51 4 T4N+ 51 Unemployed No Yes 13 10 
LO 15  M 81 4 T4N1 29 Retired No No na 11 
LO 8 M 53 4 T4N2B 33 Unemployed No No 11 na 
LO11  M 51 3 T1N1 54 Unemployed No Yes na 11 
LO21 F 77 4 T4N0 32 Retired No No 10 na 
LO12  M 55 4 T2N2 60 Retired No No 18 11 
LO18 M 63 4 TXN2 
Oral 
excisions 
+++ 
26 Sickness 
Benefit 
No No 14 11 
LO19 M 55 4 T4N3M0 12 Gardener Not 
entered 
Not 
entered 
9 na 
LO2 M 55 3 T2N1 43 Agency 
work 
Yes Yes na 10 
LO32 M 47 3 T3N0 28 Disabled No No na 10 
LO35 M 47 4 T4N1 33 Unemployed No No record 16 19 
Thy 
13 
F 53  Follicular 56 Unemployed No Yes 15 na 
Thy 
23 
F 61  Papillary 60 Retired No Yes 11 na 
Thy 4 M 59  Medullary 59 Salesman Yes No 8 na 
Thy 5  F 35  Papillary 29 Housewife No No 13 na 
Thy29 M 57  Papillary 43 Retired No No 8 na 
Thy30 F 49  Follicular 12 Care 
Worker 
Yes No 9 na 
Thy31 F 40  Papillary 15 Housewife No No 8 na 
Thy34 F 55  Medullary 15 Secretary Not 
entered 
Not 
entered 
16 na 
Thy40 F 48  Papillary 19 Sickness 
Benefit 
No No 8 na 
Thy42 F 21  Papillary 14 Student Not 
applicable 
Not 
applicable 
13 9 
Thy43 F 45  Papillary 18 Psychiatric 
Nurse 
Yes Yes 9 13 
Thy46 F 31  Papillary 30 Finance 
Assistant 
Yes No 10 Na 
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anxiety was the item to reach this level in 11 cases and depression in 5. 3 
patients scored at a high level for both anxiety and depression, 2 LO and I EO 
patient. 
The statistical comparisons for HADS did not show any significant results. 
The patients’ personal profiles were mixed in terms of stage, therapy, time from 
completion of therapy and occupational status. Two were retired, two on sickness 
benefit and three unemployed, however four were employed or were students; 
one property developer, one accountant, one secretary and one student. In this 
small series there did not seem to be any predictors of probable cases and there 
was no evidence that psychological distress was more common in the early time 
after therapy. For two patients, there. were possible confounding reasons for a 
low score. One had had a renal transplant (Thy40, Anxiety score-14) and the 
other had multiple oral excisions and considerable co-morbidity including 
pancreatitis (LO18). 
 
7.1.5.2 MHI-5 
 
The MHI-5 is scored as a simple sum of the items. As yet, no formal ‘cut off’ has 
been agreed but a high score reflects higher psychological morbidity. The highest 
possible score for an item is 6, giving a maximum score for the questionnaire of 
30. 
 
Table 7.1.5.2.1 MHI-5 scoring by All Participants and Sub-groups 
combined: 135 responses 
 
Group Number Minimum Maximum Mean Std 
Deviation 
All 135 0 30 13.34 6.57 
EL 
 16 0 25 11.81 6.18 
LL 
 15 5 22 13.47 6.77 
EO 
 27 5 24 12.44 6.51 
LO 
 35 5 30 14.46 6.95 
Thy 
 42 5 24 13.52 6.49 
 
It is interesting to note that, for this questionnaire, EL had the lowest mean score, 
in contrast to the other measures. LO had the highest score, followed by Thyroid. 
When the patients with the highest scores were identified, there was little 
correlation with HADS. Applying an arbitrary ‘cut-off’ of score >20; i.e. 2/3rds of 
the highest possible score, the following patients were identified (scores are in 
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brackets; those with an asterix also scored as borderline or probable cases using 
HADS: EL2 (25), LL10 (21), LL7 (22), EO10 (22), EO11 (22), EO18* (24), EO21 
(21), EO30 (21), EO34 (21), EO5 (21), LO10 (28), LO12* (25), LO18* (21), LO27 
(22), LO28 (22), LO32* (25), LO35 (30), Thy30 (22), Thy31(22), Thy33*(21), 
Thy34* (22), Thy36 (23), Thy37 (21), Thy39 (21), Thy42* (24), Thy44 (25), 
Thy45(22). In this series EO patients were present, although for the other 
measures this group has scored well in all domains. EL was under-represented 
compared with the results of the other questionnaires and Thyroid over-
represented in terms of high scores. 
Statistical analyses were carried out as for the other questionnaires, however, no 
significant differences were found. 
 
7.1.5.3  Summary of findings HADS and MHI-5. 
 
Both measures identified psychological morbidity in a number of patients, 
however, there were marked differences between those identified as having a 
high score. To establish which is more likely to represent an individual’s status, a 
further study would be required. However, the pattern of results for the HADS 
followed that of the other questionnaires which suggests that this may be the 
preferred measure for H&N practice.   
 
7.1.6 Test/retest data by questionnaire 
 
The same considerations applied to each questionnaire in the chapter as was the 
case for the consultation questionnaires described in Chapter 6, Section 6.1.2. 
For each questionnaire the test/retest data was compared using an independent 
t-test and the reproducibility confirmed.  The results showed that similar scores 
were attained by participants at both interventions. 
 
7.2 Patient opinions and preferences for questionnaires 
 
7.2.1 Importance and Well Written ratings by questionnaire 
For the general questionnaires the patients were asked to rate each measure for 
‘importance’ and ‘well written’ as described in Chapter 4 (4.9). They were also 
asked if they had a clear preference for an individual questionnaire. For the H&N 
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measures my main aim was to capture views at individual item level so the rating 
for ‘importance’ and ‘well written’ was attached to each question. 
Table 7.2.1.1 Preferences and Ratings for General Questionnaires 
 
 
EORTC 
QLQ C30 
All (H&N) 
FACT-G 
 
All (H&N) 
SF-36 
 
All (H&N) 
No 
Preference 
All (H&N) 
Choice 12 (8) 25 (14) 25 (12) 87 (65) 
Importance 3.65 (3.40-3.76) 3.66 (3.53-3.75) 3.66 (3.60-3.76) n/a 
Well Written 3.64 (3.47-3.74) 3.63(3.55-3.71) 3.61(3.51-3.69)  n/a 
  
The choice of questionnaire item indicated a trend towards a preference for the 
FACT-G, which was particularly popular with Thyroid patients. However, the most 
important point in relation to questionnaire choice is that at test/retest no-one who 
expressed a preference for a questionnaire chose the same one on the second 
occasion. Nine participants expressed no preference on both occasions; thirteen 
supported one measure at intervention 1 and different choice at intervention 2. 
The only valid conclusion was that patients did not express a preference for a 
single general measure. 
The ratings for ‘importance’ and ‘well written’ were subject to an obvious ceiling 
effect, with all measures being strongly endorsed. The measures chosen for the  
study were the lead questionnaires in clinical practice at international level so the 
high ratings were understandable. As with preference, the only conclusion could 
be that there were no clear grounds for choice using the ‘importance’ or the ‘well 
written’ ratings. This was also the case when the results were explored at sub-
group levels. 
Whilst for the general questionnaires ‘importance’ and ‘well written’ ratings were 
done for the whole questionnaire, for the H&N measures no overall rating was 
requested but instead, a rating was entered for each question. In terms of 
individual questions, for the H&N questionnaires, the highest and lowest scoring 
for each questionnaire was investigated. 
LL scored consistently higher than the other sub-groups and Thyroid consistently 
lower across all measures. FACT H&N had the highest scores for importance. 
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Table 7.2.1.2 Importance and Well Written Scores H&N 
questionnaires by Sub-Group 
 
Questionnaire Rating Group /Sub-Group 
All EL LL EO LO H&N Thy 
EORTC H&N Importance 3.53 3.51 3.88 3.64 3.64 3.65 3.29 
FACT H&N Importance 3.60 3.57 3.90 3.55 3.69 3.66 3.47 
UWQoLv4 Importance 3.54 3.49 3.74 3.58 3.64 3.61 3.49 
EORTC H&N Well Written 3.53 3.54 3.80 3.61 3.65 3.64 3.28 
FACT H&N Well Written 3.57 3.55 3.82 3.54 3.67 3.63 3.42 
UWQoLv4 Well Written 3.58 3.58 3.86 3.60 3.67 3.66 3.38 
 
 
For the EORTC QLQ H&N module the highest scoring questions were: dry mouth 
(mean score=3.76), pain in jaw (mean score=3.76) and painful throat (mean 
score=3.73). For FACT-H&N the highest scores were swallowing (mean 
score=3.75), dry mouth (mean score=3.73) and communication (mean 
score=3.73). For UWQoLv4 the highest scoring question was mood (mean 
score=3.76), chewing (3.74) and swallowing (3.71). No question scored 
consistently at other than a high level. 
The scores depended on views about the content; no attempt was made to ask 
participants if there were any significant omissions at individual questionnaire 
level. 
 
7.3 Patient Opinions about Questionnaires 
 
 
Comments were analysed from a random sample of 25 patients. In terms of 
general questionnaires, two, EL16 and Thy30, stated that they preferred SF-36 
as most relevant. Nine stated a preference for FACT-G, their reasons being ‘it 
gives a good summary of how you feel’. Thy32 stated simply ‘I liked the 
questions’ and Thy35 felt they were ‘more pertinent’. Thy36 said ‘it asks the right 
questions about H&N’. LO30 considered that FACT-G ‘allowed him to report how 
he felt’ and LO28 and LO29 considered that FACT-G was ‘relevant’. Thy31 
preferred EORTC ‘it is the only questionnaire which explores tiredness and pain’. 
An EL sub-group patient very much supported the EORTC because ‘the 
emotional questions are so good’. 
For H&N questionnaires Thy29 preferred UWQoL as he considered it ‘more 
detailed’ and LO30 came to the same conclusion and felt it was the only 
questionnaire which dealt with surgical issues, especially the ‘shoulder question’ 
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which he considered an important aspect of his status as did LL13. Thy13 also 
liked UWQoL believing ‘it allowed people to describe how they feel’. There were 
some criticisms of individual questions, solely for UWQoL. The voice question 
was ‘confusing’ (LO27) and LO31 indicated that the aspects of the taste question 
ruled out any response which matched his status.  
There was almost unanimous endorsement to the principle of using a 
psychological questionnaire. Typical responses were ‘they help you describe how 
you feel’. Of those who expressed a preference, 3 preferred HADS and 3 
preferred MHI-5. 
A number of participants prioritised domains. Ones which were endorsed by this 
subset of participants included pain, fatigue, eating, swallowing, appearance, 
numbness, dribbling and wearing of dentures, most of which, but not all, are part 
of the questionnaires. Important issues which went beyond questionnaire content 
were a wish to have all information even if it was bad news, to be given an honest 
assessment of long term status and to have more awareness of the impact of the 
disease on family and life in general. In terms of specific areas one patient 
requested more on tracheostomy. 
There were numerous positive comments about the study. ‘A good thing to do;, 
‘helps me think through what to talk to the doctors about’, ’helps me describe how 
I feel’, ‘very good, made me think.’ Some patients from the ‘early’ group pointed 
out that their status was good so some of the questions did not apply to them, 
however they were happy to have participated. 
 
7.4 Summary  
 
When I planned the study, my interest was in the opinions of patients about 
questionnaires and the statistical method described in Chapter 4 was powered to 
detect differences in preference by questionnaire choice and also by ‘importance’ 
and ‘well written’ ratings. In the event, choice proved unreliable, and the ratings 
exhibited a marked ceiling effect. The only valid conclusions from this part of the 
study were that patients were supportive of all the questionnaires tested. In the 
second part of the chapter their priorities and how this related to the content of 
the questionnaires was considered with clear indications as to needs for a clinic 
based questionnaire assessment. 
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The scoring proved informative with significant differences between Sub-groups 
and also for the other factors analysed (H&N v Thyroid, Early v Late, Oral v 
Larynx, Stage I&II v Stage III&IV and Gender). 
In terms of questionnaire ratings, all scored well with FACT-G and H&N 
marginally achieving the highest scores.  
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Chapter 8 - The Opinions and Preferences of 
Clinicians on the Content of Consultations and the 
use of Questionnaires 
 
8.1  Aims 
The aims of the clinician study were: 
• To gain knowledge about opinions on consultations and questionnaires to 
allow comparison with the patient views 
• To look towards a consensus which might guide creation of a 
communication tool acceptable to patients and the MDT. 
• To determine at what score a clinician would feel an item or issue was 
worthy of further exploration or assessment in consultation.  
• To gain knowledge as to who in the MDT was considered most suitable to 
pick up on issues raised by patients. 
 
8.2  Study subjects 
The subjects were drawn from members of the Leeds / Mid-Yorkshire MDT which 
meets weekly at the Institute of Oncology, St. James’s University Hospital, Leeds. 
This MDT is one of the UKs largest assessing approximately 250 new patients 
per year for therapy for H&N cancer and also acts as a tertiary referral centre. As 
the method included a detailed interview and subsequent analysis an exploratory 
level sample of convenience was used, ensuring representation across speciality, 
gender and age. Each participant completed the study according to the same 
method as described for the patients (Chapter 5). However, an added dimension 
was an enquiry at specific intervals as to which MDT member would be the best 
to manage this item if the situation was stable or, alternatively, if the situation was 
worsening. 
All interviews were undertaken by myself and were taped and transcribed to allow 
careful and detailed analysis. 
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8.3 Method 
The patient study was discussed at the outset and at 3 monthly intervals at the 
Yorkshire Cancer Network Head and Neck Cancer Site Specific Group meetings 
and all colleagues were aware of and agreed in principle to participate in the 
study. 
Using the touch-screen computer, as previously described (Chapter 4.5.2), 
participants were asked to mirror the patient intervention as far as possible. 
Demographic data was collected on area of specialist practice, duration of 
specialist practice and communications skill training. We had held a team training 
day which all members attended so, for the purposes of this question, I was 
referring to the advanced course offered by the Yorkshire Deanery as a criterion 
for training in communication skills. Recruitment was designed to capture all 
disciplines, medical, dental, nursing and allied health professionals who 
contribute to the MDT discussions and to patient care. A clinician form was 
developed to guide the interview (Appendix 8.1). The touch-screen was selected 
for data collection as this allowed clinicians to gain familiarity with the system 
most likely to form the basis of a future routine in-clinic assessment. Participants 
completed the ‘attitude to consultation’ questionnaire, followed by the three 
generic QoL questionnaires and the three H&N questionnaires. As this was in 
progress the conversation between the participant and interviewer was taped, 
using a digital hand-held device (Olympus DS 2200) with the emphasis on 
gaining as much information as possible on clinician opinions. I personally 
performed all interviews for this part of the study. Interviews were transcribed 
verbatim. To ensure that comments could be ‘tracked back’ to the question, I 
annotated the hard copy using key words to identify the quote. A portion of a 
completed transcript, partly integrated with the comments and partly as 
transcribed, is appended (Appendix 8.2) to show the way the interviews were 
conducted, how the clinicians adapted to the way the questions were presented 
and the complexity of this part of the study. 
In the first interview it became apparent that a wealth of discussion was possible 
but that this made completion of the data entry at a single session difficult to 
achieve. To allow clinicians to proceed at their own pace and to gather as much 
data as possible about their views the touch-screen was adapted to allow data to 
be collected over two sessions. Intervention 1 consisted of the ‘attitude to 
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 consultation’ questionnaire and the generic QoL questionnaires; SF-36, EORTC 
QLQ C30 and FACT-G. Intervention 2 comprised the H&N specific 
questionnaires; FACT-H&N, EORTC H&N module and the UWQoLv4. 
Participants were asked to score items at the level at which they considered a 
check should be triggered in clinic; i.e. a score which would result in an action. 
Ratings of ‘importance’ and ‘quality of wording’ were more intense than in the 
patient study in that I asked for opinions on groups of questions rather than 
simply for the whole questionnaire. I arranged the groups of questions 
pragmatically to gain opinions on what might need to be done and who was best 
placed to take responsibility for that section. This usually mapped to the domains, 
but not always so and the clustering was agreed ‘a priori’ by myself and the 
clinicians. This allowed a discussion about who, in the team, would pick up the 
item in the MDT, once the chosen questionnaire was introduced to the routine 
setting. For the H&N questionnaires, the method was continued as in the patient 
study as each item was already individually scored. Discussions were included as 
to which team member would address specific concerns as already noted above. 
 
8.4 Recruitment 
Recruitment took place during the period September 2008 to April 2009. 
Colleagues were approached and a mutually convenient time agreed to conduct 
the interview and touch-screen assessment. 
The technology performed well with few practical or technical problems until the 
end of the study when a major upgrade made further entries impossible. However 
the first participant completed his entry on the ‘offline’ version of PPM and, when 
synchronisation was attempted it was discovered that the data had been lost. 
This interview was subsequently repeated without any further hitch. On two 
occasions interviews were scheduled and had to be cancelled as PPM updates 
had been performed, a change which did not automatically take place on the 
stand alone touch-screen machines and which required a manual update through 
the IT support. department. When this occurred there were inevitably delays in 
recruitment and inconvenience to me as a researcher and to the subjects. To 
avoid the possibility of loss of data I added the scores to the ‘hard copy’ to allow 
later entry if further data loss occurred. 
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On four occasions, clinicians entered data and wished immediately to change 
their answer. Notes were made of these events to allow manual correction on the 
database. 
Recruitment at pre-arranged times with doctors proved problematic, mainly due 
to clinical pressures and unplanned clinical events which called them away. The 
only way to achieve recruitment in a reasonable period was to act 
opportunistically, interviewing colleagues at the MDT clinic on days when they 
had a small clinic list. As the workload varies considerably from clinic to clinic, 
this proved an effective strategy. 
At the point where 11 colleagues had completed the whole study and 14 had 
completed the first part, we had a major problem with the touch-screen. Updates 
to both the system and new firewall arrangements made the interface 
problematic. The Trust and University were actively working on a new wireless 
network and this would take time to introduce. Given the evidence that collection 
of data by either touch-screen or paper record is comparable, rather than delay 
the end of the study, a pragmatic decision was taken to end the study at this 
stage. I subsequently entered the data onto the PPM system to complete the 
database for analysis for 2 colleagues who completed part 2. One colleague had 
a period of sick leave so he was unable to complete the second part of the 
intervention. This gave 14 records for the first intervention and 13 for the second, 
sufficient for exploration given the detailed nature of the intervention.  
 
8.5 Data validation 
Data was exported from PPM as an Access database, transferred to an excel 
spreadsheet and manually checked against the hard copy. The errors of data 
entry were manually corrected. 
 
8.6 Data analysis 
The data was analysed by demographic characteristics, speciality, scores on the 
‘consultation’ and QoL questionnaires, ratings of ‘importance’ and ‘well-written’ 
and questionnaire preference. After transforming the scores according to the 
manuals as described for the patient data, I entered it into SPSSv15 for 
QoL in Individual Patients  Chapter 8 
201 
 
descriptive statistical analysis. The results were considered together with the 
transcripts to gain insight into reasons for scores. Note was made of positive and 
negative comments about each questionnaire and specific questions; this was 
also considered according to the speciality of the responder: e.g. SALT comment 
of questions on voice quality.  
The final part of this analysis looked at how the MDT might be used to ensure 
that the most appropriate member looked at and addressed concerns,  
 
8.7 Results 
8.7.1. Clinician demographics 
14 clinicians participated in the study, 12 completed all questionnaire based 
assessments and interviews. This sample constituted the majority of MDT 
members who had face to face clinical contact with patients. Their demographic, 
speciality data and level of advanced communication skill training were as shown 
in Table 8.1. All specialist groups currently working in the MDT were represented. 
Most participants were female which reflects the composition of the MDT, 
especially at Allied Health Professional and Nursing level, where we do not have 
any male members in the team. 
 
Table 8.1 
Clinician Demographics 
Study 
Number Gender Age 
Years 
Qual 
Time in 
Spec Speciality 
Adv 
Commun 
C01 M 45 15 6 MEDONC Y 
C02 F 42 10 4 SALT N 
C03 M 37 10 2 MFS N 
C04 F 44 25 8 CNS N 
C05 F DIETITIAN N 
C06 M 44 20 11 ENT Y 
C07 F 45 23 11 CNS Y 
C08 F 31 9 8 CNS N 
C09 M 34 16 8 REST DENT N 
C10 F 28 6 3 DIETITIAN N 
C11 M 40 16 8 MFS N 
C12 F 52 28 11 ENT N 
C13 F 43 19 10 CLIN ONC Y 
C14 F 44 7 2 SP NURSE Y 
Key: MEDONC=Medical Oncology, CLINONC=Clinical Oncology, CNS=Clinical Nurse 
Specialist, ENT= Ear, Nose and Throat Surgeon, MFS= Maxillofacial Surgeon, REST 
DENT= Restorative Dentist, SALT= Speech and Language Therapist, SP NURSE= 
Specialist Nurse.. 
QoL in Individual Patients  Chapter 8 
202 
 
 
Of the 14 participants, 9 were female and 5 male. The females represented a 
range of specialities, medical (1), surgical (1) nursing (4) and AHPs (3). The 5 
male participants were surgeons (3), a medical oncologist (1) and a restorative 
dentist (1). The mean age was 41 with a range of 28-52 and a mean of 41.63 for 
females and 40 for males. The mean time since qualification was 16.08 years 
with a range of 6 to 28 years and a mean of 16.5 for females and 15.4 for males. 
The mean time working in H&N was 8.46 years with a range of 2 to 16 years and 
a mean of 7.5 years for females and 8 for males. These results indicate that the 
opinions expressed below were those of a team well established in professional 
work at this cancer site. It is interesting to note that only five of the group had 
undertaken advanced communication skills. Some participants noted that they 
were still ‘on the Deanery waiting list’, a matter which they considered to be of 
concern. 
 
8.7.2 The ‘Consultation’ questionnaire 
The questionnaire adapted from the work of Detmar et al (2000) was completed 
by all participants. The results are presented in Table 8.2, showing the mean 
score to allow immediate comparison between the items according to scores from 
the whole group and also frequencies to indicate how many clinicians considered 
their scores to be in each category of response. 
 
Table 8.2: Clinicians’ preferences for consultations 
    Frequency  
 Question Mean 
Score 
 Rather   
not 
If patient 
mentions 
Wish to 
discuss 
Q1 Physical symptoms of illness or side 
effects of treatment  
2.0  0 0 14 
Q2 Limitations in physical activity - 
general  
1.7  1 2 11 
Q3 Limitations in physical activity - 
specific to disease  
2.0  0 0 14 
Q4 How they feel emotionally 1.7  0 4 10 
Q5 Impact of treatment on work, 
housework or leisure 
2.0  0 0 14 
Q6 Impact of treatment on social 
activities 
1.3  2 6   6 
Q7 Impact of treatment on relationships 
with partner or family 
1.6  1 4   9 
Q8 Impact of illness or treatment on 
appearance 
1.9  0 2 12 
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On preferences for the content of consultations, the group were entirely 
supportive of raising physical symptoms and side effects of treatment, limitations 
specific to the disease and impact on work or leisure. Appearance followed next, 
followed by general activities, emotion and finally impact on social activities. The 
questionnaire had been slightly modified from that used in Chapter 6 as I wished 
to understand whether clinicians differentiated between close relationships with 
family and social relationships. In the patient study these two items were grouped 
together as both partners were often together and I felt a single question was 
less intrusive. In the clinician study that sensitivity did not apply. Responses were 
at a similar level for the two, although more clinicians indicated that they ‘almost 
always’ asked about family compared to the response for social activities. Within 
these lower categories the shift in scoring was between a score of 2, i.e. wishing 
to ensure the item was included towards a score of 1, i.e. allowing the patient to 
raise these areas if he/she wished. It was unusual for a clinician to state that he 
or she would not be willing to discuss an item. The clinician who did not wish to 
discuss general physical aspects of health was a dietitian who felt that this lay 
outside her specialist area and who also did not wish to explore relationships. 
Ratings of what was included in a consultation were lower; comments were made 
that whilst it would be good to include items, clinic organisational constraints 
limited the time and the content of consultations. The areas which were 
considered to ‘almost always’ be covered were ‘symptoms and side effects’, to 
which 12 of the 14 clinicians responded at the highest level. The same response 
was given for ‘limitations specific to the disease or its therapy’ suggesting a 
strong focus in the H&N area and the functions affected by therapy (Table 8.3). 
‘Overall health’ and ‘general physical limitations’ were the next most likely to be 
discussed with a gradual decline in probability of discussion as aspects of normal 
life, emotion and relationships were considered. This change was reflected 
across the disciplines of the respondents, therefore there must be risk that 
aspects of care which patients would wish to discuss are not covered in 
consultations as all members appeared to prioritise the same items. 
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Table 8.3 Clinicians’ perceptions of the content of consultations 
  Frequency 
 Question Mean 
Score 
Never Seldom Some- 
times 
Often Almost 
Always 
Q1 Overall health  3.29 1 0 1 4 8 
Q2 Symptoms and Side Effects  3.86 0 0 0 2 12 
Q2 Limitations in physical activity - 
general  
3.14 2 0 1 4 7 
Q3 Limitations in physical activity - 
specific to disease  
3.86 0 0 0 2 12 
Q4 Impact of treatment on work, 
housework or leisure 
2.71 0 3 2 5 4 
Q5 Emotional distress 2.71 0 3 4 1 6 
Q6 Impact of treatment on relation-
ships with partner or family   
2.29 1 3 5 1 4 
Q7 Impact of treatment on social 
activities 
2.36 2 2 2 5 3 
Q8 Impact of illness or treatment on 
appearance 
2.86 0 4 0 4 6 
 
Even for the items which are scored at a lower level, clinicians still had a 
tendency to respond in the higher categories. Comparing this table with the 
preferences one above, although participants reported they were more likely to 
ask about family than about social activities, the response in this section indicates 
that conversations about close relationships were not common with only 5 
clinicians responding in the ‘often’ or ‘almost always’ categories. 
There appeared to be a strong bias towards physical impact of disease and 
therapy in both sets of responses.  
 
8.7.3 Clinicians’ statements on consultations 
In the early part of the interview, some clinicians commented on their practice 
during consultations. Clinician 13 (C13), a female Clinical Oncologist provided a 
clear and informative description of her way of carrying out a consultation. 
C13: ‘for the physical symptoms, well I definitely want to do that, so tick ‘yes’ for 
that. The ‘limitations’ definitely want to do that, ‘physical activities specific to the 
disease’ absolutely. ‘How they feel emotionally’, absolutely. ‘Impact on the illness 
or the treatment and their work’, yes. And ‘my social activities’, yes.  I ask them 
quite a lot as most of them tend to …… yes. In ‘impact’ - yes I would like to ask 
them about this, yes and ‘their appearance’ - yes’. 
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Sheila: ‘This section asks about how often you actually find that you do manage 
to include the areas we have just talked about. So it is very similar in terms of its 
questions’. 
C13: ‘so ‘overall health’ ‘almost always’. Start off with open questions, ‘symptoms 
of disease, side effects of treatments’ ‘always’.  ‘limitations in physical activity as 
a result of disease’ – ‘often’. Oh no sorry probably ‘sometimes’ ‘Limitations of 
physical as a result’ – ‘always’. ‘Limitations in doing housework’ – ‘often’. Not 
housework but things. ‘Emotional distress’ - in.. how often do you discuss them? 
Well we discuss them a lot but it depends in how much you discuss them during 
their treatment. If you say follow-up cases you may reach the stage where there 
is a lot of information that you have always wanted so I think sometimes that one 
gets picked up later. ‘Impact of the disease’ - well that again is something you 
tend to pick up when you meet them multiple times. So I would only ‘sometimes’ 
ask that. ‘Social activities - visiting friends and neighbours’ - wouldn’t ask about 
that, often ask about getting out of the house or getting to the pub but not about 
friends and neighbours so rarely. ‘Impact of disease on appearance’ - ask about 
that after surgery and when the radiotherapy has settled if they have any marks.  
That’s depending on what you see so that’s ‘rarely’ ‘sometimes’ probably 
because it depends on what they’ve done.’ 
This narrative hints at some adjustment to consultation content depending on 
patient’s experience. This was echoed by C12, a female ENT surgeon who 
indicated that her consultation style and content varied with the time since 
therapy. She said that with patients well into their follow up period she would 
always ask a very general question and then follow up issues raised. She would 
ask about specific symptoms her experience had taught her were important. For 
tonsillar cancer patients she would ask about pain on swallowing, for laryngeal 
cancer, speech. She was very aware of fatigue as a limiting and ongoing 
symptom and placed considerable emphasis on enquiring about whether patients 
of working age had had the chance to resume work. She expressed a will to talk 
to employers about the possibility of part-time work if issues such as fatigue 
made full-time work impossible. She also checked known surgical causes of 
symptoms which could impact on physical performance, such as manubrial 
splitting contributing to breathlessness. She was reluctant to engage on the 
‘impact’ issues otherwise, considering that this was best covered by her specialist 
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 nurse, having concern about opening lengthy discussions which may not require 
her medical training: ‘Some anxious patients will discuss anything’. C0I, a male 
Medical Oncologist, accepting that he treated mainly advanced cases, was keen 
to undertake a wider consultation than he was able to do, simply because time 
constraints made it necessary to have a personal list of items which would 
prompt him to take action. This was balanced by the response of the CNS’s who 
each indicated that they saw it as their role to explore with the patients the social 
aspects of living after cancer and ensuring that any practical help which might 
assist in this transition was offered. However they had some concerns that 
adding a questionnaire might ‘open Pandora’s box by raising a massive number 
of issues’.  
From this part of the study it appeared that attention was paid to each of the 
items listed by at least one member of the MDT and that the level of practical 
support and engagement with issues was likely to be more thorough than 
indicated by the consultation questionnaire alone. 
 
8.7.4 Scoring and importance ratings of questionnaires 
8.7.4.1 SF-36 
The descriptive statistics were as shown in the Table 8.4. The ‘cut off’ scores 
varied but appeared to be at a reasonable level to identify people who had 
problems. The domain which scored at the highest level was ‘bodily pain’ but it 
was interesting to note, in the light of the higher endorsement of physical items in 
the preferences and perceived content of consultation ratings that the physical 
function (PF) score was  low and the general health rating the lowest. 
 
Table 8.4  Descriptive statistics for SF-36. 
Study group PF 
Mean 
(SD) 
RP 
Mean 
(SD) 
BP 
Mean 
(SD) 
GH 
Mean 
(SD) 
Vitality 
Mean 
(SD) 
SF 
Mean 
(SD) 
RE 
Mean 
(SD) 
MH 
Mean 
(SD) 
All n=14 37.14 
(21.55) 
40.63 
(11.69) 
57.86 
(13.11) 
22.50 
(15.65) 
39.73 
(15.23) 
51.79 
(15.39) 
47.02 
916.86) 
49.64 
(12.93) 
Key: PF=Physical Function, RP=Role Physical, BP=Bodily Pain, GH=General Health, SF=Social 
Function, RE=Role Emotional, MH=Mental Health. 
Maximum Score=100. High score =Good status. 
 
On reviewing the raw data, only two questions were scored at a level which 
would require the patient to score very poorly to alert a clinician. These were the 
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two questions on vigorous activities. Two participants, C12 and C13 mentioned 
that they would not include these questions as their concern was whether 
patients could do the moderate tasks associated with everyday living and there 
was a consensus view that the physical questions were repetitive and a wish to 
reduce that section to a subset in any questionnaire adopted for clinic use. 
Similarly there was a consensus view that the general health question, as 
phrased in this questionnaire was not likely to be discriminating enough to identify 
problems. It appeared from these scores that the clinicians followed through their 
dislike of these questions with a rating low in the scale for triggering a check of 
patient status. 
 
8.7.4.2 EORTC QLQ C30 
The descriptive statistics were as shown in Table 8.5. The pattern of responses 
was a much better fit with the opinions expressed in the consultation 
questionnaires, with the lowest, i.e. most likely, threshold for checking status 
being for physical function but showing broadly similar responses across 
domains. 
 
Table 8.5 Descriptive statistics for EORTC QLQ C30. 
Study group PF 
Mean 
(SD) 
RF 
Mean 
(SD) 
EF 
Mean 
(SD) 
CF 
Mean 
(SD) 
SF  
Mean 
(SD) 
Symptom 
Score 
Mean (SD) 
All n=14 46.93 
(11.71) 
44.00 
(17.02) 
39.21 
(13.81) 
39.21 
(18.13) 
41.79 
(21.510 
52.00 
(17.10) 
Key: PF=Physical Function, RF=Role Function, EF=Emotional Function, CF=Cognitive Function, 
SF=Social Function. Symptom Score is the aggregated scores from the symptoms list. 
Maximum score = 100. Functional scales, high score = good status. Symptom score, high score = 
poor status. 
 
I have again aggregated the symptom list, which is the way this part of EORTC 
QLQ C30 is usually presented, into a single score for convenience and to allow 
an overview of the level at which a check on status would be triggered. Within the 
individual symptom questions suggested ‘cut-off’ scores were set at a very similar 
level across items except for fatigue alone where a score of 66 would be required 
to reach the threshold for attention. The mean score for the overall rating of 
HQoL was 52.86 (SD 16.84). 
During the interviews, there were no consensus negative comments about any 
item in the EORTC QLQ C30. There was some discussion of the sexuality 
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question which I have included in the section below on opinions and comments 
about questionnaires. 
 
8.7.4.3 FACT-G 
Table 8.6 shows the descriptive statistics for FACT-G. 
 
Table 8.6 Descriptive statistics for FACT-G 
Study Group GP 
Mean (SD) 
GS 
Mean (SD) 
GE 
Mean (SD) 
GF 
Mean (SD) 
All (n-14) 1.97 
(0.77) 
1.28 
(0.573) 
1.82 
(0.47) 
1.39 
(0.51) 
Key: GP=General Physical, GS=General Social, GE=General Emotional, GF=General Functional 
Maximum score =4. High score= good status. 
This pattern again followed the consultation data with GP triggering a check of 
status at the highest score, followed by GE. The scores needed to reach the cut-
off threshold as defined by the clinicians in this study were low for both GS and 
GF. 
  
8.7.4.4 EORTC QLQ H&N Module 
The scores for this questionnaire are symptom scores so a higher ‘cut off’ derived 
from the clinician ratings means a review of patient status is less likely. The 
responses show insight into common concerns in that ‘teeth’ was a category for 
which there would be a low threshold for review and problems with teeth occur 
often and can lead to complications as well as pain. 
 
Table 8.7 Descriptive statistics for EORTC QLQ H&N 35 
Study 
Group 
Domain  
HNPA 
Mean 
(SD) 
HNSW 
Mean 
(SD) 
HNSE 
Mean 
(SD) 
HNSP 
Mean 
(SD) 
HNSO 
Mean 
(SD) 
HNSC 
Mean 
(SD) 
HNSX 
Mean 
(SD) 
All (n=12) 43.67 
(14.99) 
43.00 
(12.34) 
52.75 
(22.54) 
49.92 
(16.38) 
48.58 
(15.54) 
49.58 
(14.50) 
55.67 
(20.63) 
Study 
Group 
Domain  
HNTE 
Mean 
(SD) 
HNOM 
Mean 
(SD) 
HNDR 
Mean 
(SD) 
HNSS 
Mean 
(SD) 
HNCO 
Mean 
(SD) 
HNFI 
Mean 
(SD) 
 
All (n=12) 33.08 
(14.29) 
52.83 
(17.51) 
61.25 
(19.45) 
61.33 
(13.23) 
58.42 
(20.95) 
55.58 
(21.96) 
 
Key: HNPA=Pain, HNSW=Swallowing, HNSE=Senses, HNSP=Speech, HNSO=Social Eating, 
HNSC= Social Contact, HNSX=Sexuality, HNTE=Teeth, HNOM=Mouth Opening, HNDR=Dry 
Mouth, HNSS= Sticky Saliva, HNCO=Coughing, HNFI=Feeling Ill.  
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On the other hand, the scores to trigger a review for dry mouth and sticky saliva 
were high, perhaps reflecting the fact that these are almost considered the norm 
for H&N patients. 
The yes/no questions on painkillers (HNPK), nutrition (HNNU), feeding tube 
(HNFE), weight loss and weight gain (HNWL & HNWG) were also scored. For 
HNPK the intervention level was set at 55.42 (SD 21.96) but for the other 
questions it was very high (mean 75, SD 45.23). There was less satisfaction with 
these than with the main part of the questionnaire and this may have been 
reflected in the scores. 
  
8.7.4.5 FACT H&N Module 
This questionnaire has a list of questions, some positively phrased, some 
negatively. The scores are adjusted so that a high score reflects good status. 
 
Table 8.8 Descriptive statistics for FACT H&N Module 
Study 
Group 
Domain 
Eat Food 
Mean 
(SD) 
Dry M 
Mean 
(SD) 
Breath 
Mean 
(SD) 
Voice 
Mean 
(SD) 
QuFood 
Mean 
(SD) 
App 
Mean 
(SD) 
All (n=13) 1.31 
(0.86) 
2.38 
(0.96) 
1.62 
(0.87) 
2.15 
(0.90) 
2.25 
(0.99) 
1.92 
(0.95) 
Study 
Group 
Domain 
Swallow 
Mean 
(SD) 
Comm 
Mean 
(SD) 
Solid 
Mean 
(SD) 
Pain 
Mean 
(SD) 
Smoke 
Mean 
(SD) 
Alcohol 
Mean 
(SD) 
All (n=13) 2.31 
(1.03) 
2.15 
(0.69) 
1.54 
(1.13) 
1.54 
(0.78) 
1.85 
(0.99) 
1.92 
(1.26) 
Key: EatFood=Able to eat the foods I like, DryM=My mouth is dry, Breath= I have trouble breathing, 
Voice= My voice has its usual quality and strength, QuFood=I am able to eat as much food as I 
want, App=I am unhappy with how my face and neck look, Swallow=I am able to swallow naturally 
and easily, Comm=I am able to communicate with others, Solids=I can eat solid food, Pain= I have 
pain in my mouth, face or neck, Smoke=I smoke cigarettes, Alcohol= I drink alcohol. 
Maximum score=4. High score =good status. 
 
This response contradicted the one above in that dry mouth was the domain 
which was scored to trigger a review at the highest score, hence, most likely to 
happen. The next items were swallowing and communication, again well 
recognised concerns for this patient population. 
 
8.7.4.6 UWQoLv4 
Again, in these scores, clinicians showed vigilance in areas known to be 
problematic but for this questionnaire there was rather more consistency across  
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the domains. This may be because it has a physical focus with the exception of 
the two final questions, relating to mood and anxiety. 
 
Table 8.9 Descriptive statistics for UWQoLv4 
Study 
Group 
Domain 
Pain 
Mean 
(SD) 
App 
Mean 
(SD) 
Activity 
Mean 
(SD) 
Rec 
Mean 
(SD) 
Swallow 
Mean 
(SD) 
Chewing 
Mean 
(SD) 
All (n=13) 59.62 
(21.74) 
53.85 
(22.47) 
55.77 
(23.17) 
46.15 
(13.87) 
51.54 
(20..76) 
65.38 
(37.09) 
Study 
Group 
Domain 
Speech 
Mean 
(SD) 
Shoulder 
Mean 
(SD) 
Taste 
Mean 
(SD) 
Saliva 
Mean 
(SD) 
Mood 
Mean 
(SD) 
Anxiety 
Mean 
(SD) 
All (n=13) 57.69 
(19.22) 
54.62 
(20.26) 
66.15 
(37.00) 
57.69 
(19.22) 
53.85 
(22.47) 
56.15 
(33.05) 
Key:  App=Appearance, Rec=Recreation, Swallow=Swallowing. 
Maximum score = 100. High score= good status 
 
12 clinicians completed the ‘issues’ section. Of these 10 chose swallowing, 7 
pain, 4 speech, 2 chewing, 2 mood, 1 taste and 1 appearance. Items inserted 
into the ‘other’ category were eating and voice. During the discussion there was 
some unhappiness with the voice question as it was multidimensional, asking 
about voice quality and strength, and a number of clinicians also felt that eating 
had both physical and social aspects which were not captured by the swallowing 
and chewing questions. 
 
8.7.4.7 Summary of questionnaire scoring 
The pattern of setting a level at which a review might be triggered is a difficult 
one. In these results the striking figure is the standard deviation (SD) which is 
large even for a small group. In interpreting this it is important to remember that 
most of these scores have been scaled up from single figure scales to a score 
out of 100. The result is that a difference of one point in the raw data can easily 
translate to a difference of 25 in the final score. I looked at all raw data scores 
and found that, for most questionnaires, there was a single score favoured by 
most of the clinicians and this lay, for the majority of questions, at around 50% of 
the highest possible score. There is, therefore, more consensus around ‘cut-off’ 
scoring than these figures would seem to support. I have chosen to quote the 
mean in these tables as that, rather than frequency, allowed direct comparison 
between items in a single questionnaire and also between questionnaires. 
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The emphasis on physical symptoms and side effects appeared to carry over 
from the consultation questionnaire to levels for ‘cut-off’ scores. This was further 
explored in the analysis of consultations.  
 
8.7.5 Clinicians’ views on questionnaires 
8.7.5.1 Questionnaire Choice and Importance and Well Written 
Ratings 
 
For the general questionnaire, a simple choice was requested between 
measures. Nine chose FACT-G, two the EORTC QLQ C30 and two had no 
preference.  
For the H&N questionnaires, clinicians rated each question for ‘importance’ and 
‘well written’ 
Table 8.10 Clinicians’ Ratings: Importance and Well Written 
Score Questionnaire 
SF-36 
 
Mean 
(SD) 
EORTC 
QLQ C30 
Mean 
(SD) 
FACT-G 
 
Mean 
(SD) 
EORTC 
H&N 
Mean 
(SD) 
FACT 
H&N 
Mean 
(SD) 
UWQoL 
v4 
 
Mean 
(SD) 
Importance 3.00 
(0.88) 
3.64 
(0.50) 
3.64 
(0.50) 
3.66 
(0.20) 
3.71 
(0.13) 
3.69 
(0.22) 
Well Written 2.71 
(0.73) 
3.57 
(0.51) 
3.57 
(0.51) 
3.60 
(0.29) 
3.43 
(0.33) 
3.11 
(0.18) 
 
This rating gave identical scores for the EORTC QLQ C30 and FACT-G both of 
which were well regarded by clinicians. The SF-36 had lower scores and, in 
addition, had not been selected as the preferred questionnaire by any of the 
participants.  
The H&N questionnaires all scored higher than the general measures by a small 
margin. For importance FACT H&N had the highest score, followed by UWQoL. 
EORTC was the best in terms of phrasing and, overall, the questionnaires scored 
highly. Some questions scored very highly. For the FACT H&N, ‘I have trouble 
breathing?’ and ‘I have pain in my mouth, throat or neck?’ both scored 3.92 for 
importance and the latter also scored 3.92 on the well written rating. For EORTC, 
eight questions achieved a score of 3.91 for importance. These were: ‘have you 
had soreness in your mouth?’, all of the questions about food consistency, ‘have 
you had trouble eating?’, ‘have you had trouble talking on the telephone?’ and 
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‘have you lost weight?’ These all also had high ratings for the quality of the 
writing with ‘have you lost weight’ achieving a maximum score at 4. The UWQoL 
had only one question scoring at 3.92 and that was the first one about pain. 
To balance this, there were some questions which scored poorly. For FACT H&N 
all questions scored well for importance thereby contributing to the overall high 
score for this questionnaire. Question 5, ‘I am able to eat as much food as I want’ 
had the lowest ‘well written’ rating at 2.85, followed by question 4, ‘my voice has 
its usual quality and strength’ at 3.00. For EORTC two questions scored relatively 
badly, ‘have you coughed?’ and ‘have you felt ill?’ Both of these are slightly 
outside the mainstream H&N questions. For UWQoL, the ‘issues’ rating was 
disliked having an importance rating of 3.25 and a well written rating of 2.75 and 
the overall QoL question scored 3.17 for importance and 3.08 for well written. 
Although this is a small group, clear views were expressed about the 
questionnaires which gave insight into what the qualities of a good question are 
from the end-users, both clinicians and patients. 
The final consideration in this section was who should support the patient in each 
aspect of care, as described in subsets of questions. There was a remarkable 
level of agreement that the most effective way to provide care was to have a 
specialist nurse (the clinical insight was considered very important) who would 
‘screen’ the responses and direct the patient towards the health professional who 
might meet their needs. The consensus view was that this would be a model 
which used professional time effectively and, although considerations of health 
economics lay outside the remit of my work, it was interesting to note that 
clinicians considered this would be an efficient and potentially cost effective 
model of care.   
 
8.7.6 Clinicians’ Opinions on Questionnaires, material from the 
interviews. 
 
Although this section is inevitably subjective, it provides an insight into the way 
that clinicians approach issues and also their preferences in terms of structure of 
potential questionnaires. For comparison of structure and content, copies of each 
questionnaire are available as appendices to Chapter 4. 
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8.7.6.1 SF-36 
C01 agreed with the presence of a general health question and indicated he 
would accept a rating of ‘poor’ as a cut-off score as his role is in managing people 
with advanced disease and his expectation is that their status will be poor. He 
liked the comparison with a year ago and rated it a ‘fantastic question’ gaining 
much insight from a single statement. C13 disagreed profoundly: ‘This is not the 
best way to start when the answer is ‘I’ve got cancer’. You need a much better 
way to ask about general health. H&N cancer is so difficult to live with that to ask 
them to compare now with how life was before….it might be counter-productive to 
ask people to compare what they have now to what they had before.’ C12 
concurred indicating that so much about general health ‘depends on the patient’s 
status and the time from therapy. Some we know are right at the bottom of the 
scale but for others a small change might be important. There is a risk of invoking 
a wild goose chase if someone’s rating fell and that would not be to their benefit.’ 
C02 (SALT) agreed that much would depend on ‘where the patient was in the 
cancer pathway’  C11, a Maxillofacial Surgeon, considered that general health 
was a core part of a standard medical history and thought that the question was 
poorly written. C12 also preferred including a general health question in the 
consultation so that the response could be explored and a proper judgement 
reached about any action to be taken, No participant made a positive comment 
about this question. 
The physical function questions were considered next, providing a range of 
responses from good function to poor. There was a general feeling that these 
were repetitive and that there were too many options, although to ask about 
physical activity was thought to be a good principle and there was much more 
acceptance of asking patients to rate their ability to perform everyday tasks with 
which they would be familiar. It was also suggested by C02 that there was a need 
to have established where the patient was in the pathway to set the responses in 
context. C14 considered that the questions were far too general and that the 
focus of care was H&N cancer. Discussing full general status might, she thought, 
distract attention from the real needs which only the H&N team could support. 
The limitations in physical activity questions were guardedly welcomed in that 
they might lead to interventions which could help improve status. The consensus 
was that it would be better to put a shorter time scale on this section and ask 
about the past week rather than the past year. The next questions which brought  
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together limitations due to physical or emotional factors were welcomed by some 
clinicians. C13 thought it was a ‘lovely question, further discussion would bring up 
real issues’ but others thought it would be difficult to define what the issues 
actually were as the question was so broad. The consensus in favour of 
‘limitations due to emotional factors’ was high but the concern was summed up 
by C12 who said ‘It is what you can do that matters not the time you do it for, 
giving up a valued activity altogether is really bad in terms of recovery and a 
return to as much as possible of previous activities should be encouraged’. 
Attitudes to the question about ‘bodily pain’ differed from a belief that we may 
underestimate this to a belief that this was a ‘weird way of phrasing the question, 
why not just pain which is what I would ask about in clinic’. 
The latter part of the questionnaire which asks about attitude to illness and how 
the patient feels, e.g. ‘I tend to get sick more than other people’ was highly 
criticised. ‘I feel calm and peaceful’, what sort of a question is that? ‘This whole 
section is simply weird, I don’t think patients would understand it or why we want 
ot ask these things’. C01 rated this section ‘the worst questions I have ever seen’ 
and C12 dismissed them as ‘impossible to answer and what would we be able to 
do with the answers anyway’.  
On the whole, there were few positive comments about SF-36 and, although the 
early part of the questionnaire was acknowledged to address some relevant 
issues, the later part had no support. 
The EORTC QLQ C30 was generally felt to be clearer and better written. For the 
first questions which rate physical status there was again a feeling that the list 
was repetitive and C11 was concerned that the questions were not specific 
enough to pick up a deterioration in function, Others disagreed and considered a 
longitudinal rating would be useful in practice. C10 picked up on negativity in 
terms of language in the questions which began ‘have you had problems with?’ 
suggesting that this might infer that a problem was to be expected and leading to 
a report of less good status than was actually the case. The finance question was 
welcomed especially as three patients were noted by one clinician to have 
recently lost their homes – ‘we can never underestimate the challenges our 
patients and their families face and we need to engage with them on this, it can 
be a greater worry than their cancer’. In general, this questionnaire was much 
more acceptable to the clinicians than SF-36. 
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The third general questionnaire, FACT-G, had a mixed response despite being 
the measure most clinicians chose as their preferred option. There were marked 
positives, summed up by the comment ‘I like its snappiness;’ Similar comments 
such as ‘clear and concise’ were noted and ‘I like the way this is written, very 
simple and straight forward.’. However C13 thought that the language was 
negative with comments like ‘a lack of energy’. She considered that patients 
already carry the burden of their cancer, some of the questions might make them 
feel worse. There was a general dislike of the scoring system, especially when 
double negatives were apparent as in ‘I have trouble meeting the needs…..’, i.e. 
a negative statement with responses including ‘not at all’ and ‘very much’ 
For the head and neck questionnaires the EORTC QLQ H&N was again 
considered to be clearly and well written. For the first questions which ask about 
pain and soreness as separate entities there was some support. C02 said 
‘separating these out is really good, patients certainly differentiate’, others 
however opted for a more simple question using pain alone. C12 was impressed 
with the EORTC H&N module saying ‘it has nice straightforward questions and it 
covers important things that the FACT H&N omits.’ She was the only clinician to 
pick up on the areas which were not covered by the FACT H&N. Questions which 
were not supported included ‘have you coughed?’ which was felt to be far too 
generic and difficult to interpret and the talking questions were thought to be 
repetitive. There was debate on whether a sexuality question or an intimacy one 
was better, it was agreed that close relationships were affected by H&N cancer 
and C13 put the broader context very clearly ‘The treatment is disfiguring, added 
to a poor sense of taste and a dry mouth. The chances of having physical 
satisfaction from oral contact must be poor. This is much more subtle than just 
sex’. C10 disagreed ‘I think intimacy is just too wide a term. You have to decide 
and be specific about what you are asking and a sexuality question achieves 
that’. C08 summed up the questionnaire as ‘well written and to the point’. 
FACT H&N was supported for its brevity. C14 felt it was ‘a good length to use in 
clinic with some pertinent questions’. C12 was well aware of the omissions; ‘there 
is no specific question about voice, this needs much more probing’ and C08, 
another ENT surgeon felt that the voice question was ‘too imprecise and it 
communication rather than voice which concerns patients’. Of all the questions 
the final one ‘I have pain in my mouth, throat or neck’ was felt to be the one most 
likely from all the questionnaires to flag up matters of concern.  
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The UWQoL had supporters but also those who very much disliked it. C01 liked 
the main questions which were ‘written in a way which patients would identify 
with’ but he thought the last few questions ‘ruined it’. C08 thought ‘it started well 
and then went off’. C13 was aware of the effect of her previous experience: ‘I feel 
on safe ground, I’ve used this before’. However she was concerned about the 
questions asking about more than one thing at once and that patients might not 
relate to both parts of the question and not know how to score it. C5, a dietitian, 
had issues with the taste question: ‘It tries to simplify things but it doesn’t, It 
encompasses a lot: ‘taste food normally, taste most foods normally’ well between 
those options there are lots of food groups. Not good. I don’t like any of these.’ 
‘What about I can swallow as well as ever, that could really be as badly as ever 
but the norm for them, it is open to far too much interpretation’. C10, a SALT, was 
unhappy with the chewing question: ‘chewing with what? Dentures? Own teeth? I 
think some patients would feel there is no option which they fit’. She also did not 
like the saliva question, no option for ‘too much’ which is what the complaint often 
is ‘too much but not effective in lubricating the mouth’; C02 was dismissive of the 
whole questionnaire: ‘I really don’t like this. It is not for patients. It focuses on the 
medical view of problems, I don’t know but I am sure it was designed by doctors. 
Having more than one item in a question makes answering them very difficult and 
the whole thing is far too wordy’. In her professional capacity as a SALT she had 
concerns about specific questions: speech: ‘very clinically written’, taste: ‘an 
awful question. I have read it two or three times and am still struggling with the 
gradation’. C12 also had concerns ‘pain is an issue of change, not of severity, 
activity depends on what has been done, I would worry if a T1 larynx patient 
reported a lack of activity but not otherwise, speech question is really poor, the 
issue is the quality of sound, taste is distorted rather than present or absent. I 
think this is asking the wrong question’. The ‘ratings of importance’ question was 
universally disliked with comments from ‘this is an attempt to put QoL in a single 
box’, ‘why three items, some people might only have one and others half a 
dozen.’ 
In terms of general comments, C13 suggested that QoL questionnaires should 
have positives. What about ‘I am proud of the way I am coping?’ She also 
summed up the findings from the narratives above by saying ‘I would have to go 
with EORTC even though I know it is not easy to use – I have tried it’. C01 
preferred EORTC: ‘It is clearer and more precise – despite my dislike of the final 
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questions’. C06 also chose EORTC for precision and clarity. C07 and C08 chose 
FACT H&N as ‘quickest to complete’  
 
8.8 Summary 
In summary the most favourable comments together with a lack of significant 
omissions would, from these narratives, support the EORTC QLQ C30 and H&N 
modules as the preferred measure for assessing QoL in H&N patients, however 
the scoring data was more supportive of FACT-G and H&N, showing the 
difficulties in attempting to identify a ‘preferred measure’. 
There was a clear preference to discuss physical issues rather than the wider 
range, although, from the perceived content of consultations responses there 
appeared to be a belief that most aspects of living with cancer were addressed.  
QoL in Individual Patients  Chapter 8 
218 
 
Appendix 8.1 
 Clinician Interview form 
  Quality of Life Assessment in Individual Head 
& Neck Patients 
 
Baseline clinicians’ preferences for communication and attitude 
to QOL issues 
 
Doctor-patient communication is at the centre of good clinical practice and is receiving 
increasing attention in clinical training. We are interested in which topics you feel you 
should discuss with your patient during outpatient appointments.  
 
Please tick the appropriate box below. 
 
Would you discuss with your patients during the clinic appointments: 
 
Rather not Yes, provided 
the patient 
mentions it first 
Yes, I would 
like to 
discuss this 
topic 
Physical symptoms of illness or side effects of  
treatment (e.g. pain, sickness, cough, tiredness)? 
 
Limitations in  physical activities (walking,  
climbing stairs, general fitness) 
 
Limitations in  physical activities specific to   
their disease (eating, speech, swallow, shoulder 
function) 
 
How they feel emotionally (nervous, anxious,  
depressed) as a consequence of their illness 
 or treatment 
  
The impact of illness or treatment on their work,  
housework, leisure activities? 
 
The impact on their social activities (visiting friends,  
neighbours, clubs)? 
 
The impact of illness and treatment on  
relationships with their partner or family? 
 
The impact of illness or treatment on  
their appearance? 
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Generally, how often do you discuss these issues with your patient 
during clinic consultations? 
 
Never Rarely Sometimes Often Almost always 
 
Overall health 
 
Symptoms of disease 
or side effects of treatment 
 
Limitations in physical  
activities as a results  
of disease / treatment 
(walking, climbing stairs) 
 
Limitations in  physical             
 activities specific to                  
their disease (eating, 
speech, swallow, shoulder 
function) 
 
Limitation in doing  
work / housework or  
leisure activities 
 
Emotional distress 
 
Impact of disease on  
relationships with  
family/partner 
 
Impact of disease on  
social activities (visiting 
friends, neighbours) 
 
The impact of disease on  
appearance? 
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Clinicians’ Characteristics - socio-demographic and 
professional data 
 
 
 
Date……….. 
 
Initials………..   Age……..  Gender:  M /F 
 
Doctors: 
 
Speciality :    medical oncology  clinical oncology    ENT surgery  
 
 maxillofacial surgery         plastic surgery 
 
Qualification level:  Consultant       Sp Reg  
 
MDT members: 
 
Speciality:                 CNS         Nurse          SALT       Dietitian 
 
 
Number of years practising medicine/nursing etc:  ………… 
 
Number of years working in oncology :  …………..  
 
Formal communication skills training      Yes /No         When (approximate 
date)…………… 
 
 
 
Clinicians’ opinions- tape for each question 
 
‘Cut off’: at which score does this become a problem which requires 
assessment/intervention 
 
Who should receive the information about that score? Doctor/ CNS / MDT 
member (state specialist area) 
 
What action would you expect to be taken?   
 
Are there any important areas which you feel the questionnaire 
assessment does not address? 
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8.2: Transcript of a portion of an interview 
Sheila Fisher interview with Clinician (C06) Consultant ENT Surgeon. 
  
Dated 24th November 2008. 
 
Intervention 1 & 2. 
 
Introduction: 
 
SF: What this is is a series of questions and we will look at them here, I’ll put the 
answers on the paper copy as a back up to the touch-screen so don’t worry about 
my writing and I will talk you through how we do a series of questions, and what 
goes on in answering groups of items which fit together.  At the beginning, we 
have some questions about what you would like to do in consultations and what 
you actually do. Then we go through some general quality of life questionnaires 
and finally head and neck ones. 
 
So, here is the first part and I will give you a pen. When you get onto the screen 
you basically prod it with that and the screen moves on to the next question. 
 
Consultation Preferences entries: 
  
SF: The first 1,2,3,4,5,6,7, or so are to do with what you would like to do in a 
Consultation. 
 
C06: This is a first visit or any? 
 
SF:  This is really during cancer care. 
 
C06: is that locally? 
 
THERE IS A LOT OF BACKGROUND NOISE WHICH IS MAKING IT 
DIFFICULT TO SEPARATE THE INTERVIEW WITH THE CLINIC NOISES 
 
C06: The difficulty is in my mind is how practical this will be in clinic  
or what does it cost if we try to do all the things we would like to? 
 
SF: That’s fine; we are looking really for the ideal in this first part. 
 
C06: This could be part of this computer - same as ‘c’ drive? 
 
SF: No, it would need to be somewhere where the patient can easily fill it in and 
then the results come back to the doctor or staff. 
 
 
Consultation Practice entries: 
 
C06: Often the number of patients and the need to see different people limit what 
you can actually say. 
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SF: In this part we think about what we actually do, not what we want to do. If 
you’re saying with all the standard normal constraints of life it can be difficult, how 
often do you raise these things when you see people in clinic? 
 
SF: Thank you very much. Now we are going to go onto pressing… 
 
(Entries are completed on the touch-screen) 
 
You have been the most honest of anybody on those questions about 
consultation and the limitations of time, that is really helpful.. 
 
C06: I just say what I do, I mean. 
 
SF:  That was great, thank you.   
 
 
General Questionnaires: 
 
SF-36: 
 
SF: So we are now going to start the SF-36 which is the first of the main quality of 
life questionnaires and if you want to look at printed version I can show you one. 
What I would like to do gets difficult at this stage because basically the questions 
are put to the patient so I would like you to try and answer it at a level at which 
you would have concerns about someone. So at which point you think somebody 
seems to be having a problem. I need a bit more info so from time to time I will 
stop you and ask you some extra questions. 
 
C06: Sorry so are you saying this, that’s when you’re the patient or as a … 
 
SF: As where you would be worried if a patient was to give that answer. 
 
C06: Oh alright. OK. 
 
SF:  For example ‘I can swallow,’ ‘I cough when swallowing’. You as a doctor 
would know at what level that matters so its that kind of threshold we are looking 
for.  Now the first two are actually stand alone which is quite good because it 
takes us through who should look at the item in clinic. So yes, could you proceed 
and you get three questionnaires to look at and if you are trying to think which 
you like best as you go through, at the end if you can decide, it would be lovely to 
know which one you liked best of the three questionnaires.  So it starts generally 
and then it goes on. 
 
C06:  So if it says what would make me worried? 
 
SF: What would make you say somebody in the team probably ought to be doing 
something about this patient? 
 
C06: OK, 
 
SF: And do you think that’s something that’s in the question, is it reasonable to 
understand as it is written? We ask about this separately…… so how important 
do you think it is: we are going to do 1-4 on importance and how well written. 
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C06: Important, ‘quite’ 
 
SF: ‘Quite’ so we have a screen for that, that’s great.  And ‘well written’ on 1-4 
 
C06: Mm. ok ‘well’, 
 
SF: That’s lovely, OK so if somebody was going to look at that, who in the MDT 
would you have look at it. 
 
C06: I say ‘fair’, so the patient has said they have said ‘fair’. I mean its given that 
we have already seen this patient in the MDT and we have highlighted any, you 
know, serious medical defects so this is assuming the patient from the history did 
not have anything but they are saying, my ………. 
 
SF: This would be their first thing so…… 
 
C06: Oh, so this is before MDT, alright ok. 
 
SF:  That is the idea, before MDT, so there are 2 scenarios because they have 
already prompted me on that.  The first thing is to think that they always come 
and say health is ‘fair’. Who should look at it then? And the second thing is if they 
are actually getting worse because that might be somebody different. You have 
got the options of doctors, CNS, specialist nurses and the various AHP’s and 
then dentist, benfits advisor, others.  
 
C06: I just read it and think.  I’m sorry I’m not trying to be silly but I’m trying to 
understand the scenario. So this is a head and neck cancer patient. 
 
SF: Yes, tick that box. 
 
C06: Right and so what I was saying is if I’m at the LGI on my own before they 
have come to the MDT, that’s slightly different to me and the MDT. I would say 
ok, CNS. 
 
SF: That’s great and if they were actually getting worse, would you stick with the 
CNS for that as well. 
 
C06: No the doctor, I’d say. 
 
SF: That’s lovely, now you have gone through the whole thing once so it now 
repeats this ad infinitum.  But we do this in a stage where you do a whole lot of 
questions.  Ok so now we are looking how someone is compared with a year 
ago.  Go for worse again that’s very reasonable and again is that something 
reasonable to ask and is a year ago a good time to compare with. 
 
C06: No, its reasonable, ‘quite a lot’.        (Enters this in ‘importance’ rating)  
 
SF: That’s lovely, and how well written. 
 
C06: ‘Well’. 
 
SF: So presumably you would keep this question. If so who would you have see 
them? 
 
QoL in Individual Patients  Chapter 8 
224 
 
C06: Mm. again the CNS. 
 
SF: Right and if its getting worse?  
 
C06: The doctor. 
 
SF: (at the start of a list of questions covering aspects of physical status): Right, 
now we will take this is a physical basic summary so it goes through various 
things and it goes through various degrees of difficulties so if we take the next 
1,2,3,4,5,6,7,8,9,10 together and then we will see what you think about those as 
a physical survey. 
 
TS completed. 
 
SF: Right, thank you, and that’s the end of that block. So again we are back to 
what we were doing before so do you feel that’s an important or reasonable 
summary of things and can be quite a lot or very…. 
 
C06: ‘Very important’. 
 
SF: And how well written do you think? 
 
C06: ‘Well’. 
 
SF:  And who would you have review those? 
 
C06: The physio. 
 
SF:  Right, they are very physical.  Ok so we now change it. Basically we were 
looking at impact to physical health so we had rating of physical health and now 
its impact on life so the next 4 talk about how much you are able to do in life so 
we will take those together if we may. (Questionnaire at this stage, moves onto 
role function) 
 
C06: Right 
 
SF: And what do you feel about those being impact on life rather than a rating of 
how you are? 
 
C06: (thinking about ‘importance’) Yes, ‘a little’ rather than………… 
 
SF: And how well written.   
 
C06: ‘Well written’. 
 
SF: So would you actually keep those or would you be inclined to have a 
straightforward physical rating? 
 
C06: Well I don’t think you need all of them, I think you could just have instead of 
3 or 4 you could have 2 or 1.  
 
SF: I see, have a sub-set. Fine, and who would you have look at your sub-set? 
 
C06: The OT probably 
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For comparison, I have added a portion of unedited script to show the need 
for the hard copy so that the responses and the item about which the 
participant was talking could be reconciled in the final transcript. 
 
Sheila:  now then it goes onto a collection of statements about people’s health 
and if you haven’t already guessed which country it comes from I think you will be 
certain after this one.  So we will take the next 4 and then that’s the end of this 
first one. So you are doing well. 
 
?? what would make me worry. 
 
Sheila: what do you think about those? That’s the whole questionaire. So  
 
??  I think I’m not sure what responses you would get from patients. 
 
Sheila: that’s great.  So thinking about it would the good, bad and the ugly in 
exception that we have got some more to do how do you feel about this 
questionaire.  Good bad or indifferent and we will do the important and well 
written because they are actually different. 
 
??  that’s good, its, you know I mean, any questions for patients are good. Its 
good. 
 
Sheila: now we are giving it a quite? 
 
??  yes I would say quite.  Overall questionaire because obviously there are 
some bits that are very good and some so quite. 
 
Sheila: so now we go onto basically the European version because it says it is. 
And this again is general so we are not getting into the specifics until we go 
through the 3. so this is about the same length as the other one and the 3rd one 
is shorter and then we get into the head and neck after that.  So basically no right 
or wrong answers and I will be interested in which you like better of these two 
and then we will take the preferred one forward in comparison with the 3rd.  and I 
will stop you after 5. 
 
We are basically in a physical screen again but slightly different. 
 
?? so again when I would be worried.   
 
Sheila: so we are going to impact again so its really whether you like those better 
or whether you like the other ones better. 
 
?? I think I like this one better because this is how most patients think 
 
Sheila: so are you going to give it quite a lot or very. 
 
?? very. 
 
Sheila: what about the well written rate. 
 
??  very well written. 
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Sheila: and who would you have look at it. 
 
??  physio. 
 
Sheila:  ok here we have one. But it would be good because we could find 
something for the physio to do if we have one.  We will take the next 2 on impact 
bit shorter on the impact.  Again what do you feel about those. 
 
??  quite a lot. 
 
Sheila: and well written 
 
??  yes, well written 
 
Sheila: and who would you have look at them.  Have to go with the other votes 
there has been a fair spread on this. 
 
??  the last two would visit because asking them exactly particularly. 
 
Sheila: limitations 
 
??  OK, the OT probably  ??  if its working out. 
 
Sheila: now we have got a collection of symptoms which are derived from the list 
of what cancer patients in general described so we will take 1,2,3,4,5,6,7,8,9,10. 
we stop at diarrhoea just so we get a stop point. 
What do you feel about those as a screen 
 
??  yes, mean that I think they are quite a lot. And they are very well written 
 
Sheila: alright and who would you have look at those and one or two people said 
it does depend a bit on the question, we have got nausea, a bit on appetite, we 
have got a bit on pain. 
 
??  short of breath I think I would ask the doctor and the rest of them I think for 
the pain,  
 
Sheila: pain, need to rest, trouble sleeping, weakness. 
 
??  short of breath and pain - doctor, the rest I would say, these would be CNS 
and then that one you could say physio or … 
 
Sheila: short of breath, ok. 
 
This short portion illustrates the structure of the interview.This transcript 
ran to 17 pages, the range for the study was 12 to 29 pages. 
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Chapter 9 - Comparison of Patient and Clinician 
Opinions 
 
The aim of this chapter is to bring together the findings from the previous three 
chapters and to consider how the findings from the patient study and the clinician 
study fit together, where there was consensus on which to build and where there 
were differences. This leads on to a consideration of what might be gained by the 
introduction of a carefully designed questionnaire into clinical practice. The 
final section builds on the evidence to consider the attributes required of a future 
questionnaire. 
The scene was set by the patient narratives which brought up issues of care, 
particularly communication and honesty, even when the news is bad. The other 
aspect which was apparent from the narratives was the price paid for a diagnosis 
of and therapy for H&N cancer, whether or not the outcome was successful and 
that this burden is shared by the carer, arguably at a level beyond that for other 
cancers as the impact on personal, working and social life can be so profound. 
The pilot study built on the narratives bringing the experience of patients from our 
own service into consideration. The important findings from this study were the 
views of the patients that using the questionnaire helped them talk to their 
doctors and the level of apparently unmet need that we discovered, indicating 
that we might improve the effectiveness of the pathway for our patients. The 
negative aspect was the concern of the doctors that the measure might interfere 
with priorities and the difficulty in introducing this to the routine setting. This was 
the experience of Mehanna and Morton (2006) and remained so as recently as 
earlier this year when Kanatas et al (2009) surveyed members of the British 
Association of Head and Neck Oncologists (BAHNO) to determine the current 
use of QoL measures in H&N practice. They found that 53% of clinicians used or 
had used QoL questionnaires. The main reason for not adopting them remained 
those which emerged from the pilot study, that they were too intrusive or time-
consuming in a clinic setting. Doctors were reluctant to introduce them but would 
be willing to accept a short and simple measure. This philosophy on the part of 
clinicians might explain some of the enthusiasm for the FACT-G and H&N 
questionnaires seen in my study. The question has to be whether limiting the 
number and content of questions would result in a measure which is effective in  
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determining patient need or whether there may be an alternative approach to 
using questionnaires which does not impose a burden on clinical teams, Options 
for this latter approach include the use of IT or the inclusion of a designated co-
ordinator, with the clinical expertise to direct the patient to the help they need, as 
part of the clinical team. 
The definitive study looked to consider aspects of questions which might be 
important in making them acceptable to both patients and clinicians. This 
aspiration led to the inclusion of ratings for two key components, ‘importance’, 
does the question ask about something that matters and ‘well written’, is it 
phrased in such a way that the patient and doctors have a clear understanding of 
why the question is being asked and the information it seeks to gain? 
To set the questionnaire study in context, I wished to explore the aspirations for 
and the perceived reality of the current ‘gold standard’ interaction between 
patients and their doctors, the medical consultation. To allow understanding of 
and to give some structure to this part of the study I adapted the measure used 
by Detmar et al (2000). The focus of their work was very much around the 
patient/doctor interaction and this provided the ideal resource from which to 
design the consultation assessment. 
Both patients and doctors prioritised physical aspects of their status. The matter 
of most interest was that, for the patients, the ‘preferences for consultation’ 
results (Chapter 6, Section 6,1) were very similar across sub-groups whereas the 
‘perceptions of consultation’ results indicated a trend whereby those with a higher 
therapeutic burden reported more issues being raised in consultation than those 
requiring single modality therapy. This indicated that doctors might tailor the 
consultation to their perceived needs of patients or, alternatively, patients with 
late stage disease and a higher therapeutic burden may feel able to raise a wider 
range of issues. The analysis of a series of consultations was remarkable for the 
number of issues raised by patients rather than doctors and that the issues raised 
by patients were those which merited a higher rating on our scoring system. The 
indication from this work was that, if patients can be prompted or reminded of 
issues which are troubling them, an effective interaction should be the result 
Misunderstandings, as illustrated by one example in this study, might be avoided 
and if the questionnaire acted as a core document to inform all MDT members of 
current status, a concept which is wider than the use of questionnaires for 
measurement alone, communication between team members might be improved.  
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The pilot study indicated that a well designed questionnaire might be such a 
prompt. For the clinicians, the level of endorsement of two items, ‘physical 
symptoms of disease or side effects of treatment’ and ‘limitations in physical 
therapy specific to disease’ was at a very high level with 12 from 14 participants 
claiming to discuss these items ‘almost always’ in consultations. This was echoed 
by the patients as 74.3% reported that ‘physical symptoms and side effects of 
disease’ were ‘almost always’ raised in consultations and 79.9% reported that 
‘physical activities specific to illness’ were ‘almost always’ discussed. This view 
was further endorsed by the narratives of patients about their cancer care. 
The emotional aspects were more uncertain. Of a group of 14 clinicians 6 
indicated they ‘almost always’ discussed emotional distress, 89 (61.8%) of 
patients indicated they would value such a discussion but only 14 (9.7%) 
indicated this ‘almost always’ took place and, if the category of ‘often’ is added, 
the level of reported engagement with an important area of patient experience is 
18% of clinicians. The levels of engagement, from the point of view of patients’ 
perception is even lower for social aspects of living with cancer, with only 9 
(6.3%) of patients indicating that their doctor ‘almost always’ discussed the 
impact of their illness on work and leisure or on relationships. When the category 
of ‘often’ was added the level of communication about these issues remained at 
just over 10% of consultations. 
The ‘consultation’ questionnaire was, in retrospect, limited, in that there was no 
rating of anxiety, depression or psychological morbidity beyond ‘emotional 
distress’, yet these issues are known to be important in H&N cancer and were 
one of the main areas of concern in the pilot study and raised repeatedly in the 
patient narratives and comments on questionnaires in the definitive study. The 
principle of including a psychological questionnaire in a future assessment was 
strongly supported. 
The consensus opinion, from both patients and health professionals, was that the 
emphasis in clinical practice was on physical aspects of disease and this was 
further endorsed by the patient comments about professional roles and the 
setting of ‘cut off’ scores for reviewing status suggested by health professionals. 
In summary, there was a mutual understanding between patients and their 
doctors about what was likely to be raised in a medical consultation. 
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How then does this relate to needs? 89 (61.8%) of patients indicated a wish to 
discuss how they felt emotionally, 82 (56.9%) wished to discuss the impact of 
their illness or treatment on work and leisure compared to the 6/14 already noted 
above who claimed to discuss ‘emotional issues’ ‘almost always’ and 4/14 who 
indicated that they discussed ‘impact of treatment’ on relationships with partner or 
family’ or 3/14 who indicated that they ‘almost always’ discussed the impact of 
the disease or its treatment on work and social activities’. There was a consensus 
but this consensus indicated a limited model of care with important issues omitted 
from the care pathway. Against this, we had the narrative of C12 who indicated 
the care she took to discuss work and the potential for work with her patients and 
C13 who noted, with distress, the difficult financial circumstances in which some 
of her patients found themselves. Whether a questionnaire could improve the 
number of issues raised at consultation has not to date been shown in H&N but 
the pilot study offered anecdotal evidence that a questionnaire might provoke a 
wider range of discussion and this has been explored for other cancers with 
positive results (Velikova et al, 2004). 
If a questionnaire is to be used to improve care, it is important that it captures the 
emotional and social aspects. From the patient narrative the EORTC QLQ C30 
appeared to be most effective in capturing this wider, and critically important, 
dimension of cancer survivorship. 
Moving on to the roles of health professionals the patients were very clear about 
roles – ‘I have a wonderful surgeon but he is a surgeon and a specialist.’ This 
raises further issues. Initiatives to date have focussed on equipping doctors to 
undertake a more holistic role in cancer care, hence the encouragement for 
senior doctors to attend the advanced communications skills courses. This may 
not be the most appropriate strategy. Especially in surgery, as a ‘hands on’ 
discipline, the consequences of complications of therapy can be difficult to cope 
with, as indicated in the narrative from ‘Cancer Tales’ (Chapter 1) and my own 
personal experience. To add the burden of counselling the patient and carer 
about the impact of disease may be one burden too many for the doctor. This 
aspect of professional team support has received less attention than patient 
needs but is an important aspect of the debate if the best holistic care is to be 
delivered. From the narrative above and from numerous similar examples, it 
appears that patients have an empathy with their doctor and there is a mutually 
protective association. The suggestion from the patient and partner that there  
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should be someone ‘with common sense in the middle’ has merit and this 
concept also emerged from consideration of who should address areas of 
concern in the clinician questionnaire study. The concept of someone who has 
solely the holistic care of the patient as a priority but is otherwise not responsible 
for their welfare has merit. It could be argued that this was part of the Improving 
Outcome Guidance when the concept of a ‘keyworker’ was introduced to clinical 
care. In practice the ‘keyworker’ has been a member of the current MDT who 
simply adopted an additional role but, if a questionnaire led consultation were to 
be trialled, such an individual might play a critically important clinical and 
collaborative role, placing patient needs at the core of the service and invoking 
the support of MDT members to best effectiveness. Such a service would be in 
the spirit of recent cancer reforms and a carefully designed questionnaire has the 
potential to provide the structure such a patient centred service would require. 
H&N patients have considerable needs and their lives can be severely affected 
by their cancer as indicated by the first consultation reported in Chapter 6. This 
patient’s major needs were for psychological support and yet it was this aspect of 
care which was omitted. In his case, use of a psychological questionnaire 
(HADS) would have identified his need. As he indicated in his interview his 
mental scars might be invisible but they were no less real than the physical ones. 
Whether a questionnaire might help identify those in need of support or whether 
offering psychological support via the clinic is sufficient remains to be 
investigated. There would seem from both the pilot and the definitive study a 
need for something beyond clinical acumen to assist patients in gaining 
psychological support and a questionnaire may assist this aim. From the pilot 
study it was apparent that those with depression may not request help, so 
reliance on self-referral may not be effective. A questionnaire may well have a 
role to play. Within the limits of this study, the HADS would appear to have merit 
for this purpose. Certainly a higher level of psychological presence in the MDT as 
advised by Humphris (2008) would seem imperative for best care and support. 
In terms of general and H&N specific questionnaires the ratings in terms of 
‘importance’ and ‘well written’ indicated that all questionnaires performed well. 
Both clinicians and patients scored the FACT-G and H&N questionnaires at the 
highest level. On further exploration the main reason for support was that it 
contained ‘relevant questions’ and ‘was quick and simple to complete’.  Given the 
primary outcome measure for my study was planned to be patient preference one  
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might simple endorse the FACT-G and H&N questionnaires as the patients’ and 
clinicians’ choice. However, as the study progressed I learned that this issue of a 
carefully designed questionnaire was not as simple as choice alone. There was 
not only the matter of what was included but also what was omitted. This was an 
issue for all measures. For the FACT H&N this was particularly the case as the 
questionnaire held a series of important questions but was dominated by a series 
of questions about eating. The EORTC questionnaires received the least criticism 
in terms of content but did lack questions which relate to the experience of 
patients who had undergone surgery. The UWQoL questionnaire was the best in 
terms of including surgical issues but attracted criticism for wording questions in 
such a way as to make it difficult for patients to communicate their experience 
using this measure. None of the questionnaires had an item relating to fear of 
recurrence yet this was frequently mentioned in interviews and consultations and 
is known to be a matter of distress and to be common in this group of patients 
(Humphris et al, 2003, Humphris and Ozakinci, 2006, Humphris et al, 2004, 
Hodges & Humphris, 2008). It may be possible to identify those at risk and 
develop strategies to help (Llewellyn et al, 2008) so it is important to ensure that 
fear of recurrence is built into any future questionnaire for routine clinic use. 
There is no ideal instrument at present for individual assessment but from 
consideration of both patient and clinician narratives a number of 
recommendations are possible: 
• a future questionnaire should have the breadth of content to capture the 
patients’ experience and assist in the transmission of useful information 
between the patient and their doctors and other health professionals. 
• it should be responsive to all elements of therapy likely to be 
encountered during the cancer journey. 
• it should be simple and easy to complete. 
• it should include the ability to identify psychological and social needs. 
• it should be acceptable to patients and to health professionals. 
On the first of these, there is currently no measure which meets this criterion in 
full. Of the measures tested, the SF-36 had no support from clinicians and limited 
support from patients. The FACT questionnaires gained the highest rating but 
were also noted, especially by clinicians, to have significant omissions and to be 
skewed in favour of particular elements of patient experience. For capturing the 
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 wider aspects, beyond the physical alone, the EORTC questionnaires were 
commended by both patients and health professionals. Their weakness is the 
omission of items highly relevant to surgical patients but, at a holistic level, of the 
currently validated measures, this study would support the EORTC QLQ C30 and 
H&N questionnaires as the preferred candidate for use in routine H&N practice. 
Of the two psychological measures the HADS appeared, in this study, to identify 
the cohort of patients who were scoring at a low level in other questionnaires and 
shows promise as a measure for use in H&N oncology practice. 
In future consideration should be given to development of sub-modules to 
address the issues raised in this study and to capture the experience of patients 
in terms of therapy, side effects and long term morbidity arising from therapy and 
their cancer in the context of their normal lives. For this latter consideration, the 
social and financial experiences and challenges of a working parent with young 
children might be very different from that of a retired person whose children have 
reached social and financial independence and those of someone just completing 
radical chemoradiotherapy very different to someone well into the follow-up part 
of the cancer journey. It is probable that, to really capture individual experience a 
series of sub-modules would be required. 
With the availability of modern IT, the development of an interactive, patient 
centred measure would seem feasible and access should be possible to a 
sufficiently large population to validate and evolve a patient centred measure, 
especially if a level of international collaboration can be achieved. However the 
burden of validating such a measure is considerable. The ideal starting point is to 
build on and to refine the characteristics of an existing measure and my 
recommendation, from this study is that a combination of the EORTC 
questionnaires and HADS, ideally with an item on fear of recurrence to address 
the main omission for current measures, provides the best foundation for future 
development of individual questionnaire assessments. 
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Chapter 10: Discussion 
At the time of its design, this study was unique in seeking the opinions the 
opinions and preferences of patients on the validated measures designed to 
assess their QoL. In the interim one paper has been published looking at 
questionnaire preference (Mehanna and Morton, 2006) and a further study is in 
progress. My study has brought together the views of patients and health 
professionals at a level not previously achieved and including the measures 
which published papers suggest might have a role in QoL assessment in routine 
practice. 
In terms of practical management  I was fortunate in having access to touch-
screen technology to assist data entry and I believe that this has been a very 
important factor in achieving the high level of completion of what was an 
ambitious dataset, The breadth of measures and inclusion of the preferences for 
consultation data and the psychological status questionnaire assessment and the 
tracking through to taped consultation provided a comprehensive dataset. This 
has allowed a holistic picture of the process of care to be considered to place 
what a questionnaire might add to the interaction with the healthcare 
multidisciplinary team in context. The study has also been unique in looking, in 
parallel, at the views of the health professionals who make up that 
multidisciplinary team using exactly the same assessments as those carried out 
by the patients. The depth of content of the clinician interviews gave a detailed 
narrative of contemporaneous views on team working and individual practices 
and philosophy. The patients, likewise, added greatly to the value of the 
quantitative data through thoughtful and incisive comments on consultations, on 
questions and on the process of care and team working. This detail depended, in 
the case of the patient interviews, on the presence of a trained researcher who 
would be seen as independent of the clinical team. The funding for the study was 
imperative in making this depth of investigation possible. 
In developing the design, to power a study on preference as a primary endpoint 
was novel and I had to accept that this involved a degree of risk. Given the 
accepted place of the measures in clinical practice there was a strong probability 
that a clear preference may not emerge, as indeed was the case. The choice of 
measures to be investigated was led by the literature and my own previous 
experience of working in this field. What was difficult was determining how to 
assess questionnaires and questions. This involved numerous discussions about 
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‘what is a question?’ my decision was that there are two core components: what 
the question is about and whether that matters to the patient: i.e. ‘importance’ 
and whether the writing and phrasing is such that the person undertaking the 
intervention understands the question and answers the query intended: i.e. ‘is it 
well written?’ To add these queries to an already long intervention meant a 
substantial data burden for participants. I attempted to lessen this by adopting the 
style of responses used in the questionnaires themselves and also by repeating 
these questions in exactly the same format throughout the intervention so that 
participants would become familiar with them. The risk in doing this was that they 
might simply repeat the same rating, however, at least one questionnaire item 
was present between sets of importance and well written ratings, minimising the 
risk of repetition. The results showed different ratings for ‘importance’ and ‘well 
written’, supporting this approach. 
Given the burden of questionnaires and ratings, there was need to ensure that 
this was reasonable for the patient population invited to join the study. This 
involved some compromise as the patient groups who could potentially benefit 
from inclusion of a questionnaire in their clinical care are those at the active and 
vulnerable stages in the pathway: at and shortly after diagnosis, during and in the 
immediate phase after therapy and at any stage where a cancer related event 
occurred, such as a diagnosis of recurrence. In discussion with the team, I 
decided that to subject patients at a vulnerable stage in their cancer journey to 
such an intense intervention was not acceptable. I, therefore, planned the study 
around recruitment of patients who were at least 1 year after completion of 
therapy and disease free, accepting that this group did not and could not 
represent the generality of H&N cancer patients. The alternative approach would 
have been to reduce the number of measures but a more simple design in this 
respect would not have allowed a valued judgement about the best measure for 
future practice. Although the data burden was considerable, completion of the 
intervention by almost all those who agreed to participate supported the view that 
this level of exploration was acceptable. Offering the questionnaires in random 
order also corrected for any fatigue or adaptation to the touch-screen and learned 
behaviours in making responses. 
There is a substantial volume of literature on longitudinal assessments of QoL by 
questionnaire. This is undoubtedly a valuable use of questionnaires but did not 
form a primary element of this study which has focussed on choice, ratings and 
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interviews to gain opinions. To undertake a cross-sectional study has 
methodological limitations, to ensure we captured reproducible data, we built in a 
test/retest strategy. This proved invaluable when looking at the choice of 
questionnaire. The impracticality of making a simple choice became obvious 
when no participant chose the same measure twice despite making a cogent 
statement to support their choice during their interview. 
A further decision worthy of comment is the inclusion of thyroid patients. The 
literature for this group is sparse and such studies as have been undertaken 
have used the QoL measures for H&N, mainly UWQoLv4. However, there have 
been no validation studies of any instrument for this patient group and my study, 
although it could not make definitive recommendations in view of its exploratory 
nature, gave a chance to explore whether thyroid patients had similarities to or 
differences from the remainder of the H&N cancer patients in terms of QoL. 
During the analysis of the results it became apparent that they were very different 
in terms of their characteristics, therapeutic burden, symptoms and side effects, 
return to work and QoL priorities. The data from this study has formed a base 
from which further work might be done to ensure a valid and reliable measure is 
available for these patients. The results of my study suggest that a separate 
instrument or module should be developed for thyroid patients. 
I wished to set my findings in the context of living with cancer and core to this is 
return to ‘normal’ life, in terms of work and social activity. The latter is more 
subjective, so I chose work as the parameter for inclusion in my basic dataset. 
The results were notable for the difference in experience between the study 
groups. The difficulty in terms of return to employment for the late larynx group 
confirmed our clinical impression. The immediate assumption was that this would 
adversely affect QoL, however the findings from the quantitative study did not 
support this, a matter to which I will return later in this discussion. 
The stratification of patient groups by impact of therapy is also a new concept, 
moving away from the traditional approach of using staging for this purpose. 
From the literature review there was a consensus that stage was the primary 
parameter for QoL and that this effect increased with time from diagnosis. 
Although worthy of exploration it has limitations especially in the laryngeal group 
where ‘early’ can range from narrow field radiotherapy to the larynx alone to 
much wider field irradiation plus or minus radiotherapy. In this study the main 
changes from ‘early’ to ‘late’ occurred in the oral rather than the laryngeal group 
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so this factor is unlikely to have had an impact on the results (Chapter 5, page 
117). Considation of therapeutic burden is supported by the comparative results 
from the ‘early’ and ‘late’ H&N subgroups compared to the stage results. Overall, 
more statistically significant differences were found using the ‘therapeutic burden’ 
derived sub-groups than by stage alone. The most prevalent difference was 
between LO patients who scored uniformly badly and the other sub-groups. EO 
performed particularly well. Much of the difference reflected known therapeutic 
morbidity and gave confidence in the ability of the QoL questionnaires to detect 
differences in a relatively small population, especially as we had chosen to set 
the statistical parameters at a challenging level. An unexpected and interesting 
finding was that LL patients reported relatively good QoL and EL patients 
appeared to struggle. The results for EO and LO showed a clear differentiation 
between the status of the patients, this was much less clear for larynx. Returning 
to the consultation results there was a suggestion that ‘late’ patients explored a 
greater depth of issues with their doctors and from the clinician responses some 
indication that some groups were more vulnerable and that consultations may 
vary depending on the clinician’s perception of status. Whilst it is not possible to 
explain these findings through this study alone it raises some questions in terms 
of expectations. EL patients are often seen as fortunate, they are expected to do 
well and to return to a close to normal lifestyle, LL patients are acknowledged to 
have challenges and major efforts are made both by the hospital services and 
outside bodies to provide support. It may be that the expectation placed on EL 
patients gives insufficient recognition of the challenges that they face. In 
preferences for consultation, all sub-groups scored at a very similar level, the 
‘early’ patients did not wish for a less thorough exploration of their status then the 
‘late’ group. Exploration of these sub-group findings in terms of stresses and 
expectations for future living might allow strategies to improve QoL, not so much 
for the LL patients, but for the EL patients who appear to be reporting a lower 
QoL than would have been expected. 
The consultation data emphasised the multidimensionality of the needs of this 
patient population. The evidence suggested that there were gaps in consultations 
and that these were related mainly to psychosocial needs. This is in line with the 
literature and adds further support to the need for better psychological support in 
the clinic. The HADS, in particular, appeared to have good sensitivity. At the end 
of a long intervention I had expected negative comments about ‘yet another 
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questionnaire’. The positive responses of the patients towards a measure ‘which 
lets me tell how I feel’ supports the use of this measure for routine screening. 
In terms of questionnaires and choices, I have brought together the findings from 
the patient study and the clinician study in Chapter 9. On breadth of enquiry and 
lack of criticism for content, it is my opinion that the EORTC QLQ C30 and H&N 
modules represent the best current screening questionnaire. They do not capture 
the whole experience of patients and it may well be that additional questions are 
needed, perhaps for subsets of patients, particularly those who have had surgery 
but the measure was sensitive in identifying sub-group differences and, critically 
important for clinic use, its strengths are in assessing the elements which this 
study indicates are most often not addressed in consultations. 
In summary, my main conclusions are: 
• The current practice of relying on consultations alone to manage the care 
of cancer patients does not ensure that all concerns are identified. This is 
particularly true for emotional and psychosocial issues. 
• There are substantial differences in patient characteristics, therapeutic 
burden and status between thyroid patients and other H&N cancer 
patients. A specific QoL module should be developed to meet the needs 
of thyroid patients. 
• Patients were not able to choose a questionnaire with any consistency. 
• Patients and clinicians had clear and cogent views about the process of 
care, consultations and questionnaires which provided invaluable insight 
into the needs of this patient population. 
• No current questionnaire is ideal for individual assessment but, from this 
study a combination of the EORTC QLQ C30/ H&N modules and HADS is 
recommended. 
• The main area of omission from current assessments is ‘fear of 
recurrence’. This is common and needs to be addressed in care for H&N 
and also Thyroid cancer patients. 
. 
This study was hypothesis driven, our hypothesis being that ‘carefully designed 
and structured questionnaires can be used to improve the quality of life of 
head and neck cancer patients’. Whilst such a hypothesis can only be proven 
by development of such a measure and a randomised clinical trial the results of 
this exploratory study would indicate that use of a carefully chosen measure can 
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increase the range of areas discussed in consultations and assist doctors and 
MDT members in including emotional and psychosocial aspects of patient 
experience in their clinics. Questionnaires were sensitive at identifying important 
items in a small population which would support their use in routine care. The 
availability of advanced technology makes this less of a challenge and the 
increasing use of the internet is opening possibilities for questionnaire based 
assessments to the patient’s convenience outside traditional hospital settings. 
For these reasons, I submit that the findings from this study strongly support the 
hypothesis. 
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Chapter 11: The Study in Context and Future 
Work 
 
This study has provided the most detailed research to date on opinions and 
preferences of both patients and clinicians for questionnaire assessments in H&N 
cancer and has also provided an insight into many aspects of clinical care in a 
modern cancer centre setting. Its completion is timely as cancer networks are 
currently looking at support and rehabilitation as part of the Cancer Reform 
Strategy and the wider emotional and psychosocial issues are gaining 
prominence at a time when much of the ‘hard’ infrastructure for delivery of care is 
in place. The next advances in terms of routine care and patient and carer 
experience are likely to lie in the areas addressed by this study.  
The first area in which I hope to continue to work is developing questionnaires 
which are truly designed to assist individuals in communicating with their doctors 
and health professionals, ideally in primary as well as secondary care settings. It 
is essential to preserve the validity of questionnaires designed to survey 
populations. However, when this comes at the price of eliminating an important 
element of patient experience from the measure, this raises doubts about its use 
at individual level. The elements emerging from this study relate to the therapy, 
as surgery and (chemo) radiotherapy carry a different but substantial therapeutic 
burden. It was noted by patients that the UWQoL was the only questionnaire to 
include the items which were important to them. The counter argument was that 
issues important to other groups such as fatigue, social eating and items strongly 
endorsed in other measures were not present in the UWQoL and emotional and 
wider issues were much better addressed by the EORTC questionnaires. 
Clinicians emphasised the importance of the stage in the cancer journey. If we 
are serious about the introduction of QoL measures into routine care there may 
well be a case for sub-modules which capture the experience of the individual 
such that a core measure is available but supplementary sub-modules are 
developed which capture elements of patient experience at different times and as 
a result of different therapies: a surgical module, looking at the primary site, the 
neck, the donor site and a chemoradiotherapy module looking at acute and long 
term consequences of these therapies. This is ambitious but, given the 
exponential expansion of IT there is potential to learn from patient experience in 
different settings and at different times in their journey. 
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A further area is to expand this work to look at the impact of adding a 
questionnaire to routine care for the more vulnerable groups. One obstacle to 
moving this field forwards has been the lack of evidence for any questionnaire or 
combination. I now plan to use the combination of EORTC QLQ C30 and HADS 
for further studies. To set this in context, it is recognised that the validated 
questionnaires were developed some years ago and that therapy and patient 
experience continues to evolve. The EORTC is currently developing an updated 
version of the H&N module which may overcome some of the weaknesses of the 
current questionnaire. I am working with this team and intend to continue to do so 
as, especially for work in less common cancer sites, strong collaborations are 
essential to gaining best evidence for care, as much if not more in psychosocial 
areas than therapeutic trials, as psychosocial is so much more multidimensional 
and complex.  
One fascinating area emerging from the study is whether consultations vary 
depending on clinician perception of patient status. I still have a substantial 
resource in terms of the many taped consultations and intend to explore this in 
much more detail than has been possible to date and to continue work in this 
field. 
The final area to emerge as a point of consensus was the need for a ‘person with 
common sense in the middle’, a concept voiced by a patient and his partner but 
strongly echoed by the clinicians when we discussed how information arising 
from a questionnaire assessment might best be used in clinic. Further to the IOG 
recommendations each patient has a ‘keyworker’. The reality of the service is that 
someone within the existing MDT is designated the ‘keyworker’ for part of the 
cancer pathway. This could represent a chance to establish  a role to take the 
lead in providing a holistic model of care and use a QoL assessment as part of 
that pathway. This kind of initiative would open the door to inclusion of QoL 
measures into routine care but also access to additional elements of support, 
psychological and counselling, alternative therapies for which there is at present 
a suggestion that there may be benefits in terms of living with low-grade chronic 
pain and also the infrastructure to allow good research into the effectiveness of 
this wider model of cancer care and support. 
In summary, this thesis has added to our knowledge about patient and clinician 
aspects of H&N cancer care and has provided a base from which further work 
can be developed to the benefit of patients and, I hope, assist those who care for 
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them, professionals and their families, in meeting patients’ needs at the highest 
level.  
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1. Research Training and Personal Development 
1.1  Membership of Psychosocial Oncology and Clinical Practice       
Research Group.  
 
The group, led in the early stages of this study by Professor Peter 
Selby and more recently by Professor Galina Velikova, is based in 
the Institute of Oncology, St James’s University Hospital, Leeds. 
 
It holds formal educational and research update meetings on a 
monthly basis and informal group meetings more frequently. 
 
As part of this group, my data has been presented at meetings and 
more formally through the Leeds Institute of Molecular Medicine 
Research in Progress Seminars.   
 
On a one-to one basis, supervision meetings have taken place in 
line with University recommendations. More frequent meetings and 
informal support and guidance has been offered on an ongoing 
basis. 
 
Computer/IT and administrative support has been available through 
the research group. (www.pogweb.org) 
 
 
1.1 University Training Courses 
 
Managing a PhD as a Part-time Student:      2002 
Statistics for Biomedical Research:                2005 
Thesis Writing and Surviving your Viva:        2007 
Working with Word for Long Documents:      2009 
Excel Basics:                                                  2009 
Excel Intermediate:                                         2009 
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2. UKCRN/NCRN Portfolio Adoption 
 
UKCRN CLINICAL STUDIES PORTFOLIO: Initial Study 
Registration Proforma  
For further explanation of each of the data items listed below, please refer to the 
accompanying document:  
UKCRN Description of Study Detail Data Items 
DATA 
ITEM 
STUDY DETAILS 
Study 
Acronym/Short 
Name: 
Development of a patient specific qualify of life assessment in 
head and neck cancer 
Study Title: Development of a patient specific qualify of life assessment in 
head and neck cancer                                                                                                         
REC 
reference number: 
(if this has 
been allocated) 
05/Q1205/26       
Primary 
Topic: 
Blood  Ear  
Cancer  Eye  
Cardiovascular  Infection  
Congenital Disorders   
Inflammatory & Immune System  Neurological  
Dementias & Neurodegenerative  
Diabetes   
Medicines for Children   
Renal and Urogenital   
Primary Observational 
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DATA 
ITEM 
STUDY DETAILS 
study design: 
 Interventional  Both  
Is this a 
randomised study? 
No  
 
Phase of 
study: 
Only applicable to clinical trials of investigational medicinal 
products (CTIMPS) 
Pilot/Feasibility  Experimental Medicine  I 
Overall 
sample size: 
150 approx 
Geographic
al scope: 
single centre          UK multi-centre  
 
Study 
Coordinator 
Details: 
Name: Mrs Sheila Fisher 
 Address:  
Department of Oral and Maxillofacial Surgery 
Floor 6 
Worsley Building 
Faculty of Medicine and Health, University of Leeds, 
Clarendon Way, 
Leeds, LS2 9LU. 
Email: Email: s.e.fisher@doctors.org.uk 
Tel: Tel: 0113 3436221 
Recruitment 
Contact Details: 
Name: Mrs Sheila Fisher 
 Address:  
Department of Oral and Maxillofacial Surgery 
Floor 6 
Worsley Building 
Clarendon Way, 
Leeds, LS2 9LU. 
Email: Email: s.e.fisher@leeds.ac.uk 
Tel: Tel: 0113 343 6221 
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Chief 
Investigator 
Details: 
Name: Mrs Sheila Fisher 
 Address:  
Department of Oral and Maxillofacial Surgery 
Floor 6 
Worsley Building 
Faculty of Medicine and Health 
University of Leeds, 
LS2 9LU 
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3. Peer-reviewed Presentations and Posters: 
SE Fisher, A Vikram, A Donnelly, AC Newsham, C Johnston, AB Smith, P Selby 
and G Velikova. Wishes for and perceptions of the content of medical 
consultations: a study of the views of patients treated for head & neck cancer. 
Poster at the NCRI Conference, Birmingham, 2009. 
 
SE Fisher, A Vikram, A Donnelly, AC Newsham, C Johnston, AB Smith, P Selby 
and G Velikova. 
 
SE Fisher, A Vikram, A Donnelly, AC Newsham, C Johnston, AB Smith, P Selby 
and G Velikova. Return to work in head and neck cancer patients after radical 
curative therapy. Poster at the NCRI Conference, Birmingham, 2009. 
 
SE Fisher, A Vikram, A Donnelly, AC Newsham, C Johnston, AB Smith, P Selby 
and G Velikova. Return to work after therapy for thyroid cancer with curative 
intent. 
NCRI Conference, Birmingham, 2009. 
 
SE Fisher, A Vikram, A Donnelly, AC Newsham, C Johnston, AB Smith, P Selby 
and G Velikova. Which questionnaire? Assessing the health related quality of life 
in patients with head and neck cancer. Oral Oncology Supplement 3 (2009) Doi: 
10 1016/j.oraloncology.2009.05.377.  Paper at the International Academy Oral 
Oncology 2nd International Congress, Toronto, 2009. 
 
 
SE Fisher, A Vikram, A Donnelly, AC Newsham, C Johnston, AB Smith, P Selby 
and G Velikova. Talking to patients: What are we perceived to include in 
consultations? Oral Oncology Supplement 3 (2009). Doi: 10. 1016/j.oral 
oncology. 2009.05.105. Poster presented at the International Academy of Oral 
Oncology 2nd International Congress, Toronto, 2009. 
 
Fisher SE, Vikram A, Donnelly A, Newsham AC, Johnston C, Smith AB, Selby 
PJ, Velikova G. Towards PROs in Head and Neck Cancer: patients’ views and 
opinions on consultations and QoL questionnaires. Poster presented at NCRI 
National Conference 2008 & BPOS 2008 (awarded Best Poster prize at BPOS 
meeting). 
 
Fisher SE, Vikram A, Donnelly AM. Newsham AC, Johnston C, Smith AB, 
Selby PJ and Velikova G. Quality of life in Head and Neck Cancer: Patient 
Views on Medical Consultations. British Association of Oral & Maxillofacial 
Surgeons Meeting, Cardiff, July 2008 
Fisher SE, Newsham AC, Johnston C, Smith AB, Selby PJ, Velikova G. 
Questionnaires and Consultations: a study of patients’ opinions regarding QoL 
assessment in a Head and Neck Cancer Clinic. Poster presented at NCRI 
National Conference, October 2007. 
 
Fisher SE, Donnelly AM, Newsham AC, Johnston C, Smith AB, Selby PJ, 
Velikova G. Communicating concerns: how do our patients perceive 
consultations and can a questionnaire based approach assist communication? 
Poster presentation at BAHNO Annual meeting, London, 2007. 
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Fisher SE, Donnelly A, Newsham AC, Johnston C, Smith AB, Selby PJ, Velikova 
G. Individual Assessment of Quality of Life: a communication tool for modern 
practice. Presentation at the First World Congress of the International Academy 
of Oral Oncology, Amsterdam, May 2007. 
Oral Oncology (Supplement), 2007, 2 (1), 92-93.  
 
Fisher SE, Newsham AC, Johnston C, Smith AB, Selby PJ and Velikova G. 
Individual Patient Assessments: a Communication Tool for use in Clinical 
Oncology Practice. Poster presentation at the ISOQOL Conference on Patient 
Reported Outcomes in Clinical Practice, Budapest, June 2007. 
 
Newsham AC, Donnelly AM, Johnston C, Smith AB, Selby PJ, Velikova G and 
Fisher SE. Bringing Patient Care and Clinical Trials Together: use of a new 
Integrated Database in a complex multidisciplinary setting. NCRI conference, 
Birmingham, 2006 
 
Invited Presentations:  
 
Fisher SE. How to look at Quality of Life in Clinics: lessons from listening to our 
patients. 6th International Workshop on Quality of Life in Head & Neck Cancer, 
Liverpool, 2008. 
 
Fisher SE. Incorporating QoL into Clinical Practice: from theory to clinic. 
Invited workshop lecture at EUFOS Conference, Vienna, July 2007. 
 
Fisher SE. Health related quality of life assessment in clinical practice. 5th 
International Workshop on Quality of Life in Head & Neck Cancer, November 
2006 
 
 Fisher SE, Donnelly AM, Velikova G and Selby PJ. Patient specific 
questionnaire: assessment of individual patients with H&N cancer. Head & Neck 
Cancer parallel session, NCRI conference, 2006. 
 
Fisher SE Patients, MDTs, Patients and Quality of Life Assessments: a 
complementary or conflicting triangle? 4th International Workshop on Quality of 
Life in Head & Neck Cancer, Liverpool, October 2004. 
 
Fisher SE.  Health Related Quality of Life Assessment, the ‘Individual’ View. 3rd 
International Workshop on Quality of Life in Head and Neck Cancer, University of 
Liverpool, November 2002.   
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Aim
To determine patient opinions on areas for
discussion in medical consultations and on
their perceived content of such consultations.
Conclusions
Patients were able to comment usefully on their wishes for
medical consultation and the perceived content of
consultations. The issues considered most important for
discussion were those related directly to the disease and its
treatment and these were the issues most likely to be raised.
However, emotional issues and the impact of cancer on their
daily lives was felt to be less likely to be addressed in a
medical consultation setting.
Patients’ perceptions were that important issues were not
being consistently raised in medical consultations. This
study raises interesting questions about the mutual
understanding of the content of doctor/patient interactions
and how communication can be improved so that the needs
of patients are met.
Background & Clinical Setting 
The medical consultation lies at the core of clinical
care, providing the interaction between doctors and
their patients. Both bring their own priorities to this
interaction. There has been little research into
which areas patients wish to discuss and how that
relates to what is perceived to be addressed in a
medical consultation.
This study reports the results of a prospective
observational cohort treated in a large
multidisciplinary (MDT) head & neck (H&N) cancer
clinic in the UK.
Method
H&N cancer patients attending follow-up
appointments were approached. To determine
patients’ views on medical consultations a
questionnaire was adapted from Detmar (1). The first
group of questions related to wishes with regard to
the content of consultations and the second covered
a similar range of areas but considered whether
patients felt these were included in consultations.
For the first set of questions the responses were:
0 = ‘I would not wish to discuss this item’
1= ‘I would like to discuss this item if the doctor
raises it’
2= ‘I would like to discuss this item’
For the second set of questions the patients rated
how frequently the area was discussed in
consultations in a range from ‘never’ through to
‘almost always’. The questionnaires were presented
using a computerised touch-screen system which
automatically uploaded responses to a central
server for analysis.
To ensure the range of experience and treatment
related effects were included in the sample, we
divided the participants into treatment groups.
These were early oral [EO] (oral cancer with
treatment restricted to a single modality), late oral
[LO] (multimodality therapy including surgical
ablation and reconstruction), early [EL] and late [LL]
laryngeal cancer (similar criteria, with late cases
having had a laryngectomy). We also studied
thyroid patients [Thy] as their care is often offered
through the same MDT.
To explore test /retest reliability a subgroup of
patients comprising at least 10% of the overall study
sample of 150 patients, were asked to complete the
intervention twice.
Results
152 patients agreed to join the study and full records
were achieved for 144 participants (33 EO, 36 LO, 17
EL, 15 LL and 43 Thy). 22 patients achieved 2
interventions ( 7 EO, 9 LO, 3 EL, 2 LL and 1 Thy). In
general, patients most wanted to discuss ‘physical
activities affected by treatment’, a category which
includes key areas such as speech, swallowing and
Figure 1. Patients’ wishes for 
consultations
Total group= 144 responses 
Figure 2. Patients’ perceived 
content of consultations
Total group=144 responses
Reference
Detmar S, Aaronson NK, Wever LDV, Muller M and Schomagel
JH. Journal of Clinical Oncology, 2000, 18, 3295.
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Once the questions moved beyond ‘hard’ clinical evaluations, the
gap between aspiration and reality became more marked.
Although 61.8% of patients indicated a wish to discuss how they
felt emotionally, this was perceived to be addressed ‘almost
always’ or ‘often’ in only 11.2% of consultations. Patients
endorsed a wish to discuss the impact of their disease on aspects
of their daily living at a lower level and these aspects of living with
a cancer diagnosis were unlikely to be raised in the consultation.
Patients rated a discussion about the impact of their disease on
their appearance highly with 59.7% wishing to raise it, yet in only
12.6% of consultations was this issue ‘almost always’ or ‘often’
addressed.
Sub-group scores (EO, EL, LO, LL and Thy) followed the pattern
of the study group as a whole across the range of issues
addressed in this study.
Test/ Retest:
We aimed to carry out test /retest in at least 10% of our
population and achieved this for 22 patients (15.3%) of the study
population. The level of agreement between episodes was
calculated and the kappa values for the questions gaining the
highest level of endorsement suggested a good level of
agreement (e.g. for ‘physical activities specific to illness, the
kappa coefficient was 0.52). This fell for the items with a lower
level of endorsement but the changes in score were between 1
and 2. Scores of 0 were seldom seen in any sub-group of
patients or any individual question.
Item 0 1 2
Physical symptoms & side effects of 
illness
5  
(3.5%)
32 
(22.2%)
107 
(74.3%)
General physical activities 9  
(6.3%)
38 
(26.4%)
97 
(67.4%)
Physical activities specific to illness (e.g. 
speech)
8  
(5.6%)
21 
(14.6%)
115 
(79.9%) 
How you feel emotionally 17 
(11.8%)
38 
(26.4%)
89 
(61.8%)
Impact of illness or treatment on work & 
leisure
18 
(12.5%)
44 
(30.6%)
82 
(56.9%)
Impact of illness or treatment on social 
activities
29 
(20.1%)
51 
(35.4%)
64 
(44.4%)
Impact of illness or treatment on 
relationships
25 
(17.4%)
45 
(31.3%)
74 
(51.4%)
Impact of illness or treatment on 
appearance
24 
(16.7%)
34 
(23.6%)
86 
(59.7%)
Item 0 1 2 3 4
Overall health 12 
(8.3%)
17
(11.8%)
45
(31.0%)
31
(21.4%)
39
(26.9%)
Symptoms of disease or 
treatment
(e.g. pain, sickness, fatigue)
14
(9.7%)
19
(13.2%)
35
(24.3%)
38
(26.4%)
38
(26.4%)
General physical limitations 
as a result of disease or 
treatment
49
(34.0%)
26
(18.1%)
27
(18.8%)
15
(10.4%)
27
(18.8%)
Physical limitations specific 
to disease and treatment 
(e.g. speech)
21
(14.6%)
20
(13.9%)
35
(24.3%)
34
(23.6%)
34
(23.6%)
Emotional distress 49
(34.0%)
41
(28.5%)
28
(19.4%)
12
(8.3%)
14
(9.7%)
Impact of illness or 
treatment on work & leisure
65
(45.1%)
36
(25.0%)
27
(18.8%)
7
(4.9%)
9
(6.3%)
Impact of illness or 
treatment on relationships
60
(41.7%)
39
(27.1%)
30
(20.8%)
6
(4.2%)
9
(6.3%)
Impact of illness or 
treatment on appearance
60
(41.7%)
38
(26.2%)
24
(16.6%)
9
(6.3%)
9
(6.3%)
Key to scale: 0= ‘rather not’, 1= ‘discuss if raised by doctor’, 2= ‘want to discuss’ 
Key to scale: 0= ‘never’, 1= ‘rarely’, 2= ‘sometimes’, 3= ‘often’, 4= ‘almost always’ 
eating, with their doctors. This was closely followed by
‘symptoms and side effects of treatment’. These matched
the perception of what was most likely to be discussed,
although 24% of patients indicated that symptoms and side
effects were ‘never’ or ‘rarely’ mentioned and 29% gave the
same results for physical limitations due to the disease or
its treatment.
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discussion in medical consultations and on
their perceived content of such consultations.
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Patients were able to comment usefully on their wishes for
medical consultation and the perceived content of
consultations. The issues considered most important for
discussion were those related directly to the disease and its
treatment and these were the issues most likely to be raised.
However, emotional issues and the impact of cancer on their
daily lives was felt to be less likely to be addressed in a
medical consultation setting.
Patients’ perceptions were that important issues were not
being consistently raised in medical consultations. This
study raises interesting questions about the mutual
understanding of the content of doctor/patient interactions
and how communication can be improved so that the needs
of patients are met.
Background & Clinical Setting 
The medical consultation lies at the core of clinical
care, providing the interaction between doctors and
their patients. Both bring their own priorities to this
interaction. There has been little research into
which areas patients wish to discuss and how that
relates to what is perceived to be addressed in a
medical consultation.
This study reports the results of a prospective
observational cohort treated in a large
multidisciplinary (MDT) head & neck (H&N) cancer
clinic in the UK.
Method
H&N cancer patients attending follow-up
appointments were approached. To determine
patients’ views on medical consultations a
questionnaire was adapted from Detmar (1). The first
group of questions related to wishes with regard to
the content of consultations and the second covered
a similar range of areas but considered whether
patients felt these were included in consultations.
For the first set of questions the responses were:
0 = ‘I would not wish to discuss this item’
1= ‘I would like to discuss this item if the doctor
raises it’
2= ‘I would like to discuss this item’
For the second set of questions the patients rated
how frequently the area was discussed in
consultations in a range from ‘never’ through to
‘almost always’. The questionnaires were presented
using a computerised touch-screen system which
automatically uploaded responses to a central
server for analysis.
To ensure the range of experience and treatment
related effects were included in the sample, we
divided the participants into treatment groups.
These were early oral [EO] (oral cancer with
treatment restricted to a single modality), late oral
[LO] (multimodality therapy including surgical
ablation and reconstruction), early [EL] and late [LL]
laryngeal cancer (similar criteria, with late cases
having had a laryngectomy). We also studied
thyroid patients [Thy] as their care is often offered
through the same MDT.
To explore test /retest reliability a subgroup of
patients comprising at least 10% of the overall study
sample of 150 patients, were asked to complete the
intervention twice.
Results
152 patients agreed to join the study and full records
were achieved for 144 participants (33 EO, 36 LO, 17
EL, 15 LL and 43 Thy). 22 patients achieved 2
interventions ( 7 EO, 9 LO, 3 EL, 2 LL and 1 Thy). In
general, patients most wanted to discuss ‘physical
activities affected by treatment’, a category which
includes key areas such as speech, swallowing and
Figure 1. Patients’ wishes for 
consultations
Total group= 144 responses 
Figure 2. Patients’ perceived 
content of consultations
Total group=144 responses
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Once the questions moved beyond ‘hard’ clinical evaluations, the
gap between aspiration and reality became more marked.
Although 61.8% of patients indicated a wish to discuss how they
felt emotionally, this was perceived to be addressed ‘almost
always’ or ‘often’ in only 11.2% of consultations. Patients
endorsed a wish to discuss the impact of their disease on aspects
of their daily living at a lower level and these aspects of living with
a cancer diagnosis were unlikely to be raised in the consultation.
Patients rated a discussion about the impact of their disease on
their appearance highly with 59.7% wishing to raise it, yet in only
12.6% of consultations was this issue ‘almost always’ or ‘often’
addressed.
Sub-group scores (EO, EL, LO, LL and Thy) followed the pattern
of the study group as a whole across the range of issues
addressed in this study.
Test/ Retest:
We aimed to carry out test /retest in at least 10% of our
population and achieved this for 22 patients (15.3%) of the study
population. The level of agreement between episodes was
calculated and the kappa values for the questions gaining the
highest level of endorsement suggested a good level of
agreement (e.g. for ‘physical activities specific to illness, the
kappa coefficient was 0.52). This fell for the items with a lower
level of endorsement but the changes in score were between 1
and 2. Scores of 0 were seldom seen in any sub-group of
patients or any individual question.
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Physical symptoms & side effects of 
illness
5  
(3.5%)
32 
(22.2%)
107 
(74.3%)
General physical activities 9  
(6.3%)
38 
(26.4%)
97 
(67.4%)
Physical activities specific to illness (e.g. 
speech)
8  
(5.6%)
21 
(14.6%)
115 
(79.9%) 
How you feel emotionally 17 
(11.8%)
38 
(26.4%)
89 
(61.8%)
Impact of illness or treatment on work & 
leisure
18 
(12.5%)
44 
(30.6%)
82 
(56.9%)
Impact of illness or treatment on social 
activities
29 
(20.1%)
51 
(35.4%)
64 
(44.4%)
Impact of illness or treatment on 
relationships
25 
(17.4%)
45 
(31.3%)
74 
(51.4%)
Impact of illness or treatment on 
appearance
24 
(16.7%)
34 
(23.6%)
86 
(59.7%)
Item 0 1 2 3 4
Overall health 12 
(8.3%)
17
(11.8%)
45
(31.0%)
31
(21.4%)
39
(26.9%)
Symptoms of disease or 
treatment
(e.g. pain, sickness, fatigue)
14
(9.7%)
19
(13.2%)
35
(24.3%)
38
(26.4%)
38
(26.4%)
General physical limitations 
as a result of disease or 
treatment
49
(34.0%)
26
(18.1%)
27
(18.8%)
15
(10.4%)
27
(18.8%)
Physical limitations specific 
to disease and treatment 
(e.g. speech)
21
(14.6%)
20
(13.9%)
35
(24.3%)
34
(23.6%)
34
(23.6%)
Emotional distress 49
(34.0%)
41
(28.5%)
28
(19.4%)
12
(8.3%)
14
(9.7%)
Impact of illness or 
treatment on work & leisure
65
(45.1%)
36
(25.0%)
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(18.8%)
7
(4.9%)
9
(6.3%)
Impact of illness or 
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60
(41.7%)
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(27.1%)
30
(20.8%)
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(4.2%)
9
(6.3%)
Impact of illness or 
treatment on appearance
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(41.7%)
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(26.2%)
24
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(6.3%)
Key to scale: 0= ‘rather not’, 1= ‘discuss if raised by doctor’, 2= ‘want to discuss’ 
Key to scale: 0= ‘never’, 1= ‘rarely’, 2= ‘sometimes’, 3= ‘often’, 4= ‘almost always’ 
eating, with their doctors. This was closely followed by
‘symptoms and side effects of treatment’. These matched
the perception of what was most likely to be discussed,
although 24% of patients indicated that symptoms and side
effects were ‘never’ or ‘rarely’ mentioned and 29% gave the
same results for physical limitations due to the disease or
its treatment.
 
 
NCRI, 2009  
 
 
QoL in Individual Patients  Supplementary Material 
262 
 
 
 
Leeds Dental Institute
FACULTY OF MEDICINE AND HEALTH
Return to work in Head and Neck (H&N) Cancer Patients after radical 
curative therapy.
Sheila E Fisher (1,3,4), Alexander C Newsham (2,3), Colin Johnston (2,3), Aine Donnelly (3),
Aditya Vikram (3),  Adam B Smith (5), Peter J Selby (2,3), Galina Velikova (2,3)
1.Leeds Institute of Molecular Medicine, University of Leeds, UK. 2. CR-UK Clinical Medicine Centre, St. James’s University 
Hospital, Leeds, UK. 3. CR-UK Psychosocial Oncology and Clinical Research Group, Leeds Institute of Molecular Medicine, 
University of Leeds, UK. 4. School of Health Studies, University of Bradford, UK. 5. Centre for Health & Social Care, Leeds 
Institute of Health Sciences, University of Leeds, UK, 
Aim
To determine the rate of return to
previous employment in a group of
patients with H&N cancer.
Comments
This study reports very different experiences by stage
and site of H&N cancer.
The results would indicate that patients diagnosed with
early stage disease and requiring single modality
therapy have a good chance of returning to their
previous employment, this being the case for 3 out of 4
early larynx patients and 11 out of 14 early oral patients
who were in paid employment. In these patient groups
only one patient reported loss of employment which he
thought was related to his cancer diagnosis.
There is a contrast between early and late stage
disease. The work experience of late larynx patients is
particularly poor with two notable exceptions.
Approximately 50% of the late oral patients in this
study returned to work in their previous post.
Living with cancer and survivorship issues are
increasingly important as more patients remain clear of
their original disease. Work needs to be done with
employers to assist those patients who are of working
age, especially those presenting with late stage
disease.
Background & Clinical Setting 
H&N cancer patients are well recognised to face
additional challenges after a cancer diagnosis
because of the effect of the disease and therapy on
important functional and social aspects of life.
However, few studies have looked specifically at
return to work. This study reports the results of a
prospective observational cohort treated in a large
multidisciplinary (MDT) head & neck (H&N) cancer
clinic in the UK.
Method
H&N cancer patients attending follow-up
appointments were approached as part of a larger
study on opinions and preferences in terms of
medical consultations and quality of life. We asked
their permission to record their occupational status
at diagnosis and current status.
To ensure the range of experience and treatment
related effects were included in the sample, we
divided the participants into treatment groups.
These were early oral [EO] (oral cancer with
treatment restricted to a single modality), late oral
[LO] (multimodality therapy including surgical
ablation and reconstruction), early [EL] and late [LL]
laryngeal cancer (similar criteria, with late cases
having had a laryngectomy).
Results
152 patients agreed to join the full study, of whom 61
indicated they were in work at the time of their
diagnosis. A summary of work status is given in Figure
1.
61 patients were working at diagnosis and 43
remained in work at the time of the study, however 18
had had or chosen to change employment.
The experience was very varied across groups as
indicated below.
Early larynx (EL): 10 patients
9 males: 4 in paid work: HGV driver, Builder and
Salesman reported no change in occupation, car
restorer did report a change in occupation.
1 patient unemployed (unchanged), 2 on incapacity
benefits (unchanged)
2 no occupation noted.
1 female (no occupation noted)
Late larynx (LL): 11 patients.
8 males: 5 in paid work. Only one, a successful local
politician, is known to have remained in his previous
employment. One patient reported the change to
highways inspector was due to his previous business
entering receivership, an event he did not associate
with his cancer. A bakery worker took early retirement
as he could not cope with the dust and the current
working status of a courier driver is uncertain. The
final patient in this group reported a positive outcome
Figure 1. Return to work by 
subgroup
Total group=61 responses
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Group Gender Employment Status
Diagnosis Working Same Changed 
EL Male 9 4 3 1
Female 1 0 0 0
LL Male 8 5 1 4
Female 3 0 0 0
EO Male 11 10 7 3
Female 5 4 4 0
LO Male 23 19 10 9
Female 1 1 0 1
Total 61 43 25 18
from his cancer. He has come out of retirement in his 70s
to teach communication with cancer patient skills to
medical students and AHPs (Allied Health Professionals.
I patient was unemployed (status unchanged).
For two male patients no details were entered; one of
these had had multiple primary cancers and the other
reported with a second primary cancer shortly after
completing the study and died a few months later. It would
seem unlikely that either of these patients were able to
undertake work.
3 females: none in paid employment. I was and remained
a housewife, the other two were and remained
unemployed. One noted that she felt very discriminated
against when she applied for work and that her
laryngectomy prevented her applying for posts which met
her previous skills in telemarketing.
Early oral:
11 males: 10 were in paid employment at the time of
diagnosis, of these seven reported continued employment
in the same job. Work ranged from self-employed
businessmen (2), civil service, TV presenter and
broadcaster to haulier, engineering fitter and
warehouseman. The remaining three whose current status
is uncertain included a printer, warehouseman and a
washing machine repairer. Only in one instance is a cancer
related loss of job with subsequent continued
unemployment noted.
5 females: 4 were in paid employment, as a manager (2
patients), a property developer and a dental nurse. All
continued in their previous work. The remaining patient
was and remained a housewife.
Late oral:
23 males: 19 were in paid employment at diagnosis.10 of
whom continued in their previous employment (an
accountant, engineers [4 patients], a manager, a postman
a lorry driver, a welder and one man who did not state his
occupation). One patient chose to train as a teacher and,
although his previous employment is not noted, this may
well represent choice; a further patient notes a change to
agency work but not a reason for this. Outcomes are not
noted for 2 patients, a gardener and a security officer.
Of the remainder a Carer in a Residential Home had to
case work because of PEG feeding and continued severe
morbidity, a medical physics technician struggled to return
to work and achieved this transiently after prolonged absence
but then developed paroxysmal atrial fibrillation and had to
stop. Three patients reported losing their jobs (one manual
worker and the other two occupation unknown) specifically as
a result of their cancer and its treatment.
The four who were not in paid employment at diagnosis were
unemployed (2) or on incapacity benefit (2).
1 female: She changed her occupation to carer as a result of
her cancer.
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Aim
To determine the rate of return to
previous employment in a group of
patients with H&N cancer.
Comments
This study reports very different experiences by stage
and site of H&N cancer.
The results would indicate that patients diagnosed with
early stage disease and requiring single modality
therapy have a good chance of returning to their
previous employment, this being the case for 3 out of 4
early larynx patients and 11 out of 14 early oral patients
who were in paid employment. In these patient groups
only one patient reported loss of employment which he
thought was related to his cancer diagnosis.
There is a contrast between early and late stage
disease. The work experience of late larynx patients is
particularly poor with two notable exceptions.
Approximately 50% of the late oral patients in this
study returned to work in their previous post.
Living with cancer and survivorship issues are
increasingly important as more patients remain clear of
their original disease. Work needs to be done with
employers to assist those patients who are of working
age, especially those presenting with late stage
disease.
Background & Clinical Setting 
H&N cancer patients are well recognised to face
additional challenges after a cancer diagnosis
because of the effect of the disease and therapy on
important functional and social aspects of life.
However, few studies have looked specifically at
return to work. This study reports the results of a
prospective observational cohort treated in a large
multidisciplinary (MDT) head & neck (H&N) cancer
clinic in the UK.
Method
H&N cancer patients attending follow-up
appointments were approached as part of a larger
study on opinions and preferences in terms of
medical consultations and quality of life. We asked
their permission to record their occupational status
at diagnosis and current status.
To ensure the range of experience and treatment
related effects were included in the sample, we
divided the participants into treatment groups.
These were early oral [EO] (oral cancer with
treatment restricted to a single modality), late oral
[LO] (multimodality therapy including surgical
ablation and reconstruction), early [EL] and late [LL]
laryngeal cancer (similar criteria, with late cases
having had a laryngectomy).
Results
152 patients agreed to join the full study, of whom 61
indicated they were in work at the time of their
diagnosis. A summary of work status is given in Figure
1.
61 patients were working at diagnosis and 43
remained in work at the time of the study, however 18
had had or chosen to change employment.
The experience was very varied across groups as
indicated below.
Early larynx (EL): 10 patients
9 males: 4 in paid work: HGV driver, Builder and
Salesman reported no change in occupation, car
restorer did report a change in occupation.
1 patient unemployed (unchanged), 2 on incapacity
benefits (unchanged)
2 no occupation noted.
1 female (no occupation noted)
Late larynx (LL): 11 patients.
8 males: 5 in paid work. Only one, a successful local
politician, is known to have remained in his previous
employment. One patient reported the change to
highways inspector was due to his previous business
entering receivership, an event he did not associate
with his cancer. A bakery worker took early retirement
as he could not cope with the dust and the current
working status of a courier driver is uncertain. The
final patient in this group reported a positive outcome
Figure 1. Return to work by 
subgroup
Total group=61 responses
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Group Gender Employment Status
Diagnosis Working Same Changed 
EL Male 9 4 3 1
Female 1 0 0 0
LL Male 8 5 1 4
Female 3 0 0 0
EO Male 11 10 7 3
Female 5 4 4 0
LO Male 23 19 10 9
Female 1 1 0 1
Total 61 43 25 18
from his cancer. He has come out of retirement in his 70s
to teach communication with cancer patient skills to
medical students and AHPs (Allied Health Professionals.
I patient was unemployed (status unchanged).
For two male patients no details were entered; one of
these had had multiple primary cancers and the other
reported with a second primary cancer shortly after
completing the study and died a few months later. It would
seem unlikely that either of these patients were able to
undertake work.
3 females: none in paid employment. I was and remained
a housewife, the other two were and remained
unemployed. One noted that she felt very discriminated
against when she applied for work and that her
laryngectomy prevented her applying for posts which met
her previous skills in telemarketing.
Early oral:
11 males: 10 were in paid employment at the time of
diagnosis, of these seven reported continued employment
in the same job. Work ranged from self-employed
businessmen (2), civil service, TV presenter and
broadcaster to haulier, engineering fitter and
warehouseman. The remaining three whose current status
is uncertain included a printer, warehouseman and a
washing machine repairer. Only in one instance is a cancer
related loss of job with subsequent continued
unemployment noted.
5 females: 4 were in paid employment, as a manager (2
patients), a property developer and a dental nurse. All
continued in their previous work. The remaining patient
was and remained a housewife.
Late oral:
23 males: 19 were in paid employment at diagnosis.10 of
whom continued in their previous employment (an
accountant, engineers [4 patients], a manager, a postman
a lorry driver, a welder and one man who did not state his
occupation). One patient chose to train as a teacher and,
although his previous employment is not noted, this may
well represent choice; a further patient notes a change to
agency work but not a reason for this. Outcomes are not
noted for 2 patients, a gardener and a security officer.
Of the remainder a Carer in a Residential Home had to
case work because of PEG feeding and continued severe
morbidity, a medical physics technician struggled to return
to work and achieved this transiently after prolonged absence
but then developed paroxysmal atrial fibrillation and had to
stop. Three patients reported losing their jobs (one manual
worker and the other two occupation unknown) specifically as
a result of their cancer and its treatment.
The four who were not in paid employment at diagnosis were
unemployed (2) or on incapacity benefit (2).
1 female: She changed her occupation to carer as a result of
her cancer.
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Aim
To determine patient opinions on areas for discussion in medical 
consultations and on their perceived content of such consultations.
Conclusions
Patients were able to comment usefully on their wishes for medical consultation
and the perceived content of consultations. The issues considered most
important for discussion were those related directly to the disease and its
treatment and these were the issues most likely to be raised. However, emotional
issues and the impact of cancer on their daily lives was felt to be less likely to be
addressed in a medical consultation setting.
Patients’ perceptions were that important issues were not being consistently
raised in medical consultations. This study raises interesting questions about the
mutual understanding of the content of doctor/patient interactions and how
communication can be improved so that the needs of patients are met.
Background & Clinical Setting 
The medical consultation lies at the core of clinical care, providing the 
interaction between doctors and their patients. Both bring their own 
priorities to this interaction. There has been little research into which 
areas patients wish to discuss and how that relates to what is 
perceived to be addressed in a medical consultation.
This study reports the results of a prospective observational cohort 
treated in a large multidisciplinary (MDT) head & neck (H&N) cancer 
clinic in the UK.
Method
H&N cancer patients attending follow-up appointments were
approached. To determine patients’ views on medical consultations a
questionnaire was adapted from Detmar (1). The first group of
questions related to wishes with regard to the content of consultations
and the second covered a similar range of areas but considered
whether patients felt these were included in consultations.
For the first set of questions the responses were:
0 = ‘I would not wish to discuss this item’
1= ‘I would like to discuss this item if the doctor raises it’
2= ‘I would like to discuss this item’
For the second set of questions the patients rated how frequently the
area was discussed in consultations in a range from ‘never’ through to
‘almost always’. The questionnaires were presented using a
computerised touch-screen system which automatically uploaded
responses to a central server for analysis.
To ensure the range of experience and treatment related effects were
included in the sample, we divided the participants into treatment
groups. These were early oral [EO] (oral cancer with treatment
restricted to a single modality), late oral [LO] (multimodality therapy
including surgical ablation and reconstruction), early [EL] and late [LL]
laryngeal cancer (similar criteria, with late cases having had a
laryngectomy). We also studied thyroid patients [Thy] as their care is
often offered through the same MDT.
To explore test /retest reliability a subgroup of patients comprising at
least 10% of the overall study sample of 150 patients, were asked to
complete the intervention twice.
Results
152 patients agreed to join the study and full records were achieved for
144 participants (33 EO, 36 LO, 17 EL, 15 LL and 43 Thy). 22 patients
achieved 2 interventions ( 7 EO, 9 LO, 3 EL, 2 LL and 1 Thy).
Figure 1. Patients’ wishes for consultations
Total group= 144 responses 
Figure 2. Patients’ perceived content of 
consultations
Total group=144 responses
Reference
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Once the questions moved beyond ‘hard’ clinical evaluations, the gap between
aspiration and reality became more marked. Although 61.8% of patients indicated a
wish to discuss how they felt emotionally, this was perceived to be addressed ‘almost
always’ or ‘often’ in only 11.2% of consultations. Patients endorsed a wish to discuss the
impact of their disease on aspects of their daily living at a lower level and these aspects
of living with a cancer diagnosis were unlikely to be raised in the consultation.
Patients rated a discussion about the impact of their disease on their appearance highly
with 59.7% wishing to raise it, yet in only 12.6% of consultations was this issue ‘almost
always’ or ‘often’ addressed.
Sub-group scores (EO, EL, LO, LL and Thy) followed the pattern of the study group as a
whole across the range of issues addressed in this study.
Test/ Retest:
We aimed to carry out test /retest in at least 10% of our population and achieved this for
22 patients (15.3%) of the study population. The level of agreement between episodes
was calculated and the kappa values for the questions gaining the highest level of
endorsement suggested a good level of agreement (e.g. for ‘physical activities specific
to illness, the kappa coefficient was 0.52). This fell for the items with a lower level of
endorsement but the changes in score were between 1 and 2. Scores of 0 were seldom
seen in any sub-group of patients or any individual question.
Item 0 1 2
Physical symptoms & side effects of illness 5  (3.5%) 32 (22.2%) 107 (74.3%)
General physical activities 9  (6.3%) 38 (26.4%) 97 (67.4%)
Physical activities specific to illness (e.g. speech) 8  (5.6%) 21 (14.6%) 115 (79.9%) 
How you feel emotionally 17 (11.8%) 38 (26.4%) 89 (61.8%)
Impact of illness or treatment on work & leisure 18 (12.5%) 44 (30.6%) 82 (56.9%)
Impact of illness or treatment on social activities 29 (20.1%) 51 (35.4%) 64 (44.4%)
Impact of illness or treatment on relationships 25 (17.4%) 45 (31.3%) 74 (51.4%)
Impact of illness or treatment on appearance 24 (16.7%) 34 (23.6%) 86 (59.7%)
Item 0 1 2 3 4
Overall health 12 
(8.3%)
17
(11.8%)
45
(31.0%)
31
(21.4%)
39
(26.9%)
Symptoms of disease or treatment
(e.g. pain, sickness, fatigue)
14
(9.7%)
19
(13.2%)
35
(24.3%)
38
(26.4%)
38
(26.4%)
General physical limitations as a 
result of disease or treatment
49
(34.0%)
26
(18.1%)
27
(18.8%)
15
(10.4%)
27
(18.8%)
Physical limitations specific to 
disease and treatment (e.g. speech)
21
(14.6%)
20
(13.9%)
35
(24.3%)
34
(23.6%)
34
(23.6%)
Emotional distress 49
(34.0%)
41
(28.5%)
28
(19.4%)
12
(8.3%)
14
(9.7%)
Impact of illness or treatment on work 
& leisure
65
(45.1%)
36
(25.0%)
27
(18.8%)
7
(4.9%)
9
(6.3%)
Impact of illness or treatment on 
relationships
60
(41.7%)
39
(27.1%)
30
(20.8%)
6
(4.2%)
9
(6.3%)
Impact of illness or treatment on 
appearance
60
(41.7%)
38
(26.2%)
24
(16.6%)
9
(6.3%)
9
(6.3%)
Key to scale: 0= ‘rather not’, 1= ‘discuss if raised by doctor’, 2= ‘want to discuss’ 
Key to scale: 0= ‘never’, 1= ‘rarely’, 2= ‘sometimes’, 3= ‘often’, 4= ‘almost always’ 
In general, patients most wanted to discuss ‘physical activities affected by
treatment’, a category which includes key areas such as speech, swallowing
and eating, with their doctors. This was closely followed by ‘symptoms and
side effects of treatment’. These matched the perception of what was perceived
most likely to be discussed, although 24% of patients indicated that symptoms
and side effects were ‘never’ or ‘rarely’ mentioned and 29% gave the same
results for physical limitations due to the disease or its treatment.
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Abstract
This study focuses on the views of Head and Neck [H&N] Cancer patients on important topics for medical 
consultations and their preferences for formal questionnaire assessment of their Health Related Quality of Life [QoL]. 
We report ratings of questionnaires and the perceived content of consultations. Our long term aim is to introduce 
individual assessment of QoL by a patient centered, touch-screen based communication tool for use in clinics.
Aims
To determine patient opinions on the 
content and wording of a future health 
related quality of life assessment tool. 
To assess wishes for and perceived content 
of medical consultations in a H&N Oncology 
clinical network. 
Conclusions
Although patients did not endorse a particular questionnaire,
they demonstrated ability to comment on aspects of
questionnaire design and the trend was towards preference
of FACT-G which was reported in interviews as clear and
addressing the important issues.
Patients’ perceptions were that important issues were not
being consistently raised in medical consultations.
This study raises interesting questions about the mutual
understanding of the content of doctor/patient interactions
and how communication can be improved so that the needs
of patients are met.
Background & Clinical Setting 
Head and Neck (H&N) patients are acknowledged to
face significant challenges during their cancer journey,
not only those common to all sites but also the loss of
key functions. Aesthetic and functional outcomes after
major surgery +/- chemoradiotherapy can make
adjustment to social and working environments very
difficult.
Our initial study, of simple cross-sectional design using
the University of Washington (UWQoLv4)
questionnaire, showed that 129 out of 147 patients
scored below our ‘a priori’ cut-off level in at least one
domain. Resources limited detailed assessment to the
40 with the lowest scores, of whom 30 reported unmet
needs which had not been previously identified.
Our conclusion was that patients did have problems
which were not identified as part of their standard care
and that a screening questionnaire could help to identify
these.
From this study we derived our hypothesis that:
‘Carefully developed and structured questionnaires
can be used to improve the quality of life of head
and neck patients’.
We wished to place the patient at the core of
development and the second phase of this programme,
reported here, is exploration of their views on medical
consultation as experienced in the head and neck clinic
and on questionnaire content and wording.
Method
H&N cancer patients attending follow-up appointments
were approached. Generic and head and neck specific
(SF-36v2, EORTC QLQ C30 and H&N modules, FACT
G and H&N and UWQoLv4) questionnaires were
completed using touch-screens. Patients were
interviewed regarding their preferences and invited to
comment. To determine patients’ views on medical
consultations a questionnaire was adapted from
Detmar (1).
Patients were asked to rate the importance of
questions and the wording of questions on a 1-4 Likert
scale, where 4 represents a ‘very good’ interpretation of
patient need and 1 represents ‘not at all’.
Results
150 patients were accrued to the study, including patients with
oral, laryngeal and thyroid cancers. 19 patients completed a
follow up assessment, providing a total of 169 records for
analysis. Basic full group data is reported here. Patients did not
endorse a particular questionnaire.101 patients (61%) stated no
preference, 29 (18%) preferred the FACT-G, 20 (12%) the SF-36
and 16 (10%) the EORTC QLQ C30. Considering ‘importance’;
i.e. that the questionnaire raised the topics the patient would wish
to see in an assessment, 63.5% considered that the FACT had
greatest efficacy, followed by 57.2% for the SF-36 and 56.9% for
the EORTC. For clarity of wording the EORTC and FACT-G
gained similar scores at 59.9% and 58.7% respectively.
Ratings for content of a consultation indicated that ‘disease
specific limitations’ (80.4% would wish to mention) was most
important to patients, however it was perceived to be covered in
only a third of consultations. ‘Symptoms and side effects’ as a
medical rather than an impact on life rating was the area
perceived to be included by doctors (59.6%). Emotional distress
was rated as important but was perceived rarely or never to be
addressed in the majority of medical consultations.
Figure 1. Patient views on 
questionnaires
Figure 2. Patients’ wishes for 
consultations (169 returns)
Figure 3. Patients’ perceived content 
of consultations (168 returns)
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Item Not discuss
If doctor 
mentions
Like to 
discuss
Symptoms/Side Effects 
of Treatment
6  (3.6%) 40  (23.7%) 123  (72.8%)
Physical activity 11 (6.5%) 42  (24.9%) 116  (68.6%)
Disease specific 
limitations
9  (5.3%) 24  (14.2%) 136* (80.4%)
Emotional aspects 19 (11.2%) 44  (26.0%) 106* (62.7%)
Impact on work 22 (13.0%) 48  (28.4%) 99  (58.5%)
Impact on relationships 33 (19.5%) 58  (34.3%) 78  (46.2%)
Impact on appearance 28 (16.6%) 56  (33.1%) 87  (51.5%)
Item Never Rarely
Some
times
Often                     Almost
Always
Overall health 28 (16.9%) 29 (17.5%) 55 (33.1%) 18  (10.8%) 28  (16.6%)
Symptoms/Side Effects 16  (9.6%) 23 (13.6%) 43 (25.9%) 48  (28.9%) 51  (30.7%)
Physical activity 28 (16.9%) 22 (13.3%) 48 (28.9%) 43 (25.9%) 37  (22.3%)
Specific to disease* 47 (28.3%) 31 (18.7%) 32 (18.9%) 26  (15.7%) 29  (17.5%)
Limitation in work or 
leisure
33 (19.9%) 23  (13.6%) 48 (28.9%) 46 (27.7%) 32 (19.27%)
Emotional distress* 60 (36.1%) 51 (30.7%) 42 (25.3%) 13  (7.8%) 13  (7.8%)
Relationships with family 78 (47.0%) 37 (22.3%) 45 (27.1%) 8   (4.8%) 10  (6.0%)
Social relationships 71 (42.8%) 42 (25.3%) 45 (27.1%) 12  (7.2%) 10  (6.0%)
Appearance 56 (45.9%) 33 (27.0%) 22 (18.0%) 5   (4.1%) 6   (4.9%)
Important Well written
1 2 3 4 1 2 3 4
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(37.7)
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SF-36    n
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(43.4)
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(51.2)
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Abstract
This study focuses on assessment of health related quality of life in patients with Head and Neck Cancer. Our aim is 
to introduce individual assessment of QoL into patient care by developing a tool to assist patients in communicating 
their status to healthcare professionals in such a way that it forms a basis for their care and support.
Aim
To determine patient opinions on the 
content and wording of a future health 
related quality of life assessment tool.  
Conclusions
Although patients did not endorse a particular questionnaire,
they demonstrated ability to comment on aspects of
questionnaire design.
Patients’ perceptions were that important issues were not
being consistently raised in medical consultations. This
study raises interesting questions about the mutual
understanding of the content of doctor/patient interactions
and how communication can be improved so that the needs
of patients are met.
Background & Clinical Setting 
Head and Neck (H&N) patients are acknowledged to
face significant challenges during their cancer journey,
not only those common to all sites but also the loss of
key functions. Aesthetic outcomes after major surgery
can make adjustment to social and working
environments very difficult.
In the UK, care is provided by multi-disciplinary cancer
teams (MDTs) including all health professionals with
expertise relevant to their care. Whilst this model of
care provides access to a range of expertise, it is
important that needs are identified. Our initial study, of
simple cross-sectional design using the University of
Washington (UWQoLv4) questionnaire which has been
specifically developed as a screening tool for this
patient group, showed that 129 out of 147 patients
scored below our ‘a priori’ cut-off level in at least one
domain. Resources limited detailed assessment to the
40 with the lowest scores, of whom 30 reported unmet
needs which had not been previously identified.
Our conclusion was that patients did have problems
which were not identified as part of their standard care
and that a screening questionnaire could help to identify
these.
From this study we derived our hypothesis that:
‘Carefully developed and structured questionnaires
can be used to improve the quality of life of head
and neck patients’.
We wished to place the patient at the core of
development and the second phase of this programme,
reported here, is exploration of their views on medical
consultation as experienced in the head and neck clinic
and on questionnaire content and wording.
Method
H&N cancer patients attending follow-up appointments
were approached. Generic and head and neck specific
(SF-36v2, EORTC QLQ C30 and H&N modules, FACT
G and H&N and UWQoLv4) questionnaires were
completed using touchscreens. Patients were
interviewed regarding their preferences and invited to
comment. To determine patients’ views on medical
consultations a questionnaire was adapted from
Detmar (1).
Patients were asked to rate the importance of
questions and the wording of questions on a 1-4 Likert
scale.
Results
To date 122 records are available for assessment. Patients did
not endorse a particular questionnaire, 69 stating no preference,
11 favouring the EORTC QLQ C30, 14 the FACT G and 15 the
SF-36 v2. Detailed assessments on the H&N questionnaires will
be performed when accrual is complete (150 patients). In terms
of raising important questions, 63.6% considered that the FACT
had greatest efficacy, followed by 57.9% for the SF-36 and 55%
for the EORTC. However, the EORTC gained the highest rating
for wording (60.8%) followed by the FACT (57.9%) and SF-36
(52.1%).
Ratings for content of a consultation indicated that ‘disease
specific limitations was the most important area. ‘Symptoms and
side effects of treatment (71.3%), ‘physical activity’ (69.7%) and
‘emotional aspects (62.3%) were considered important. When
this was compared with the perceived content of consultations,
less than a third of patients felt that these issues were
consistently addressed by their doctors. Emotional distress was
perceived rarely or never to be addressed in the majority of
medical consultations.
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Figure 1. Patient views on 
questionnaires
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Like to 
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Not 
discussItem
60  (49.2%)24 (19.7%) Impact on appearance
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68  (55.7%)18 (14.8%)Impact on work
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96* (78.7%)6  (4.9%)Disease specific 
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85  (69.7%)7  (5.7%)Physical activity
87  (71.3%)5  (4.1%)Symptoms/Side Effects 
of Treatment
Figure 2. Patients’ wishes for 
consultations
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5   (4.1%)22 (18.0%)
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Figure 3. Patients’ perceived 
content of consultations
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Introduction
Secondary use of patient databases is essential if research and development (R&D) at point of care is to be expanded. However, 
integration of effective databases, primarily designed to facilitate patient care with R&D needs, represents a complex challenge. We 
present a system which allows online management of complex datasets for clinical trials within care records. This has been trialled in a 
complex multidisciplinary setting and represents an ideal resource for clinicians and researchers working together. 
Clinical Trials Database
The trials database was developed for use in Oncology at the Leeds Teaching 
Hospitals NHS Trust and the University of Leeds. It integrates seamlessly with 
the electronic patient record, the patient pathway manager (PPM) which records 
the ‘pathway’ or sequence of events in a patient’s care episode.
PPM is written in SQL Server, Microsoft’s data warehousing and relational 
database management system, with a Visual Basic graphical user interface, 
facilitating easy management and browsing (Fig 1).
Eligible patients are identified by diagnosis, clinic or Consultant and ‘flagged’ for 
download. Thereafter their progress is tracked in PPM. 
Clinical Setting
We have used the database in a multi-site/ multidisciplinary setting, entering 
patients into a trial assessing HRQoLin patients with Head and Neck cancer. 
Responses are entered via a stand-alone touchscreen, which synchronises with 
the central database. Quantitative data (questionnaire scores) and qualitative 
data (transcripts of interviews and consultations) are entered directly at the time 
of intervention.
Prior to the clinic PPM is searched on-line and eligible patients can be identified 
by name, by disease, by Consultant or by clinic. The PPM record is uploaded 
from the central database into the trials browser. The study forms have been 
entered into the trials browser and the system tracks the patient through from 
approach to entry or refusal and to completion of episode(s). On return from the 
clinic, data is uploaded to the central database.
For the current trial, where entry can take place at multiple sites, the versatility 
of this system has been essential, allowing the use of a lap-top computer in a 
quiet environment to provide trial participants with the ideal setting in which to 
participate
Figure 2. Use of database in the clinical setting                              
Data Entry
Trial data is entered onto the laptop using the questionnaires required for the 
study. The trial record is linked through to the PPM clinical record.
The entry screen provides information and the patient progresses through the 
screens until data collection is complete.
Figure 3. Collection of questionnaire data
To enter a response, the patient simply clicks the screen.
Data is automatically uploaded into the trials database and saved for 
analysis.   
Summary
This system has proved reliable and user-friendly for 
clinicians and researchers. It combines core patient data 
with trial data, ensuring security, accuracy (avoids 
transcription errors) and ease of data exploration and 
analysis.
Combining advanced technology in the way demonstrated, 
can achieve much in optimising collaborations between 
clinical and research teams and encouraging accrual to 
clinical trials. It provides a practical tool for routine 
collection of trials related or clinically related data (such as 
collection of data on health related quality of life) and the 
technology allows immediate feedback to the clinician in 
any preferred format, tables, graphs and print outs, thus 
facilitating management in a complex clinical setting.
Figure 1. The PPM/Trials Browser Interface
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